


- 300 -


bromo-4-methoxymethoxy-3-*iso*-propylbenzene according to the procedure described in Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000) and transformed into the title compound according to the procedure described for the synthesis of compound 7-17, step b; (0.12 g, 85%); ¹H NMR (300 MHz, CD₃OD): δ 6.97 (s, 1 H), 6.83 (s, 2 H), 6.77 (d, *J* = 7.5 Hz, 1 H), 6.65 (d, *J* = 7.5 Hz, 1 H), 4.0 (d, *J* = 9.9 Hz, 2 H), 3.75 (s, 2 H), 3.20 - 3.29 (m, 1 H), 2.28 (s, 6 H), 1.19 (d, *J* = 6.6 Hz, 6 H); LC-MS *m/z* = 363 [C₂₀H₂₅O₆P -H]⁺; (94%) HPLC conditions: ODSAQ AQ-303-5 column; mobile phase = CH₃OH: 0.05%TFA/H₂O (7:3) flow rate = 1.0 mL/min; detection = UV @ 254 nm retention time in min: 10.92; Anal Calcd for (C₂₀H₂₅O₆P + 1.2 H₂O): C, 59.12; H, 7.15. Found: C, 58.96; H, 6.77.

Compound 7-20: [4-(4'-hydroxy-3'-*iso*-propylbenzyl)-3-methyl-phenoxy]methylphosphonic Acid



[0625] Intermediate 4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-3-methyl-phenol was prepared from 4-bromo-3-methyl-phenol (*J. Med. Chem.* 12:1350 (1980)) and 4-methoxymethoxy-3-*iso*-propylbenzaldehyde according to the procedure described in Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000) and transformed into the title compound by the procedure used for the synthesis of compound 7. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.04 (s, 1 H), 7.02-6.99 (d, *J* = 8.7 Hz, 1 H), 6.92 (s, 1 H), 6.81-6.76 (m, 2 H), 6.67 (s, 2 H), 4.03 (d, *J* = 10.5 Hz, 2 H), 3.76 (s, 2 H), 3.16-3.14 (m, 1 H), 2.19 (s, 3 H), 1.14-1.12 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.11;

Compound 7-21: [2,5-Dimethyl-4-(4'-methoxy-2'-methyl-3'-*iso*-propylbenzyl)phenoxy]methylphosphonic acid



Step a:

[0626] First step: To a stirring solution of 2,5-dimethyl-4-methoxybenzaldehyde (0.82 g, 5.0 mmol) at - 20 °C in CH₂Cl₂ (10 mL) was added BBr₃ (10 mL, 1M in CH₂Cl₂). The reaction mixture was stirred at room temperature for 16 hrs. It was added ice and diluted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate/hexanes (1:1) to afford 2,5-dimethyl-4-hydroxybenzaldehyde as a yellow solid (0.43 g, 57%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.41 (s, 1 H), 9.99 (s, 1 H), 7.56 (s, 1 H), 6.69 (s, 1 H), 2.51 (s, 3 H), 2.14 (s, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; R_f = 0.48.

Step b:

[0627] To a stirring solution of 2,5-dimethyl-4-hydroxy-benzaldehyde (0.43 g, 2.86 mmol) in DMF (8 mL) at room temperature was added imidazole (0.43 g, 6.29 mmol) and chloro-triisopropyl-silane (0.74 mL, 3.43 mmol). The mixture was stirred at room temperature for 16 hrs. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (15:75) to afford 2,5-dimethyl-4-triisopropylsilyloxy-benzaldehyde as a colorless oil (0.7 g, 80%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.07 (s, 1 H), 7.65 (s, 1 H), 6.69 (s, 1 H), 2.55 (s, 3 H), 2.21 (s, 3 H), 1.35 (m, 3 H), 1.10 (d, J = 6.9 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% ethyl acetate in hexanes; R_f = 0.68.

[0628] Intermediate 2,5-dimethyl-4-(4'-methoxy-2'-methyl-3'-*iso*-propylbenzyl) phenol was prepared from 2,5-dimethyl-4-triisopropylsilyloxybenzaldehyde and 1-bromo-4-methoxy-2-methyl-3-*iso*-propylbenzene according to the procedure described in Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000) and transformed into the title compound by the procedure described for the synthesis of compound 7: ^1H NMR (300 MHz, DMSO-*d*₆): δ 6.93 (s, 1 H), 6.75 (d, *J* = 8.4 Hz, 1 H), 6.65 (d, *J* = 8.4 Hz, 1 H), 6.64 (s, 1 H), 4.09 (d, *J* = 9.9 Hz, 2 H), 3.79 (s, 2 H), 3.77 (s, 3 H), 3.34 (m, 1 H), 2.22 (s, 3 H), 2.20 (s, 3 H), 2.10 (s, 3 H), 1.31 (d, *J* = 7.2 Hz, 6 H); LC-MS *m/z* = 391 [C₂₁H₂₉O₅P - H]⁻.

Alternative method for the preparation of compound 7:

Step a:

[0629] A 3 neck 2 liter flask fitted with mechanical stirring, nitrogen bubbler, sodium hydroxide trap, and a cool water bath was charged with 2-*iso*-propyl phenol (157.8 g, 1.1 mol) and dichloromethane (1000 ml). While maintaining the internal temperature at 15 °C to 20 °C, bromine (179.4 g, 1.1 mol) was added dropwise over 45 min. (The rate of addition is controlled so that the bromine color dissipates almost immediately). The reaction was complete by TLC (silica gel plates, 20% EtOAC/hexanes, *R*_f S.M. = 0.7, *R*_f product = 0.8). The flask was purged with nitrogen to remove most of the hydrogen bromide. The reaction mixture was then concentrated to an oil (252.0 g, 100%) which is pure enough to use in the next step. NMR: See Berthelot *et al.*, *Can J. Chem.* 67:2061 (1989).

Step b:

[0630] A 3 liter 3 neck round bottom flask equipped with mechanical stirring, temperature probe, cooling bath, and addition funnel with nitrogen inlet was charged with 4-bromo-2-*iso*-propylphenol (160 g, 0.75 mol) and methylene chloride (750 ml). While maintaining the temperature between 15 °C and 20 °C, a solution of diisopropylethylamine (146 g, 1.13 mol) and chloromethyl methyl ether (66.4 g, 0.83 mol) in methylene chloride (100 ml) was added

over 15 minutes. The solution was heated to reflux for 16 hours. The reaction was complete by TLC (silica gel plates, 10% EtOAc/hexanes, R_f S.M. = 0.5, R_f product = 0.9). After cooling to room temperature, the reaction was quenched by the addition of water (800 ml). After separation of layers, the aqueous phase was extracted with methylene chloride (500 ml). The combined organic layers were dried over $MgSO_4$, and then concentrated to an oil (204 g). The oil was purified by column chromatography (1.8 kg silica gel, 2.5% EtOAc/hexanes) to yield a clear oil (154 g, 79%). NMR See Chiellini *et al.*, *Biorg. Med. Chem. Lett.* 10:2607 (2000).

Alternative Step b

[0631] A 5 liter 4 neck indented round bottom flask equipped with a mechanical multi-paddle stirrer, and an addition funnel with nitrogen inlet was charged with 4-bromo-2-*iso*-propylphenol (100 g, 0.47 mol) and methylene chloride (2000 ml). Under high agitation, half of the P_2O_5 (75 g, 1.1 mol) was added. The reaction was stirred for one hour during which time dough balls formed. Additional P_2O_5 (75 g, 1.1 mol) was added and stirred for one hour. The reaction was complete by TLC (silica gel plates, 10% EtOAc/hexanes, R_f S.M. = 0.5, R_f product = 0.9). The reaction was carefully quenched by the addition of 10% K_2CO_3 (2000 ml). After separation of layers, the aqueous phase was extracted with methylene chloride (1000 ml). The combined organic layers were dried over $MgSO_4$, and then concentrated to an oil (116 g). The oil was purified by column chromatography (1.5 kg silica gel, 2.5% EtOAc/hexanes) to yield a clear oil (99.9 g, 83%).

Step c:

[0632] A 2 liter 3 neck round bottom flask equipped with mechanical stirring, cooling bath, temperature probe, and addition funnel with nitrogen inlet was charged with 4-bromo-3,5-dimethylphenol (90.0 g, 448 mmol), imidazole (90 g, 1.32 mol), and methylene chloride (900 ml). The solution was cooled to 10 °C. Triisopropylsilyl chloride (95.0 g, 493 mmol) was added over 10 minutes. The temperature rose to 20 °C. The solution became turbid, and a white precipitate formed. The reaction mixture was stirred at room temperature for

2.5 hours. The reaction was complete by TLC (silica gel plates, 10 % EtOAc/hexane, R_f S.M. = 0.3, R_f product = 0.9). Water (600 ml) was added and stirred for 20 minutes. After separation of layers, the organic phase was dried over MgSO₄ and concentrated to an oil (178 g) which is acceptable for use in the next step. The oil was purified by column chromatography (1.8 kg silica gel, 5 % EtOAc/hexane) to yield an oil (153 g, 96 %). NMR See Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000).

Step d:

[0633] A 3 liter 3 neck round bottom flask equipped with mechanical stirring, thermometer, cooling bath and 250 ml addition funnel was charged with 4-bromo-3,5-dimethylphenoxytrisopropylsilane (150 g, 420 mmol) and THF (1125 ml). The solution was cooled to -73 °C. While maintaining the temperature at less than or equal to -70 °C, 2.5 M n-butyllithium (252 ml, 630 mmol) was added over 1.5 hours. The solution was stirred at -73 °C for an additional 2.5 hours. While maintaining the temperature at less than or equal to -70 °C, a solution of dimethylformamide (61.3 g, 840 mmol) in THF (60 ml) was added over 35 minutes. After stirring for 30 minutes at -73 °C, TLC indicated that the reaction was complete (silica gel plates, 10 % EtOAc/hexane, R_f S.M. = 0.9, R_f product = 0.7). The reaction was warmed to room temperature, and then quenched by the addition of saturated ammonium chloride in water (1000 ml). After separation of layers, the aqueous phase was extracted with MTBE (250 ml). The combined organic layers were dried over MgSO₄, and concentrated to an oil (125 g). The oil was purified by column chromatography (1.5 kg silica gel, 5 % EtOAc/hexanes) to yield an oil (113 g, 87 %). NMR See Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000).

Step e:

[0634] A 5 liter 3 neck round bottom flask equipped with a cooling bath, mechanical stirring, temperature probe, and addition funnel with nitrogen inlet was charged with bromo-4-methoxymethoxy-3-*iso*-propyl (136 g, 525 mmol) and THF (1300 ml). The solution was cooled to -75 °C. While maintaining the temperature at less than or equal to -70 °C, n-butyllithium solution (310

ml, 775 mmol) was added over 45 minutes. The solution was stirred at -75 °C for 1 hour. While maintaining the temperature at less than or equal to -70 °C, a solution of 2,6-dimethyl-4-triisopropylsilyloxybenzaldehyde (134 g, 438 mmol) in THF (200 ml) was added over 2 hours. The solution was stirred at -75 °C for 1 hour. TLC indicated that the reaction was complete (silica gel plates, 10 % EtOAc/hexane, R_f Bromide = 0.9, R_f Aldehyde = 0.7, R_f product = 0.2). After warming to room temperature, the reaction was quenched with saturated ammonium chloride in water (200 ml). After separation of layers, the aqueous phase was extracted with ethyl acetate (800 ml). The combined organic layers were washed with brine (700 ml), dried over $MgSO_4$, and concentrated to an oil (262 g). The oil was split into halves, and each half was purified by column chromatography (1.8 kg silica gel, 5 to 10 % EtOAc/hexane) to yield the product as a clear oil containing some EtOAc (148 g of product, 69 %). The fractions containing the product and an impurity were combined to give a clear oil (19.3 g). This was purified by column chromatography (400 g silica gel, 5 to 10 % EtOAc/hexanes) to give additional product as a clear oil (16.9 g, 7 %). NMR See Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000).

Step f:

[0635] A 2 liter round bottom flask equipped with magnetic stirring and a 3 way adapter was charged with (4-methoxymethoxy-3-*iso*-propylphenyl)-(2,6-dimethyl-4-triisopropylsilyloxy)-methanol (72.1 g, 139 mmol), ethyl acetate (665 ml), acetic acid (35 ml), and 10 % Pd on Carbon (5.22 g). The flask was purged 3 times with nitrogen, and then a hydrogen balloon was attached to the adapter. After purging 3 times with hydrogen, the mixture was stirred at room temperature for 3 hours. The reaction was complete by TLC (silica gel plates, 10 % EtOAc/hexane, R_f S.M. = 0.2, R_f product = 0.9). After purging with nitrogen, the mixture was filtered through a small pad of Celite; rinsed with EtOAc (70 ml). The filtrate was washed with water (2 x 100 ml), and then by saturated $NaHCO_3$ in water until the wash was basic (4 x 100 ml). The

organic layer was dried over MgSO₄ and then concentrated to an oil (62.5 g, 96 %). NMR See Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000).

Step g:

[0636] A 1 liter 1 neck round bottom flask equipped with magnetic stirring was charged with the 2,6-dimethyl-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-4-triisopropylsilyloxybenzene (62.5 g, 133 mmol) and THF (600 ml). Tetraethylammonium fluoride hydrate (25.9 g, 174 mmol) was slightly ground in a beaker and then charged to the flask. The slurry was stirred at room temperature for 1 hour until TLC indicated that the reaction was complete (silica gel plates, 20 % EtOAc/hexane, R_f S.M. = 0.9, R_f product = 0.4). Water (300 ml) was added and stirred for 15 minutes. The mixture was diluted with MTBE (600 ml), and the layers were separated. The aqueous phase was extracted with MTBE (600 ml). The combined organic layers were washed with water (100 ml) followed by brine (200 ml). After drying over MgSO₄, the organic layer was concentrated to an oil (65 g). This was purified by column chromatography (1300 g silica gel, 10 to 20 % EtOAc/hexanes) to give the product as a clear oil (57.0 g, 95 %). NMR See Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000).

Step h:

[0637] A 5 liter 3 neck round bottom flask equipped with a cooling bath, mechanical stirring, temperature probe, and addition funnel with nitrogen inlet was charged with 60% sodium hydride in mineral oil (10.62 g, 266 mmol). The sodium hydride was washed with hexanes (150 ml). Dimethylformamide (250 ml) was added, and the mixture cooled to 5°C. While maintaining the temperature < 10°C a solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-phenol (55.53 g, 117 mmol) in DMF (150 ml) was added over 30 minutes. The solution was stirred at room temperature for 1 hour, and then cooled back to 5°C. While maintaining the temperature at less than or equal to 10 °C, a solution of the diethyl *p*-toluenesulfonyloxymethyl-phosphonate (86.93 g, 269 mmol) in DMF (150 ml) was added over 15 minutes. The solution was stirred at room temperature for 16 hours. The reaction was

concentrated to a paste. The paste was treated with water (330 ml) and extracted with ethyl acetate (330 ml, 2x 250 ml). The combined organic layers were washed with brine (150 ml), dried over MgSO₄, and concentrated to an oil (116 g). The oil was purified by column chromatography (1.5 kg silica gel, 10 to 50 % EtOAc/hexane) to yield the product as a clear oil containing some EtOAc (54.76 g of product, 66 %). The fractions containing the product and diethyl p-toluenesulfonyloxymethyl were combined to give a clear oil (6.03 g). This was purified by column chromatography (120 g silica gel, 30 to 40 % EtOAc/hexanes) to give the product as a clear oil (3.74 g, 4 %). NMR see compound 7, step a.

Step i:

[0638] A 500 ml 3 neck round bottom flask equipped with magnetic stirring, temperature probe, addition funnel with a nitrogen inlet, and a cooling bath was charged with the diethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate (19.61 g, 42.2 mmol) and dichloromethane (200 ml). The solution was cooled to -30 °C. Trimethylsilyl bromide (64.96 g, 424 mmol) was added over 15 min. The bath was removed, and the solution stirred at room temperature for 16 hours. The reaction was concentrated on the rotary evaporator at 50 °C. The oil was then put on the vacuum pump for 30 minutes. The oil was dissolved in acetonitrile/water (110 ml/110 ml) and stirred at 50 °C for 30 min. The solution was concentrated to an oil. Acetonitrile (110 ml) was added, and the solution was concentrated to an oil. Methanol/toluene (30/190 ml) was added and the solution was concentrated to an oil. Methanol/toluene (30/190 ml) was added and the solution was concentrated to a foam. Toluene (220 ml) was added and the solution was concentrated to a solid. Toluene/hexane (190 ml/30 ml) was added, and the mixture was sonicated for 5 minutes. The solids were scraped down the sides of the flask, and the mixture was stirred at room temperature for 2 hours. The solids were collected by vacuum filtration and washed with hexane/toluene (2 ml/8 ml). The solids were dried overnight in the vacuum


oven at 45 to 50 °C to yield the titled compound as an off-white solid (14.36 g). NMR see compound 7, step b.

Preparation of Diethyl p-toluenesulfonyloxyethylphosphonate

[0639] A 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer, condenser, thermometer and heating mantle. The flask was flushed with nitrogen and charged with diethyl phosphite (554 g, 3.77 mol), paraformaldehyde (142 g, 4.72 mol), toluene (2 L) and triethylamine (53 mL, 5.76 mol). The mixture was stirred at 85-90 ° for 2 h, then at reflux for 1 h. The resulting yellow solution was cooled to 4 °C (ice bath) and p-toluenesulfonyl chloride (718 g, 3.77 mol) was added. The condenser was replaced with an addition funnel and triethylamine (750 mL) was added slowly with stirring, maintaining the temperature <10 °C. After the addition was complete (45 min.), the resulting mixture was stirred at ambient temperature for 14 h. The mixture was filtered and the filtercake was washed with toluene (2 X 250 mL). The combined filtrate and washings were washed with water (2 X 1 L, dried (MgSO_4 , 200 g), filtered through Celite 521, and concentrated under reduced pressure to provide 1004 g of a cloudy yellow oil (77.6%). ^1H NMR (CDCl_3): NMR (DMSO): 7.82 (d, $J = 8.2$ Hz, 2H), 7.48 (d, $J = 8.2$ Hz, 2H), 4.36 (d, $J = 9.6$ Hz, 2H), 4.00 (m, 4H), 2.41 (s, 3H), 1.16 (m, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 40% EtOAc/hexanes, $R_f = 0.24$.

Example 8

Compound 8: [3,5-diiodo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenoxy]methylphosphonic acid



Step a:

[0640] To a solution of 4-benzyloxyphenol (0.2 g, 0.93 mmol) in dichloromethane (9.3 mL) at 0 °C was added bis(pyridine)iodonium tetrafluoroborate (0.76 g, 2.06 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 4-benzyloxy-3,5-diiodophenol as an off-white solid (0.22 g, 50%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.60 (s, 1 H), 8.06 (m, 2 H), 7.72 (s, 2 H), 7.59 (m, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.45.

Step b:

[0641] To a mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (0.77 g, 1.51 mmol) and copper powder (0.13 g, 2.01 mmol) in CH₂Cl₂ (4.4 mL) at 0 °C was added a solution of TEA (0.15 mL, 1.10 mmol) and 4-benzyloxy-3,5-diiodophenol (0.47 g, 1.00 mmol) in dichloromethane (4.0 mL). The reaction mixture was stirred at room temperature for 24 h and filtered through a Celite plug. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenyl benzoate as an off-white solid (0.61 g, 98%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.10 (m, 2 H), 7.96 (s, 2 H), 7.73 (m, 1 H), 7.60 (m, 2 H), 6.85 (d, *J* = 9.0 Hz, 1H), 6.73 (d, *J* = 3.0 Hz, 1H), 6.35 (m, 1 H), 3.74 (s, 3 H), 3.21 (m, 1 H), 1.13 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (1:9); R_f = 0.42.

Step c:

[0642] A mixture of 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenyl benzoate (0.10 g, 0.16 mmol) and 1 N NaOH (0.81 mL, 0.81 mmol) in methanol (1.63 mL) was at room temperature for 24 h. The reaction mixture was neutralized with 2 N HCl, diluted with H₂O and extracted with CH₂Cl₂ (10 mLx2). The organic layers were concentrated under reduced pressure and the crude product was purified preparatory TLC with acetone-hexanes (1:4) as

- 310 -

mobile phase to afford 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenol as an off-white solid (0.079 g, 95%): ¹H NMR (300 MHz, DMSO-d₆): δ 9.99 (s, 1 H), 7.28 (s, 2 H), 6.81 (d, *J* = 12.0 Hz, 1 H), 6.67 (d, *J* = 3.0 Hz, 1 H), 6.30 (m, 1 H), 3.72 (s, 3 H), 3.18 (m, 1 H), 1.11 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (7:3); R_f = 0.42.

Step d:

[0643] To a stirred solution of 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenol (0.28 g, 0.55 mmol) in dichloromethane (17.0 mL) at -78 °C was added BBr₃ (13.1 mL, 13.1 mmol, 1.0 M solution in CH₂Cl₂). The reaction mixture was stirred at -78 °C for 10 min, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice and extracted with CH₂Cl₂ (20 mLx2). The organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (3:7) to afford 3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenol as an off-white solid (0.18 g, 66%): ¹H NMR (300 MHz, DMSO-d₆): δ 9.95 (s, 1 H), 8.91 (s, 1 H), 7.27 (s, 2 H), 6.62 (d, *J* = 9.0 Hz, 1 H), 6.56 (d, *J* = 3.0 Hz, 1 H), 6.18 (m, 1 H), 3.72 (s, 3 H), 3.14 (m, 1 H), 1.10 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (7:3); R_f = 0.28.

Step e:

[0644] To a mixture of 3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenol (0.067 g, 0.14 mmol) and Cs₂CO₃ (0.220 g, 0.675 mmol) in DMF (1.35mL) at 0 °C was added trifluoromethanesulfonic acid diethoxyphosphorylmethyl ester (0.040 g, 0.14 mmol). The reaction mixture was stirred at room temperature for 5 h, quenched with 1 N HCl and extracted with EtOAc (10 mLx2). The organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by preparatory TLC with acetone-hexane (2:3) as mobile phase to afford diethyl [3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonate

- 311 -


as an off-white solid (0.048 g, 55%): ^1H NMR (300 MHz, DMSO-d₆): δ 8.95 (s, 1 H), 7.57 (s, 2 H), 6.63 (d, J = 9.0 Hz, 1 H), 6.56 (d, J = 3.0 Hz, 1 H), 6.19 (m, 1 H), 4.51 (d, J = 9.0 Hz, 2 H), 4.08 (m, 4 H), 3.14 (m, 1 H), 1.25 (m, 6 H), 1.10 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (3:2); R_f = 0.29.

Step f:

[0645] To a solution of diethyl [3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonate (0.14 g, 0.22 mmol) in CH₂Cl₂ (2.5 mL) at 0 °C was added bromotrimethylsilane (0.28 mL, 2.20 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile-water (1:1, 5.0 mL) and solvent was removed under reduced pressure. The crude product was treated methanol (10 mL) and the solvent was removed under reduced pressure to afford [3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonic acid as an off-white solid (0.080 g, 63%): mp 180 °C, dec; LC-MS *m/z* = 589 [C₁₆H₁₇I₂O₆P - H]⁺; HPLC conditions: Column = 3 Chromolith SpeedRODs RP-18e, 100×4.6 mm; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄) with 5% acetonitrile. Flow rate = 4 mL/min; UV@ 255 nm. Retention time in minutes. (*t*_r = 6.46, 97% purity).

[0646] Using the appropriate starting material, compounds 8-1 and 8-2 were prepared in an analogous manner to that described for the synthesis of compound 8.


Compound 8-1: [3,5-dibromo-4-(3'-*iso*-propyl-4'-hydroxyphenoxy)phenoxy]methylphosphonic acid



- 312 -

[0647] Prepared from 4-benzoyloxy-3,5-dibromophenol according to the procedure described in compound 8: mp: 77-80 °C; LC-MS *m/z* = 495,497 [C₁₆H₁₇Br₂O₆P - H]⁺; ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (s, 1 H), 7.42 (s, 2 H), 6.63 (m, 2 H), 6.22 (m, 1 H), 4.21 (d, *J* = 9.0 Hz, 2 H), 3.11 (m, 1 H), 1.10 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₆H₁₇Br₂O₆P + 0.2 C₆H₁₄): C, 40.06; H, 3.78. Found: C, 40.25, H, 3.89.


Compound 8-2: [3,5-dichloro-4-(3'-*iso*-propyl-4'-hydroxyphenoxy)-phenoxy]methylphosphonic acid



[0648] Prepared from 2,6-dichloro-4-(2-methoxyethoxy)phenol (*Synth. Commu.* 27:107 (1997)) according to the procedure described in compound 8:: m.p.73-76 °C; LC-MS *m/z* = 407 [C₁₆H₁₇Cl₂O₆P - H]⁺; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.10 (s, 1 H), 7.34 (s, 2 H), 6.72 (m, 2 H), 6.32 (m, 1 H), 4.28 (d, *J* = 9.0 Hz, 2 H), 3.22 (m, 1 H), 1.17 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₆H₁₇Cl₂O₆P + 0.2 C₄H₈O₂ + 0.4 H₂O): C, 46.71; H, 4.53. Found: C, 46.95, H, 4.50.

Example 9

Compound 9: 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)-phenoxy]benzylphosphonic acid



Step a:

[0649] To a stirred solution of bis(4-methoxyphenyl)iodonium tetrafluoroborate (5.2 g, 13.5 mmol, Yokoyama *et al.*, *J. Med. Chem.* 38:695 (1995)) and copper powder (1.14 g, 18.1 mmol) in CH₂Cl₂ (30 mL) at 0 °C was added a solution of methyl 3,5-dichloro-4-hydroxybenzoate (39, 2.0 g, 9.0 mmol) and Et₃N (1.1 g, 1.5 mL, 12.0 mmol) in CH₂Cl₂ (10 mL). The reaction mixture was stirred at room temperature for 24 h and filtered through a Celite plug. The filtrate was washed with 2 N HCl (20 mL) and extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with brine and water, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford methyl 3,5-dichloro-4-(4'-methoxyphenoxy)benzoate as a white solid (1.59 g, 55%): mp 82-85 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (s, 2 H), 6.85 (dd, *J* = 2.7, 4.8 Hz, 1 H), 6.80 (dd, *J* = 1.8, 4.5 Hz, 1 H), 6.78 (t, *J* = 3.3 Hz, 1 H), 6.74 (d, *J* = 2.4 Hz, 1 H), 3.94 (s, 3 H), 3.76 (s, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.7.

Step b:

[0650] To a stirred solution of methyl 3,5-dichloro-4-(4'-methoxyphenoxy)benzoate (1.5 g, 4.5 mmol) in CH₂Cl₂ (50 mL) at -78 °C was added BBr₃ (11.4 mL, 11.4 mmol, 1 M solution in CH₂Cl₂). The reaction mixture was stirred at room temperature for 14 h, poured into ice water (100 mL) and stirred for 1 h. The reaction mixture was extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was recrystallized from CH₂Cl₂, filtered and dried under reduced pressure to afford 3,5-dichloro-4-(4'-hydroxyphenoxy)benzoic acid as a brown solid (1.02 g, 75%): mp 163-165 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.02 (bs, 1 H), 8.0 (s, 2 H), 6.67 (m, 4 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.3.

Step c:

- 314 -

[0651] To a stirred cold solution of CH₃OH (35 mL) and acetyl chloride (7 mL, 86.0 mmol) at 0 °C was added dropwise a solution of 3,5-dichloro-(4'-hydroxyphenoxy)benzoic acid (1.3 g, 4.3 mmol) in CH₃OH (5 mL). The reaction mixture was heated under reflux for 5 h and cooled to room temperature. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (100 mL). The resulting solution was washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was triturated with hexane-ether (8:2), filtered and dried under reduced pressure to afford methyl 3,5-dichloro-4-(4'-hydroxyphenoxy) benzoate as a brown solid (1.22 g, 90%); mp 152 -155 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.22 (s, 1 H), 8.08 (s, 2 H), 6.77 (t, *J* = 3.0 Hz, 1 H), 6.74 (t, *J* = 2.7 Hz, 1 H), 6.72 (t, *J* = 2.7Hz, 1 H), 6.68 (d, *J* = 2.7 Hz, 1 H), 3.87 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.5.

Step d:

[0652] To a stirred solution of methyl 3,5-dichloro-4-(4'-hydroxyphenoxy)benzoate (1.2 g, 3.8 mmol) in CHCl₃ (10 mL) at 0 °C was added chlorosulfonic acid (3.9 mL, 38.3 mmol). The reaction mixture was stirred at 0 °C for 1 h and allowed to warm to room temperature. The reaction mixture was stirred for 2 h, poured into ice water and extracted with ethyl acetate (3x100 mL). The combined organic layers were washed with water, dried over MgSO₄ and concentrated under reduced pressure to afford the crude product, which was used in the next step without purification. The crude product (1.1g, 2.6 mmol) was dissolved in THF (10 mL) and to it was added a solution of piperidine (0.68 g, 1 mL) in THF (5 mL). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (50 mL) and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:7) to afford desired methyl 3,5-dichloro-4-[4'-hydroxy-3'-(N-piperidinylsulfonamido) phenoxy]benzoate as a white solid

(0.78 g, 60%): mp 122-125 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.58 (s, 1 H), 7.04 - 7.10 (m, 2 H), 6.85 (d, *J* = 2.7 Hz, 2 H), 3.96 (s, 3 H), 3.02 (t, *J* = 5.1 Hz, 4 H), 1.63 - 1.59 (m, 4 H), 1.50 - 1.40 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:7); R_f = 0.35.

Step e:

[0653] To a stirred solution of methyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzoate (0.95 g, 2.0 mmol) in CH₂Cl₂ (15 mL) at -78 °C was added DIBAL-H (6.1 mL, 6.1 mmol, 1 M solution in CH₂Cl₂). The reaction mixture was stirred at room temperature for 5 h, cooled to 0 °C, quenched with saturated aqueous NaF solution (20 mL) and stirred at room temperature for 1 h. The reaction mixture was filtered and the filtrate was extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzyl alcohol as a white solid (0.66 g, 75%): mp 142 -145 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.54 (s, 1 H), 7.40 (s, 2 H), 7.09 (dd, *J* = 3.0, 9.3 Hz, 1 H), 6.98 (dd, *J* = 3.0, 9.3Hz, 1 H), 6.84 (d, *J* = 2.4 Hz, 1 H), 4.70 (d, *J* = 3.9 Hz, 2 H), 3.02 (t, *J* = 2.4 Hz, 4 H), 1.70 - 1.50 (m, 4 H), 1.47 - 1.50 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.4.

Step f:

[0654] To a stirred solution of 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzyl alcohol (0.40 g, 0.92 mmol) in ethyl ether-DME (9:1, 10 mL) at 0 °C was added phosphorous tribromide (1.2 g, 0.5 mL, 4.64 mmol). The reaction mixture was stirred at 0 °C for 5 h, quenched with ice (10 g) and stirred at 0 °C for 30 min. The reaction mixture was extracted with ether (100 mL) and washed with brine. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dichloro-4-

[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzyl bromide as a colorless oil (0.34 g, 75%): ^1H NMR (300 MHz, CDCl_3): δ 8.57 (s, 1 H), 7.42 (s, 2 H), 7.0 (dd, J = 3.0, 9.3 Hz, 1 H), 6.97 (d, J = 9.3 Hz, 1 H), 6.86 (d, J = 2.7 Hz, 1 H), 4.41 (s, 2 H), 3.02 (t, J = 5.1 Hz, 4 H), 1.65 - 1.55 (m, 4 H), 1.50 - 1.45 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:7); R_f = 0.75.

Step g:

[0655] To a stirred solution of 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzyl bromide (0.12 g, 0.25 mmol) in toluene (5 mL) at room temperature was added triethylphosphite (0.42 g, 2.5 mmol). The reaction mixture was heated at 130 °C for 8 h and cooled to room temperature. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzylphosphonate as a white solid (0.12 g, 90%): mp 132 -135 °C; ^1H NMR (300 MHz, CDCl_3): δ 8.55 (s, 1 H), 7.33 (d, J = 2.7 Hz, 2 H), 7.05 (dd, J = 3.0, 9.3 Hz, 1 H), 6.97 (d, J = 9.3 Hz, 1 H), 6.83 (d, J = 3.3 Hz, 1 H), 4.09 (q, J = 6.9 Hz, 4 H), 3.07 (d, J = 21.6, 2 H), 3.02 (t, J = 6.0 Hz, 4 H), 1.67- 1.57 (m, 4 H), 1.50 - 1.42 (m, 2 H), 1.30 (t, J = 9.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.4.

Step h:


[0656] To a stirred solution of diethyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]benzylphosphonate (0.1 g, 0.18 mmol) in CH_2Cl_2 (5 mL) at 0 °C was added TMSBr (0.27 g, 0.3 mL, 1.8 mmol). The reaction mixture was stirred at 0 °C for 30 min, allowed to warm to room temperature and stirred for 16 h. The solvent was removed under reduced pressure and the residue was dissolved in CH_3OH (3 mL). The solvent was removed under reduced pressure. The residue was triturated with water (3 mL). The mixture was filtered and dried under reduced pressure to afford 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-piperidinylsulfonamido)phenoxy]-

- 317 -

benzylphosphonic acid as a white solid (0.07 g, 78%): mp 68 -72 °C; LC-MS *m/z* = 496 [C₁₈H₂₀Cl₂NO₇PS+H]⁺; Anal Calcd for (C₂₀H₁₆Cl₂FO₅P+0.5CH₂Cl₂): C, 41.28; H, 3.93; N, 2.60; S, 5.96. Found: C, 41.27; H, 3.86; N, 2.84; S, 5.84.

Example 10

Compound 10: 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-exo-2-norbornyl-sulfonamido)phenoxy]benzylphosphonic acid



Step a:

[0657] Methyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-exo-2-norbornyl-sulfonamido)phenoxy]benzoate was synthesized as a white solid (0.89 g, 55%) from methyl-3,5-dichloro-4-(4'-hydroxy)phenoxybenzoate (1.3 g, 3.1 mmol) by following the procedure described in example 9, step d: mp 142 -145 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.43 (s, 1 H), 8.05 (s, 2 H), 7.06 (dd, *J* = 3.0, 8.7 Hz, 1 H), 6.98 (d, *J* = 9.3 Hz, 1 H), 6.92 (d, *J* = 3.0 Hz, 1 H), 4.53 (d, *J* = 7.5 Hz, 1 H), 3.95 (s, 3 H), 3.12 (m, 1 H), 2.20 (bs, 1 H), 2.04 (bs, 1 H), 1.66 - 1.58 (m, 2 H), 1.46 - 1.40 (m, 2 H), 1.28 - 1.24 (m, 2 H), 1.20 - 1.16 (m, 1 H), 1.02 (dd, *J* = 1.8, 7.8 Hz, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.3.

Step b:

[0658] 3,5-Dichloro-4-[4'-hydroxy-3'-(*N*-exo-2-norbornylsulfonamido)-phenoxy]benzyl alcohol was prepared as a white solid (0.46 g, 85%) from methyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-exo-2-norbornylsulfonamido)-phenoxy]benzoate (0.5 g, 0.97 mmol) by following the procedure described in example 9, step e: mp 130 - 132 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.51

(s, 2 H), 7.03 (dd, $J = 3.3, 9.0$ Hz, 1 H), 6.89 (d, $J = 8.7$ Hz, 1 H), 6.81 (d, $J = 3.0$ Hz, 1 H), 4.51 (s, 2 H), 2.90 (dd, $J = 4.2, 8.1$ Hz, 1 H), 2.06 (bs, 1 H), 1.86 (bs, 1 H), 1.37 (dd, $J = 10.2, 24.3$ Hz, 2 H), 1.30 - 1.22 (m, 2 H), 0.98 - 0.90 (m, 2 H), 0.85 - 0.79 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); $R_f = 0.3$.

Step c:

[0659] 3,5-Dichloro-4-[4'-hydroxy-3'-(*N*-*exo*-2-norbornylsulfonamido)-phenoxy]benzyl bromide was prepared as a colorless oil (0.08 g, 75%) from 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-*exo*-2-norbornylsulfonamido)phenoxy]-benzyl alcohol (0.1 g, 0.20 mmol) by following the procedure described in example 9, step f: 1H NMR (300 MHz, CDCl₃): δ 8.33 (s, 1 H), 7.34 (s, 2 H), 7.0 (dd, $J = 3.0, 8.7$ Hz, 1 H), 6.90 (d, $J = 9.0$ Hz, 1 H), 6.85 (d, $J = 3.0$ Hz, 1 H), 4.33 (s, 2 H), 3.05 (m, 1 H), 2.14 (bs, 1 H), 1.97 (bs, 1 H), 1.59 - 1.49 (m, 2 H), 1.38 - 1.32 (m, 2 H), 1.21 - 1.16 (m, 2 H), 1.12 - 1.06 (m, 1 H), 0.95 (dd, $J = 1.8, 8.1$ Hz, 1 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); $R_f = 0.75$.

Step d:

[0660] Diethyl 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-*exo*-2-norbornylsulfonamido)phenoxy]-benzylphosphonate was prepared as a colorless oil (0.2 g, 83%) from 3,5-dichloro-4-[4'-hydroxy-3'-(*N*-*exo*-2-norbornylsulfonamido)phenoxy]benzyl bromide (0.22 g, 0.40 mmol) by following the procedure described in example 9, step g: 1H NMR (300 MHz, CDCl₃): δ 8.47 (s, 1 H), 7.33 (d, $J = 2.7$ Hz, 2 H), 7.09 (dd, $J = 2.7, 8.7$ Hz, 1 H), 6.97 (dd, $J = 2.7, 9.0$ Hz, 1 H), 6.88 (d, $J = 3.0$ Hz, 1 H), 4.75 (d, $J = 7.2$ Hz, 1 H), 4.09 (q, $J = 6.9$ Hz, 2 H), 3.49 (s, 1 H), 3.14 (d, $J = 21.6$ Hz, 2 H), 3.11 - 3.05 (m, 1 H), 2.2 (bs, 1 H), 2.05 (d, $J = 3.3$ Hz, 1 H), 1.44 - 1.22 (m, 6 H), 1.20 - 1.15 (m, 1 H), 1.14 - 1.02 (m, 1 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); $R_f = 0.3$.


Step e:

[0661] 3,5-Dichloro-4-[3'-(*N*-*exo*-2-norbornylsulfonamido)-4'-hydroxy-phenoxy]benzylphosphonic acid was prepared as a white solid (50 mg, 75%)

from diethyl 3,5-dichloro-4-[3'-(*N*-*exo*-2-norbornylsulfonamido)-4'-hydroxyphenoxy]benzylphosphonate (0.075 g, 0.40 mmol) by following the procedure described in example 9, step h: mp 210 - 212 °C; LC-MS *m/z* 522 [C₂₀H₂₂Cl₂NO₇PS]⁺; Anal Calcd for (C₂₀H₂₂Cl₂NO₇PS + 0.7 CH₂Cl₂): C, 42.78; H, 4.06; N, 2.41. Found: C, 42.77; H, 4.17; N, 2.62.

Example 11

Compound 11: 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy]-benzylphosphonic acid



Step a:

[0662] To a stirred solution of methyl 3,5-dichloro-(4'-hydroxyphenoxy)benzoate (0.5 g, 1.52 mmol) and *p*-fluorobenzoyl chloride (0.69 g, 0.45 mL 3.8 mmol) in CH₂Cl₂ (50 mL) at room temperature was added TiCl₄ (7.6 mL, 7.6 mmol, 1 M solution in CH₂Cl₂). The reaction mixture was stirred at room temperature for 8 days, quenched with saturated aqueous NH₄Cl (25 mL) and stirred for 2 h. The reaction mixture was extracted with CH₂Cl₂ (2x100 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was triturated with hexanes-ethyl ether (8:2), filtered and dried under reduced pressure to afford methyl 3,5-dichloro-4-[3'-(4-fluorobenzoyl)-4'-methoxyphenoxy]benzoate as a yellow solid. (0.39 g, 62%): mp 112 - 115 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (s, 2 H), 7.81 (dd, *J* = 5.7, 9.0 Hz, 2 H), 7.09 (t, *J* = 8.4 Hz, 2 H), 6.93 (d, *J* = 2.7 Hz, 1 H), 6.92 (s, 1 H), 6.81 (d, *J* = 3.0 Hz, 1 H), 3.94 (s, 3 H), 3.69 (s, 3 H);

TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.75.

Step b:

[0663] To a stirred solution of methyl 3,5-dichloro-4-[3'-(4-fluorobenzoyl)-4'-methoxyphenoxy]benzoate (350 mg, 0.78 mmol) and TFA (2 mL) in CH_2Cl_2 (50 mL) at room temperature was added triethylsilane (0.5 mL, 3.1 mmol). The reaction mixture was stirred at room temperature for 16 h, quenched with water (25 mL) and extracted with ether (100 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was triturated with hexanes, filtered and dried under reduced pressure to afford methyl 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]benzoate as a brown solid (0.31 g, 92%); mp 108 -110 °C; ^1H NMR (300 MHz, CDCl_3): δ 7.98 (s, 2 H), 7.06 (dd, J = 6.0, 9.0 Hz, 2 H), 6.88 (t, J = 8.7 Hz, 2 H), 6.70 (d, J = 9.0 Hz, 1 H), 6.58 (d, J = 3.0 Hz, 1 H), 6.48 (dd, J = 3.3, 9.0 Hz, 1 H), 3.89 (s, 3 H), 3.83 (s, 2 H), 3.71 (s, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:8); R_f = 0.8.

Step c:

[0664] To a stirred suspension of LiAlH_4 (0.26 g, 6.95 mmol) in THF (40 mL) at 0 °C was slowly added a solution of methyl 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]benzoate (1.2 g, 2.76 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 20 h and cooled to 0 °C. The reaction mixture was quenched with 15% aqueous NaOH (1.5 mL), diluted with H_2O (3.0 mL) and stirred for 1 h. The reaction mixture was filtered through a Celite plug and the filtrate was extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]benzyl alcohol as an oil (0.78 g, 70%); ^1H NMR (300 MHz, CDCl_3): δ 7.47 (s, 2 H), 7.16 (dd, J =

6.0, 8.7 Hz, 2 H), 7.04 (t, J = 8.7 Hz, 2 H), 6.84 (d, J = 9.0 Hz, 1 H), 6.67 (d, J = 3.0 Hz, 1 H), 6.45 (dd, J = 5.4, 9.3 Hz, 1 H), 5.45 (t, J = 5.7 Hz, 1 H), 4.48 (d, J = 5.7 Hz, 2 H), 3.82 (s, 2 H), 3.69 (s, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.45.

Step d:

[0665] To a stirred solution of 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy] benzyl alcohol (0.53 g, 1.29 mmol) in CH_2Cl_2 (20 mL) at -78 °C was added BBr_3 (0.82 g, 3.2 mmol). The reaction mixture was stirred at room temperature for 16 h, poured into ice water (100 mL) and extracted with CH_2Cl_2 (200 mL). The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluted with ethyl acetate-hexanes (1:4) to afford 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy] benzyl bromide as a colorless oil (0.4 g, 67%): ^1H NMR (300 MHz, CDCl_3): δ 7.39 (s, 2 H), 7.14 (dd, J = 5.4, 8.7 Hz, 2 H), 6.95 (t, J = 8.7 Hz, 2 H), 6.66 (d, J = 9.0 Hz, 1 H), 6.62 (d, J = 2.7 Hz, 1 H), 6.53 (dd, J = 3.0, 8.7 Hz, 1 H), 4.04 (s, 2 H), 3.90 (s, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.8.

Step e:

[0666] To a stirred solution of 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy] benzyl bromide (0.25 g, 0.55 mmol) in toluene (5 mL) at room temperature was added triethylphosphite (0.91 g, 5.5 mmol). The reaction mixture was heated at 120 °C for 8 h and cooled to room temperature. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy]benzylphosphonate as a colorless oil (0.2 g, 68%): ^1H NMR (300 MHz, CDCl_3): δ 7.29 (d, J = 2.7 Hz, 2 H), 7.15 (dd, J = 5.4, 9.0 Hz, 2 H), 6.95 (t, J = 8.7 Hz, 2 H), 6.66 (d, J = 4.8 Hz, 1 H), 6.65 (s, 1 H), 6.46 (dd, J = 3.0, 8.7 Hz, 1 H), 4.07 (q, J = 7.2 Hz,

- 322 -


4 H), 3.89 (s, 2 H), 3.04 (d, $J = 21.3$ Hz, 2 H), 1.27 (t, $J = 7.2$ Hz, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.3$.

Step f:

[0667] To a stirred solution of diethyl 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy]benzyl phosphonate (0.09 g, 0.18 mmol) in CH_2Cl_2 (5 mL) at 0 °C was added TMSBr (0.28 g, 0.3 mL). The reaction mixture was stirred at 0 °C for 30 min, allowed to warm to room temperature. The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was dissolved in CH_3OH (5 mL) and the solvent was removed under reduced pressure. The residue was triturated with water (3 mL), filtered and dried under reduced pressure to afford 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy]benzylphosphonic acid as a white solid (0.075 g, 94%); mp 207-210 °C; LC-MS $m/z = 457$ [$\text{C}_{20}\text{H}_{16}\text{Cl}_2\text{FO}_5\text{P} + \text{H}^+$][†]; Anal. Calcd for ($\text{C}_{20}\text{H}_{16}\text{Cl}_2\text{FO}_5\text{P} + 0.8 \text{ CH}_2\text{Cl}_2$): C, 47.78; H, 3.39. Found: C, 47.78; H, 3.39.

Example 12

Compound 12-1: di(pivaloyloxymethyl) [3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate




[0668] To a mixture of [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy] methylphosphonic acid (0.2 g, 0.5 mmol) and *N,N*-diisopropylethylamine (0.57 mL, 3.0 mmol) in CH_3CN (5.0 mL) at 0 °C was added pivaloyloxymethyl iodide (0.6 mL, 3.0 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The crude product was purified by column

- 323 -

chromatography on silica gel, eluting with acetone-hexanes (1:3) to afford the title compound as a white solid (0.22 g, 76%): ^1H NMR (300 MHz, CD₃OD): δ 6.79 (d, $J = 3.0$ Hz, 1 H), 6.68 (s, 2 H), 6.45-6.60 (m, 2 H), 5.75 (m, 4 H), 4.44 (d, $J = 9.9$ Hz, 2 H), 3.88 (s, 2 H), 3.20 (m, 1 H), 2.20 (s, 6 H), 1.20 (s, 18 H), 1.12 (d, $J = 7.2$ Hz, 6 H); LC-MS m/z = 593 [C₃₁H₄₅O₉P + H]⁺; Anal. Calcd for (C₃₁H₄₅O₉P+0.3H₂O): C, 62.26; H, 7.69. Found: C, 62.15; H, 7.77.


[0669] Using the appropriate starting material, compounds 12-2 and 12-9 were prepared in an analogous manner to that described for the synthesis of compound 12-1.

Compound 12-2: di(ethoxycarbonyloxymethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy] methylphosphonate:




[0670] ^1H NMR (300 MHz, DMSO-*d*₆): δ 9.01 (s, 1 H), 6.86 (s, 1 H), 6.73 (s, 2 H), 6.63-6.61 (m, 1 H), 6.47-6.45 (m, 1 H), 5.72 (s, 2 H), 5.68 (s, 2 H), 4.51-4.48 (d, $J = 7.5$ Hz, 2 H), 4.17-4.12 (m, 4 H), 3.82 (s, 2 H), 3.13 (m, 1 H), 2.18-2.16 (m, 6 H), 1.23-1.18 (m, 6 H), 1.12-1.10 (d, $J = 6.0$ Hz, 6 H); LC-MS m/z = 569 [C₂₇H₃₇O₁₁P + H]⁺; Anal. Calcd for (C₂₇H₃₇O₁₁P): C, 57.04; H, 6.56. Found: C, 56.60, H, 6.14.

Compound 12-3: di(isopropoxycarbonyloxymethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate:




[0671] ^1H NMR (300 MHz, DMSO-*d*₆): δ 8.97 (s, 1 H), 6.81 (s, 1 H), 6.69 (s, 2 H), 6.59-6.56 (m, 1 H), 6.43-6.40 (m, 1 H), 5.68 (s, 2 H), 5.63 (s, 2 H), 4.81-4.73 (m, 2 H), 4.46-4.43 (d, *J* = 7.5 Hz, 2 H), 3.78 (s, 2 H), 3.12-3.07 (m, 1 H), 2.14 (s, 6 H), 1.21-1.16 (m, 12 H), 1.08-1.06 (d, *J* = 6.0 Hz, 6 H); LC-MS *m/z* = 597 [C₂₉H₄₁O₁₁P + H]⁺; Anal. Calcd for (C₂₉H₄₁O₁₁P): C, 58.38; H, 6.93. Found: C, 58.10, H, 7.54.

Compound 12-4: Di-(pivaloyloxymethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-sec-butylbenzyl)phenoxy]methylphosphonate:



[0672] ^1H NMR (300 MHz, DMSO-*d*₆): δ 8.95 (s, 1 H), 6.76 (s, 1 H), 6.72 (s, 2 H), 6.64-6.61 (d, 1 H), 6.65-6.47 (d, 1 H), 5.73 (s, 2 H), 5.68 (s, 2 H), 4.48-4.45 (d, 2 H), 3.81 (s, 2 H), 2.93-2.90 (q, 1 H), 2.17 (s, 6 H), 1.52-1.44 (m, 2 H), 1.17-1.11 (m, 18 H), 1.08-1.06 (d, 3 H), 0.78-0.73 (t, 3 H); LC-MS *m/z* = 607.2 [C₃₂H₄₇O₉P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.56; Anal. Calcd for (C₃₂H₄₇O₉P + 0.25 C₃H₆O): C, 63.32; H, 7.87. Found: C, 63.72; H, 8.19.


Compound 12-5: Di-(pivaloyloxymethyl)[3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl] phosphonate:



- 325 -


[0673] mp: 90-91 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 9.07 (s, 1H), 7.66 (s, 1H), 6.68-6.66 (m, 2H), 6.26-6.22 (d, 1H), 5.67-5.58 (q, 4H), 3.56-3.48 (d, 2H), 3.19-3.14 (m, 1H), 1.19-1.11 (m, 24H); LC-MS m/z = 709.4 [$\text{C}_{28}\text{H}_{37}\text{Br}_2\text{O}_9\text{P} + \text{H}^+$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.50; Anal. Calcd for ($\text{C}_{28}\text{H}_{37}\text{Br}_2\text{O}_9\text{P}$): C, 47.48; H, 5.26. Found: C, 47.09; H, 4.87.

Compound 12-6: Di-(pivaloyloxymethyl)[3,5-dimethyl-4-(4-fluorobenzyl)-4'-hydroxy-benzyl]phenoxy]methylphosphonate



[0674] ^1H NMR (300 MHz, DMSO- d_6): δ 9.17(1H, s), 7.18-7.02(m, 3H), 6.71-6.64 (m, 4H), 6.54 (m, 1H), 4.45 (d, 2H, J = 10Hz), 3.76 (s, 4H), 2.12 (s, 6H), 1.13 (s, 18H); LC-MS m/z = 633 [$\text{C}_{33}\text{H}_{44}\text{O}_9\text{P} + \text{H}^+$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate 50% in hexane; R_f = 0.48; Anal. Calcd for ($\text{C}_{33}\text{H}_{44}\text{FO}_9\text{P} + 0.5 \text{ H}_2\text{O}$): C, 62.99; H, 6.90. Found: C, 62.99; H, 6.90.


Compound 12-7: Di(pivaloyloxymethyl)[3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonate



- 326 -

[0675] mp: 144-147 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 8.99 (s, 1 H), 7.59 (s, 2 H), 6.68 (m, 1 H), 6.56 (m, 1 H), 6.25 (m, 1 H), 5.73 (d, J = 12.0 Hz, 2 H), 4.64 (d, J = 10.5 Hz, 2 H), 3.16 (m, 1 H), 1.17 (m, 18 H), 1.12 (d, J = 6.0 Hz, 6 H); LC-MS m/z = 819 [C₂₈H₃₇O₁₀I₂P + H]⁺; HPLC conditions: Column = Agilent Zorbax SB-Aq RP-18 filter, 150×3.0; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄). Flow rate = 1.0 mL/min; UV@ 255 nm. Retention time in minutes. (rt = 14.66/25.00, 93% purity); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.39.


Compound 12-8: Di(pivaloyloxymethyl)[3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate



[0676] ^1H NMR (200 MHz, DMSO- d_6): δ 9.09 (s, 1 H), 7.21 (s, 2 H), 6.94 (s, 1 H), 6.64 (s, 2 H), 5.72 (d, J = 21.0 Hz, 2 H), 4.64 (d, J = 15 Hz, 2 H), 4.00 (s, 2 H), 3.15 (m, 1 H), 1.25 (m, 18 H), 1.11 (d, J = 4.5 Hz, 6 H); LC-MS m/z = 633 [C₂₉H₃₉O₉Cl₂P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:2); R_f = 0.62. Anal. Calcd for (C₂₉H₃₉O₉Cl₂P + 0.3 H₂O + 0.2 CH₃CO₂CH₂CH₃): C, 54.49; H, 6.32. Found: C, 54.52, H, 6.33.

Compound 12-9: Di(pivaloyloxymethyl)[4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-ylamino]methylphosphonate


- 327 -



[0677] The title compound was prepared according to the procedure described for the synthesis of example 12 using [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-ylamino]methylphosphonic (US 6747048 B2):

[0678] ^1H NMR (200 MHz, DMSO-*d*₆): δ 9.20 (s, 1 H), 7.54 (t, *J* = 6.0 Hz, 1 H), 6.80 (d, *J* = 3.4 Hz, 1 H), 6.68 (d, *J* = 8.8 Hz, 1 H), 6.44 (dd, *J* = 3.4, 8.8 Hz, 1 H), 5.62 (d, *J* = 12.4 Hz, 4 H), 3.97 (m, 2 H), 3.22 (m, 1 H), 1.07 – 1.17 (m, 24 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:2); *R*_f = 0.51; LC-MS *m/z* = 654 [C₂₇H₃₆Cl₂FN₂O₉P + H]⁺; Anal Calcd for (C₂₇H₃₆Cl₂FN₂O₉P + 0.2Et₂OAc): C, 49.76; H, 5.65; N, 4.17. Found: C, 50.02; H, 6.02; N, 4.07.


Compound 12-10: Isopropoxycarbonyloxymethyl [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]methylphosphonite



[0679] mp: 58–61 °C; ^1H NMR (200 MHz, DMSO-*d*₆): δ 9.05 (s, 1H), 7.65 (d, *J* = 2.4 Hz, 2H), 6.67 (m, 2H), 6.23 (dd, *J* = 2.8, 10.2 Hz, 1H), 5.56 (d, *J* = 11.0 Hz, 2H), 4.80 (m, 1H), 3.36 (d, *J* = 10.2 Hz, 3H), 3.14 (m, 1H), 1.48 (d, *J* = 10.2 Hz, 3H), 1.25 (d, *J* = 6.8 Hz, 6H), 1.11 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 595 [C₂₂H₂₇Br₂O₇P + H]⁺; Anal. Calcd for (C₂₂H₂₇Br₂O₇P): C, 44.47; H, 4.58. Found: C, 44.19; H, 4.80.


Compound 12-11: 2-[3,5-dimethyl-4-(4'-fluorobenzyl)-4'-hydroxybenzyl]phenyl]ethylphosphonic acid isopropoxycarbonyloxymethyl ester methyl ester

- 328 -




[0680] ^1H NMR (300 MHz, DMSO- d_6): δ 9.17 (s, 1H), 6.88 – 7.22 (m, 4H), 6.88 (s, 2H), 6.71 (d, J = 2.1 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 6.55 (dd, J = 2.1, 8.1 Hz, 1H), 5.55 (d, J = 12.9 Hz, 2H), 4.83 (m, 1H), 3.79 (s, 2H), 3.76 (s, 2H), 3.63 (d, J = 11.1 Hz, 3H), 2.65 (m, 2H), 2.12 (s, 6H), 2.05 (m, 2H), 1.22 (m, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (9:1); R_f = 0.42; LC-MS m/z = 559 [C₃₀H₃₆FO₇P + H]⁺; Anal Calcd for (C₃₀H₃₆FO₇P): C, 64.51; H, 6.50. Found: C, 64.54; H, 6.26.

Compound 12-12: Pivaloxymethyl methyl 3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzylphosphonate




[0681] ^1H NMR (300 MHz, CD₃OD): δ 7.03 (d, J = 2.1 Hz, 2H), 6.83 (d, J = 2.1 Hz, 1H), 6.54 (m, 2H), 5.96 (m, 2H), 3.96 (s, 2H), 3.74 (d, J = 10.8 Hz, 3H), 3.25 (d, J = 21.0 Hz, 2H), 3.21 (m, 1H), 2.25 (s, 6H), 1.25 (s, 9H), 1.13 (d, J = 7.0 Hz, 6H); LC-MS m/z = 477 [C₂₆H₃₇O₆P + H]⁺.

Compound 12-13: Pivaloyloxymethyl [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonate



[0682] ^1H NMR (300 MHz, DMSO- d_6): δ 9.04 (s, 1H), 7.50 (s, 2H), 6.66 (m, 2H), 6.30 (m, 1H), 5.69 (d, J = 13.5 Hz, 2H), 4.51 (d, J = 7.5 Hz, 3H), 3.17 (m, 1H), 1.68 (d, J = 15.0 Hz, 3H); 1.14 (m, 15H); LC-MS m/z = 608 [C₂₃H₂₉Br₂O₇P + H]⁺.

Example 12-16: 1-(Pivaloyloxyethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)benzyl]methylphosphinate



Step a:

[0683] To a mixture of acetaldehyde (0.84 mL, 16.6 mmol) in zinc chloride (62 mg, 0.45 mmol) was added dropwise 2,2-dimethyl-propionaldehyde (2.05 mL, 16.6 mmol). The mixture was then heated to 50 °C for 16 h. The blackish material was filtered through a plug of silica gel with dichloromethane to afford 2,2-dimethyl-propionic acid 1-chloro-ethyl ester as an oil (2.4 g, 88%) after the removal of dichloromethane under reduced pressure: ^1H NMR (300 MHz, CDCl₃): δ 6.64-6.59 (m, 1H), 1.82 (d, J = 6.7 Hz, 3H), 1.36 (s, 9H).

Step b:


[0684] To a mixture of 2,2-dimethyl-propionic acid 1-chloro-ethyl ester (2.4 g, 14.6 mmol) in acetonitrile (10 mL) was added sodium iodide (4.4 g, 30.0 mmol). The mixture was stirred in the absence of light for 16 h. The volatiles were removed under reduced pressure, taken up in hexanes (25 mL) and filtered through a plug of silica gel to afford 2,2-dimethyl-propionic acid 1-

iodo-ethyl ester as oil (1g g, 27 %) after the removal of hexanes under reduced pressure: ^1H NMR (300 MHz, CDCl_3): δ 6.92-6.85 (m, 1H), 2.21 (d, 3H), 1.36 (s, 9H).

Step c:

[0685] The title compound was prepared from 3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)methylphosphinic acid (example 72) according to the procedure described for the synthesis of Example 12, compound 12-1. ^1H NMR (300 MHz, CDCl_3): δ 7.30-6.94 (m, 3H), 6.64-6.60 (m, 1H), 6.53-6.50 (m, 1H), 3.95 (s, 2H), 3.39 -3.08 (m, 3H), 2.21 (s, 6H), 1.64-1.20 (m, 21H), 1.13 (t, 6H); LC-MS $m/z = 475.6$ [$\text{C}_{27}\text{H}_{39}\text{O}_5\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{27}\text{H}_{39}\text{O}_5\text{P} + 0.4 \text{ H}_2\text{O}$): C, 68.33; H, 8.28. Found: C, 68.09; H, 8.29.

Example 12-16: Cis and Trans R-2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane



[0686] The title compounds were prepared from *R*-1-(3-chlorophenyl)-1,3-propanediol and [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]-methylphosphonic acid (compound 7) according to the procedure described in example 13-1.

Example 12-16-*cis*:


MP 72-75 °C; ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 9.00 (s, 1H), 7.51 (m, 1H), 7.38-7.36 (m, 3H), 6.86 (d, $J = 2.0$ Hz, 1H), 6.77 (s, 2H), 6.68 (d, $J = 8.0$ Hz, 1H), 6.43 (m, 1H), 5.76-5.71 (m, 1H), 4.61-4.36 (m, 4H), 3.83 (s, 2H), 3.15-3.05 (m, 1H), 2.24-2.17 (m, 2H), 2.14 (s, 6H), 1.12 (d, $J = 6.9$ Hz, 6H); LC-MS $m/z = 515$ [$\text{C}_{28}\text{H}_{32}\text{ClO}_5\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{28}\text{H}_{32}\text{ClO}_5\text{P} + 0.2 \text{ H}_2\text{O} + 0.2 \text{ CH}_3\text{COCH}_3$): C, 64.79; H, 6.39; Cl, 6.69. Found: C, 64.86; H, 6.48;

Cl, 6.70; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 4:1 ethyl acetate-hexanes; R_f = 0.19.

Example 12-16-trans:

MP 81-83 °C; ^1H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 7.50 (m, 1H), 7.49-7.43 (m, 3H), 6.87 (d, *J* = 2.0 Hz, 1H), 6.84 (s, 2H), 6.63 (d, *J* = 11.0 Hz, 1H), 6.47 (m, 1H), 5.82 (m, 1H), 4.80 (m, 1H), 4.65 (d, *J* = 16.0 Hz, 2H), 3.83 (s, 2H), 3.14 (m, 1H), 2.24-2.17 (m, 8H), 1.13 (d, *J* = 6.9 Hz, 6H); LC-MS *m/z* = 515 [C₂₈H₃₂ClO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂ClO₅P + 0.2 H₂O + 0.2 CH₃COCH₃): C, 64.79; H, 6.39; Cl, 6.69. Found: C, 65.02; H, 6.46; Cl, 6.54; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 4:1 ethyl acetate-hexanes; R_f = 0.44.

Example 12-19: Isopropyl oxy carbonyl oxymethyl[3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]phenoxyl methyl phosphonate monomethyl ester



[0687] The title compound was prepared from [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]phenoxyl methyl phosphonate monomethyl ester (compound 69-6) according to the procedures described for the synthesis of compound 12-3. ^1H NMR (300 MHz, DMSO-*d*₆): δ 9.04 (s, 1H), 7.50 (s, 2H), 6.66 (m, 2H), 6.28 (m, 1H), 5.69 (d, *J* = 12.0 Hz, 2H), 4.84 (m, 1H), 4.66 (d, *J* = 15.0 Hz, 2H), 3.80 (d, *J* = 20.0 Hz, 3H), 3.17 (m, 1H), 1.24 (m, 7H), 1.14 (m, 7H); LC-MS *m/z* = 627 [C₂₂H₂₇Br₂O₉P + H]⁺; Anal. Calcd for (C₂₂H₂₇Br₂O₉P + 0.3 CH₃COCH₃): C, 42.73; H, 4.51. Found: C, 43.09; H, 4.18; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.64.


Example 13

Cis and *Trans* (*S*)-2-[*(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)-phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane*

[0688] To a mixture of [4-(4'-hydroxy-3'-iso-propylbenzyl)-3,5-dimethyl-phenoxy] methylphosphonic acid (0.2 g, 0.55 mmol), 1-(3-chlorophenyl)-1,3-propane diol (0.31 g, 1.6 mmol) and pyridine (1 mL) in DMF (5 mL) at room temperature was added 1,3-dicyclohexylcarbodiimide (0.34 g, 1.6 mmol). The reaction mixture was heated at 70 °C for 4 h, cooled to room temperature and filtered through a Celite plug. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with 4% methanol in CH₂Cl₂ to afford *Cis* (0.06 g, 15%) and *Trans* (*S*)-2-[3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl) phenoxy]methyl-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphonane (0.05 g, 12%) as white solids.

Compound 13-1-*cis*:

[0689] mp 77-82 °C; LC-MS *m/z* = 516 [C₂₈H₃₂ClO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂ClO₅P+0.2 H₂O): C, 64.85; H, 6.30. Found: C, 64.93; H, 6.65. M.P.: 77-82.0 °C.




[0690] Alternative improved method for the preparation of compound:
Compound 13-1-*cis*: *Cis* (*S*)-2-[*(3,5-Dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(3-Chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane:*

[0691] A solution of *cis* (*S*)-2-[*(4-(4'-acetoxy-3'-iso-propylbenzyl)-3,5-dimethylphenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane (compound 59-cis, 2.5 g, 4.49 mmol) and 4.0 M HCl in*

dioxane (2.5 mL, 10.0 mmol) in methanol (25 mL) was stirred at 20 °C for 3.5 hrs. The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-dichloromethane (1:4) to afford *cis* (*S*)-2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4-(3-Chlorophenyl)-2-oxo-2*h*⁵-[1,3,2]-dioxaphosphinane (1.9g, 83%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.97 (s, 1H), 7.47 (m, 1H), 7.38-7.31 (m, 3H), 6.82 (d, *J* = 2.1 Hz, 1H), 6.73 (s, 2H), 6.59 (d, *J* = 8.1 Hz, 1H), 6.43 (dd, *J* = 8.1 and 2.0 Hz, 1H), 5.76-5.71 (m, 1H), 4.61-4.36 (m, 4H), 3.78 (s, 2H), 3.15-3.05 (m, 1H), 2.24-2.17 (m, 2H), 2.14 (s, 6H), 1.07 (d, *J* = 6.9 Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane-acetone (9:1); R_f = 0.28; Anal Calcd for (C₂₈H₃₂ClO₅P + 0.2 H₂O): C, 64.85; H, 6.30. Found: C, 64.64; H, 6.36. Water by KF titration = 0.66%.

Compound 13-1-*trans*:

[0692] mp 88-93 °C; LC-MS *m/z* = 516 [C₂₈H₃₂ClO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂ClO₅P+0.2 H₂O): C, 64.85; H, 6.30. Found: C, 64.93; H, 6.65. M.P.: 88-93.0 °C.




[0693] Using the appropriate starting material, compounds 13-2 to 13-14 were prepared in an analogous manner to that described for the synthesis of compound 13-1.

[0694] *Cis* and *Trans* 2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4-(3-bromophenyl)-2-oxo-2*h*⁵-[1,3,2]-dioxaphosphonane:

- 334 -


Compound 13-2-cis:

[0695] mp 70-75 °C; LC-MS m/z = 559,561 [C₂₈H₃₂BrO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂BrO₅P): C, 60.12; H, 5.77. Found: C, 60.03, H, 5.76; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 3:2 hexanes-acetone; rf = 0.31.



Compound 13-2-trans:

[0696] mp 80-85 °C; LC-MS m/z = 559,561 [C₂₈H₃₂BrO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂BrO₅P): C, 60.12; H, 5.77. Found: C, 59.76, H, 5.72; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 3:2 hexanes-acetone; rf = 0.49.




[0697] *Cis* and *Trans* 2-[{(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(3-fluorophenyl)-2-oxo-2 λ⁵-[1,3,2]-dioxaphosphonane:

Compound 13-3-cis:


[0698] mp 75-80 °C; LC-MS m/z = 499 [C₂₈H₃₂FO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₂FO₅P + 0.2 EtOAc): C, 67.02; H, 6.56. Found: C, 67.01, H, 6.58; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 3:2 acetone-hexanes; rf = 0.19.

- 335 -



Compound 13-3-trans:


[0699] mp 80-85 °C; LC-MS m/z = 499 [$C_{28}H_{32}FO_5P + H$]⁺; Anal. Calcd for ($C_{28}H_{32}FO_5P + 0.2$ EtOAc): C, 67.02; H, 6.56. Found: C, 66.93, H, 6.61; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 3:2 acetone-hexanes; R_f = 0.52.



[0700] *Cis* and *Trans* 2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)-methyl]-4-(pyrid-3-yl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane:

Compound 13-4-trans:


[0701] mp 75-78 °C; LC-MS m/z = 482 [$C_{27}H_{32}NO_5P + H$]⁺; Anal. Calcd for $C_{27}H_{32}NO_5P$: C, 67.35; H, 6.70; N, 2.91. Found: C, 67.17; H, 6.89; N, 2.62; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = CH_2Cl_2 -MeOH (2%); R_f = 0.3.



- 336 -

Compound 13-4-cis:


[0702] (108 mg, 50%): mp 75-78 °C; LC-MS $m/z = 482$ [C₂₇H₃₂NO₅P+H]⁺; Anal Calcd for C₂₇H₃₂NO₅P: C, 67.35; H, 6.70, N, 2.91. Found: C, 67.78; H, 6.76; N, 2.63; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = CH₂Cl₂-MeOH (2%); R_f = 0.27.



[0703] *Cis* and *Trans* 2-[{3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4-(pyrid-4-yl)-2-oxo-2*N*-[1,3,2]-dioxaphosphonane:

Compound 13-5-trans:


[0704] (52%), mp 75-77 °C; LC-MS $m/z = 482$ [C₂₇H₃₂NO₅P+H]⁺; Anal Calcd for (C₂₇H₃₂NO₅P+0.4 H₂O): C, 66.35; H, 6.76; N, 2.87. Found: C, 66.08; H, 6.55; N, 2.74; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = CH₂Cl₂-MeOH (2%); R_f = 0.3.



Compound 13-5-cis:

[0705] (20%), mp 75-77 °C; LC-MS $m/z = 482$ [C₂₇H₃₂NO₅P+H]⁺; Anal Calcd: (MF:C₂₇H₃₂NO₅P) Calcd: C:67.35, H:6.70, N:2.91; Found: C: 67.02, H:6.78, N:2.81; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = CH₂Cl₂-MeOH (2%); R_f = 0.25.


- 337 -



[0706] *Cis* and *Trans* 2-[{(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(4-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphonane:


Compound 13-6-trans:

[0707] mp 77-80 °C; LC-MS *m/z* = 515 [C₂₈H₃₂ClO₅P]⁺; Anal Calcd: (MF:C₂₈H₃₂ClO₅P+0.1 H₂O+0.4 EtOAc) Calcd: C:64.34, H:6.48; Found: C: 64.56, H:6.91; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate/hexanes (3:2); R_f = 0.6.



Compound 13-6-cis:

[0708] yellow solid, mp 77-80 °C; LC-MS *m/z* = 515 [C₂₈H₃₂ClO₅P+H]⁺; Anal Calcd: (MF:C₂₈H₃₂ClO₅P+0.1 H₂O+0.1 CH₂Cl₂) Calcd: C:64.65, H:6.25; Found: C:64.61, H:6.66; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate/hexanes (3:2); R_f = 0.5.




- 338 -

[0709] *Cis* and *Trans* 2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4-(3,5-dichlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane:


Compound 13-7-*trans*:

[0710] mp 79-81 °C; LC-MS *m/z* = 549 [C₂₇H₃₂Cl₂O₅P+H]⁺; Anal Calcd for (C₂₈H₃₁Cl₂O₅P+0.35 H₂O): C, 60.45; H, 5.74; Cl, 12.87. Found: C, 60.15; H, 5.67, Cl, 11.97; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate/hexanes (3:2); R_f = 0.6.




Compound 13-7-*cis*:

[0711] (50%) mp 79 - 81 °C; LC-MS *m/z* = 549 [C₂₈H₃₁Cl₂O₅P]⁺; Anal Calcd for (C₂₈H₃₁Cl₂O₅P+0.1 H₂O): C, 60.94; H, 5.70; Cl, 12.97. Found: C, 60.77; H, 6.18; Cl, 11.56; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (3:2); R_f = 0.5.




Compound 13-8: *Cis*-(S)-2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*sec*-butylbenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane




[0712] mp: 66-70 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 8.91 (s, 1 H), 7.39-7.36 (m, 3H), 6.76 (s, 1H), 6.75 (s, 2H), 6.60-5.57 (d, 1H), 6.47-6.44 (d, 1H), 5.75-5.71 (m, 1H), 4.61-4.53 (m, 2H), 4.47-4.36 (m, 2H), 3.78 (s, 2H), 2.92-2.85 (q, 1H), 2.25-2.20 (m, 2H), 2.14 (s, 6H), 1.51-1.36 (m, 2H), 1.05-1.03 (d, 3H), 0.74-0.70 (t, 3H); LC-MS m/z = 529.0 [$\text{C}_{29}\text{H}_{34}\text{ClO}_5\text{P} + \text{H}^+$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.17; Anal. Calcd for ($\text{C}_{29}\text{H}_{34}\text{ClO}_5\text{P} + 0.3 \text{CH}_3\text{CO}_2\text{CH}_2\text{CH}_3 + 0.4 \text{H}_2\text{O}$): C, 64.47; H, 6.66. Found: C, 64.64; H, 6.82.

Compound 13-9: *Cis-(S)-2-[3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane*




[0713] mp: 83-85 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 9.06 (s, 1H), 7.75 (s, 2H), 7.44-7.42 (m, 3H), 7.32-7.28 (m, 1H), 6.68-6.65 (d, 1H), 6.58 (s, 1H), 6.31-6.27 (d, 1H), 5.69-5.65 (d, 1H), 4.59-4.51 (t, 1H), 4.37-4.28 (t, 1H), 3.61-3.53 (d, 2H), 3.18-3.07 (m, 1H), 2.29-2.17 (m, 1H), 1.84-1.77 (m, 1H), 1.07-1.03 (d, 6H); LC-MS m/z = 630.8 [$\text{C}_{25}\text{H}_{24}\text{Br}_2\text{ClO}_5\text{P} + \text{H}^+$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.56; Anal. Calcd for ($\text{C}_{25}\text{H}_{24}\text{Br}_2\text{ClO}_5\text{P}$): C, 47.61; H, 3.84. Found: C, 47.88; H, 4.23.

Compound 13-10: *Cis* (*S*)-2-[*(3,5-diido-4-(4'-hydroxy-3'-iso-propylphenoxy)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane*



[0714] mp: 82-86 °C; ¹H NMR (300 MHz, DMSO-*d*₆): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (s, 1 H), 7.62 (s, 1 H), 7.51 (m, 1 H), 7.44 (s, 2 H), 7.38 (m, 3 H), 6.68 (m, 1 H), 6.60 (s, 1 H), 6.25 (m, 1 H), 5.80 (m, 1 H), 4.65 (m, 3 H), 4.45 (m, 1 H), 3.16 (m, 1 H), 2.26 (m, 1 H), 1.13 (d, *J* = 6.0 Hz, 6 H); LC-MS *m/z* = 741 [C₂₅H₂₄ClI₂O₆P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.17. Anal. Calcd for (C₂₅H₂₄ClI₂O₆P + 0.2 CH₃CO₂CH₂CH₃): C, 40.86; H, 3.40. Found: C, 41.02, H, 3.49.

Compound 13-11: *Cis* (*S*)-2-[*(3,5-dichloro-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane*



[0715] ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.10 (s, 1 H), 7.43 (s, 1 H), 7.38-7.31 (m, 4 H), 7.24 (m, 1 H), 6.97 (s, 1 H), 6.64 (s, 2 H), 5.75 (m, 1 H), 4.69-4.61 (m, 2 H), 4.50-4.41 (m, 2 H), 4.05 (s, 2 H), 3.12 (m, 1 H), 2.21 (s, 2 H), 1.11 (d, *J* = 9.0 Hz, 6 H); LC-MS *m/z* = 554 [C₂₆H₂₆Cl₃O₃P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl


- 341 -

acetate-hexanes (4:1); $R_f = 0.24$. Anal. Calcd for $(C_{26}H_{26}Cl_3O_5P + 0.5 H_2O + 0.2 CH_3CO_2CH_2CH_3)$: C, 55.27; H, 4.95. Found: C, 55.21, H, 4.96.


Cis and *Trans* 2-[4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-ylaminomethyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane

[0716] To a stirring solution of [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-ylamino]methylphosphonic (0.2 g, 0.47 mmol, US 6747048 B2) and (S)-1-(3-chlorophenyl)-1,3-propanediol (0.18 g, 0.94 mmol) in DMF (6 mL) at room temperature was add pyridine (0.46 mL, 5.64 mmol) and EDCl (0.27 g, 1.41 mmol). The reaction mixture was stirred at 68 °C for 16 hrs. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford:

Compound 13-12-*trans*:



[0717] (60 mg, 22%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1 H), 7.67 (t, *J* = 6.0 Hz, 1 H), 7.36-7.48 (m, 4 H), 6.81 (d, *J* = 3.0 Hz, 1 H), 6.69 (d, *J* = 9.0 Hz, 1 H), 6.44 (dd, *J* = 3.0, 9.0 Hz, 1 H), 5.78 (t, *J* = 7.5 Hz, 1 H), 4.71 (m, 1 H), 4.45 (m, 1 H), 4.11 (m, 2 H), 3.17 (m, 1 H), 2.19 (s, 1 H), 1.14 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:1); $R_f = 0.44$; LC-MS *m/z* = 576 [$C_{24}H_{23}Cl_3FN_2O_5P + H^+$]; Anal. Calcd for $(C_{24}H_{23}Cl_3FN_2O_5P + 0.2CH_2Cl_2 + 0.3H_2O)$: C, 48.58; H, 4.04; N, 4.68. Found: C, 48.64; H, 3.66; N, 4.83.

Compound 13-12-*cis*:

[0718] (90 mg, 33%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.20 (s, 1 H), 7.67 (t, J = 6.0 Hz, 1 H), 7.21-7.37 (m, 4 H), 6.71 (d, J = 3.0 Hz, 1 H), 6.63 (d, J = 9.0 Hz, 1 H), 6.34 (dd, J = 3.0, 9.0 Hz, 1 H), 5.65 (d, J = 10.4 Hz, 1 H), 4.21 – 4.61 (m, 2 H), 4.11 (m, 1 H), 3.80 (m, 1 H), 3.07 (m, 1 H), 2.11 (m, 1 H), 1.88 (m, 1 H), 1.04 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.53; LC-MS m/z = 576 [$\text{C}_{24}\text{H}_{23}\text{Cl}_3\text{FN}_2\text{O}_5\text{P} + \text{H}]^+$; Anal Calcd for ($\text{C}_{24}\text{H}_{23}\text{Cl}_3\text{FN}_2\text{O}_5\text{P} + 0.1\text{CH}_2\text{Cl}_2 + 0.4\text{H}_2\text{O}$): C, 48.94; H, 4.09; N, 4.74. Found: C, 48.57; H, 3.69; N, 4.92.


Step a:

[0719] To a solution of diisopropyl amine (12.4 mL, 88.2 mmol) in THF (50 mL) at -78°C was added n-butyllithium (35.3 mL, 88.2 mmol). The reaction mixture was stirred at -78°C for 30 min, at which time ethyl acetate was added (16.1 mL, 163.2 mmol). After 1 h, 3-chlorobenzaldehyde was added and the reaction mixture was allowed to warm to room temperature over 2h. The reaction mixture was quenched with aqueous saturated NH_4Cl (20 mL) and extracted with ethyl acetate (2 x 20mL). The organic layer was rinsed with water (20 mL) and brine (20 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford yellow oil. The crude product was purified by column chromatography on silica gel, eluted with ethyl acetate-hexanes (1:4) to afford ethyl 3-(3-chloro-phenyl)-3-hydroxy-propionate as a yellow oil (10.0 g, 99.0 %). ^1H NMR (400 MHz, d-DMSO): δ 7.43-7.30 (m, 4H), 5.66 (d, 1H), 5.01-4.95 (q, 1H), 4.14-4.04 (m, 2H), 2.71-2.58 (m, 2H), 1.24-1.17 (t, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:3); R_f = 0.50.

Step b:

[0720] To a solution of ethyl 3-(3-chloro-phenyl)-3-hydroxy-propionate (10.0g, 44.1 mmol) in THF (100 mL) and diethyl ether (100 mL) at -78°C was added methyl magnesium bromide (61.7 mL of a 3.0M solution in diethyl ether, 185.1 mmol). The reaction mixture was allowed to warm to room temperature and stir for 16 h. The reaction mixture was cooled to -50°C and quenched with aqueous saturated NH₄Cl (20mL), and extracted with diethyl ether (2 x 20 mL). The organic layer was rinsed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluted with ethyl acetate-hexanes (1:3) to afford 1-(3-Chloro-phenyl)-3-methyl-butane-1,3-diol as a yellow oil (5.65 g, 59.7 %). ¹H NMR (400 MHz, d-DMSO): δ 7.40-7.26 (m, 4H), 5.46 (d, 1H), 4.90-4.85 (q, 1H), 4.70 (s, 1H), 1.75-1.62 (m, 2H), 1.23-1.22 (d, 3H), 1.19-1.18 (d, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:3); R_f = 0.32.

Compound 13-13-cis: *Cis* 2-[(3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy)methyl]-4,4-dimethyl-6-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane




[0721] ¹H NMR (400 MHz, d-DMSO): δ 9.05 (s, 1 H), 7.59 (s, 1H), 7.47-7.43 (m, 3H), 6.91 (s, 1H), 6.81 (s, 2H), 6.68-6.65 (d, 1H), 6.53-6.50 (d, 1H), 5.92-5.87 (t, 1H), 4.54-4.40 (m, 2H), 3.87 (s, 2H), 3.23-3.14 (q, 1H), 2.55-2.23 (m, 8H), 1.69 (s, 3H), 1.44 (s, 3H), 1.17-1.14 (d, 6H); LC-MS m/z = 544.8 [C₃₀H₃₆ClO₅P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.16; Anal. Calcd for

- 344 -


(C₃₀H₃₆ClO₅P + 1.0 CH₃CO₂CH₂CH₃): C, 64.70; H, 7.03; Found: C, 64.50; H, 7.32.

Compound 13-13-trans: *Trans* 2-[{(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4,4-dimethyl-6-(3-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphonane



[0722] LC-MS *m/z* = 544.8 [C₃₀H₃₆ClO₅P + H]⁺; ¹H NMR (400 MHz, d-DMSO): δ 9.00 (s, 1H), 7.54 (s, 1H), 7.49-7.44 (m, 3H), 6.86 (s, 1H), 6.79 (s, 2H), 6.63-6.60 (d, 1H), 6.46-6.43 (d, 1H), 5.85-5.82 (t, 1H), 4.46-4.43 (d, 2H), 3.82 (s, 2H), 3.16-3.11 (q, 1H), 2.28-2.25 (d, 2H), 2.18 (s, 6H), 1.62 (s, 3H), 1.47 (s, 3H), 1.12-1.10 (d, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.27; Anal. Calcd for (C₃₀H₃₆ClO₅P + 1.4 CH₃CO₂CH₂CH₃): C, 64.17; H, 7.14; Found: C, 64.06; H, 6.98.


Compound 13-14-cis: *Cis* (S) 2-[{(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphonane



[0723] (0.041 g, 14%); ¹H NMR (300 MHz, CD₃OD): δ 7.46(s, 1H), 7.28(m, 3H), 7.11-6.91(m, 4H), 6.63(m, 5H), 5.72(d, 1H, *J* = 11.4 Hz), 4.71(m, 1H), 4.51(m, 3H), 3.84(m, 4H), 2.44(m, 1H), 2.22(m, 1H), 2.15(s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexane 25% in


ethyl acetate; R_f = 0.21; LC-MS m/z = 582 [C₃₂H₄₁ClFO₅P + H]⁺; Anal Calcd for (C₃₂H₄₁ClFO₅P + 0.5 H₂O): C, 65.14; H, 5.47. Found: C, 65.31; H, 5.67.

Compound 13-14-trans: *Trans* (S) 2-[(3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphonane



[0724] (0.030 g, 10%); ¹H NMR (300 MHz, CD₃OD): δ 7.46(s, 1H), 7.28(m, 3H), 7.11-6.91(m, 4H), 6.63(m, 5H), 5.86(d, 1H, J = 11.4 Hz), 4.57(m, 4H), 3.84(m, 4H), 2.34(m, 1H), 2.25(m, 1H), 2.15(s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexane 25% in ethyl acetate; R_f = 0.41; LC-MS m/z = 582 [C₃₂H₄₁ClFO₅P + H]⁺; Anal Calcd for (C₃₂H₄₁ClFO₅P + 0.5 H₂O): C, 65.14; H, 5.47. Found: C, 65.24; H, 5.77.

Compound 13-15-cis: *Cis* (S)-2-[(3,5-Dimethyl-4-(5'-iodo-4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphinane




[0725] To a solution of *cis* (S)-2-[(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2λ⁵-[1,3,2]-dioxaphosphinane (compound 13-1-cis, 0.20 g, 0.39 mmol) in CH₂Cl₂ (3.0 mL) at 0 °C was added bis(pyridine)iodonium tetrafluoroborate (0.16 g, 0.43 mmol). The reaction mixture was stirred at 0 °C for 1 h and the solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford

the title compound (0.20 g, 80%) as a yellow solid: mp: 73-76 °C; ¹H NMR (300 MHz, CD₃OD): δ 7.50 (s, 1H), 7.35 (m, 3H), 7.08 (d, *J* = 2.4 Hz, 1H), 6.90 (d, *J* = 2.4 Hz, 1H), 6.79 (s, 2H), 5.78 (m, 1H), 4.53-4.80 (m, 2H), 4.54 (d, *J* = 11.2 Hz, 1H), 3.94 (s, 2H), 3.28 2.45 (m, 2H), 2.24 (s, 6H), 1.17 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 641 [C₂₈H₃₁ClO₅P + H]⁺; Anal. Calcd for (C₂₈H₃₁ClO₅P): C, 52.48; H, 4.88. Found: C, 52.13; H, 4.52.

Example 14


Compound 14: di(*S*-acetyl-2-thioethyl) [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy]methylphosphonate



[0726] A mixture of *S*-acetyl-2-thioethanol (0.12 g, 0.96 mmol), [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonic acid (0.10 g, 0.25 mmol), pyridine (1.0 mL) and dicyclohexylcarbodiimide (0.14 g, 0.69 mmol) in DMF (2.5 mL) was heated at 70 °C for 16h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford di(*S*-acyl-2-thioethyl) [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate as an oil (0.09 g, 56%): LC-MS *m/z* = 569 [C₂₇H₃₇O₇PS₂ + H]⁺; Anal. Calcd for (C₂₇H₃₇O₇PS₂): C, 57.03; H, 6.56. Found: C, 57.02, H, 7.03; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = 2/3 hexanes/EtOAc; phosphonic acid *rf* = 0.00, *rf* = 0.35.

Example 15


Compound 15-1: di-N-(*l*-1-ethoxycarbonylethylamino) [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy]methylphosphonamide



[0727] To a stirred solution of [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy)methyl phosphonic acid (1, 0.3 g, 0.8 mmol) and DMF(0.1 mL, 0.08 mmol) in 1,2 dichloroethane (10 mL) at room temperature was added oxalylchloride (0.55 g, 2.8 mmol). The reaction mixture was heated at 50 °C for 3 h, cooled to room temperature and concentrated under reduced pressure. To the residue at 0 °C was added a solution of alanine ethylester (0.57 g, 4.3 mmol) and *N,N*-diisopropylethylamine(0.6 mL, 4.3 mmol) in CH₂Cl₂. The reaction mixture was stirred for 14 h at room temperature and concentrated under reduced pressure. The residue was partitioned between EtOAc (50 mL) and aqueous NaHCO₃ solution (100 mL). The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with CH₂Cl₂-MeOH (95:5) to afford Di(ethoxycarbonyl-1-ethylamino) [3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy]methylphosphonamide as a yellow solid (175 mg, 52%): mp 48-50 °C; LC-MS *m/z* = 563 [C₂₉H₄₃N₂O₇P+H]⁺; Anal Calcd for: (C₂₉H₄₃N₂O₇P+0.2 CH₂Cl₂): C, 60.24; H, 7.52; N, 4.80. Found: C, 59.86; H, 8.01; N, 5.12.

[0728] Using the appropriate starting material, compounds 15-2 to 15-9 were prepared in an analogous manner to that described for the synthesis of compound 15-1.


Compound 15-2: di-*N*-(1-ethoxycarbonyl-1-methylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy]methylphosphonamide



[0729] LC-MS $m/z = 591$ [C₂₉H₄₃N₂O₇P+H]⁺; Anal Calcd for (C₂₉H₄₃N₂O₇P+0.2 CH₂Cl₂): C, 60.24; H, 7.52; N, 4.80. Found: C, 59.86; H, 8.01; N, 5.12; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate/ hexanes (4:1); R_f = 0.4.


[0730] Using the appropriate starting material, compound 15-3 was prepared in an analogous manner to that described for the synthesis of compound 15-1.

Compound 15-3: di-*N*-(1-ethoxycarbonyl-2-methyl-propylamino)[3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonamide




[0731] mp: 52-55 °C; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:1); R_f = 0.4; ¹H NMR (300 MHz, CDCl₃): 8.684 (d, $J = 2.1$ Hz, 1 H), 6.52 (d, $J = 7.2$ Hz, 1 H), 6.42 (dd, $J = 1.8, 4.5$ Hz, 1 H), 4.02-4.20 (m, 6 H), 3.70-3.95 (m, 2 H), 3.80 (s, 2 H), 3.05-3.35 (m, 3 H), 2.13 (s, 6 H), 1.09-1.20 (m, 9 H), 0.95 (t, $J = 6.9$ Hz, 3 H), 0.81 (dd, $J = 2.1, 6.9$ Hz, 6 H); LC-MS $m/z = 619$ [C₃₃H₅₁N₂O₇P + H]⁺; Anal Calcd for: (C₃₃H₅₁N₂O₇P + 0.75 H₂O): C, 62.29; H, 8.37; N, 4.43. Found: C, 62.48; H, 8.89; N, 4.37.

Compound 15-4: di-N-(L-1-ethoxycarbonylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*sec*-butylbenzyl)phenoxy]methylphosphonamide



[0732] ^1H NMR (300 MHz, DMSO- d_6): δ 8.94 (s, 1H), 6.77 (s, 1H), 6.64-6.61 (m, 3H), 6.51-6.48 (d, 1H), 4.87-4.75 (q, 2H), 4.09-3.99 (m, 4H), 3.81 (s, 2H), 2.95-2.88 (q, 1H), 2.17 (s, 6H), 1.57-1.37 (m, 2H), 1.31-1.29 (d, 6H), 1.26-1.16 (m, 4H), 1.08-1.06 (d, 3H), 0.78-0.73 (t, 3H); LC-MS m/z = 577.6 [C₃₀H₄₅N₂O₇P + H] $^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.58; Anal. Calcd for (C₃₀H₄₅N₂O₇P + 1.1 H₂O): C, 60.41; H, 7.98; N, 4.70. Found: C, 60.12; H, 7.58; N, 4.49.


Compound 15-5: di-N-(L-1-ethoxycarbonylethylamino)[3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl]phosphonamide



[0733] ^1H NMR (300 MHz, DMSO- d_6): δ 9.08 (s, 1H), 7.68 (s, 2H), 6.69-6.66 (d, 1H), 6.63 (s, 1H), 6.31-6.28 (d, 1H), 4.76-4.61 (q, 2H), 4.09-4.01 (m, 8H), 3.17-3.08 (q, 1H), 1.27-1.10 (m, 18H); LC-MS m/z = 679.4 [C₂₆H₃₅Br₂N₂O₇P + H] $^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane-ethyl acetate (1:1); R_f = 0.34; Anal. Calcd for

(C₂₆H₃₅Br₂N₂O₇P + 0.6 CF₃CO₂H): C, 43.92; H, 4.84; N, 3.78. Found: C, 43.51; H, 4.78; N, 4.26.


Compound 15-6: di-N-(L-1-ethoxycarbonylethylamino)[4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methyl phosphonamide



[0734] To a stirring suspension of [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methylphosphonic (0.11 g, 0.26 mmol, US 6747048 B2) and L-alanine (0.16 g, 10.4 mmol) at room temperature in pyridine (2 mL) was added TEA (0.14 mL, 1.04 mmol), followed by a fresh prepared solution of aldrithio-2 (0.25 g, 1.12 mmol) and PPh₃ (0.29 g, 1.12 mmol) in pyridine (2 mL). The reaction mixture was stirred at 85 °C for 16 hrs. The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford the title compound as a yellow foam (40 mg, 25%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1 H), 6.99 (t, *J* = 6.0 Hz, 1 H), 6.78 (d, *J* = 3.0 Hz, 1 H), 6.68 (d, *J* = 9.0 Hz, 1 H), 6.46 (dd, *J* = 3.0, 9.0 Hz, 1 H), 4.86 (m, 1 H), 4.66 (m, 1 H), 4.07 (m, 4 H), 3.83 (m, 2 H), 3.44 (m, 2 H), 3.16 (m, 1 H), 1.11 – 1.27 (m, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.54; LC-MS *m/z* = 624 [C₂₅H₃₄Cl₂FN₄O₇P + H]⁺; Anal Calcd for (C₂₅H₃₄Cl₂FN₄O₇P): C, 48.16; H, 5.50; N, 8.99. Found: C, 47.99; H, 5.26; N, 8.77.


Compound 15-7: Di-N-(L-1-ethoxycarbonylethylamino)[3,5-dichloro-4-(4'-hydroxy-3'-iso-propylbenzyl)]phenoxy)methylphosphonamide

- 351 -



[0735] ^1H NMR (300 MHz, DMSO- d_6): δ 9.11 (s, 1 H), 7.12 (s, 2 H), 6.97 (m, 1 H), 6.66 (m, 2 H), 4.89 (m, 2 H), 4.22 (m, 2 H), 4.05-3.93 (m, 8 H), 3.14 (m, 1 H), 1.28 (m, 6 H), 1.16 (m, 12 H); LC-MS m/z = 603 [C₂₇H₃₃Cl₂N₂O₂P + H]⁺; Anal. Calcd for (C₂₇H₃₃Cl₂N₂O₂P + 0.5 H₂O): C, 52.95; H, 6.25; N, 4.57. Found: C, 52.97; H, 6.32; N, 4.71; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.26.


Compound 15-8: Di-*N*-(*l*-1-ethoxycarbonylethylamino)[3,5-diido-4-(4'-hydroxy-3'-*iso*-propylphenoxy)]phenoxy)methylphosphonamide



[0736] ^1H NMR (300 MHz, DMSO- d_6): δ 8.99 (s, 1 H), 7.50 (s, 2 H), 6.68 (m, 1 H), 6.56 (m, 1 H), 6.25 (m, 1 H), 4.87 (m, 2 H), 4.18 (m, 2 H), 4.06-3.95 (m, 6 H), 3.17 (m, 1 H), 1.32 (m, 6 H), 1.21-1.11 (m, 12 H); LC-MS m/z = 789 [C₂₆H₃₅I₂N₂O₈P + H]⁺; Anal. Calcd for (C₂₆H₃₅I₂N₂O₈P + 0.1 H₂O): C, 39.52; H, 4.49; N, 3.55. Found: C, 39.49; H, 4.50; N, 3.46; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.13.


Compound 15-9: Di-*N*-(*l*-1-ethoxycarbonylethylamino)[3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl]phenoxy)methylphosphonamide

- 352 -




[0737] ^1H NMR (300 MHz, CD₃OD): δ 7.12(m, 2H), 7.89(m, 2H), 6.61(m, 5H), 4.19(dd, 2H, $J = 2.4$ Hz and $J = 14$ Hz), 4.08(m, 5H), 3.84(s, 2H), 3.81(s, 2H), 2.15(s, 6H), 2.25(m, 1H), 2.15(s, 6H), 1.40(d, 6H, $J = 7.5$ Hz), 1.21(m, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; $R_f = 0.18$; LC-MS $m/z = 629$ [C₃₃H₄₂FN₂O₇P + H]⁺; Anal Calcd for (C₃₃H₄₂FN₂O₇P + 1.1 H₂O): C, 61.12; H, 6.87, N, 4.32. Found: C, 60.85; H, 6.78, N, 4.72.

Compound 15-10: *N*-(*l*-1-ethoxycarbonylthylamino)[3,5-dichloro-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy]methylphosphinamide



[0738] ^1H NMR (300 MHz, CD₃OD): δ 7.11(m, 4H), 6.92(t, 2H, $J = 8.7$ Hz), 6.76(m, 2H), 6.63(d, 1H, $J = 8$ Hz), 4.26(d, 2H, $J = 7.8$ Hz), 4.12(m, 3H), 3.98(m, 2H), 3.83(s, 2H), 1.58(m, 3H), 1.38(m, 3H); TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate-methanol [20:1]; $R_f = 0.2$; LC-MS $m/z = 568$ [C₂₇H₂₉Cl₂NFO₅P + H]⁺; Anal Calcd for (C₂₇H₂₉Cl₂NFO₅P): C, 56.27; H, 5.34; N, 2.40. Found: C, 56.17; H, 5.71; N, 2.62.


Compound 15-11: Methyl *N*-(*l*-1-ethoxycarbonylethylamino) [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)methylphosphonamide



- 353 -

[0739] ^1H NMR (200 MHz, CD₃OD): δ 7.12 (s, 2H), 7.18 (m, 2H), 7.94 (t, J =8 Hz, 2H), 6.70 (d, J =8.8 Hz, 1H), 4.33 (m, 2H), 4.08 (m, 1H), 3.83 (s, 2H), 3.77(m, 3H), 1.41(m, 3H), 1.27 (m, 3H); TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate; R_f=0.30; LC-MS m/z 676 [C₂₆H₂₇Br₂FO₇P + H]⁺.


Compound 15-15: Di-N-(*l*-1-propylcarbonyl-1-methylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-benzyl]-phosphonamide



[0740] The title compound was prepared from compound 7 according to the procedure described for the synthesis of compound 15-1, as a white foam: ^1H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 6.84 (s, 1H), 6.69 (s, 2H), 6.62 (d, J =7.8 Hz, 1H), 6.47 (d, J =7.8 Hz, 1H), 4.58 (d, J =11.1 Hz, 2H), 4.00 (m, 6H), 3.81 (s, 2H), 3.14 (m, 1H), 2.18 (s, 6H), 1.62 (m, 4H), 1.47 (d, J =13.5 Hz, 12H), 1.11 (d, J =6.9 Hz, 6H), 0.91 (m, 6H); LC-MS m/z = 619 [C₃₅H₅₅N₂O₇P + H]⁺; Anal. Calcd for (C₃₅H₅₅N₂O₇P + 0.5 CH₂Cl₂): C, 60.85; H, 7.93; N, 4.24. Found: C, 60.72; H, 7.83; N, 4.16.


Compound 15-16: Di-N-(*l*-isopropylcarbonyl-1-methylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-benzyl]-phosphonamide

- 354 -



[0741] The title compound was prepared from compound 7 according to the procedure described for the synthesis of compound 15-1, as a white foam: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 6.85 (s, 1H), 6.69 (s, 2H), 6.62 (d, *J* = 8.1 Hz, 1H), 6.47 (d, *J* = 8.1 Hz, 1H), 4.89 (m, 2H), 4.54 (d, *J* = 10.8 Hz, 2H), 4.05 (d, *J* = 10.8 Hz, 2H), 3.81 (s, 2H), 3.11 (m, 1H), 2.18 (s, 6H), 1.45 (d, *J* = 16.5 Hz, 12H), 1.21 (m, 12H), 1.11 (d, *J* = 6.9 Hz, 6H); LC-MS *m/z* = 619 [C₃₅H₅₅N₂O₇P + H]⁺; Anal. Calcd for (C₃₅H₅₅N₂O₇P + 0.4 H₂O): C, 63.32; H, 8.34; N, 4.48. Found: C, 63.36; H, 8.64; N, 4.44.

Compound 15-17: Di-*N*-(*l*-ethoxycarbonyl-methylamino)[4-(4'-hydroxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl]phosphonamide



Step a:

[0742] A solution consisting of [4-(4'-hydroxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl]phosphonic acid (compound 61, 1.2 g, 3.1 mmol) and acetic anhydride (2 mL) in toluene (5 mL) was refluxed overnight. The volatiles were removed under vacuum and to the oily residue was added THF (3 mL) and H₂O (1 mL). The mixture was stirred at rt for 5 hrs before being concentrated under vacuum. Co-evaporation of the residue with toluene afforded [4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl]-

phosphonic acid as an off-white foam. ^1H NMR (300 MHz, DMSO- d_6): δ 7.11 (d, $J = 2.1$ Hz, 1H), 6.86 (d, $J = 8.4$ Hz, 1H), 6.79 (s, 1H), 6.65 (dd, $J = 8.4$ Hz and 2.1 Hz, 1H), 4.04 (d, $J = 10.5$ Hz, 2H), 3.96 (s, 2H), 2.96-2.87 (m, 1H), 2.27 (s, 3H), 2.20 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H), 1.10 (d, $J = 7.8$ Hz, 6H); ^{31}P NMR (DMSO- d_6) δ 15.32 (s); LC-MS m/z = 419 [C₂₂H₂₉O₆P-H]⁺.

Step b:


[0743] A solution consisting of [4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy methyl]phosphonic acid (216 mg, 0.51 mmol), oxalyl chloride (0.18 mL, 2.1 mmol) and DMF (1 drop) in dichloroethane (15 mL) was heated at 50 °C for 2 hrs. The reaction mixture was then concentrated under vacuum and the oil residue dissolved in dichloromethane. After cooling to 0°C, ethyl glycine as a 5 M solution in dichloromethane (0.41 mL, 2.1 mmol) and Hunigs base (0.35 mmol, 2.1 mmol) were added. The resulting solution was allowed to reach rt overnight. The reaction mixture was washed with a pH 7 phosphate buffer solution, dried over Na₂SO₄ and concentrated under vacuum to afford a dark amber-colored oil which was purified by preparative TLC (2mm, SiO₂) using ethyl acetate/hexane (9:1) as eluant. Evaporation of the solvent gave {l-ethoxycarbonyl-methylamino}-[4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy methyl]phosphonamide as an amber oil (174 mg, 57%): ^1H NMR (300 MHz, CDCl₃): δ 7.01 (s, 1H), 6.81 (d, $J = 8.1$ Hz, 1H), 6.67 (d, $J = 8.1$ Hz, 1H), 6.61 (s, 1H), 4.27 (d, $J = 9.6$ Hz, 2H), 4.20-4.08 (m, 4H), 3.99 (s, 2H), 3.96-3.74 (m, 4H), 3.00-2.91 (m, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H), 1.28-1.22 (m, 6H), 1.16 (d, $J = 6.6$ Hz, 6H); ^{31}P NMR (CDCl₃) δ 22.63 (s); LC-MS m/z = 591 [C₃₀H₄₂N₂O₈P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.47.

Step c:

[0744] A solution of {l-Ethoxycarbonyl-methylamino}-[4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy methyl]phosphonamide (174 mg, 0.30 mmol) and anhydrous hydrazine (0.03 mL, 0.84 mmol) in t-BuOH (3 mL) was heated at 30 °C for 48 hrs. The mixture was concentrated under

vacuum and the residue dissolved in ethyl acetate. After washing with a solution of H₂O/AcOH (5:1), the organic portion was dried over Na₂SO₄ and concentrated under vacuum to afford crude product which was purified by preparative TLC (2mm, SiO₂) using dichloromethane/methanol (20:1) as eluant. Evaporation of the solvent gave the title compound as an amber oil (64 mg, 40%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.96 (s, 1H), 6.85 (s, 1H), 6.70 (s, 1H), 6.59 (d, *J* = 8.4 Hz, 1H), 6.43 (d, *J* = 8.4 Hz, 1H), 4.83 (t, *J* = 10.5 Hz, 1H), 4.70 (t, *J* = 10.5 Hz, 1H), 4.08-3.90 (m, 8H), 3.83 (s, 2H), 3.17-3.08 (m, 1H), 2.19 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 1.29 (d, *J* = 6.9 Hz, 6H), 1.17-1.09 (m, 6H); ³¹P NMR (DMSO-*d*₆) δ 21.56 (s); LC-MS *m/z* = 549 [C₂₈H₄₁N₂O₇P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane/methanol (10:1); R_f = 0.42; Anal. Calcd for (C₂₈H₄₁N₂O₇P + 0.2 H₂O): C, 60.90; H, 7.56; N, 5.07. Found: C, 60.95, H, 7.63; N, 5.21.


Compound 15-18: Di-*N*-{[1-ethoxycarbonyl-ethylamino]-[4-(4'-hydroxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl}phosphonamide



[0745] The title compound was prepared from [4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl]phosphonic acid (compound 15-17, step b) according to the procedure described for the synthesis of compound 15-17, step c as an amber-colored oil (51%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.96 (s, 1H), 6.85 (s, 1H), 6.70 (s, 1H), 6.59 (d, *J* = 8.4 Hz, 1H), 6.43 (d, *J* = 8.4 Hz, 1H), 4.83 (t, *J* = 10.5 Hz, 1H), 4.70 (t, *J* = 10.5 Hz, 1H), 4.08-3.90 (m, 8H), 3.83 (s, 2H), 3.17-3.08 (m, 1H), 2.19 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 1.29 (d, *J* = 6.9 Hz, 6H), 1.17-1.12 (m, 6H), 1.10 (d, *J* = 7.2 Hz, 6H); ³¹P NMR (DMSO-*d*₆) δ 19.33 (s); LC-MS *m/z* = 577 [C₃₀H₄₅N₂O₇P +

$\text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane/methanol (10:1); $R_f = 0.47$; Anal. Calcd for $(\text{C}_{30}\text{H}_{45}\text{N}_2\text{O}_7\text{P} + 0.5 \text{ H}_2\text{O})$: C, 61.52; H, 7.92; N, 4.78. Found: C, 61.75, H, 8.02; N, 5.02.


Compound 15-19: Di-*N*-(*I*-1-ethoxycarbonyl-1-methylethylamino){[4-(4'-hydroxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]methyl}phosphonamide



Step b:


[0746] The title compound was prepared from [4-(4'-acetoxy-3'-isopropylbenzyl)-2,3,5-trimethylphenoxy]phosphonic acid (compound 15-17, step b) according to the procedure described for the synthesis of compound 15-17, step c as an amber-colored oil (62%): ^1H NMR (300 MHz, DMSO- d_6): δ 8.96 (s, 1H), 6.85 (s, 1H), 6.70 (s, 1H), 6.59 (d, $J = 8.4$ Hz, 1H), 6.43 (d, $J = 8.4$ Hz, 1H), 4.56 (d, $J = 10.8$ Hz, 2H), 4.13-4.00 (m, 6H), 3.83 (s, 2H), 3.17-3.08 (m, 1H), 2.19 (s, 3H), 2.14 (s, 3H), 2.08 (s, 3H), 1.49 (s, 6H), 1.42 (s, 6H), 1.19 (t, $J = 7.2$ Hz, 6H), 1.10 (d, $J = 6.9$ Hz, 6H); ^{31}P NMR (DMSO- d_6) δ 16.97 (s); LC-MS $m/z = 606$ $[\text{C}_{32}\text{H}_{49}\text{N}_2\text{O}_7\text{P} + \text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane/methanol (10:1); $R_f = 0.54$; Anal. Calcd for $(\text{C}_{32}\text{H}_{49}\text{N}_2\text{O}_7\text{P})$: C, 63.56; H, 8.17; N, 4.63. Found: C, 63.58, H, 7.97; N, 4.45.

Compound 15-20: Di-*N*-(*I*-1-ethoxycarbonyl-2-methyl-propylamino){[3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy]methyl}phosphonamide



[0747] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white foam: ^1H NMR (300 MHz, DMSO- d_6): δ 9.00 (s, 1H), 6.82 (s, 1H), 6.63 (s, 2H), 6.61 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 8.1 Hz, 1H), 4.87 (m, 2H), 4.54 (m, 1H), 4.12 (m, 3H), 3.82 (s, 2H), 3.68 (m, 2H), 3.14 (m, 1H), 2.17 (s, 6H), 1.98 (m, 2H), 1.23 (d, J = 6.3 Hz, 6H), 1.12 (m, 12H), 0.89 (m, 12H); LC-MS m/z = 647 [$\text{C}_{35}\text{H}_{55}\text{N}_2\text{O}_7\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{35}\text{H}_{55}\text{N}_2\text{O}_7\text{P} + 0.3\text{H}_2\text{O}$): C, 64.46; H, 8.59; N, 4.30. Found: C, 64.29; H, 8.49; N, 4.13.


Compound 15-21: Di-*N*-(*t*-1-propyloxycarbonyl-2-methyl-propylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide



[0748] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white foam: ^1H NMR (300 MHz, DMSO- d_6): δ 9.00 (s, 1H), 6.83 (d, J = 2.1 Hz, 1H), 6.61 (m, 3H), 6.47 (dd, J = 8.1, 2.1 Hz, 1H), 4.57 (t, J = 8.7 Hz, 1H), 4.24 (t, J = 8.7 Hz, 1H), 3.92 (m, 6H), 3.81 (s, 2H), 3.68 (m, 2H), 3.14 (m, 1H), 2.17 (s, 6H), 1.98 (m, 2H), 1.57 (m, 4H), 1.11 (d, J = 6.9 Hz, 6H), 0.89


(m, 18H); LC-MS $m/z = 647$ [C₃₅H₅₅N₂O₇P + H]⁺; Anal. Calcd for (C₃₅H₅₅N₂O₇P): C, 64.99; H, 8.57; N, 4.33. Found: C, 64.60; H, 8.78; N, 4.39.

Compound 15-22: Di-N-(1-ethoxycarbonyl-1-(5-pentylamino))[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide acetic acid salt




[0749] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy)methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white foam: ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.83 (d, *J* = 2.1 Hz, 1H), 6.61 (m, 3H), 6.47 (dd, *J* = 8.1, 2.1 Hz, 1H), 4.77 (t, *J* = 8.7 Hz, 1H), 4.61 (t, *J* = 8.7 Hz, 1H), 4.02 (m, 6H), 3.81 (s, 4H), 3.14 (m, 1H), 2.58 (m, 4H), 2.17 (s, 6H), 1.83 (s, 6H), 1.61 (m, 4H), 1.38 (m, 8H), 1.11 (m, 12H); LC-MS $m/z = 677$ [C₃₅H₅₇N₄O₇P + H]⁺; Anal. Calcd for (C₃₅H₅₇N₄O₇P + 2AcOH + 0.2EtOH + 1.5H₂O): C, 56.80; H, 8.37; N, 6.72. Found: C, 56.51; H, 8.07; N, 7.04.

Compound 15-23: Di-N-(ethoxycarbonyl-methylamino)[3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy]methylphosphonamide




[0750] The title compound was prepared from [3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl]phenoxy)methylphosphonic acid (compound 40) according to the procedure described for the synthesis of compound 15-17 as a white foam: ^1H NMR (300 MHz, DMSO- d_6): δ 9.17 (s, 1H), 7.11 (m, 4H), 6.64 (m, 5H), 4.77 (m, 2H), 4.06 (m, 6H), 3.77 (s, 4H), 3.66 (s, 4H), 2.14 (s, 6H), 1.17 (t, $J = 6.9$ Hz, 6H); LC-MS $m/z = 601$ [$\text{C}_{31}\text{H}_{38}\text{FN}_2\text{O}_7\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{31}\text{H}_{38}\text{FN}_2\text{O}_7\text{P} + 0.3\text{H}_2\text{O}$): C, 61.44; H, 6.42; N, 4.62. Found: C, 61.14; H, 6.10; N, 4.48.

Compound 15-24: Di-*N*-(*l*-1-ethoxycarbonyl-ethylamino)[3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl]phenoxy)methylphosphonamide




[0751] The title compound was prepared from [3,5-dimethyl-4-(3'-4-fluorobenzyl)-4'-hydroxybenzyl]phenoxy)methylphosphonic acid (compound 40) according to the procedure described for the synthesis of compound 15-17 as a white foam: ^1H NMR (300 MHz, DMSO- d_6): δ 9.17 (s, 1H), 7.11 (m, 4H), 6.64 (m, 5H), 4.77 (m, 2H), 4.06 (m, 8H), 3.77 (s, 4H), 2.14 (s, 6H), 1.26 (d, $J = 6.9$ Hz, 6H), 1.14 (m, 6H); LC-MS $m/z = 629$ [$\text{C}_{33}\text{H}_{42}\text{FN}_2\text{O}_7\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{33}\text{H}_{42}\text{FN}_2\text{O}_7\text{P}$): C, 63.05; H, 6.73; N, 4.46. Found: C, 62.77; H, 6.50; N, 4.26.

Compound 15-25: Di-*N*-(*l*-1-ethoxycarbonyl-1-methyl-ethylamino)[3,5-dimethyl-4-(3'(4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy)methylphosphonamide




[0752] The title compound was prepared from [3,5-dimethyl-4-(4-fluorobenzyl)-4'-hydroxybenzyl]phenoxy)methylphosphonic acid (compound 40) according to the procedure described for the synthesis of compound 15-17 as a white foam: ^1H NMR (300 MHz, DMSO- d_6): δ 9.17 (s, 1H), 7.11 (m, 4H), 6.64 (m, 5H), 4.57 (d, J = 7.2 Hz, 2H), 4.06 (m, 6H), 3.74 (s, 4H), 2.11 (s, 6H), 1.44 (s, 6H), 1.40 (s, 6H), 1.16 (d, J = 6.9 Hz, 6H); LC-MS m/z 657 [$\text{C}_{35}\text{H}_{46}\text{FN}_2\text{O}_7\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{35}\text{H}_{46}\text{FN}_2\text{O}_7\text{P} + 0.5\text{TFA}$): C, 60.58; H, 6.57; N, 3.92. Found: C, 60.28; H, 6.24; N, 3.68.

Compound 15-26: Di-*N*-(*l*-1-ethoxycarbonyl-1-ethylamino)-4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonamide




[0753] The title compound was prepared from 4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonic acid (Example 45) according to the procedure described for the synthesis of Example 15-1. MP: 66-69 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.52 (d, J = 2.1 Hz, 1H), 7.28 (s, 1H), 6.84 (d, J = 2.1 Hz, 1H), 6.56 (m, 2H), 4.08 (m, 8H), 3.20 (m, 1H), 2.46 (s, 3H), 2.37 (s, 3H), 1.42 (m, 6H), 1.24 (t, J = 6.9 Hz, 3H), 1.15 (m, 9H); LC-MS m/z 573 [$\text{C}_{30}\text{H}_{41}\text{N}_2\text{O}_7\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{30}\text{H}_{41}\text{N}_2\text{O}_7\text{P}$): C, 62.92; H, 7.22; N, 4.89. Found: C, 62.98; H, 7.26; N, 4.71.

Compound 15-27: Di-*N*-(ethoxycarbonyl-methylamino)-4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonamide




[0754] The title compound was prepared from from 4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonic acid (Example 45) according to the procedure described for the synthesis of Example 15-1. MP: 58-61 °C; ¹H NMR (300 MHz, CD₃OD): δ 7.56 (d, *J* = 2.1 Hz, 1H), 7.28 (s, 1H), 6.84 (d, *J* = 2.1 Hz, 1H), 6.56 (m, 2H), 4.17 (q, *J* = 6.9 Hz, 4H), 4.08 (s, 2H), 3.83 (m, 4H), 3.22 (m, 1H), 2.47 (s, 3H), 2.37 (s, 3H), 1.24 (m, 6H), 1.14 (d, *J* = 7.1 Hz, 6H); LC-MS *m/z* = 545 [C₂₈H₃₇N₂O₇P + H]⁺; Anal. Calcd for (C₂₈H₃₇N₂O₇P): C, 61.76; H, 6.85; N, 5.14. Found: C, 61.47; H, 6.88; N, 5.01.

Compound 15-28: Di-*N*-(1-ethoxycarbonyl-1-methyl-1-ethylamino)-4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonamide




[0755] The title compound was prepared from 4,6-dimethyl-5-(4'-hydroxy-3'-isopropylbenzyl)benzofuran-2-phosphonic acid (Example 45) according to the procedure described for the synthesis of Example 15-1. MP: 50-53 °C; ¹H NMR (300 MHz, CD₃OD): δ 7.45 (d, *J* = 2.1 Hz, 1H), 7.30 (s, 1H), 6.84 (d, *J* = 2.1 Hz, 1H), 6.56 (m, 2H), 4.17 (q, *J* = 6.9 Hz, 4H), 4.10 (s, 2H), 3.22 (m, 1H), 2.47 (s, 3H), 2.37 (s, 3H), 1.60 (s, 6H), 1.49 (s, 6H), 1.24 (t, *J* = 6.9 Hz, 6H), 1.14 (d, *J* = 7.1 Hz, 6H); LC-MS *m/z* = 601 [C₃₂H₄₅N₂O₇P + H]⁺; Anal. Calcd for (C₃₂H₄₅N₂O₇P + 0.7 H₂O): C, 62.67; H, 7.63; N, 4.57. Found: C, 62.40; H, 7.90; N, 4.79.

Example 15-29: Di-*N*-(*l*-1-isopropoxycarbonylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide



[0756] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white foam. MP 55-58 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (s, 1H), 6.84 (s, 1H), 6.63 (m, 3H), 6.48 (m, 1H), 4.87-4.71 (m, 4H), 4.06 (d, *J* = 15.0 Hz, 2H), 3.88 (m, 2H), 3.81 (s, 2H), 3.20 (m, 1H), 2.17 (s, 6H), 1.30 (m, 6H), 1.20-1.09 (m, 18H); LC-MS *m/z* = 591 [C₃₁H₄₇N₂O₇P + H]⁺; Anal. Calcd for (C₃₁H₄₇N₂O₇P + 0.4 H₂O): C, 62.27; H, 8.06; N, 4.69. Found: C, 62.24; H, 7.99; N, 4.76; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (2:5); R_f = 0.33.


Example 15-30: Di-*N*-(*l*-1-ethoxycarbonyl-2-phenylethylamino)-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide



[0757] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white


foam. MP 60-63 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 9.00 (s, 1H), 7.30-7.15 (m, 10H), 6.84 (s, 1H), 6.64 (m, 1H), 6.50 (m, 3H), 4.75 (m, 1H), 4.38 (m, 1H), 4.00 (m, 6H), 3.95 (s, 2H), 3.65 (d, J = 15.0 Hz, 2H), 3.20 (m, 1H), 2.95 (m, 5H), 2.15 (s, 6H), 1.12 (m, 12H); LC-MS m/z = 715 [C₄₁H₅₁N₂O₇P + H]⁺; Anal. Calcd for (C₄₁H₅₁N₂O₇P + 0.4 H₂O): C, 68.20; H, 7.23; N, 3.88. Found: C, 68.16; H, 7.26; N, 3.86; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (2:5); R_f = 0.35.

Example 15-31: Di-N-(*i*-propyloxycarbonyl-ethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide




[0758] The title compound was prepared from [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 as a white foam. ^1H NMR (300 MHz, DMSO- d_6): δ 8.99 (s, 1H), 6.83 (s, 1H), 6.63 (m, 3H), 6.48 (m, 1H), 4.83-4.75 (m, 2H), 4.08 (d, J = 15.0 Hz, 2H), 3.99-3.94 (m, 6H), 3.81 (s, 2H), 3.18 (m, 1H), 2.17 (s, 6H), 1.55 (m, 4H), 1.29 (d, J = 6.0 Hz, 2H), 1.11 (d, J = 7.0 Hz, 2H), 0.88 (m, 6H); LC-MS m/z = 591 [C₃₁H₄₇N₂O₇P + H]⁺; Anal. Calcd for (C₃₁H₄₇N₂O₇P + 0.3 H₂O): C, 62.46; H, 8.05; N, 4.70. Found: C, 62.44; H, 7.95; N, 4.73; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (2:5); R_f = 0.13.

Example 15-32: Di-N-(ethoxycarbonylmethylamino)[3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonamide



[0759] The title compound was prepared from [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]phenoxylmethylphosphonic acid (compound 8-1) according to the procedures described for the synthesis of compound 15-17. MP 63-66 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.35 (s, 2H), 6.61 (m, 2H), 6.33 (m, 1H), 4.36 (d, J = 15.0 Hz, 2H), 4.15 (m, 4H), 3.80 (m, 4H), 3.20 (m, 1H), 2.17 (s, 6H), 1.28 (m, 6H), 1.15 (d, J = 7.0 Hz, 2H); LC-MS m/z 667 [C₂₄H₃₁Br₂N₂O₈P + H]⁺; Anal. Calcd for (C₂₄H₃₁Br₂N₂O₈P + 0.1 CH₃COCH₃): C, 43.43; H, 4.74; N, 4.17. Found: C, 44.05; H, 4.47; N, 4.02; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methanol-dichloromethane (1:24); R_f = 0.22.


Example 15-33: Di-N-(1-ethoxycarbonyl-ethylamino)[3,5-dibromo-4-(4'-hydroxy-3'-iso-propylphenoxy)phenoxy]methylphosphonamide



[0760] The title compound was prepared from [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]phenoxylmethylphosphonic acid (compound 8-1) according to the procedures described for the synthesis of compound 15-17. MP 62-65 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.35 (s, 2H), 6.61 (m, 2H), 6.33 (m, 1H), 4.36 (d, J = 15.0 Hz, 2H), 4.15 (m, 4H), 3.80 (m, 4H), 3.20 (m, 1H), 2.17 (s, 6H), 1.28 (m, 6H), 1.15 (d, J = 7.0 Hz, 2H); LC-MS m/z 695 [C₂₄H₃₁Br₂N₂O₈P + H]⁺; Anal. Calcd for (C₂₄H₃₁Br₂N₂O₈P): C, 44.98; H, 5.08; N, 4.03. Found: C, 45.16; H, 5.07; N, 4.04; TLC conditions: Uniplate


silica gel, 250 microns; Mobile phase = methanol-dichloromethane (1:24); R_f = 0.26.

Example 15-34: Di-*N*-(1-ethoxycarbonyl-1-methyl-ethylamino)[3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]methylphosphonamide



[0761] The title compound was prepared from [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)]phenoxy)methylphosphonic acid (compound 8-1) according to the procedures described for the synthesis of compound 15-1. MP 62-65 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.41 (s, 2H), 6.63 (m, 2H), 6.36 (m, 1H), 4.31 (d, J = 15.0 Hz, 2H), 4.15 (m, 5H), 3.20 (m, 1H), 1.61 (d, J = 25.0 Hz, 12H), 1.29 (m, 9H), 1.15 (d, J = 7.5 Hz, 6H); LC-MS m/z = 723 [C₂₈H₃₉Br₂N₂O₈P + H]⁺; Anal. Calcd for (C₂₈H₃₉Br₂N₂O₈P): C, 46.55; H, 5.44; N, 3.88. Found: C, 46.71; H, 5.42; N, 3.90; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methanol-dichloromethane (1:24); R_f = 0.41.


Compound 15-35: Di-*N*-(ethoxycarbonyl-methylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*propylbenzyl)phenoxy]methylphosphonamide



[0762] To a stirred solution of [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)]-phenoxy)methylphosphonic acid (example 7) (0.41 g, 1.11

mmol) and DMF (0.1 mL, 1.11 mmol) in dichloromethane (5.6 mL) at 0 °C was added oxalyl chloride (0.38 mL, 4.4 mmol). The reaction mixture was heated to 50 °C for 3 h, cooled to room temperature and concentrated under reduced pressure. To the residue at -78 °C was added a solution of glycine ethyl ester hydrochloride (0.65 g, 4.44 mmol) and triethylamine (1.25 mL, 8.88 mmol) in dichloromethane (5.3 mL). The reaction mixture was stirred for 14 h at room temperature, filtered to remove salts, and concentrated under reduced pressure. The residue was partitioned between ethyl acetate (50 mL) and aqueous NaHCO₃ solution (100 mL). The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with CH₂Cl₂-MeOH (95:5) to afford the title compound as an off-white foam (41.3 mg, 20.2%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.97 (s, 1H), 6.81 (s, 1H), 6.63 (s, 2H), 6.57 (d, *J* = 8.4 Hz, 1H), 6.43 (d, *J* = 7.8 Hz, 1H), 4.76 (m, 2H), 4.07 (m, 2H), 4.00 (d, *J* = 6.6 Hz, 2H), 3.78 (s, 1H), 3.66 (m, 4H), 3.08 (m, 1H), 2.15 (s, 6H), 1.16 (t, 6H), 1.07 (d, *J* = 6.6 Hz, 6H); LC-MS *m/z* = 535.3 [C₂₇H₃₉N₂O₇P + H]⁺; Anal. Calcd for (C₂₇H₃₉N₂O₇P): C, 60.66; H, 7.35; N, 5.24. Found: C, 60.51; H, 7.12; N, 4.93.


Compound 15-36: Di-*N*-(isopropyloxycarbonyl-methylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxyethyl]phosphonamide



[0763] The title compound was prepared from [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)]-phenoxyethylphosphonic acid (example 7) and glycine *iso*-propylester hydrochloride according to the procedure described for the synthesis of compound 15-35. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.97 (s, 1H), 6.81 (s, 1H), 6.63 (s, 2H), 6.57 (d, *J* = 8.4 Hz, 1H), 6.43 (d, *J* = 7.8 Hz,


1H), 4.86 (m, 2H), 4.72 (m, 2H), 4.10 (d, $J = 9.3$ Hz, 2H), 3.78 (s, 2H), 3.61 (m, 4H), 3.12 (m, 1H), 2.14 (s, 6H), 1.14 (d, $J = 6.0$ Hz, 12H), 1.08 (d, $J = 6.6$ Hz, 6H); LC-MS $m/z = 563.3$ [$C_{29}H_{43}N_2O_7P + H]^+$; Anal. Calcd for ($C_{29}H_{43}N_2O_7P$): C, 61.91; H, 7.70; N, 4.98. Found: C, 61.81; H, 7.69; N, 5.11.

Compound 15-39: Di-*N*-(propyloxycarbonyl-methylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxymethyl]phosphonamide




[0764] The title compound was prepared from [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)]-phenoxyethylphosphonic acid (example 7) and glycine *n*-propylester hydrochloride according to the procedure described for the synthesis of compound 15-35: 1H NMR (300 MHz, DMSO- d_6): δ 8.96 (s, 1H), 6.81 (s, 1H), 6.62 (s, 2H), 6.57 (d, $J = 8.4$ Hz, 1H), 6.43 (d, $J = 10.2$ Hz, 1H), 4.78 (m, 2H), 4.08 (d, $J = 9.0$ Hz, 2H), 3.94 (t, 4H), 3.78 (s, 2H), 3.65 (m, 4H), 3.10 (m, 1H), 2.14 (s, 6H), 1.56 (m, 4H), 1.08 (d, $J = 6.6$ Hz, 6H), 0.87 (t, 6H); LC-MS $m/z = 563.6$ [$C_{29}H_{43}N_2O_7P + H]^+$; Anal. Calcd for ($C_{29}H_{43}N_2O_7P + 0.1$ eq C_3H_6O): C, 61.91; H, 7.73; N, 4.93. Found: C, 61.87; H, 8.12; N, 4.77.

Compound 15-40: Di-*N*-(1-propyloxycarbonyl-1-(5-pentylamino))[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonamide acetic acid salt




[0765] To a stirred suspension of 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)phosphonic acid (compound 7, 0.25 g, 0.68 mmol) in 1,2 dichloroethane (10 mL) at rt were added oxalylchloride (0.34 g, 2.7 mmol) and DMF(0.1 mL, 0.68 mmol). The reaction mixture was heated at 50 °C for 3 h, and cooled to rt. The reaction mixture was concentrated under reduced pressure and azeotroped with toluene (2x10 mL). The crude compound was treated with lysine propylester (freebase form) (0.1.0 g, 2.72 mmol) and *N,N*-diisopropylethylamine (0.8 mL, 2.72 mmol) in CH₂Cl₂ at 0 °C. The reaction mixture was stirred for 14 h at rt and the reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc (50 mL) and aqueous NaHCO₃ solution (50 mL). The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, eluting with ethyl acetate:hexanes (3:2), treated with acetic acid and filtered to give the title compound as a white solid (78 mg, 92%, MP: 65-68 °C, 98% pure). ¹H NMR (300 MHz, CDCl₃): δ 6.81 (s, 1H), 6.69 (s, 2H), 6.61-6.55 (m, 2H), 4.25 (dd, *J* = 2.0, 6.4 Hz, 4H), 4.18-4.0 (m, 6H), 3.92 (s, 2H), 3.31-3.20 (m, 1H), 2.91 (q, *J* = 5.7 Hz, 4H), 2.24 (s, 2H), 1.93 (s, 3H), 1.80-1.50 (m, 14H), 1.14 (d, *J* = 6.6 Hz, 6H), 0.99 (t, *J* = 7.5 Hz, 3H), 0.91 (t, *J* = 7.5 Hz, 3H); LC-MS *m/z* = 705 [C₃₇H₆₁N₄O₇P+H]⁺; HPLC conditions: YMC packODS-Aq12S051546W column; mobile phase = CH₃OH:5%TFA (7:3) flow rate = 1.0 mL/min; detection = UV 220, 254, 280 nm retention time in min: 13.20; Anal. Calcd: (MF:C₃₇H₆₁N₄O₇P + 2.0 AcOH + 1.5 H₂O) Calcd: C:57.80, H:8.52, N:6.58; Found: C:57.53, H:8.67, N:6.25.

Compound 15-41: Di-*N*-(1-isopropoxy carbonyl-1-(5-pentylamino))[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonamide acetic acid salt




[0766] The title compound was prepared from 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy methyl phosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-40 as a white solid: (100 mg, 95%, MP: 62-64 °C, 98% pure). ^1H NMR (300 MHz, CDCl_3): δ 6.82 (s, 1H), 6.70 (s, 2H), 6.62-6.56 (m, 2H), 4.25 (m, 2H), 4.05-4.0 (m, 2H), 3.92 (s, 2H), 3.30-3.20 (m, 1H), 2.98-2.38 (m, 4H), 2.24 (s, 2H), 2.02-1.40 (m, 16H), 1.30 (d, J = 6.6 Hz, 6H), 1.22 (d, J = 6.9 Hz, 6H), 1.14 (d, J = 6.9 Hz, 6H); LC-MS m/z = 705 [$\text{C}_{37}\text{H}_{61}\text{N}_4\text{O}_7\text{P} + \text{H}]^+$; HPLC conditions: YMCpackSB-Aq12S051546W column; mobile phase = $\text{CH}_3\text{OH}:5\%\text{TFA}$ (7:3) flow rate = 1.0 mL/min; detection = UV 220, 254, 280 nm retention time in min: 5.79; Anal. Calcd: ($\text{MF:C}_{37}\text{H}_{61}\text{N}_4\text{O}_7\text{P} + 2.0\text{ AcOH} + 2.1\text{ H}_2\text{O}$) Calcd: C:57.07, H:8.55, N:6.49; Found: C:56.79, H:8.52, N:6.31.

Compound 15-42: Di-*N*-(1-ethoxycarbonyl-1-methyl ethylamino)[3,5-dichloro-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy methyl]phosphonamide




[0767] The title compound was prepared from [3,5-dichloro-4-(4'-hydroxy-3'-isopropylbenzyl)-phenoxymethyl]-phosphonic acid (example 7-5) according to the procedure described for the synthesis of example 15-1. MP 43-45 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.10 (s, 1H), 7.18 (s, 2H), 6.98 (s, 1H), 6.67 (m, 2H), 4.46 (d, *J* = 10.8 Hz, 2H), 4.06-4.63 (m, 9H), 3.14 (m, 1H), 1.43 (d, *J* = 11.4 Hz, 12H), 1.22 (t, 6H), 1.10 (d, *J* = 6.6 Hz, 6H); LC-MS *m/z* = 632 [C₂₉H₄₁Cl₂N₂O₇P + H]⁺; Anal. Calcd for (C₂₉H₄₁Cl₂N₂O₇P + 0.1 TFA): C, 54.55; H, 6.44; N, 4.36. Found: C, 54.44; H, 6.74; N, 4.48.

Compound 15-43: Di-*N*-(*I*-1-propyloxycarbonyl-2-phenylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl)phenoxy]methylphosphonamide



[0768] The title compound was prepared from 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxymethyl)phosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 to afford a white foam. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (s, 1H), 7.30-7.13 (m, 10H), 6.83 (s, 1H), 6.62-6.45 (m, 3H), 4.73 (t, *J* = 11.7 Hz, 1H), 4.36 (t, *J* = 11.7 Hz, 1H), 4.06-3.80 (m, 6H), 3.80 (s, 2H), 3.63 (d, *J* = 9.3 Hz, 2H), 3.17-3.08 (m, 1H), 2.95-2.75 (m, 4H), 2.17 (s, 6H), 1.55-1.42 (m, 4H), 1.09 (d, *J* = 6.9 Hz, 6H), 0.85-0.74 (m, 6H); ³¹P NMR (DMSO-*d*₆) δ 18.87 (s); LC-MS *m/z* = 743 [C₄₃H₅₅N₂O₇P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate/dichloromethane (2:1); R_f = 0.58; Anal. Calcd for (C₄₃H₅₅N₂O₇P + 0.3 H₂O): C, 69.02; H, 7.49; N, 3.74. Found: C, 69.01, H, 7.60; N, 3.65.


Compound 15-44: Di-*N*-(*l*-1-isopropoxy carbonyl-2-phenylethylamino)-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]-methylphosphonamide



[0769] The title compound was prepared from 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy methyl phosphonic acid (compound 7) according to the procedure described for the synthesis of compound 15-1 to afford a white foam. ^1H NMR (300 MHz, DMSO- d_6): δ 8.99 (s, 1H), 7.30-7.13 (m, 10H), 6.83 (s, 1H), 6.62-6.45 (m, 3H), 4.85-4.73 (m, 2H), 4.66 (t, J = 11.4 Hz, 1H), 4.34 (t, J = 11.4 Hz, 1H), 4.06-3.88 (m, 2H), 3.80 (s, 2H), 3.65 (d, J = 9.6 Hz, 2H), 3.17-3.08 (m, 1H), 2.95-2.75 (m, 4H), 2.17 (s, 6H), 1.17-1.00 (m, 18H); ^{31}P NMR (DMSO- d_6) δ 18.89 (s); LC-MS m/z = 743 [$\text{C}_{43}\text{H}_{55}\text{N}_2\text{O}_7\text{P} + \text{H}^+$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate/dichloromethane (2:1); R_f = 0.56; Anal. Calcd for ($\text{C}_{43}\text{H}_{55}\text{N}_2\text{O}_7\text{P}$): C, 69.56; H, 7.46; N, 3.77. Found: C, 69.30, H, 7.59; N, 3.72.

Example 16

Compound 16: 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-benzylphosphonic acid



Alternative synthesis for the compound of Example 16

Step a:

[0770] To a solution of 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl alcohol in CH₂Cl₂ (5.0 mL) at -78 °C is added BBr₃. The reaction mixture is stirred at room temperature for 16 h, poured into ice water and extracted with ethyl acetate. The organic layer is dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel, eluting with acetone-hexanes to afford 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl bromide.

Step b:


[0771] Diethyl 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl phosphonate is prepared from 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzyl bromide by following the procedure described in example 9, step g.

Step c:

[0772] 3,5-Dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzylphosphonic acid is prepared from diethyl 3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzylphosphonate by following the procedure described in example 9, step h.

Example 17


Compound 17: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-phenoxy]acetic acid



[0773] Compound 17 was synthesized by a literature method (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000))


Example 18

Compound 18: 3,5-dichloro-4-[4'-hydroxy-3'-*iso*-propylphenoxy]-benzeneacetic acid



Example 19

Compound 19: [3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)]-benzylphosphonic acid



Step a:

[0774] To a mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (4.55 g, 8.88 mmol) and copper powder (0.88 g, 13.80 mmol) in CH₂Cl₂ (40.0 mL) at 0 °C was added a solution of TEA (1.06 mL, 3.71 mmol) and methyl 3,5-dichloro-4-hydroxybenzoate (1.65 g, 6.90 mmol) in dichloromethane (20.0 mL). The reaction mixture was stirred at room temperature for 3 d and filtered through a Celite plug. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:19) to afford methyl 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzoate as an orange oil (2.02 g, 80%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.10 (m, 1 H), 6.85 (m, 2 H), 6.50 (m, 1 H), 3.90 (s, 3 H), 3.76 (s, 3 H), 3.21 (m, 1 H), 1.14 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); R_f = 0.51.

Step b:

[0775] To a mixture of methyl 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)-benzoate (1.40 g, 3.37 mmol) in THF (10.0 mL) at 0 °C was added a solution of DIBAL-H (8.12 mL, 8.12 mmol, 1.0 M solution in THF). The reaction mixture was stirred at room temperature for 16 h, quenched with cold 1 N HCl and diluted with ethyl acetate. The organic layer was washed with 1 N HCl and brine, dried over MgSO₄, filtered and concentrated under reduced pressure to afford 4-(3'-*iso*-propyl-4'-methoxyphenoxy)-3,5-dichlorobenzyl alcohol as an off-white solid (0.94 g, 100%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.54 (s, 2 H), 6.81 (m, 2 H), 6.40 (m, 1 H), 5.51 (m, 1 H), 4.54 (d, *J* = 6.0 Hz, 2 H), 3.75 (s, 3 H), 3.21 (m, 1 H), 1.13 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); R_f = 0.27.

Step c:

[0776] To a stirred solution of triphenylphosphine (0.42 g, 1.61 mmol) and CBr₄ (0.534 g, 1.61 mmol) in diethyl ether (15.0 mL) at room temperature was added 4-(3'-*iso*-propyl-4'-methoxyphenoxy)-3,5-dichlorobenzyl alcohol (0.50 g, 1.46 mmol). The reaction mixture was stirred at room temperature for 16 h, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzylbromide (0.320 g, 54%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.77 (s, 2 H), 6.82 (m, 2 H), 6.38 (m, 1 H), 4.75 (s, 2 H), 3.75 (s, 3 H), 3.22 (m, 1 H), 1.13 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (1:4); R_f = 0.46.

Step d:

[0777] A mixture of 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzyl bromide (0.61 g, 1.51 mmol) and triethylphosphite (0.61 g, 3.56 mmol) in DMF (2.0 mL) was heated under reflux for 4 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with water and brine. The organic layer was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with


acetone-hexanes (3:7) to afford diethyl 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzylphosphonate as an oil (0.59 g, 85%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.55 (s, 2 H), 6.88 (d, *J* = 9.0 Hz, 1 H), 6.75 (d, *J* = 3.0 Hz, 1 H), 6.43 (m, 1 H), 4.01 (m, 4 H), 3.75 (s, 3 H), 3.41 (m, 2 H), 3.22 (m, 1 H), 1.20 (m, 6 H), 1.12 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.22.

Step e:

[0778] To a solution of diethyl 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzylphosphonate (0.59 g, 1.28 mmol) in CH₂Cl₂ (10.0 mL) at -30 °C was added bromotrimethylsilane (2.53 mL, 19.2 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (25.0 mL), cooled to -78 °C and to it was added BBr₃ (19.0 mL, 19.0 mmol, 1.0 M solution in CH₂Cl₂). The reaction mixture was stirred at -78 °C for 10 min, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice, concentrated and extracted with ethyl acetate. The organic layer was washed with water (20 mLx2), dried over MgSO₄ and filtered. The solvent was removed under reduced pressure to afford 3,5-dichloro-4-(3'-*iso*-propyl-4'-hydroxyphenoxy)benzylphosphonic acid as a brown solid (0.20 g, 40%): mp: 178-181 °C; LC-MS m/z = 391 [C₁₆H₁₇Cl₂O₃P - H]⁺; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.08 (s, 1 H), 7.48 (s, 2 H), 6.72 (m, 2 H), 6.25 (m, 1 H), 3.18 (m, 1 H), 3.00 (d, *J* = 21.0 Hz, 2 H), 3.11 (m, 1 H), 1.14 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₆H₁₇Cl₂O₃P + 0.2 C₄H₈O₂ + 0.5 H₂O): C, 48.30; H, 4.73. Found: C, 48.69, H, 5.16.


[0779] Using the appropriate starting material, compounds 19-1 to 19-3 was prepared in an analogous manner to that described for the synthesis of compound 19.

Compound 19-1: diethyl [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propyl-phenoxy)]benzylphosphonate




[0780] Prepared from methyl 3,5-dibromo-4-hydroxybenzoate (*J. Med. Chem.* 46:1580 (2003)) according to the procedure described for the synthesis of compound 19. mp: 145 °C; LC-MS *m/z* = 536 [C₂₀H₂₅Br₂O₅P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 7.53 (s, 2 H), 6.50 (m, 2 H), 6.23 (m, 1 H), 3.98 (m, 4 H), 3.11 (m, 1 H), 1.21 (m, 6 H), 1.02 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₂₀H₂₅Br₂O₅P): C, 44.80; H, 4.70. Found: C, 45.19, H, 4.80.

Compound 19-2: [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)]-benzylphosphonic Acid



[0781] Prepared from compound 19-1 according to the procedure described for the synthesis of compound 19 step e. mp: 76-79 °C; LC-MS *m/z* = 480 [C₁₆H₁₇Br₂O₅P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 7.52 (s, 2 H), 6.55 (m, 2 H), 6.20 (m, 1 H), 3.14 (m, 1 H), 3.00 (d, *J* = 21.0 Hz, 2 H), 1.06 (d, *J* = 6.0 Hz, 6 H); HPLC conditions: Column = 3 Chromolith SpeedRODs RP-18e, 100×4.6 mm; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄) with 5% acetonitrile. Flow rate = 4 mL/min; UV@ 255 nm. Retention time in minutes. (rt = 5.80, 96% purity).


Compound 19-3: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)]-benzylphosphonic acid



[0782] Prepared from methyl 3,5-dimethyl-4-hydroxybenzoate according to the procedure described for the synthesis of compound 19. mp: 79-82 °C; LC-MS m/z = 351 [C₁₈H₂₃O₅P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 6.93 (s, 2 H), 6.51 (m, 2 H), 6.13 (m, 1 H), 3.13 (m, 1 H), 2.98 (d, J = 21.0 Hz, 2 H), 1.96 (s, 6 H), 1.04 (d, J = 6.0 Hz, 6 H); Anal. Calcd for (C₁₈H₂₃O₅P + 1.2 H₂O): C, 58.12; H, 6.88. Found: C, 58.01; H, 7.00.

Example 20

Compound 20 [3,5-dimethyl-4-N-(4'-hydroxy-3-*iso*-propylphenylamino)-phenoxy]methylphosphonic acid



Step a:

[0783] A solution of 4-amino-3,5-dimethylphenol (5.0 g, 36.46 mmol, Fieser, L. F. *Organic Syntheses*, Collect Vol II, 1943, 39), imidazole (6.21 g, 77.37 mmol) and triisopropylsilyl chloride (7.70 g, 40.1 mmol) in CH₂Cl₂ (80 mL) was stirred at room temperature for 1 h. The reaction mixture was diluted with CH₂Cl₂ (100.0 mL) and washed with water and brine. The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:19) to afford 2,6-dimethyl-4-triisopropylsilyloxyphenylamine (8.46 g, 79%): ¹H NMR (300 MHz, CDCl₃): δ 6.57 (s, 2 H), 2.19 (s, 6 H), 1.23 (m, 3 H), 1.12 (m, 18 H). TLC

conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.51.

Step b:

[0784] A mixture of $Pd_2(db\alpha)_3$ (800 mg, 0.87 mmol) and BINAP (1.09 g, 1.75 mmol) in toluene (70 mL) at 100 °C in a sealed tube was heated for 30 min. The reaction mixture was cooled to room temperature and to it was added 2,6-dimethyl-4-triisopropylsilyloxyphenylamine (6.15 g, 20.98 mmol) followed by 4-bromo-2-*iso*-propyl-1-methoxymethoxybenzene (4.0 g, 17.48 mmol) and potassium *tert*-butoxide (2.18 g, 22.72 mmol). The reaction mixture was heated at 110 °C in the sealed tube for 16 h, cooled to room temperature and filtered through a plug of Celite. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford *N*, *N*-(2,6-dimethyl-4-triisopropylsilyloxyphenyl)-*(3-iso-propyl-4-methoxymethoxyphenyl)amine* as a yellow solid (4.8 g, 58%): 1H NMR (300 MHz, $CDCl_3$): δ 6.88 (d, J = 8.7 Hz, 1 H), 6.67 (s, 1 H), 6.41 (d, J = 2.7 Hz, 1 H), 6.22 (m, 1 H), 5.11 (s, 2 H), 3.52 (s, 3 H), 3.28 (m, 1 H), 2.17 (s, 6 H), 1.28 (m, 3 H), 1.15 (m, 24 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.70.

Step c:

[0785] To a solution of *N*, *N*-(2,6-dimethyl-4-triisopropylsilyloxyphenyl)-*(3-iso-propyl-4-methoxymethoxyphenyl)amine* (800 mg, 1.70 mmol) in THF (10.0 mL) at 0 °C was added TBAF (2.55 mmol, 1.0 M in THF). The reaction mixture was stirred at room temperature for 16 h, diluted with ethyl acetate (10.0 mL) and quenched with H_2O (10.0 mL). The aqueous layer was extracted with ethyl acetate (10.0 mL) and the combined organic layers were dried over $MgSO_4$. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dimethyl-4-*N*-(3-*iso*-propyl-4'-methoxymethoxyphenylamino)phenol (280 mg, 52%): 1H NMR (300 MHz, $CDCl_3$): δ 6.88 (d, J = 8.1 Hz, 1 H), 6.63 (s, 2 H), 6.47 (m, 1 H), 6.21(m, 1 H),

5.12 (s, 2 H), 3.52 (s, 3H), 3.30 (m, 1 H), 2.19 (s, 6 H), 1.2 (d, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.45.

Step d:

[0786] To a solution of sodium hydride (22 mg, 0.86 mmol) in DMF at 0 °C was added a solution of 3,5-dimethyl-4-N-(3-*iso*-propyl-4'-methoxymethoxyphenylamino)phenol (270 mg, 0.86 mmol) in DMF (2.0 mL). The reaction mixture was stirred at room temperature for 1 h and to it was added a solution of diethyl tosyloxymethylphosphonate (0.34 g, 1.03 mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (10.0 mL) and saturated aqueous NaHCO₃ (10.0 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (10.0 mL). The combined organic layers were dried over MgSO₄, filtrated and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl [3,5-dimethyl-4-N-(3-*iso*-propyl-4'-methoxymethoxyphenylamino)phenoxy]methylphosphonate (160 mg, 52%): ¹H NMR (300 MHz, CDCl₃): δ 6.88 (d, J = 8.4 Hz, 1 H), 6.75 (s, 2 H), 6.46 (m, 1 H), 6.20 (m, 1 H), 5.12 (s, 2 H), 4.25 (m, 6 H), 3.52 (s, 3 H), 3.28 (m, 1 H), 2.21 (s, 6 H), 1.40 (m, 6 H), 1.20 (d, J = 6.9 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.29.


Step e:

[0787] To a solution of diethyl [3,5-dimethyl-4-N-(3-*iso*-propyl-4'-methoxymethoxyphenylamino)phenoxy]methylphosphonate (150 mg, 0.32 mmol) in CH₂Cl₂ (10 mL) at room temperature was added TMSBr (0.51 mL, 3.88 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was treated with water (5.0 mL), stirred for 2 h and extracted with ethyl acetate (10.0 mLx2). The combined organic layers were dried over MgSO₄, filtrated and

concentrated under reduced pressure. The crude product was purified by preparatory LC-MS to afford [3,5-dimethyl-4-*N*-(4'-hydroxy-3-*iso*-propylphenylamino)phenoxy]methylphosphonic acid as a blue solid (40 mg, 33.9%): ^1H NMR (300 MHz, CDCl₃): δ 8.3 (s, 1 H), 6.74 (s, 2 H), 6.49 (d, J = 8.4 Hz, 1 H), 6.36 (d, J = 2.4 Hz, 1 H), 5.92 (m, 1 H), 4.05 (d, J = 10.5 Hz, 2 H), 3.11 (m, 1 H), 2.10 (s, 6 H), 1.10 (d, J = 6.9 Hz, 6 H). mp > 200 °C; LC-MS *m/z* = 366 [C₁₈H₂₄NO₅P + H]⁺; Anal. Calcd for (C₁₈H₂₄NO₅P + 0.5 H₂O + 0.2 HCl): C, 56.65; H, 6.66; N, 3.67. Found: C, 56.45; H, 6.73; N, 3.71.

[0788] Using the appropriate starting material, compound 20-1 was prepared in an analogous manner to that described for the synthesis of compound 20.


Compound 20-1 [3,5-dimethyl-4-(4'-hydroxy-3-*iso*-propylphenylmethylamino)phenoxy]methylphosphonic acid



[0789] Prepared by standard reductive amination (*J. Org. Chem.* 37:1673 (1972)) of *N*, *N*-(2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(3-*iso*-propyl-4-methoxymethoxyphenyl)amine with formaldehyde followed by the same procedure described for the synthesis compound 20. ^1H NMR (300 MHz, CDCl₃): δ 8.28 (s, 1 H), 6.76 (s, 2 H), 6.54 (d, J = 8.8 Hz, 1 H), 6.15 (m, 1 H), 5.94 (m, 1 H), 4.05 (d, J = 10.2 Hz, 2 H), 3.13 (m, 1 H), 3.02 (s, 3 H), 1.97 (s, 6 H), 1.06 (d, J = 7.0 Hz, 6 H). mp > 200 °C. LC-MS *m/z* = 379 [C₁₉H₂₆NO₅P + H]⁺; Anal. Calcd for (C₁₉H₂₆NO₅P + 0.3 HBr + 0.1 CH₂Cl₂): C, 55.41; H, 6.46; N, 3.38. Found: C, 55.35; H, 6.55; N, 3.43.

Example 21

Compound 21: 2-[3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenyl]-2-oxoethylphosphonic acid



Step a:

[0790] To a stirred solution of diethyl methylphosphonate (0.4 g, 2.6 mmol) in anhydrous THF (15 mL) at -78 °C was added *n*-BuLi (1.95 mL, 1.95 mmol, 1 M solution in hexanes). The reaction mixture was stirred at -78 °C for 1 h and to it was added a solution of methyl 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzoate (0.24 g, 0.65 mmol, step a, example 19) in THF (5 mL). The reaction mixture was stirred at -78 °C for 1 h, quenched with 10% AcOH (10 mL) and H₂O (50 mL) and extracted with ethyl acetate (50 mLx2). The combined organic layers were washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl 2-[3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)]-2-oxoethylphosphonate as a colorless oil (0.28 g, 63%): ¹H NMR (300 MHz, CDCl₃): δ 8.05 (s, 2 H), 6.85 (d, *J* = 3.3 Hz, 1 H), 6.71 (d, *J* = 9.0 Hz, 1 H), 6.40 (dd, *J* = 3.3, 9.0 Hz, 1 H), 4.08 (q, *J* = 6.3 Hz, 1 H), 3.81 (s, 3 H), 3.60 (d, *J* = 23.1 Hz, 2 H), 3.35 - 3.25 (m, 1 H), 1.32 (t, *J* = 6.9 Hz, 6 H), 1.19 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.2.

Step b:

[0791] To a stirred solution of diethyl 2-[3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)]-2-oxoethylphosphonate (0.26 g, 0.54 mmol) in CH₂Cl₂ (7 mL) at 0 °C was added TMSBr (0.83 g, 0.8 mL, 5.4 mmol). The reaction mixture was stirred at 0 °C for 30 min, allowed to warm to room temperature and stirred for 16 h. The solvent was removed under reduced pressure and the residue was dissolved in CH₃OH (3 mL). The solvent was removed under reduced pressure to afford 2-[3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]-2-oxoethylphosphonic acid as a white solid (0.2 g,


83%): ^1H NMR (300 MHz, CD₃OD): δ 8.09 (s, 2 H), 6.83 (d, J = 3.3 Hz, 1 H), 6.71 (d, J = 9.0 Hz, 1 H), 6.40 (dd, J = 3.3, 9.0 Hz, 1 H), 3.81 (s, 3 H), 3.60 (d, J = 22.1 Hz, 2 H), 3.35-3.25 (m, 1 H), 1.19 (d, J = 6.9 Hz, 6 H).

Step c:

[0792] To a stirred solution of 2-[3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]-2-oxoethylphosphonic acid (0.17 g, 0.40 mmol) in CH₂Cl₂ (5 mL) at -78 °C was added BBr₃ (1.0 mL, 1.0 mmol, 1.0 M in CH₂Cl₂). The reaction mixture was stirred at room temperature for 14 h, poured into ice water (25 mL) and stirred for 1 h. The reaction mixture was extracted with ethyl acetate (50 mLx2). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was recrystallized from CH₂Cl₂, filtered and dried to afford 2-[3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy) phenyl]-2-oxoethylphosphonic acid as a yellow solid (0.14 g, 92%, m.p.: 83-85 °C, 98% pure): ^1H NMR (300 MHz, CD₃OD): δ 8.18 (s, 2 H), 6.71 (d, J = 3.0 Hz, 1 H), 6.65 (d, J = 8.7 Hz, 1 H) 6.37 (dd, J = 3.0, 8.7 Hz, 1 H), 3.65 (d, J = 37.8 Hz, 2 H) 3.30 - 3.20 (m, 1 H), 1.18 (d, J = 6.9 Hz, 6 H); LC-MS m/z = 420 [C₁₇H₁₇Cl₂O₆P + H]⁺; HPLC conditions: ODSAQ AQ-303-5 column; mobile phase = CH₃OH:TFA (7:3) flow rate = 1.0 mL/min; detection = UV @ 254 nm retention time in min: 13.26; Anal Calcd: (C₁₇H₁₇Cl₂O₆P) Calcd: C: 48.09; H: 4.18. Found: C, 47.97; H: 4.39.

Example 22

Compound 22: [3,5-dichloro-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenylamino]methylphosphonic acid



Step a:

[0793] To a solution of 4-amino-2,6-dichlorophenol (4.0 g, 22.5 mmol) in THF (25 mL) was added *t*-BOC anhydride (5.88 g, 27.0 mmol). The reaction mixture was heated under reflux for 2.5 h and the solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 3,5-dichloro-4-hydroxyphenylcarbamic acid *t*-butyl ester as an off-white solid (5.80 g, 93%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.70 (s, 1 H), 9.44 (s, 1 H), 7.46 (s, 2 H), 1.48 (s, 9 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.39.

Step b:

[0794] To a mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (2.76 g, 5.39 mmol) and copper powder (0.46 g, 7.18 mmol) in CH₂Cl₂ (20.0 mL) at 0 °C was added a solution of TEA (0.55 mL, 3.95 mmol) and 3,5-dichloro-4-hydroxyphenylcarbamic acid *tert*-butyl ester (1.00 g, 3.59 mmol) in dichloromethane (10.0 mL). The reaction mixture was stirred at room temperature for 14 h and filtered through a Celite plug. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:19) to afford 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylcarbamic acid *tert*-butyl ester as an off-white solid (1.45 g, 95%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.81 (s, 1 H), 7.68 (m, 2 H), 6.79 (m, 2 H), 6.42 (m, 1 H), 3.75 (s, 3 H), 3.20 (m, 1 H), 1.51 (s, 9 H), 1.33 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.64.

Step c:


[0795] To a mixture of 3,5-dichloro-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylcarbamic acid *tert*-butyl ester (0.400 g, 0.94 mmol) in THF (12.0 mL) at 0 °C was added sodium hydride (0.064 g, 1.22 mmol, 60% dispersion in oil). The reaction mixture was stirred at room temperature for 1 h and cooled to 0 °C. To the stirring mixture was added diethyl

trifluoromethanesulfonyloxymethylphosphonate (0.18 g, 0.94 mmol). The reaction mixture was stirred at room temperature for 2 h, quenched with water and diluted with ethyl acetate. The organic layer was washed with water and brine and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:3) to afford diethyl *N*-*tert*-butoxycarbonyl-[3,5-dichloro-4-(3-*iso*-propyl-4'-methoxyphenoxy)phenylamino]methylphosphonate as an oil (0.34 g, 63%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.64 (s, 2 H), 6.90 (m, 1 H), 6.76 (s, 1 H), 6.45 (m, 1 H), 4.95 (d, *J* = 9.0 Hz, 2 H); 4.01 (m, 4 H); 3.76 (s, 3 H), 3.21 (m, 1 H), 1.43 (s, 9 H), 1.20 (m, 6 H), 1.13 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.15

Step d:

[0796] To a solution of diethyl *N*-*tert*-butoxycarbonyl-[3,5-dichloro-4-(3-*iso*-propyl-4'-methoxy-phenoxy)phenylamino]methylphosphonate (0.25 g, 0.43 mmol) in CH₂Cl₂ (6.0 mL) at 0 °C was added bromotrimethylsilane (0.86 mL, 6.50 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (5.0 mL), cooled to -78 °C and to it was added BBr₃ (2.84 mL, 2.84 mmol, 1.0 M solution in CH₂Cl₂). The reaction mixture was stirred at -78 °C for 10 min, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice, diluted with ethyl acetate and washed with water. The organic layer was dried over MgSO₄ and concentrated under reduced pressure to afford [3,5-dichloro-4-(4'-hydroxy-3-*iso*-propylphenoxy)phenylamino]methylphosphonic acid as an off-white solid (0.15 g, 85% over two steps): mp: 97-100 °C; LC-MS *m/z* = 405,407 [C₁₆H₁₈Cl₂NO₃P + H]⁺; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.02 (s, 2 H), 6.90 (m, 2 H), 6.71 (m, 2 H), 6.32 (m, 2 H), 3.36 (m, 2 H), 3.21 (m, 1 H), 1.17 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₆H₁₈Cl₂NO₃P + 0.1 C₄H₈O₂ + 0.3 H₂O): C, 46.85; H, 4.65; N, 3.33. Found: C, 47.09; H, 4.94; N, 3.50.


Compound 22-1: [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenylamino]methylphosphonic acid



[0797] The title compound was prepared from 4-amino-2,6-dibromophenol according to the procedure described for the synthesis of Example 22, steps a-d; ^1H NMR (200 MHz, DMSO- d_6): δ 8.95 (m, 1H), 7.02 (s, 2H), 6.63 (m, 2H), 6.23 (m, 1H), 3.31 (d, J = 12.0 Hz, 2H), 3.14 (m, 1H), 1.12 (d, J = 6.0 Hz, 6H); LC-MS m/z = 496 [$C_{16}H_{18}Br_2NO_5P + H$] $^+$; HPLC conditions: Column = Agilent zorbax RP18, 150×3.0 mm; Mobile phase = Solvent B (Acetonitrile) = HPLC grade acetonitrile; Solvent A (buffer) = 20 mM potassium phosphate buffer (pH 4.7). Flow rate = 0.75 mL/min; UV@ 254 nm. Retention time in minutes. (t_R = 8.70/20 min, 92% purity).

Example 23

Compound 23: N-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-benzamido]methylphosphonic acid



Step a:

[0798] To a solution of methyl 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzoate (8.53 g, 16.7 mmol, intermediate for the synthesis of Example 19-3) in methanol (60.0 mL) at 0 °C was added a solution of 1 N NaOH (28.15 mL, 28.15 mmol). The reaction mixture was stirred at room temperature for 16 h and acidified with cold concentrated HCl. The reaction

mixture was extracted with ethyl acetate (10.0 mL) and the organic layer was dried over MgSO₄. The solvent was removed under reduced pressure to afford 4-(3'-*iso*-propyl-4'-methoxyphenoxy)-3,5-dimethylbenzoic acid as a pink solid (1.38 g, 78%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.88 (s, 1 H), 7.76 (s, 2 H), 6.85 (m, 1 H), 6.75 (m, 1 H), 6.34 (m, 1 H), 3.73 (s, 3H), 3.20 (m, 1 H), 2.11 (s, 6 H), 1.12 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); R_f = 0.00.

Step b:

[0799] To a mixture of 4-(3'-*iso*-propyl-4'-methoxyphenoxy)-3,5-dimethylbenzoic acid (0.20 g, 0.63 mmol), diethyl aminomethylphosphonate (0.19 g, 0.76 mmol) and triethylamine in CH₂Cl₂ (10.0 mL) at 0 °C was added EDCl (0.18 g, 0.763 mmol) followed by 1-hydroxy-7-azabenzotriazole (0.09 mg, 0.63 mmol). The reaction mixture was stirred at room temperature for 16 h, concentrated and diluted with ethyl acetate (10.0 mL). The organic layer was washed with water (10 mLx3) and brine, dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by preparatory TLC to afford diethyl *N*-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)-benzamido]methylphosphonate as an oil (0.20 g, 68%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.77 (m, 1 H), 7.69 (s, 2 H), 6.84 (d, *J* = 9.0 Hz, 1 H), 6.75 (m, 1 H), 6.36 (m, 1 H), 4.05 (m, 4 H), 3.76 (m, 5 H), 3.21 (m, 1 H), 2.11 (s, 6 H), 1.21 (m, 6 H), 1.13 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (1:1); R_f = 0.28.


Step c:

[0800] To a solution of diethyl *N*-[4-(3'-*iso*-propyl-4'-methoxyphenoxy)-3,5-dimethylbenzamido]methylphosphonate (0.20 g, 0.43 mmol) in CH₂Cl₂ (4.3 mL) at -30 °C was added bromotrimethylsilane (0.56 mL, 4.31 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (5.0 mL), cooled to -78 °C, and to it was added BBr₃ (1.29 mL, 1.29 mmol, 1.0 M solution in CH₂Cl₂). The reaction mixture was stirred

at -78 °C for 3 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice, extracted with ethyl acetate (10.0 mL) and washed with 2% HCl (20 mLx2) and water (20 mLx2). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure to afford *N*-[3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylphenoxy)benzamido]methylphosphonic acid as an pink solid (0.08 g, 47% over two steps); mp: 163–166 °C; LC-MS *m/z* = 394 [C₁₉H₂₄NO₆P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 7.52 (s, 2 H), 6.51 (m, 2 H), 6.19 (m, 1 H), 3.70 (d, *J* = 12.0 Hz, 2 H), 3.14 (m, 1 H), 2.04 (s, 6 H), 1.01 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₉H₂₄NO₆P + 1.0 H₂O): C, 55.47; H, 6.37; N, 3.40. Found: C, 55.30; H, 6.32; N, 3.12.

Example 24

Compound 24: 2-[3,5-dimethoxy-4-(4'-hydroxy-3'-iso propylbenzyl)phenyl]-ethylphosphonic acid



Step a:

[0801] To a solution of 3,5-dimethoxy-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (0.6 g, 1.73 mmol, intermediate for the synthesis of Example 7-2) and DMAP (0.85 g, 6.92 mmol) in CH₂Cl₂ (20 mL) at 0 °C was slowly added trifluoromethanesulfonyl anhydride (0.44 mL, 2.6 mmol). The reaction mixture was stirred at 0 °C for 2 h and quenched by water (10.0 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 3,5-dimethoxy-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)-1-trifluoromethanesulfonyloxyphenyl as a light yellow oil (0.83 g, 100%): ¹H

NMR (300 MHz, DMSO-*d*₆): δ 7.09 (s, 1 H), 6.87 (s, 2 H), 6.80 (s, 2 H), 5.15 (s, 2 H), 3.84 (s, 6 H), 3.81 (s, 2 H), 3.36 (s, 3 H), 3.20 (m, 1 H), 1.14 (d, *J* = 6.6 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.73.

Step b:

[0802] A mixture of 3,5-dimethoxy-4-(3'-*iso*-propyl-4'-methoxy-methoxybenzyl)-1-trifluoromethanesulfonyloxyphenyl (0.83 g, 1.73 mmol), triethylamine (0.96 mL, 6.92 mmol), Pd(PPh₃)₂Cl₂ (0.12 g, 0.17 mmol) and diethyl vinylphosphonate (0.37 mL, 2.43 mmol) in DMF (8 mL) was heated at 80 °C for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was separated, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-CH₂Cl₂ (1:1) to afford diethyl 2-[4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)-3,5-dimethoxy-phenyl]vinylphosphonate as a light yellow oil (0.1 g, 12%): ¹H NMR (300 MHz, CDCl₃): δ 7.50 (d, *J* = 17.4 Hz, 1 H), 7.29 (s, 1 H), 7.11 (m, 2 H), 6.72 (s, 2 H), 6.22 (t, *J* = 17.1 Hz, 1 H), 5.17 (s, 2 H), 4.21 (m, 4 H), 3.96 (s, 2 H), 3.87 (s, 6 H), 3.49 (s, 3 H), 3.31 (m, 1 H), 1.40 (t, *J* = 6.9 Hz, 6 H), 1.23 (d, *J* = 6.6 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-CH₂Cl₂ (1:3); R_f = 0.4.


Step c:

[0803] A mixture of diethyl 2-[3,5-dimethoxy-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenyl]vinylphosphonate (0.1 g, 0.2 mmol) and Pd/C (20 mg, 10%) in MeOH (20 mL) was stirred under one atmosphere of hydrogen at room temperature for 16 h. The mixture was filtered through a Celite plug. The solvent was removed under reduced pressure and the residue (90 mg) was dissolved in CH₂Cl₂ (5 mL). Deprotection with TMSBr as described for the synthesis of Compound 7, step b afforded 2-[3,5-dimethoxy-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenyl]ethylphosphonic acid as light pink foam (73 mg, 91%). ¹H NMR (200 MHz, DMSO-*d*₆): δ 8.88 (s, 1 H), 7.01 (d,

J = 1.8 Hz, 1 H), 6.71 (dd, *J* = 1.8 Hz, *J* = 8.0 Hz, 1 H), 6.55 (d, *J* = 8.4 Hz, 1 H), 6.5 (s, 2 H), 3.76 (s, 6 H), 3.69 (s, 2 H), 3.08 (m, 1 H), 2.72 (m, 2 H), 1.82 (m, 2 H), 1.08 (d, *J* = 7.0 Hz, 6 H), LC-MS *m/z* = 395 [C₂₀H₂₇O₆P + H]⁺; Anal Calcd for (C₂₀H₂₇O₆P + 1.3 H₂O): C, 57.49; H, 7.14. Found: C, 57.24; H, 7.24.


[0804] Using the appropriate starting material, compounds 24-1 to 24-4 were prepared in an analogous manner to that described for the synthesis of compound 24.

Compound 24-1: 2-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-phenyl]ethylphosphonic acid



[0805] Prepared from 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)). mp: 65-68 °C; ¹H NMR (300 MHz, CD₃OD): δ 6.93 (s, 2 H), 6.86 (d, *J* = 1.8 Hz, 1 H), 6.60 (d, *J* = 8.4 Hz, 1 H), 6.54 (dd, *J* = 1.8 Hz, *J* = 8.0 Hz, 1 H), 3.94 (s, 2 H), 3.24 (m, 1 H), 2.82 (m, 2 H), 2.23 (s, 6 H), 2.01 (m, 2 H), 1.15 (d, *J* = 7.0 Hz, 6 H), LC-MS *m/z* = 363 [C₂₀H₂₇O₄P]⁺; Anal Calcd for (C₂₀H₂₇O₄P + 0.6 H₂O + 0.4 CH₃OH): C, 63.47; H, 7.78. Found: C, 63.39; H, 8.06.


Compound 24-2: *trans*-2-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-phenyl]vinylphosphonic acid



[0806] Prepared from 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)).


mp: 82-84 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.38 (m, 1 H), 7.27 (s, 2 H), 6.84 (d, J = 1.8 Hz, 1 H), 6.62 (d, J = 8.4 Hz, 1 H), 6.54 (dd, J = 1.8 Hz, J = 8.0 Hz, 1 H), 6.42 (m, 1 H), 4.00 (s, 2 H), 3.24 (m, 1 H), 2.28 (s, 6 H), 1.15 (d, J = 7.0 Hz, 6 H), LC-MS m/z = 361 [C₂₀H₂₅O₄P + H]⁺; Anal Calcd for (C₂₀H₂₅O₄P + 0.3 H₂O): C, 65.67; H, 7.05. Found: C, 65.43; H, 7.13.

Compound 24-3: 2-[4-(3'-sec-butyl-4'-hydroxy-benzyl)-3,5-dimethyl-phenyl]-ethylphosphonic acid



[0807] The title compound was prepared from intermediate 4-(3'-sec-butyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenol, prepared from 4-bromo-2-methyl-phenol according to the procedure described in Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000), and transformed into the title compound by the procedure used for the synthesis of compound 24 as a light yellow foam; ^1H NMR (200 MHz, DMSO-*d*₆): δ 8.88 (s, 1 H), 6.86 (s, 2 H), 6.80 (s, 1 H), 6.61 (d, J = 8.0 Hz, 1 H), 6.46 (d, J = 8.0 Hz, 1 H), 3.81 (s, 2 H), 2.88 (m, 1 H), 2.65 (m, 2 H), 2.15 (s, 6 H), 1.75 (m, 2 H), 1.46 (m, 2 H), 1.06 (d, J = 7.0 Hz, 3 H), 0.74 (t, J = 7.4 Hz, 3 H), LC-MS m/z = 377 [C₂₁H₂₉O₄P + H]⁺; Anal Calcd for (C₂₁H₂₉O₄P + 1.6 H₂O): C, 62.24; H, 8.01. Found: C, 61.87; H, 7.82.

Compound 24-4: 2-[3,5-dimethyl-4-(3'-Ethyl-4'-hydroxy-benzyl)phenyl]-ethylphosphonic acid




[0808] Intermediate 4-(3'-ethyl-4'-methoxybenzyl)-3,5-dimethylphenol, prepared according to the procedure described in Chiellini *et al.*, *Bioorg. Med.*

Chem. Lett. 10:2607 (2000), was transformed into the title compound by the procedure used for the synthesis of compound 24 as a foam (94 mg, 19%); LC- MS *m/z* = 347 [C₁₈H₂₃O₃P – H]; ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.98(s, 1H), 6.86(d, 1H, *J* = 3 Hz), 6.72(d, 1H, *J* = 1.8 Hz), 6.60(s, 2H), 6.49(dd, 1H, *J* = 2.8 Hz, *J* = 8.4 Hz), 3.82(s, 2H), 2.71(m, 2H), 2.26(s, 3H), 2.09(s, 3H), 1.66(m, 2H), 1.06(t, 3H, *J* = 9 Hz); Uniplate silica gel, 250 microus; Mobile phase = isopropyl alcohol/ammonium hydroxide/water [7:2:1]; R_f = 0.22; Anal. Calcd for (C₁₉H₂₅O₄P + 1.1 H₂O): C, 61.98; H, 7.45; Found: C, 61.88, H, 7.19.

Example 25

Compound 25: [3'-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzoyl)phenoxy]-methylphosphonic acid



Step a:

[0809] To a stirring solution of (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(3'-*iso*-propyl-4'-methoxymethoxyphenyl)methanol (0.620 g, 1.27 mmol), (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in THF (10.0 mL) at 0 °C was added tetrabutylammonium fluoride (1.91 mL, 1.91 mmol, 1.0 M solution in THF). The reaction mixture was stirred at room temperature for 20 min, diluted with diethyl ether and washed with water (20 mL×2) and brine. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzylhydroxy)phenol as an oil (0.370 g, 88%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.07 (s, 1H), 7.20 (m, 1H), 6.90 (m, 1H), 6.78 (m, 1H), 6.39 (s, 2H), 5.98 (d, *J* = 3.0 Hz, 1H), 5.52 (d, *J* = 3.0 Hz, 1H), 5.18 (s, 2H), 3.38

(s, 3 H), 3.25 (m, 1 H), 2.12 (s, 6 H), 1.16 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.15.

Step b:

[0810] To a mixture of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzylhydroxy)phenol (0.380 g, 1.15 mmol) in DMF (10.0 mL) at 0 °C was added Cs₂CO₃ (1.87 g, 5.75 mmol). After 5 min, diethyl trifluoromethanesulfonyloxymethyl phosphonate (0.24 g, 1.15 mmol) was added. The reaction mixture was stirred at 0 °C for 5 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was quenched with 1 N HCl, diluted with ethyl acetate, and washed with water (10 mLx4) and brine. The organic layer was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:4) as mobile phase to afford diethyl [3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzylhydroxy)phenoxy]methylphosphonate as an oil (0.41 g, 74%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.20 (m, 1 H), 6.92 (m, 1 H), 6.78 (m, 1 H), 6.67 (s, 2 H), 6.03 (d, *J* = 3.0 Hz, 1 H), 5.64 (d, *J* = 3.0 Hz, 1 H), 5.18 (s, 2H), 4.38 (d, *J* = 9.0 Hz, 2 H), 4.11 (m, 4 H), 3.38 (s, 3 H), 3.25 (m, 1 H), 2.19 (s, 6 H), 1.24 (m, 6 H), 1.16 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (6:4); R_f = 0.35.

Step c:

[0811] To a stirred solution of diethyl [3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzylhydroxy)phenoxy]methylphosphonate (0.32 g, 0.66 mmol) in dichloromethane (8.0 mL) at 0 °C was added Dess-Martin periodinane (2.08 mL, 0.99 mmol, 0.48 M solution in CH₂Cl₂). The reaction mixture was stirred room temperature for 16 h, concentrated, diluted with diethyl ether (10.0 mL). To the solution was added a solution of 580 mg of Na₂S₂O₃ pentahydrate in 60 mL saturated NaHCO₃). After 15 min, the reaction mixture was diluted with ethyl acetate and water and washed with saturated NaHCO₃ and brine. The organic layer was concentrated under reduced pressure. The crude product was purified by column chromatography


on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl [3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzoyl)phenoxy]methylphosphonate as an oil (0.285 g, 89%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.22 (m, 1 H), 7.43 (m, 1 H), 7.13 (m, 1 H), 6.85 (s, 2 H), 5.35 (s, 2 H), 4.49 (d, J = 7.5 Hz, 2 H), 4.16 (m, 4 H), 3.43 (s, 3 H), 3.27 (m, 1 H), 2.02 (s, 6 H), 1.29 (m, 6 H), 1.20 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane-methanol (3:97); R_f = 0.52.

Step d:

[0812] To a solution of diethyl [3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzoyl)phenoxy]methylphosphonate (0.075 g, 0.16 mmol) in CH₂Cl₂ (3.0 mL) at -30 °C was added bromotrimethylsilane (0.31 mL, 2.4 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile-water (4:1, 5.0 mL) and sonicated. The solvents were removed under reduced pressure. The residue was dissolved in 1 N NaOH and extracted with dichloromethane and ethyl acetate. The aqueous layer was acidified with 2 N HCl and extracted with ethyl acetate. The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure to afford [3,5-dimethyl-4-(4'-hydroxy-3-*iso*-propylbenzoyl)phenoxy]methylphosphonic acid as a pink solid (0.05 g, 84%): mp 138 °C; LC-MS *m/z* = 379 [C₁₉H₂₃O₆P + H]⁺; ^1H NMR (300 MHz, DMSO- d_6): δ 10.50 (s, 1 H), 7.64 (s, 1 H), 7.27 (m, 1 H), 6.87 (m, 1 H), 6.78 (m, 1 H), 4.18 (m, 2 H), 3.18 (m, 1 H), 2.00 (s, 6 H), 3.11 (m, 1 H), 1.17 (d, J = 6.0 Hz, 6 H); HPLC conditions: Column = 3 Chromolith SpeedRODs RP-18e, 100×4.6 mm; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄) with 5% acetonitrile. Flow rate = 4 mL/min; UV@ 255 nm. Retention time in minutes. (rt = 5.30, 95% purity).

Example 26

Compound 26: 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)-phenoxy]ethylphosphonic acid



Step a:

[0813] To a stirring solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (1.00 g, 3.18 mmol, Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in DMF (30.0 mL) was added Cs₂CO₃ (5.18 g, 15.90 mmol) followed by 1,2-dibromoethane (1.64 g, 19.08 mmol). The reaction mixture was stirred at 60 °C for 2 d, diluted with ethyl acetate and washed with water (20 mLx4) and brine. The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:19) to afford 1-(2-bromoethoxy)-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)-3,5-dimethylbenzene as an oil (0.26 g, 16%): ¹H NMR (300 MHz, CDCl₃): δ 6.94 (m, 2 H), 6.67 (m, 3 H), 5.18 (s, 2 H), 4.32 (m, 2 H), 3.95 (s, 2 H), 3.68 (m, 2 H), 3.51 (s, 3 H), 3.37 (s, 3 H), 3.32 (m, 1 H), 2.26 (s, 6 H), 1.22 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.91.

Step b:

[0814] A mixture of 1-(2-bromoethoxy)-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)-3,5-dimethylbenzene (0.15 g, 0.36 mmol) and triethylphosphite (0.18 g, 1.07 mmol) in DMF (2.0 mL) was heated under reflux for 4 h. The reaction mixture was cooled to rt, diluted with ethyl acetate and extracted with water (10 mLx4) and brine. The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The


residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:1) to afford diethyl 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenoxy]ethylphosphonate as an oil (0.085 g, 50%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.96 (m, 1 H), 6.89 (m, 1 H), 6.62 (m, 3 H), 5.16 (s, 2 H), 4.12 (m, 2 H), 4.07 (m, 4 H) 3.86 (s, 2 H), 3.37 (s, 3 H), 3.22 (m, 1 H), 2.30 (m, 2 H), 2.17 (s, 6 H), 1.25 (m, 6 H), 1.12 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:7); R_f = 0.10.

Step c:

[0815] Deprotection of diethyl 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenoxy]ethylphosphonate with bromotrimethylsilane afforded 2-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]ethylphosphonic acid as a brown oil (0.055 g, 87%): mp: 58-61 °C; LC-MS *m/z* = 379, [C₂₀H₂₇O₅P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 6.84 (s, 1 H), 6.66 (s, 2 H), 6.56 (m, 2 H), 4.26 (m, 2 H), 3.90 (s, 2 H), 3.22 (m, 1 H), 2.30 (m, 1 H), 2.22 (s, 6 H), 1.15 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₂₀H₂₇O₅P + 0.6 H₂O): C, 61.72; H, 7.30. Found: C, 61.96, H, 7.73.

Example 27

Compound 27: [3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenoxy]-methylphosphonic acid



Step a:

[0816] To a solution of 2-bromopropene (6.0 g, 49.60 mmol) in diethyl ether (200 mL) at -78 °C was added *t*-butyllithium (36.0 mL). The reaction mixture was stirred at -78 °C for 3 h and to it was added tributyltin chloride (16.1 g, 49.60 mmol). The reaction mixture was allowed to warm up to room

temperature and stirred for 16 h. The reaction mixture was filtered through a plug of Celite and the filtrate was washed with saturated NH₄Cl. The organic layer was dried over MgSO₄, filtered and concentrated to afford the crude product as colorless oil that was used for next step without further purification.

Step b:

[0817] To a solution of 3-bromo-4-fluorobenzaldehyde (1.23 g, 6.04mmol) in dioxane (20 mL) was added the product obtained from *step a* followed by Pd(Ph₃)₂Cl₂. The reaction mixture was heated at 110 °C for 16 h, cooled to room temperature and filtered through a plug of Celite. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:19) to afford 4-fluoro-3-isopropenylbenzaldehyde (500 mg, 50%): ¹H NMR (300 MHz, CDCl₃): δ 7.89 (m, 1 H), 7.82 (m, 1 H), 7.24(m, 1 H), 5.36 (s, 2 H), 2.21 (s, 3 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:19); R_f= 0.60.

Step c:

[0818] To a solution of 4-bromo-3,5-dimethyl-triisopropylsilanoxylbenzene (1.29 g, 3.6 mmol, Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in THF at -78 °C was added *n*-butyllithium (1.58 mL, 3.96 mmol, 2.5 M in THF). After 30 min, a solution of 4-fluoro-3-isopropenylbenzaldehyde (500 mg, 3.0 mmol) in THF was added. The reaction mixture was stirred at -78 °C for 1 h, allowed to warm to room temperature, diluted with EtOAc and quenched with water. The organic layer was dried over MgSO₄, filtered and concentrated to afford crude 1-(2,6-dimethyl-4-triisopropylsilyl oxyphenyl)-1-(4'-fluoro-3'-isopropenylphenyl)methanol as an oil: ¹H NMR (200 MHz, CDCl₃): δ 7.18 (m, 1 H), 7.02 (m, 1 H), 6.94 (m, 1 H), 6.56 (s, 2 H), 6.22 (s, 1 H), 5.18 (m, 2 H), 2.20 (s, 6 H), 2.08 (s, 3 H), 1.25 (m, 3 H), 1.11 (m, 18).

Step d:

[0819] A solution of 1-(2,6-dimethyl-4-triisopropylsilyl oxyphenyl)-1-(4'-fluoro-3'-isopropenylphenyl)methanol (1.2 g, 2.71 mmol) and Pd/C (0.1 g, 10%) in EtOH/HOAc (9:1, 10 mL) was stirred under a H₂ atmosphere for 16

h. The reaction mixture was filtrated through a plug of Celite and concentrated to afford the crude 3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)trisopropylsilsanoxybenzene that was used for the next step without further purification.

Step e:


[0820] To a solution of 3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)trisopropylsilsanoxybenzene in THF (10 mL) at 0 °C was added TBAF (1 M, 4.0 mL). The reaction mixture was stirred for 3 h, diluted with ethyl acetate 920 mL and quenched with water (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenol (450 mg, 61% for two steps): ¹H NMR (300 MHz, CDCl₃): δ 6.97 (d, *J* = 7.4 Hz, 1 H), 6.86 (m, 1 H), 6.69 (m, 1 H), 6.60 (s, 2 H), 3.95 (s, 2 H), 3.20 (m, 1 H), 2.22 (s, 6 H), 1.25 (d, *J* = 6.4 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.50.

Step f:

[0821] [3,5-Dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenoxy]methyl-phosphonic acid was prepared from 3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenol following the same procedure as described in compound 7, step b: ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.03 (m, 1 H), 6.93 (m, 1 H), 6.71 (s, 2 H), 6.64 (m, 1 H), 4.03 (d, *J* = 10.2 Hz, 2 H), 3.89 (s, 2 H), 3.09 (m, 1 H), 2.15 (s, 6 H), 1.16 (d, *J* = 6.6 Hz, 6 H). mp: > 200 °C; LC-MS *m/z* = 367 [C₁₉H₂₄FO₄P + H]⁺; Anal. Calcd for (C₁₉H₂₄FO₄P + 0.4 H₂O): C, 61.09; H, 6.69. Found: C, 60.85; H, 6.32.

[0822] Using the appropriate starting material, compound 27-1 was prepared in an analogous manner to that described for the synthesis of compound 27.

Compound 27-1: [3,5-dichloro-4-(4'-fluoro-3'-*iso*-propylbenzyl)-phenoxy]methylphosphonic acid



[0823] Intermediate (2,6-dichloro-4-triisopropylsilyloxy-phenyl)-(4-fluoro-3-*iso*-propyl-phenyl)-methanol was prepared by the procedure described for the synthesis of compound 27, steps a, b, c, d as an oil (520 mg, 98%): ¹H NMR (300 MHz, CDCl₃): δ 7.24 (m, 1H), 6.98 (m, 2H), 6.91 (s, 2H), 6.52 (s, 1H), 4.48 (s, 1H), 3.24 (m, 1H), 1.25 (m, 3H), 1.15 (s, 24H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:19); R_f = 0.86.

Step d:


[0824] To a solution of (2,6-dimethyl-4-triisopropylsilyloxy-phenyl)-(4-fluoro-3-*iso*-propyl-phenyl)-methanol (520 mg, 1.08 mmol) in CH₂Cl₂ (10 mL) was added TFA (1.53 M, 0.7 mL) followed by triethylsilane (0.6 mL, 3.77 mmol) at r.t. After stirring for 2h, the reaction mixture was diluted with EtOAc and water and the layers were separated. The aqueous layer was further extracted with EtOAc. The combined organic layers were washed with Sat. NaHCO₃, water and brine, dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography (silica gel, hexanes) to provide 3,5-dichloro-4-(4'-fluoro-3'-*iso*-propyl-benzyl)-phenoxy]-triisopropylsilane as a colorless liquid (360 mg, 72%): ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 1H), 6.91 (m, 4H), 4.21 (s, 2H), 3.19 (m, 1H), 1.24 (m, 3H), 1.17 (m, 24H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes; R_f = 0.68.

[0825] Intermediate 3,5-dichloro-4-(4'-fluoro-3'-*iso*-propyl-benzyl)-phenoxy]-triisopropylsilane was transformed into the title compound by the procedure described for the synthesis of compound 35, steps e, f and h to give a white solid (55 mg, 35%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.22 (s, 2H), 7.18 (m, 1H), 7.04 (m, 1H), 6.87 (m, 1H), 4.22 (d, *J* = 9.6 Hz, 2H), 6.60 (s, 2H), 3.12 (m, 1H), 1.19 (d, *J* = 6.9 Hz, 6H). mp = 132~135, LC-MS *m/z* = 408

$[C_{17}H_{18}Cl_2FO_4P + H]^+$; Anal. Calcd for $(C_{17}H_{18}Cl_2FO_4P + 0.2 H_2O)$: C, 49.70; H, 4.51. Found: C, 49.58; H, 4.24.

Example 28

Compound 28: *trans*-2-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenyl]vinylphosphonic acid



Step a:

[0826] To a mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (4.80 g, 9.38 mmol) and copper powder (0.79 g, 12.52 mmol) in CH_2Cl_2 (15.0 mL) at 0 °C was added a solution of triethylamine (0.96 mL, 6.89 mmol) and 3,5-dimethyl-4-hydroxybenzaldehyde (0.94 g, 6.26 mmol) in dichloromethane (15.0 mL). The reaction mixture was stirred at room temperature for 3 d and filtered through a Celite plug. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:19) to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzaldehyde as an oil (2.00 g, 100%): 1H NMR (300 MHz, DMSO- d_6): δ 9.96 (s, 1 H), 7.75 (s, 2 H), 6.85 (m, 1 H), 6.73 (m, 1 H), 6.36 (m, 1 H), 3.74 (s, 3 H), 3.19 (m, 1 H), 2.15 (s, 6 H), 1.12 (d, $J = 6.0$ Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); $R_f = 0.51$.

Step b:

[0827] To a mixture of tetrachethyl methylenediphosphonate (0.20 mL, 0.80 mmol) and THF (7.0 mL) at 0 °C was added sodium hydride (0.033 g, 0.804 mmol, 60% dispersion in oil). The reaction mixture was stirred at room temperature for 30 min and to it was added 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzaldehyde (0.20 g, 0.67 mmol). The reaction mixture was stirred at room temperature for 1 h, quenched with cold aqueous solution


of NH₄Cl, diluted with ethyl acetate and washed with water and brine. The solvent was removed under reduced pressure and the residue was purified by preparatory TLC on silica gel, eluting with acetone-hexanes (1:4) to afford diethyl *trans*-2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]vinylphosphonate as an oil (0.21 g, 74%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.53 (s, 2 H), 7.32 (m, 2 H), 6.84 (m, 1 H), 6.74 (m, 1 H), 6.59 (m, 2 H), 6.36 (m, 1 H), 4.00 (m, 4 H), 3.73 (s, 3 H), 3.20 (m, 1 H), 2.07 (s, 6 H), 1.27 (m, 6 H), 1.10 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.13.

Step c:

[0828] To a solution of diethyl *trans*-2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]vinylphosphonate (0.22 g, 0.50 mmol) in CH₂Cl₂ (5.0 mL) at -30 °C was added bromotrimethylsilane (0.66 mL, 5.00 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (5.0 mL) and cooled to -78 °C. To it was added BBr₃ (1.49 mL, 1.49 mmol, 1.0 M solution in CH₂Cl₂). The reaction mixture was stirred at -78 °C for 3 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice, concentrated, and extracted with ethyl acetate. The organic solution was washed with 2% HCl (20 mL) and water (20 mLx3), dried over MgSO₄ and filtered. The solvent was removed under reduced pressure to afford *trans*-2-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenyl]vinylphosphonic acid as an off-white solid (0.08 g, 44% over two steps): mp 92-94 °C; LC-MS *m/z* = 363 [C₁₉H₂₃O₅P + H]⁺; ¹H NMR (300 MHz, CD₃OD): δ 7.35 (s, 2 H), 7.10 (s, 1 H), 6.65 (s, 2 H), 6.32 (m, 2 H), 3.21 (m, 1 H), 2.12 (s, 6 H), 1.15 (d, *J* = 6.0 Hz, 6 H); HPLC conditions: Column = 3 Chromolith SpeedRODs RP-18e, 100×4.6 mm; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄) with 5% acetonitrile. Flow rate = 4 mL/min; UV@ 255 nm. Retention time in minutes. (rt = 5.71, 98% purity).

Example 29

Compound 29: 3-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenyl]-propylphosphonic acid



Step a:

[0829] To a mixture of triethyl phosphonoacetate (0.16 mL, 0.80 mmol) in THF (7.0 mL) at 0 °C was added NaH (0.033 g, 0.804 mmol, 60% dispersion in oil). The reaction mixture was stirred room temperature for 30 min and to it was added 3,5-dimethyl-4-(3-*iso*-propyl-4-methoxyphenoxy)benzaldehyde (0.20 g, 0.67 mmol, Example 28, step a). The reaction mixture was stirred at room temperature for 1 h, quenched with cold saturated NH₄Cl, diluted with ethyl acetate and washed with water and brine. The solvent was removed under reduced pressure and the residue was purified by preparatory TLC on silica gel, eluting with acetone-hexanes (3:17) to afford ethyl *trans*-3-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]acrylate as an oil (0.24 g, 97%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.60 (m, 3 H), 6.83 (m, 1 H), 6.76 (m, 1 H), 6.60 (m, 1 H), 6.36 (m, 1 H), 4.21 (m, 4 H), 3.73 (s, 3H), 3.21 (m, 1 H), 2.08 (s, 6 H), 1.27 (m, 6 H), 1.12 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.62.

Step b:

[0830] To a mixture of ethyl *trans*-3-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]acrylate (1.10 g, 3.35 mmol) in THF (20.0 mL) at 0 °C was added DIBAL-H (4.68 mL, 4.68 mmol, 1.0 M solution in THF). The reaction mixture was stirred at room temperature for 2 h, quenched with cold 1 N HCl, diluted with ethyl acetate and washed with water and brine. The solvent was removed under reduced pressure and the residue was purified by

column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford *trans*-3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]-prop-2-en-1-ol as an oil (0.50 g, 81%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.22 (s, 2 H), 6.97 (m, 0.5 H), 6.84 (m, 1.5 H), 6.73 (m, 1 H), 6.36 (m, 2 H), 4.87 (m, 1 H), 4.14 (m, 2 H), 3.73 (s, 3 H), 3.21 (m, 1 H), 2.05 (s, 6 H), 1.11 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); R_f = 0.11.

Step c:

[0831] To a mixture of *trans*-3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]-prop-2-en-1-ol (0.50 g, 1.53 mmol) in methanol (15.0 mL) was added 10% Pd/C (0.10 g, 20% wt/wt). The reaction mixture was stirred under H₂ (balloon) at room temperature for 6 h and filtered through a plug of Celite. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (3:7) to afford 3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propanol as an oil (0.36 g, 72%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.97 (s, 2 H), 6.82 (m, 1 H), 6.74 (m, 1 H), 6.30 (m, 1 H), 4.49 (m, 1 H), 3.73 (s, 3 H), 3.43 (m, 2 H), 3.21 (m, 1 H), 2.57 (m, 2 H), 2.03 (s, 6 H), 1.73 (m, 2 H), 1.11 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (17:3); R_f = 0.26.

Step d:

[0832] To a stirred solution of triphenylphosphine (0.36 g, 1.39 mmol) and CBr₄ (0.46 g, 1.39 mmol) in diethyl ether (12.0 mL) at room temperature was added 3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propanol (0.35 g, 1.06 mmol). The reaction mixture was stirred for 16 h, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 1-bromo-3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propane as an oil (0.30 g, 72%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.00 (s, 2 H), 6.83 (m, 1 H), 6.80 (m, 1H), 6.31 (m, 1 H), 3.73 (s, 3 H), 3.53 (m, 2 H), 3.20 (m, 1 H), 2.70 (m, 2 H), 2.12 (m, 2 H), 2.03 (s, 6 H), 1.11 (d, *J*

= 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.75.

Step e:

[0833] A mixture of 1-bromo-3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propane (0.30 g, 0.77 mmol) and triethylphosphite (0.39 g, 2.31 mmol) in DMF (7.0 mL) was heated under reflux for 2.5 h and cooled to room temperature. The mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:3) to afford diethyl 3-[3,5-dimethyl 4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propylphosphonate as an oil (0.11 g, 32%); 1H NMR (300 MHz, DMSO- d_6): δ 6.97 (s, 2 H), 6.83 (d, J = 9.0 Hz, 1 H), 6.72 (d, J = 3.0 Hz, 1 H), 6.32 (m, 1 H), 3.99 (m, 4 H), 3.73 (s, 3 H), 3.35 (m, 2 H), 3.17 (m, 1 H), 2.62 (m, 2 H), 2.02 (s, 6 H), 1.75 (m, 4 H), 1.23 (m, 6 H), 1.10 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:4); R_f = 0.17.

Step f:


[0834] To a solution of diethyl 3-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]propylphosphonate (0.10 g, 0.22 mmol) in CH_2Cl_2 (5.0 mL) at -30 °C was added bromotrimethylsilane (0.30 mL, 2.23 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (3.0 mL) and cooled to -78 °C. To it was added BBr_3 (0.66 mL, 0.66 mmol, 1.0 M solution in CH_2Cl_2). The reaction mixture was stirred at -78 °C for 3 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was poured into ice, concentrated and extracted with ethyl acetate (10 mL). The organic solution was washed with 0.5 M HCl (20 mLx2) and water (20 mLx2), dried over $MgSO_4$, filtered and concentrated under reduced pressure to afford 3-[3,5-dimethyl 4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenyl]propylphosphonic acid as a white solid (0.50 g, 60% over two steps); mp: 60-63 °C; LC-MS m/z = 379 [$C_{20}H_{27}O_5P + H]^+$; 1H NMR

- 405 -

(200 MHz, DMSO-*d*₆): δ 8.80 (s, 1 H), 6.85 (s, 2 H), 6.56 (m, 2 H), 6.10 (m, 1 H), 3.05 (m, 1 H), 2.40 (m, 2 H), 1.90 (s, 6 H), 1.49 (m, 2 H), 1.33 (s, 2 H), 1.03 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₂₀H₂₇O₅P + 1.1 H₂O): C, 60.32; H, 7.39. Found: C, 60.19 H, 7.32.

Example 30

Compound 30: 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)-phenyl]ethylphosphonic acid



Step a:

[0835] A solution of diethyl *trans*-2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]vinylphosphonate (1.77 g, 4.10 mmol, Example 28, step b) and Pd/C (177 mg) in EtOH/HOAc (10 mL, 9:1) was stirred under a H₂ atmosphere for 5 h. The reaction mixture was filtrated through a plug of Celite and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]ethylphosphonate (1.29 g, 74%): ¹H NMR (300 MHz, CDCl₃): δ 6.94 (s, 2 H), 6.81 (d, *J* = 3.0 Hz, 1 H), 6.68 (d, *J* = 8.7 Hz, 1 H), 6.36 (m, 1 H), 4.15 (m, 4 H), 3.30 (m, 1 H), 2.88 (m, 2 H), 2.13 (s, 6 H), 2.05 (m, 2 H), 1.37 (m, 6 H), 1.21 (d, *J* = 6.9 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.35.


Step b:

[0836] Deprotection of diethyl 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]ethylphosphonate with bromotrimethylsilane afforded 2-[3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl]-

ethylphosphonic acid: ^1H NMR (300 MHz, DMSO- d_6): δ 6.98 (s, 2 H), 6.78 (d, $J = 9.3$ Hz, 1 H), 6.72 (d, $J = 2.7$ Hz, 1 H), 6.26 (m, 1 H), 3.70 (s, 3 H), 3.16 (m, 1 H), 2.71 (m, 2 H), 2.00 (s, 6 H), 1.81 (m, 2 H), 1.10 (d, $J = 6.6$ Hz, 6 H). LC-MS $m/z = 379$ [C₂₀H₂₇O₅P + H]⁺; Anal. Calcd for (C₂₀H₂₇O₅P + 0.7 H₂O): C, 61.43; H, 7.32. Found: C, 61.59; H, 7.60.

Example 31

Compound 31: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]-methylphosphonic acid




[0837] To a solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzaldehyde (0.18 g, 0.60 mmol, Example 28, step a) in dichloromethane (6.0 mL) at 0 °C was added *m*-chloroperoxybenzoic acid (0.22 g, 0.905 mmol). The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was diluted with ethyl acetate. The organic solution was washed with saturated sodium bicarbonate (2x10mL) and water. The solvent was removed under reduced pressure and the residue was dissolved in methanol (5 mL). To the solution was added 1 N NaOH (1.81 mL, 1.81 mmol) and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with ethyl acetate, acidified with 2 N HCl and washed with brine. The solvent was evaporated and the residue was purified by preparatory TLC eluting with acetone-hexanes (1:4) to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenol as an oil (0.08 g, 47%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.17 (s, 1 H), 6.82 (m, 1 H), 6.70 (m, 1 H), 6.51 (s, 2 H), 6.32 (m, 1 H), 3.71 (s, 3 H), 3.18 (m, 1 H), 1.95 (s, 6 H), 1.12 (d, $J = 6.0$ Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.44.

[0838] Intermediate 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)-phenol was converted to [3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenoxy]methylphosphonic acid following the procedure described for the synthesis of compound 8: mp 60-64 °C; LC-MS *m/z* = 367 [C₁₈H₂₃O₆P + H]⁺; ¹H NMR (200 MHz, DMSO-*d*₆): δ 8.88 (s, 1 H), 6.76 (s, 2 H), 6.60 (m, 2 H), 6.17 (m, 1 H), 4.04 (d, *J* = 15.0 Hz, 2 H), 3.13 (m, 1 H), 2.01 (s, 6 H), 1.10 (d, *J* = 6.0 Hz, 6 H); Anal. Calcd for (C₁₈H₂₃O₆P + 0.7 H₂O): C, 57.05; H, 6.49. Found: C, 57.10 H, 6.63.

Example 32:

Compound 32: 3-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)]-phenyl-2-oxopropylphosphonic acid



Step a:

[0839] To a stirred solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzaldehyde (4.1 g, 15.2 mmol, Example 28, step a) in methanol (35 mL) at 0 °C was slowly added NaBH₄ (1.16 g, 30.5 mmol). The reaction mixture was stirred at room temperature for 5 h and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (150 mL), washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:4) to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzyl alcohol as a white solid (3.4 g, 83%, m.p.: 78-80 °C): ¹H NMR (300 MHz, CDCl₃): δ 7.12 (s, 2 H), 6.80 (d, *J* = 3.3 Hz, 2 H), 6.67 (d, *J* = 9.0 Hz, 1 H), 6.36 (dd, *J* = 3.0, 8.7 Hz, 1 H), 4.68 (s, 2 H), 3.80 (s, 3 H), 3.35 - 3.25 (m, 1 H), 2.16 (s, 6 H), 1.19 (d, *J* = 7.2 Hz, 6

H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:4); R_f = 0.5.

Step b:

[0840] To a stirred solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzyl alcohol (1.0 g, 3.4 mmol) in DME (10 mL) at 0 °C was added phosphorous tribromide (1.8 g, 0.5 mL, 6.8 mmol). The reaction mixture was stirred at 0 °C for 5 h, quenched with methanol (2 mL) and stirred for 30 min. The reaction mixture was poured into ice water and extracted with ether (100 mL). The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford crude 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzyl bromide as an oil (1.02 g, 82%); ^1H NMR (300 MHz, CDCl_3): δ 7.15 (s, 2 H), 6.81 (d, J = 3.0 Hz, 1 H), 6.67 (d, J = 9.0 Hz, 1 H), 6.34 (dd, J = 3.0, 8.7 Hz, 1 H), 4.51 (s, 2 H), 3.80 (s, 3 H), 3.40 - 3.25 (m, 1 H), 2.15 (s, 6 H), 1.20 (d, J = 7.2 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:4); R_f = 0.7.

Step c:

[0841] To a stirred solution of sodium cyanide (0.23 g, 4.69 mmol) in H_2O (2 mL) at room temperature was added a solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)benzyl bromide (0.85 g, 2.34 mmol) in ethanol (5 mL). The reaction mixture was heated at 80 °C for 2 h, cooled to room temperature, and poured into ice water (100 mL). The mixture was stirred for 1 h and extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with water and brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenyl-acetonitrile as a brown solid (0.64 g, 85%, m.p.: 56 - 58 °C); ^1H NMR (300 MHz, CDCl_3): δ 7.07 (s, 2 H), 6.78 (d, J = 3.3 Hz, 1 H), 6.68 (d, J = 9.0 Hz, 1 H), 6.35 (dd, J = 3.0, 8.7 Hz, 1 H), 3.80 (s, 3 H), 3.73 (s, 2 H), 3.40 - 3.25 (m,

1 H), 2.16 (s, 6 H), 1.19 (d, J = 7.2 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.5.

Step d:

[0842] To a stirred solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylacetonitrile (0.75 g, 2.42 mmol) in acetic acid (7 mL) was added a 50% solution of H_2SO_4 (14 mL). The reaction mixture was heated at 105 °C, for 3 h, cooled to room temperature and poured into ice water (100 mL). The mixture was stirred for 1 h and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with water and brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylacetic acid as a brownish solid (0.62 g, 85%, m.p.: 118-120 °C): 1H NMR (300 MHz, $CDCl_3$): δ 7.11 (s, 2 H), 6.82 (d, J = 2.7 Hz, 1 H), 6.80 (d, J = 8.7 Hz, 1 H), 6.37 (dd, J = 3.3, 8.7 Hz, 1 H), 3.80 (s, 3 H), 3.61 (s, 2 H), 3.38-3.25 (m, 1 H), 2.11 (s, 6 H), 1.17 (d, J = 7.2 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.2.

Step e:

[0843] To a stirred cold solution of methanol (15 mL) and acetyl chloride (3 mL, 86.0 mmol) at 0 °C was added dropwise a solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylacetic acid (0.7 g, 4.3 mmol) in methanol (5 mL). The reaction mixture was heated under reflux for 5 h and cooled to room temperature. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (100 mL). The organic solution was washed with water and brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was triturated with hexane, filtered and dried under reduced pressure to afford methyl 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylacetate as a yellow solid (0.69 g, 95%): 1H NMR (300 MHz, $CDCl_3$): δ 7.02 (s, 2 H), 6.82 (d, J = 2.7 Hz, 1 H), 6.66 (d, J = 8.7 Hz, 1 H), 6.38 (dd, J = 3.3, 8.7 Hz, 1 H), 3.79 (s, 3 H), 3.75 (s, 3 H), 3.60 (s, 2 H), 3.28 - 3.25 (m, 1 H), 2.14 (s, 6 H), 1.20 (d, J = 7.2 Hz, 6 H);


TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.6$.

Step f:

[0844] 3-[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenyl]-2-oxopropylphosphonic acid was prepared from methyl-3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenoxy)phenylacetate following the same procedure as described in compound 21: mp: 80-82 °C; ^1H NMR (300 MHz, CDCl_3): δ 6.85 (s, 2 H), 6.51 (d, $J = 2.1$ Hz, 1 H), 6.48 (d, $J = 8.4$ Hz, 1 H), 6.14 (dd, $J = 3.0, 9.0$ Hz, 1 H), 4.80 (s, 2 H), 3.80 (s, 2 H), 3.20-3.10 (m, 1 H), 2.99 (d, $J = 22.5$ Hz, 1 H), 1.97 (s, 6 H), 1.03 (d, $J = 6.9$ Hz, 6 H); LC-MS $m/z = 393$ [$\text{C}_{20}\text{H}_{25}\text{O}_6\text{P} + \text{H}^+$] ‡ ; HPLC conditions: ODSAQ AQ-303-5 column; mobile phase = CH_3OH :5%TFA(7:3) flow rate = 1.0 mL/min; detection = UV @ 254 nm retention time in min: 11.19; Anal Calcd for ($\text{C}_{20}\text{H}_{25}\text{O}_6\text{P} + 0.2 \text{ CH}_2\text{Cl}_2$): C, 58.82; H, 6.22. Found: C, 58.75; H, 6.30.

Example 33:

Compound 33: [3,5-dimethyl-4-(4'-Hydroxy-3'-*iso*-propyl-phenyl)-methoxymethyl]phenoxy]methylphosphonic acid



Step a:

[0845] To a solution of (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(3-*iso*-propyl-4-methoxymethoxyphenyl)methanol (1.60 g, 3.29 mmol, Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in THF (30.0 mL) at 0 °C was added TBAF (4.93 mL, 4.93 mmol, 1.0 M solution in THF). The reaction mixture was stirred at room temperature for 60 min, diluted with diethyl ether (10.0 mL) and washed with water (20 mLx2). The organic layer was dried over MgSO_4 and concentrated under reduced pressure. The crude product was

purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 3,5-dimethyl-4-[(3'-*iso*-propyl-4'-methoxymethoxyphenyl)-hydroxymethyl]phenol as a white solid (1.00 g, 92%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.05 (s, 1 H), 7.17 (m, 1 H), 6.90 (m, 1 H), 6.77 (m, 1 H), 6.37 (s, 2 H), 5.97 (d, *J* = 6.0 Hz, 1 H), 5.51 (d, *J* = 6.0 Hz, 1 H) 5.15 (s, 2H), 3.36 (s, 3 H), 3.23 (m, 1 H), 2.10 (s, 6 H), 1.16 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.17.

Step b:

[0846] To a mixture of 3,5-dimethyl-4-[(3'-*iso*-propyl-4'-methoxymethoxyphenyl)-hydroxymethyl]phenol (0.380 g, 1.15 mmol) in DMF (10.0 mL) at 0 °C was added Cs₂CO₃ (1.87 g, 5.75 mmol). After 5 min, trifluoromethanesulfonic acid diethoxyphosphorylmethyl ester (0.24 g, 1.15 mmol) was added. The reaction mixture was stirred at room temperature for 16 h, quenched with 1 N HCl, diluted with ethyl acetate and extracted with water (10 mLx4). The organic layer was dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:4) to afford diethyl [3,5-dimethyl-4-[(3'-*iso*-propyl-4'-methoxymethoxyphenyl)-hydroxymethyl]phenoxy]methylphosphonate as an oil (0.41 g, 74%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.20 (m, 1 H), 6.92 (m, 1 H), 6.78 (m, 1 H), 6.67 (s, 2 H), 6.03 (d, *J* = 3.0 Hz, 1 H), 5.64 (d, *J* = 3.0 Hz, 1 H), 5.18 (s, 2H), 4.38 (d, *J* = 9.0 Hz, 2 H), 4.11 (m, 4 H), 3.38 (s, 3 H), 3.25 (m, 1 H), 2.19 (s, 6 H), 1.24 (m, 6 H), 1.16 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (6:4); R_f = 0.35.

Step c:

[0847] To a solution of diethyl [3,5-dimethyl-4-[(3'-*iso*-propyl-4'-methoxymethoxyphenyl)-hydroxymethyl]phenoxy]methylphosphonate (0.200 g, 0.42 mmol) in MeOH (6.0 mL) at 0 °C was added 2 M HCl (2.1 mL, 4.20 mmol). The reaction mixture was stirred at 0 °C for 3 h and at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (10.0


mL) and washed with water (20 mLx2). The organic layer was dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:1) to afford diethyl [3,5-dimethyl-4-[(4'-hydroxy-3'-*iso*-propylphenyl)methoxymethyl]phenoxy]methylphosphonate as an oil (0.125 g, 69%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.16 (s, 1 H), 7.03 (s, 1 H), 6.71 (s, 2 H), 6.59 (m, 2 H), 5.63 (s, 2 H), 4.41 (d, *J* = 15.0 Hz, 2 H), 4.11 (m, 4 H) 3.20 (s, 3H), 2.17 (s, 6 H), 1.21 (m, 6 H), 1.11 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (1:1); R_f = 0.50.

Step d:

[0848] To a solution of diethyl [3,5-dimethyl-4-[(4'-hydroxy-3'-*iso*-propylphenyl)methoxymethyl]phenoxy]methylphosphonate (0.065 g, 0.15 mmol) and 1,1,1,3,3,3-hexamethylidisilazane (0.38 mL, 1.80 mmol) in CH₂Cl₂ (3.0 mL) at -30 °C was added bromotrimethylsilane (0.12 mL, 0.90 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile-water (4:1, 5.0 mLx3) and sonicated. The solvent was removed under reduced pressure and the residue was dissolved in 1 M NaOH (5 mL). The aqueous solution was extracted with ethyl acetate (5mLx2) and acidified with 2 M HCl. The mixture was diluted with ethyl acetate and washed several times with water. The organic layer was dried over MgSO₄ and concentrated under reduced pressure to afford the title compound as a red powder (0.035 g, 62%); ¹H NMR (300 MHz, D₂O): δ 7.03 (s, 1 H), 6.78-6.67 (m, 4 H), 6.14 (s, 1 H), 4.02 (d, *J* = 10.5 Hz, 2 H), 3.21 (s, 3 H), 2.09 (s, 6 H), 1.01 (m, 6 H); HPLC conditions: Column = 3 Chromolith SpeedRODs RP-18e, 100×4.6 mm; Mobile phase = Solvent A (Acetonitrile) = HPLC grade acetonitrile; Solvent B (buffer) = 20 mM ammonium phosphate buffer (pH 6.1, 0.018 M NH₄H₂PO₄/0.002 M (NH₄)₂HPO₄) with 5% acetonitrile. Flow rate = 4 mL/min; UV@ 255 nm. Retention time in minutes. (rt = 5.70, 93% purity).

Example 34:

Compound 34: [3,5-dimethyl-4-(4'-hydroxy-3'-iodobenzyl)phenoxy]-methylphosphonic acid




Step a

[0849] To a mixture of diethyl [3,5-dimethyl-4-(4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (0.26 g, 0.61 mmol, prepared from commercially available 4-bromophenol according to the procedure described in compound 7) in methanol (3.0 mL) at 0 °C was added 2 N HCl (1.0 mL). The reaction mixture was stirred at room temperature for 24 h, quenched with water (10.0 mL) and extracted with ethyl acetate (10.0 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure to afford diethyl [3,5-dimethyl-4-(4'-hydroxybenzyl)phenoxy]methylphosphonate (0.22 g, 95%) as colorless oil: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.11 (s, 1 H), 6.60-6.80 (m, 6 H), 4.35 (d, *J* = 14.7 Hz, 2 H), 4.11 (m, 4 H), 3.80 (s, 2 H), 2.15 (s, 6 H), 1.25 (t, *J* = 10.5 Hz, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.40.

[0850] [3,5-Dimethyl-4-(4'-hydroxy-3'-iodobenzyl)phenoxy]methylphosphonic acid was prepared from diethyl [3,5-dimethyl-4-(4'-hydroxybenzyl)phenoxy]methylphosphonate according to the procedure described in compound 2 steps f and g: ¹H NMR (300 MHz, CD₃OD): δ 7.27 (d, *J* = 2.4 Hz, 1 H), 6.83 (dd, *J* = 8.1, 2.1 Hz, 1 H), 6.76 (s, 2 H), 6.72 (d, *J* = 8.1 Hz, 1 H), 4.23 (d, *J* = 10.2 Hz, 2 H), 3.91 (s, 2 H), 2.23 (s, 6 H); LC-MS m/z = 449 [C₁₆H₁₈IO₅P + H]⁺; Anal Calcd for (C₁₆H₁₈IO₅P + 0.7 H₂O): C, 41.70; H, 4.24. Found: C, 41.73; H, 4.56.

Example 35:

Compound 35: [3,5-dimethyl-4-(3'-carboxyl-4'-hydroxy-benzyl)phenoxy]-methylphosphonic acid



Step a:

[0851] To the suspension of NaH (3.25 g, 0.135 mol) in DMF (150 mL) was added 4-hydroxy-benzaldehyde (15.0 g, 0.123 mol) in DMF (10 mL) at 0 °C, 5 min. later the reaction mixture became a cake. The heterogeneous mixture was stirred at 0 °C for 30 min. MOMCl (9.96 g, 0.123 mol) was added slowly and the reaction mixture was allowed to warm up to r.t. After stirring at r.t. for 16 h, the volatiles were removed under vacuum. The residue was partitioned between ethyl acetate and water and the water layer was further extracted with ethyl acetate. The combined ethyl acetate extracts were dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes;1:4) to afford 4-methoxymethoxy-benzaldehyde (19.0 g, 93%): ¹H NMR (300 MHz, CDCl₃): δ 9.94 (s, 1H), 7.88 (m, 2H), 7.18 (m, 2H), 5.29 (s, 2H), 3.53 (s, 2H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.86.

Step b:

[0852] To a solution of (4-bromo-3,5-dimethyl-phenoxy)triisopropylsilane (8.0 g, 23.30 mmol) in THF (50 mL) was added a solution of n-butyllithium (2.5 M in THF, 90 mL) at -78 °C. The heterogeneous mixture was stirred at -78 °C for 1 h A solution of 4-methoxymethoxy-benzaldehyde (3.09 g, 18.58 mmol) in THF (5 mL) was added and the mixture was stirred at -78 °C for 1 h then warmed up to r.t. The reaction was then diluted with ethyl acetate and water, the layers were separated and the aqueous layer was extracted with

ethyl acetate. The combined organic extracts were dried (MgSO_4), filtered and concentrated to afford crude (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(4-methoxymethoxyphenyl)methanol. Carried on to the next step without further purification.

Step c:

[0853] A degassed solution of crude (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(4-methoxymethoxyphenyl)methanol (12.0 g, 26.84 mmol) and Pd/C (1.2 g) in EtOAc/HOAc (19/1) was stirred under an atmosphere of hydrogen (1 atm) at r.t. After 5 h, the catalyst was filtered through a pad of Celite, rinsed with ethyl acetate and the combined filtrates concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes;1:9) to afford 4-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-methoxymethoxybenzene (4.0 g, 41.5% for two steps): ^1H NMR (300 MHz, CDCl_3): δ 6.93 (s, 4H), 6.63 (s, 2H), 5.16 (s, 2H), 3.94 (s, 2H), 3.50 (m, 3H), 1.58 (s, 6H), 1.29 (m, 3H), 1.13 (m, 18H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:19); R_f = 0.80.

Step d:

[0854] To a solution of 4-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-methoxymethoxybenzene (2.0 g, 4.66 mmol) in ether was added TMEDA (1.05 mL, 6.99 mmol), followed by nBuLi (2.5 M in THF, 2.8 mL) at -20°C . The reaction mixture was warmed up to 0°C and stirred for 1 h DMF (0.72 mL, 9.32 mmol) was then added and after stirring at 0°C for 2 h, the reaction mixture was quenched with a saturated solution of NH_4Cl and diluted with EtOAc. The water layer was extracted with EtOAc and the combined organic extracts were dried (MgSO_4), filtered and concentrated to give the crude product 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxybenzaldehyde (2.1 g, 98%): ^1H NMR (300 MHz, d₆-DMSO): δ 10.33 (s, 1H), 7.24 (m, 3H), 6.58 (s, 2H), 5.31 (s, 2H), 3.91 (s, 2H), 3.33 (s, 6H), 1.23 (m, 3H), 1.06 (m, 18H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.55.

Step e:

[0855] To a solution of 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxy-benzaldehyde (1.4 g, 3.07 mmol) in THF (15 mL) was added TBAF (1 M, 3.68 mL) at 0 °C. After stirring at r.t. for 2 h, the reaction mixture was diluted with EtOAc and water. The water layer was extracted with EtOAc and the combined organic extracts were dried (MgSO_4), filtered and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes; 1:9) to afford 5-(4-hydroxy-2,6-dimethylbenzyl)-2-methoxymethoxybenzaldehyde (590 mg, 64% for two steps): ^1H NMR (200 MHz, CDCl_3): δ 10.45 (s, 1H), 7.54 (s, 1H), 7.27 (m, 1H), 7.09 (m, 1H), 6.56 (s, 2H), 5.25 (s, 2H), 3.92 (s, 2H), 3.50 (s, 3H), 2.16 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.68.

Step f:

[0856] To a solution of 5-(4-hydroxy-2,6-dimethylbenzyl)-2-methoxymethoxybenzaldehyde (590 mg, 1.97 mmol) in DMF (10 mL) was added Cs_2CO_3 (3.2 g, 9.83 mmol), followed by trifluoromethanesulfonic acid diethoxy-phosphorylmethyl ester (649 mg, 2.16 mmol) at r.t. After stirring at r.t. for 16 h, the reaction mixture was concentrated under reduced pressure and the residue was partitioned between EtOAc and water. The water layer was extracted with EtOAc and the combined organic extracts were dried (MgSO_4), filtered and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes; 1:1) to afford diethyl [4-(3'-formyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methyl-phosphonate (650 mg, 72%): ^1H NMR (300 MHz, CDCl_3): δ 10.42 (s, 1H), 7.51 (s, 1H), 7.09 (m, 2H), 6.67 (s, 2H), 5.25 (s, 2H), 4.26 (m, 6H), 3.94 (s, 2H), 3.50 (s, 3H), 2.19 (s, 6H), 1.37 (m, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.55.

Step g:

[0857] To a solution of [4-(3'-formyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate (650 mg, 1.44 mmol) in THF (1.0 mL)


at r.t. was added a solution of NaH₂PO₄ (52 mg, 0.43 mmol) in water (0.2 mL), 30% H₂O₂ (30%, 0.16 mL) followed by a solution of sodium chlorite (245 mg, 2.17 mmol) in water (1.0 mL). After stirring at r.t. for 30 min., the reaction mixture was diluted with EtOAc and water. The water layer was extracted with EtOAc and the combined organic extracts were washed with water, brine, dried (MgSO₄), filtered and concentrated to afford diethyl [3,5-dimethyl-4-(3'-carboxyl-4'-hydroxybenzyl)phenoxy]methylphosphonate as yellow solid (585 mg, 86.9%): ¹H NMR (300 MHz, CDCl₃): δ 7.91 (m, 1H), 7.11 (m, 2H), 6.68 (s, 2H), 4.25 (m, 6H), 3.96 (s, 2H), 3.54 (s, 3H), 2.19 (s, 6H), 1.37 (m, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = MeOH-ethyl acetate (1:9); R_f = 0.2.

Step h:

[0858] To the solution of diethyl [3,5-dimethyl-4-(3'-carboxyl-4'-hydroxybenzyl)phenoxy]methylphosphonate (100 mg, 0.21 mmol) in CH₂Cl₂ (10 mL) was added TMSBr (0.28 mL, 2.10 mmol) at r.t. After stirring at r.t. for 16 h, the reaction mixture was concentrated and the residue was suspended in MeOH. After stirring for 2 h, the volatiles were removed and the residue was azeotroped with CH₂Cl₂ twice to provide [3,5-dimethyl-4-(3'-carboxyl-4'-hydroxybenzyl)phenoxy]methylphosphonic acid as a white solid (48 mg, 61.5%): mp. >200 °C; ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.38 (d, *J* = 2.1 Hz, 1H), 7.17 (m, 1H), 6.87 (d, *J* = 8.4 Hz, 1H), 6.74 (s, 2H), 4.06 (d, *J* = 10.2 Hz, 2H), 3.89 (s, 2H), 2.18 (s, 6H). mp >200, LC-MS *m/z* = 367 [C₁₇H₁₉O₇P + H]⁺; Anal. Calcd for (C₁₇H₁₉O₇P + 0.4 H₂O): C, 54.67; H, 5.34. Found: C, 54.57; H, 5.60.

Example 36:

Compound 36: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylcarbamoylbenzyl)phenoxy]methylphosphonic acid



Step a:


[0859] To a solution of diethyl [3,5-dimethyl-4-(3'-carboxy-4'-hydroxybenzyl)phenoxy]methylphosphonate (compound 35, step f; 122 mg, 0.262 mmol) in DMF (5.0 mL) was added EDCI (60 mg, 0.314 mmol), HOAT (53 mg, 0.393 mmol), diisopropylethylamine (0.23 mL, 1.31 mmol) and isopropylamine (0.03 mL, 0.288 mmol). After stirring at r.t. for 16 h, the reaction mixture was concentrated under reduced pressure and the residue was partitioned between EtOAc and a saturated solution of NaHCO₃. The aqueous layer was extracted with EtOAc and the combined organic extracts were washed with water, brine, dried (MgSO₄), filtered and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes; 1:1) to afford diethyl [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylcarbamoylbenzyl)-phenoxy]methylphosphonic acid as yellowish liquid (40 mg, 30%). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.45.

Step b:

[0860] The title compound was prepared by the procedure described for the synthesis of compound 35, step f as an off-white solid (30 mg, 93.7%); mp.: 90 °C, dec; ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.52 (d, *J* = 7.5 Hz, 1H), 7.77 (d, *J* = 1.5 Hz, 1H), 6.73 (m, 4H), 4.14 (m, 1H), 4.06 (d, *J* = 10.2 Hz, 2H), 3.88 (s, 2H), 2.18 (s, 6H), 1.21 (d, *J* = 6.9 Hz, 6H). mp: decomposed at 90, LC-MS *m/z* = 408 [C₂₀H₂₆NO₆P + H]⁺; Anal. Calcd for (C₂₀H₂₆NO₆P + 0.26 acetone + 1.4 HBr): C, 46.58; H, 5.45; N, 2.61. Found: C, 46.49; H, 5.84; N, 2.93.

Example 37:

Compound 37: [3,5-dimethyl-4-(4'-hydroxy-3'-phenethylcarbamoylbenzyl)-phenoxy]methylphosphonic acid



Step a:

[0861] 5-(2,6-dimethyl-4-triisopropylsilanyloxybenzyl)-2-methoxymethoxybenzaldehyde (example 35; step e) was transformed into 5-(2,6-dimethyl-4-triisopropylsilanyloxybenzyl)-2-methoxymethoxybenzoic acid by the procedure used for the synthesis of compound 35, step g: yellow solid (360 mg, 86.9%); ¹H NMR (200 MHz, CDCl₃): δ 7.94 (s, 1H), 7.08 (m, 2H), 6.60 (s, 2H), 5.36 (s, 2H), 3.95 (s, 2H), 3.53 (s, 3H), 2.14 (s, 6H), 1.26 (m, 3H), 1.14 (m, 18H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = MeOH-ethyl acetate (1:9); R_f = 0.45.

Step b:

[0862] N-phenethyl-5-(2,6-dimethyl-4-triisopropylsilanyloxybenzyl)-2-methoxymethoxybenzamide was prepared by the procedure used for the synthesis of compound 36, step a: colorless liquid (330 mg, 75%); ¹H NMR (300 MHz, CDCl₃): δ 8.05 (d, J = 2.4 Hz, 1H), 7.84 (m, 1H), 7.82 (m, 5H), 6.97 (d, J = 9.0 Hz, 1H), 6.64 (m, 1H), 6.61 (s, 2H), 5.01 (s, 2H), 3.97 (s, 2H), 3.82 (m, 2H), 3.30 (s, 3H), 2.97 (m, 2H), 2.18 (s, 6H), 1.28 (m, 3H), 1.14 (m, 18H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.55.

Step c:

[0863] N-phenethyl-5-(2,6-dimethyl-4-hydroxybenzyl)-2-methoxymethoxybenzamide was prepared by the procedure used for the synthesis of compound 35, step c: (170 mg, 70%); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.45.

Step d:


[0864] Diethyl[3,5-dimethyl-4-(4'-methoxymethoxy-3'-phenethylcarbamoyl-benzyl)phenoxy]methylphosphonate was prepared by the procedure used for the synthesis of compound 35, step f: (185 mg, 80%); ^1H NMR (300 MHz, CDCl_3): δ 7.98 (d, $J = 2.1$ Hz, 1H), 7.85 (m, 1H), 7.32 (m, 5H), 7.01 (d, $J = 5.4$ Hz, 1H), 6.91 (m, 1H), 6.69 (s, 2H), 4.29 (m, 4H), 3.98 (s, 2H), 3.81 (m, 2H), 3.31 (s, 3H), 2.96 (m, 2H), 2.22 (s, 6H), 1.41 (m, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.52$.

Step e:

[0865] The title compound was prepared by the procedure used for the synthesis of compound 35, step h: white solid (40 mg, 48.8%): mp.: 100 °C, dec; ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 8.85 (m, 1H), 7.67 (d, $J = 2.1$ Hz, 1H), 7.32 (m, 5H), 6.86 (m, 2H), 6.78 (s, 2H), 4.10 (d, $J = 10.5$ Hz, 2H), 3.91 (s, 2H), 3.57 (m, 2H), 2.92 (m, 2H), 2.24 (s, 6H). mp: decomposed at 100, LC-MS $m/z = 470$ [$\text{C}_{25}\text{H}_{28}\text{NO}_6\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{25}\text{H}_{28}\text{NO}_6\text{P} + 0.9\text{ HBr}$): C, 55.37; H, 5.37; N,

Example 38:

Compound 38: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]-methylphosphonic acid



Step a:

[0866] To a stirring solution of bromobenzene (0.45 g, 2.89 mmol) in THF (20 mL) at -78 °C was added *n*-BuLi (1.16 mL, 2.5 M in hexanes). The mixture was stirred at -78 °C for 1 h and a solution of 5-(2,6-dimethyl-4-

triisopropylsilyloxybenzyl)-2-methoxymethoxybenzaldehyde (example 35; step e, 1.2 g, 2.63 mmol) was added. The reaction mixture was stirred at -78 °C for 1 h, allowed to warm to room temperature and stirred for 1 h. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford [5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxy-phenyl]-phenyl-methanol as an yellow oil (1.4 g, 99.6%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.23 (m, 6 H), 6.85 (d, *J* = 8.8 Hz, 1 H), 6.68 (m, 1 H), 6.56 (s, 2 H), 5.92 (d, *J* = 4.0 Hz, 1 H), 5.62 (d, *J* = 4.0 Hz, 1 H), 5.10 (q, *J* = 4.0 Hz, 2 H), 3.84 (s, 2 H), 3.23 (s, 3 H), 2.11 (s, 6 H), 1.23 (m, 3 H), 1.06 (d, *J* = 6.4 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.50.

Step b:

[0867] To a solution of [5-(2,6-dimethyl-4-triisopropylsilyloxy-benzyl)-2-methoxymethoxy-phenyl]-phenyl-methanol (1.4 g, 2.6 mmol) in ethyl acetate (20 mL) and acetic acid (1.5 mL) was added Pd/C (0.15 g). The mixture was stirred under H₂ atmosphere for 16 h. The mixture was filtered through a celite plug. The solvent was removed under reduced pressure. The residue was dissolved in CH₂Cl₂ (26 mL), ethyl-diisopropyl-amine (0.69 mL, 3.95 mmol) and chloromethyl methyl ether (0.26 mL, 3.42 mmol) were added. The reaction mixture was refluxed for 16 h and quenched with water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (15:75) to afford [4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenoxy]-triisopropylsilane as an oil (0.9 g, 66%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.20 (m, 5 H), 6.90 (d, *J* = 8.4 Hz, 1 H), 6.79 (s, 1 H), 6.70 (m, 1 H), 6.54 (s, 2 H), 5.12 (s, 2 H), 3.83 (s, 2 H), 3.81 (s, 2 H), 3.25 (s, 3 H), 2.09 (s, 6 H), 1.23 (m, 3 H), 1.06 (d, *J* = 6.6 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.66.

Step c:

[0868] To a stirring solution of [4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenoxy]-triisopropylsilane (0.9 g, 1.73 mmol) in THF (20 mL) at room temperature was added tetrabutylammonium fluoride (2.3 mL, 1.0 M in THF). The reaction mixture was stirred at room temperature for 1 h, diluted with diethyl ether and washed with water (30 mLx2). The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenol as a light yellow oil (0.6 g, 86%): ^1H NMR (200 MHz, DMSO- d_6): δ 8.98 (s, 1 H), 7.16 (m, 5 H), 6.87 (m, 2 H), 6.70 (m, 1 H), 6.43 (s, 2 H), 5.12 (s, 2 H), 3.85 (s, 2 H), 3.76 (s, 2 H), 3.24 (s, 3 H), 2.06 (s, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; R_f = 0.34.

Step d:


[0869] Diethyl [4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenoxy]methylphosphonate was prepared by the procedure used for the synthesis of compound 35, step f as a light yellow oil (0.09 g, 64%): ^1H NMR (200 MHz, DMSO- d_6): δ 7.22 (m, 5 H), 6.87 (m, 2 H), 6.70 (m, 3 H), 5.12 (s, 2 H), 4.35 (d, J = 10 Hz, 2 H), 4.11 (m, 4 H), 3.85 (s, 2 H), 3.82 (s, 2 H), 3.24 (s, 3 H), 2.13 (s, 6 H), 1.25 (t, J = 7 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 40% ethyl acetate in hexanes; R_f = 0.27.

Step e:

[0870] The title compound was prepared by the procedure used for the synthesis of compound 35, step h as a white foam (32 mg, 44%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.14 (s, 1 H), 7.21 (m, 5 H), 6.67 (m, 4 H), 6.56 (m, 1 H), 4.02 (d, J = 10.2 Hz, 2 H), 3.78 (s, 2 H), 3.75 (s, 2 H), 2.12 (s, 6 H); LC-MS m/z = 413 [$\text{C}_{23}\text{H}_{25}\text{O}_5\text{P} + \text{H}]^+$; Anal Calcd for ($\text{C}_{23}\text{H}_{25}\text{O}_5\text{P} + 0.2\text{Et}_2\text{O} + 0.6\text{H}_2\text{O}$): C, 65.26; H, 6.49. Found: C, 65.07; H, 6.38.

Example 39:

Compound 39: [3,5-dimethyl-4-[3'-(4-fluoro-benzoyl)-4'-hydroxy-benzyl]phenoxy]methylphosphonic acid



Step a:

[0871] [5-(2,6-dimethyl-4-triisopropylsilanyloxy-benzyl)-2-methoxymethoxy-phenyl]-[4-fluoro-phenyl]-methanol was prepared by the procedure used for the synthesis of example 38, step a as an oil (0.68 g, 56%): ^1H NMR (200 MHz, DMSO- d_6): δ 7.26 (m, 3 H), 7.06 (m, 2 H), 6.85 (d, J = 8.4 Hz, 1 H), 6.71 (m, 1 H), 6.56 (s, 2 H), 5.91 (d, J = 4.0 Hz, 1 H), 5.68 (d, J = 4.0 Hz, 1 H), 5.10 (q, J = 3.4 Hz, 2 H), 3.84 (s, 2 H), 3.22 (s, 3 H), 2.11 (s, 6 H), 1.23 (m, 3 H), 1.06 (d, J = 6.2 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.26.

Step b:

[0872] To a stirring solution of [5-(2,6-dimethyl-4-triisopropylsilanyloxy-benzyl)-2-methoxymethoxy-phenyl]-[4-fluoro-phenyl]-methanol (0.68 g, 1.2 mmol) in dichloromethane (25 mL) at 0 °C was added Dess-Martin periodinane (3.9 mL, 0.48 M solution in CH₂Cl₂). The reaction mixture was stirred at room temperature for 4 h, concentrated, diluted with ethyl acetate. To the solution was added a solution of Na₂S₂O₃ pentahydrate (50 mg) in 60 mL saturated NaHCO₃. After 15 min, the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude 5-(2,6-dimethyl-4-triisopropylsilanyloxy-benzyl)-(4-fluorobenzoyl)-2-methoxymethoxy-phenyl as an oil (0.68 g, 100%): ^1H NMR (200 MHz, DMSO- d_6): δ 7.72 (m, 2 H), 7.33 (m, 2 H), 7.12 (m, 2 H), 6.86 (s, 1 H), 6.56

(s, 2 H), 5.04 (s, 2 H), 3.92 (s, 2 H), 3.14 (s, 3 H), 2.13 (s, 6 H), 1.21 (m, 3 H), 1.03 (d, $J = 6.2$ Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; $R_f = 0.26$.

Step c:

[0873] To a stirring solution of 4-(2⁹,6⁹-dimethyl-4⁹-triisopropylsilyloxybenzyl)-2-(4-fluorobenzoyl)-phenol was prepared by the procedure used for the synthesis of example 35 step c as a white solid (0.42 g, 86%): mp 140–142 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.05 (s, 1 H), 7.78 (m, 2 H), 7.36 (m, 2 H), 7.13 (m, 2 H), 6.95 (d, $J = 1.5$ Hz, 1 H), 6.47 (s, 2 H), 5.05 (s, 2 H), 3.90 (s, 2 H), 3.15 (s, 3 H), 2.12 (s, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; $R_f = 0.63$.

Step d:


[0874] Diethyl[3,5-dimethyl-4-[3⁹-(4-fluoro-benzoyl)-4⁹-hydroxy-benzyl]-phenoxy]methylphosphonate was prepared by the procedure used for the synthesis of example 35 step f as a light yellow oil (0.054 g, 19%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.76 (m, 2 H), 7.36 (m, 2 H), 7.13 (m, 2 H), 6.94 (d, $J = 1.5$ Hz, 1 H), 6.77 (s, 2 H), 5.05 (s, 2 H), 4.36 (d, $J = 9.6$ Hz, 2 H), 4.11 (m, 4 H), 3.95 (s, 2 H), 3.15 (s, 3 H), 2.20 (s, 6 H), 1.25 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 67% ethyl acetate in hexanes; $R_f = 0.37$.

Step d:

[0875] The title compound was prepared by the procedure used for the synthesis of example 35 step h as a yellow foam (22 mg, 50%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 10.14 (s, 1 H), 7.74 (m, 2 H), 7.31 (m, 2 H), 7.03 (m, 1 H), 6.92 (m, 2 H), 6.69 (s, 2 H), 4.02 (d, $J = 10.6$ Hz, 2 H), 3.87 (s, 2 H), 2.16 (s, 6 H); LC-MS *m/z* = 445 [C₂₃H₂₂FO₆P + H]⁺; Anal Calcd for (C₂₃H₂₂FO₆P + 0.2 Et₂O + 0.3 CF₃COOH): C, 59.39; H, 4.96. Found: C, 59.62; H, 4.64.

Example 40:

Compound 40: [3,5-dimethyl-4-[3'-(4-fluoro-benzyl)-4'-hydroxy-benzyl]-phenoxy]methylphosphonic acid



Step a:

[0876] To a stirring solution of diethyl [3,5-dimethyl-4-[3'-(4-fluoro-benzyl)-4'-hydroxy-benzyl]phenoxy]methylphosphonic acid (0.13 g, 0.24 mmol) in MeOH (8 mL) at 0 °C was added NaBH₄ (90 mg, 2.4 mmol). The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford diethyl [3,5-dimethyl-4-[3'-(4-fluorophenyl-hydroxymethyl)-4'-hydroxy-benzyl]phenoxy]methylphosphonic acid as an oil (0.13 g, 100%). This crude product was dissolved in CH₂Cl₂ (10 mL) and Et₃SiH (0.38 mL, 2.4 mmol) and TFA (0.18 mL, 2.4 mmol) were added. The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [3,5-dimethyl-4-[3'-(4-fluoro-benzyl)-4'-hydroxy-benzyl]phenoxy]methylphosphonate as an oil (80 mg, 69%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.18 (s, 1 H), 7.13 (m, 4 H), 6.67 (m, 5 H), 4.33 (d, *J* = 10 Hz, 2 H), 4.11 (m, 4H), 3.76 (s, 4 H), 2.12 (s, 6H), 1.25 (t, *J* =


7 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.5.

Step b:

[0877] The title compound was prepared by the procedure used for the synthesis of example 35 step h as a yellow solid (60 mg, 85%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.11 (s, 1 H), 7.13 (m, 4 H), 6.63 (m, 5 H), 4.01 (d, J = 10.2 Hz, 2 H), 3.76 (s, 4 H), 2.12 (s, 6 H); LC-MS m/z = 431 [$\text{C}_{23}\text{H}_{24}\text{FO}_5\text{P} + \text{H}]^+$; Anal Calcd for ($\text{C}_{23}\text{H}_{24}\text{FO}_5\text{P} + 0.6 \text{ H}_2\text{O} + 0.2 \text{ Et}_2\text{O}$): C, 62.68; H, 6.01. Found: C, 62.31; H, 6.16; mp: 169 - 171 °C.

Example 41:

Compound 41: [3,5-dimethyl-4-[3'-benzyl-4'-hydroxy-benzyl]benzoyl]-methylphosphonic acid



Step a:

[0878] To a solution of 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenol (example 38, step c, 0.5 g, 1.38 mmol) and DMAP (0.67 g, 5.52 mmol) in CH_2Cl_2 (20 mL) at 0 °C was slowly added trifluoromethanesulfonyl anhydride (0.35 mL, 2.1 mmol). The reaction mixture was stirred at 0 °C for 2 h and quenched by water (10 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenyl trifluoromethanesulfonate as an oil (0.5 g, 73%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.14 - 7.28 (m, 7 H), 6.94 (d, J = 8.4 Hz, 1 H), 6.85 (d, J = 2.4 Hz, 1 H), 6.70 (m, 1 H), 5.15 (s, 2 H), 3.94 (s, 2 H), 3.88 (s, 2 H), 3.27 (s, 3

H), 2.24 (s, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:75); R_f = 0.55.

Step b:

[0879] To a solution of 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenyl trifluoromethanesulfonate (0.5 g, 1 mmol) in DMF (8 mL) in a bomb apparatus was added MeOH (0.82 mL, 20 mmol), Pd(OAc)₂ (23 mg, 0.1 mmol), bis-(diphenylphosphino)propane (42 mg, 0.1 mmol) and TEA (0.28 mL, 2 mmol). 60 psi of CO was then infused and the reaction mixture was stirred at 90 °C for 16 h. The cooled bomb was vented and the reaction mixture was poured into cold 1N HCl, extracted with EtOAc twice, the combined EtOAc were washed with brine, dried over MgSO₄, filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (15:75) to afford methyl 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-benzoate as a yellow oil (360 mg, 88%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.66 (s, 2 H), 7.16 (m, 5 H), 6.90 (m, 2 H), 6.71 (m, 1 H), 5.15 (s, 2 H), 3.98 (s, 2 H), 3.87 (s, 2 H), 3.85 (s, 3 H), 3.26 (s, 3H), 2.25 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:75); R_f = 0.50.

Step c:

[0880] To a stirring solution of diethyl methylphosphonate (0.39 mL, 2.67 mmol) in THF (10 mL) at -78 °C was added *n*-BuLi (2.5 M in hexanes, 1.07 mL), the reaction mixture was stirred at -78 °C for 1 h, then methyl 4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-benzoate (360 mg, 0.89 mmol) in THF (10 mL) was added at the same temperature. The reaction mixture was stirred at -78 °C for 1.5 h, then at room temperature for 1 h. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [3,5-dimethyl-4-[3'-benzyl-4'-hydroxy-benzyl]benzoyl]methylphosphonate as a light yellow oil (350 mg, 75%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.72 (s, 2 H), 7.16 (m, 5


H), 6.92 (m, 2 H), 6.71 (m, 1 H), 5.14 (s, 2 H), 4.04 (m, 6 H), 3.99 (s, 2 H), 3.82 (d, $J = 22.2$ Hz, 2 H), 3.26 (s, 3H), 2.27 (s, 6H), 1.19 (t, $J = 7.5$ Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:1); $R_f = 0.35$.

Step d:

[0881] The title compound was prepared by the procedure described for the synthesis of example 35, step h as a white foam (55 mg, 88%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.21 (s, 1 H), 7.66 (s, 2 H), 7.21 (m, 5 H), 6.65 (m, 2 H), 6.55 (m, 1 H), 3.89 (s, 2 H), 3.79 (s, 2 H), 3.45 (d, $J = 22.8$ Hz, 2 H), 2.16 (s, 6 H); LC-MS $m/z = 425$ [C₂₄H₂₅O₅P + H]⁺; Anal Calcd for (C₂₄H₂₅O₅P + H₂O): C, 63.60; H, 6.27. Found: C, 63.87; H, 6.43.


[0882] Using the appropriate starting material, compounds 41-1 to 41-3 were prepared in an analogous manner to that described for the synthesis of compound 41.

Compound 41-2: 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propyl-benzyl)phenyl]-2-oxo-ethylphosphonic acid



[0883] The title compound was prepared from 3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propyl-benzyl)- phenol (compound 27, step e) by the procedure described for the synthesis of compound 41 as a white solid (106 mg, 81.5%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.70 (s, 2H), 7.10 (m, 1H), 6.98 (m, 1H), 6.65 (m, 1H), 4.00 (s, 2H), 3.48 (d, $J = 22.4$ Hz, 2H), 3.09 (m, 1H), 2.26 (s, 6H), 1.17 (d, $J = 7.0$ Hz, 6H). mp = 138~140, LC-MS $m/z = 379$ [C₂₀H₂₄FO₄P + H]⁺; Anal. Calcd for (C₂₀H₂₄FO₄P): C, 63.49; H, 6.39. Found: C, 63.40; H, 6.63.


Compound 41-3: 2-[3,5-dichloro-4-(4-fluoro-*iso*-propyl-benzyl)-phenyl]-2-oxo-ethylphosphonic acid



[0884] 3,5-Dichloro-4-(4-fluoro-3-*iso*-propyl-benzyl)-phenol, intermediate for the synthesis of compound 27-2, was transformed into the title compound by the procedure described for the synthesis of compound 41 to give a white solid (65 mg, 82%): ^1H NMR (300 MHz, DMSO-*d*₆): δ 8.08 (s, 2H), 7.25 (m, 1H), 7.05 (m, 1H), 6.90 (m, 1H), 4.32 (s, 2H), 3.60 (d, *J* = 22.5 Hz, 2H), 3.12 (m, 1H), 1.20 (d, *J* = 6.9 Hz, 6H). mp = 132~134, LC-MS *m/z* = 417 [C₁₈H₁₈Cl₂FO₄P + H]⁺; Anal. Calcd for (C₁₈H₁₈Cl₂FO₄P): C, 51.57; H, 4.33. Found: C, 51.37; H, 4.65.

Example 42:

Compound 42: 2-[3,5-dimethyl-4-[3'-benzyl-4'-hydroxy-benzyl]phenyl]-ethylphosphonic acid



Step a:

[0885] To a stirring solution of diethyl [3,5-dimethyl-4-[3'-benzyl-4'-hydroxy-benzyl]benzoyl]methylphosphonate (example 41, step c, 0.27 g, 0.52 mmol) in MeOH (10 mL) at 0 °C was added NaBH₄ (78 mg, 2.1 mmol). The reaction mixture was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford diethyl 2-[4-(3'-benzyl-4'-

methoxymethoxy-benzyl)-3,5-dimethyl-phenyl]-2-hydroxy-ethyl-phosphonate as an oil (0.27 g, 100%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.18 (m, 5 H), 7.03 (s, 2 H), 6.93 (m, 2 H), 6.70 (m, 1 H), 5.39 (d, J = 4.5 Hz, 1 H), 5.14 (s, 2 H), 4.80 (m, 1 H), 3.85 (m, 8 H), 3.26 (s, 3H), 2.18 (s, 6H), 1.19 (m, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:1); R_f = 0.29.


Step b:

[0886] To a stirring solution of diethyl 2-[4-(3'-benzyl-4'-methoxymethoxy-benzyl)-3,5-dimethyl-phenyl]-2-hydroxy-ethyl-phosphonate (0.24 g, 0.46 mmol) in CH₂Cl₂ (10 mL) at room temperature was added Et₃SiH (0.34 mL, 2.1 mmol) and TFA (0.4 mL, 5.4 mmol). The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:1) to afford 2-[4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethyl-phenyl]ethylphosphonate as an oil (55 mg, 26%): ^1H NMR (300 MHz, DMSO- d_6): δ 9.16 (s, 1 H), 7.22 (m, 5 H), 6.91 (s, 2 H), 6.76 (s, 1 H), 6.62 (m, 2 H), 4.00 (m, 4 H), 3.80 (s, 4 H), 2.68 (m, 2 H), 2.14 (s, 6H), 2.06 (m, 2H), 1.23 (m, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:1); R_f = 0.33.

Step c:

[0887] The title compound was prepared by the procedure described for the synthesis of example 35, step h as a light yellow solid (28 mg, 58%): mp: 168–170 °C; ^1H NMR (200 MHz, DMSO- d_6): δ 9.11 (s, 1 H), 7.19 (m, 5 H), 6.85 (s, 2 H), 6.63 (m, 3 H), 3.77 (s, 4 H), 2.66 (m, 2 H), 2.12 (s, 6 H), 1.76 (m, 2 H); LC-MS m/z = 411 [C₂₄H₂₇O₄P + H]⁺; Anal Calcd for (C₂₄H₂₇O₄P + 1.6 H₂O): C, 68.14; H, 6.77. Found: C, 68.19; H, 6.55;.

Compound 42-2: 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propyl-benzyl)phenyl]-ethylphosphonic acid



Step a:

[0888] Intermediate diethyl 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenyl]-2-oxo-ethylphosphonate for the synthesis of compound 41-1 was transformed into diethyl 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenyl]-2-hydroxy-ethylphosphonate by the procedure described for the synthesis of compound 42, step a to give a yellow liquid (580 mg, 96.2%): ^1H NMR (300 MHz, CDCl_3): δ 7.12 (s, 2H), 6.99 (m, 1H), 6.84 (m, 1H), 6.66 (m, 1H), 5.09 (s, 1H), 4.19 (m, 4H), 4.01 (s, 1H), 3.18 (m, 1H), 2.22 (s, 6H), 2.20 (m, 2H), 1.36 (m, 6H), 1.25 (d, $J = 6.4$ Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); $R_f = 0.58$.

Step b:

[0889] A degassed solution of diethyl 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenyl]-2-hydroxy-ethylphosphonate (500 mg, 1.15 mmol) and Pd/C (50 mg) in EtOH/HOAc(19/1) was stirred under 1 atmosphere of hydrogen at r.t. After 5h, the catalyst was filtered through a pad of celite and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate-hexanes; 9:1) to afford diethyl 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenyl]ethylphosphonate (450 mg, 93.5%): ^1H NMR (300 MHz, CDCl_3): δ 6.99 (s, 1H), 6.98 (s, 2H), 6.88 (m, 1H), 6.66 (m, 1H), 4.65 (m, 4H), 3.99 (s, 2H), 3.19 (m, 1H), 2.88 (m, 2H), 2.24 (s, 6H), 2.10 (m, 2H), 1.51 (m, 6H), 1.25 (d, $J = 6.9$ Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.53$.


Step c:

[0890] Diethyl 2-[3,5-dimethyl-4-(4'-fluoro-3'-*iso*-propylbenzyl)phenyl]-ethylphosphonate was transformed into the title compound by the procedure described for the synthesis of compound 35, step h to give a white solid (60

mg, 35%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.09 (m, 1H), 6.98 (m, 1H), 6.92 (s, 2H), 6.66 (m, 1H), 3.94 (s, 2H), 3.95 (s, 2H), 3.11 (m, 1H), 2.70 (m, 2H), 2.18 (s, 6H), 1.80 (m, 2H), 1.19 (d, $J = 7.2$ Hz, 6H). mp = 116~118, LC-MS m/z = 365 [C₂₀H₂₆FO₃P + H]⁺; Anal. Calcd for (C₂₀H₂₆FO₃P): C, 65.92; H, 7.19. Found: C, 65.68; H, 7.19.

Example 43

Compound 43: [3,5-dimethyl-4-S-[(4'-hydroxy-3'-*iso*-propylphenyl)-sulfanyl]phenoxy]methylphosphonate:



Step a:

[0891] A mixture of 3,5-Dimethyl-4-iodophenol (2.0 g, 8.06mmol), potassium carbonate (3.33 g, 24.2 mmol) and methyl iodine (602 μ l, 9.67 mmol) in DMF (20 mL) under a nitrogen atmosphere was heated at 65 °C, with stirring for 16 hours. The cooled reaction was diluted with ethyl acetate (50 mL), filtered into a sep-funnel and washed with water (2x 25mL) then brine (25 mL). The organics were dried over sodium sulfate, filtered and the solvent removed under reduced pressure to give (1.68 g, 79%); ^1H NMR (300 MHz, DMSO- d_6): δ 6.79(s, 2H), 3.72(s, 3H), 2.37(s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% ethyl acetate in hexane; R_f = 0.47.

Step b:

[0892] Copper iodine (70 mg, 0.37 mmol), neocuprinine (80 mg, 0.37 mmol) and potassium *t*-butoxide (470 mg, 4.05 mmol) were added in this order to a solution of 4-methoxy-3-*iso*-propyl-thiophenol (U.S. 6,747,048 B2, 600mg, 2.3 mmol) and 3,5-dimethyl-4-iodoanisole (678 mg, 3.72 mmol) in toluene (10mL). After refluxing overnight, the cooled reaction mixture was poured into ethyl acetate (50 mL) and washed twice with 1 N HCl then brine. The

organics were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate 100:0 to 40:1) to give 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxyphenylsulfanyl)anisole (0.358 g, 49%); ¹H NMR (200 MHz, DMSO-*d*₆): δ 6.87-6.80(m, 4H), 6.56(m, 1H), 3.76(s, 3H), 3.71(s, 3H), 3.15(m, 1H), 2.34(s, 6H), 1.06(d, 6H, *J* = 7Hz); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 25% ethyl acetate in hexane; R_f = 0.36

Step c:

[0893] 3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propyl-phenylsulfanyl)phenol was prepared from 2,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxy-phenylsulfanyl)-anisole according to the procedure described in example 8, step d. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.58(bs, 1H), 9.21(bs, 1H), 6.77(m, 1H), 6.63(m, 3H), 6.46(dd, 1H, *J* = 2.7 Hz and *J* = 8.1 Hz), 3.09(m, 1H), 2.28(s, 6H), 1.06(d, 6H, *J* = 7.2 Hz); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate 25% in hexane; R_f = 0.12

Step d:

[0894] Diethyl[3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propyl-phenylsulfanyl)-phenoxy]methyl phosphonate was prepared according to the procedure described in compound 8, step e: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.26(s, 1H), 6.92(s, 2H), 6.81(d, 1H, *J* = 2.4 Hz), 6.65(d, 1H, *J* = 8.4 Hz), 6.47(dd, 1H, *J* = 2.1 Hz and *J* = 8 Hz), 4.42(d, 2H, *J* = 10 Hz), 4.11(m, 4H), 3.10(m, 1H), 2.35(s, 6H), 1.25(m, 6H), 1.06(d, 6H, *J* = 2.9 Hz); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate 50% in hexane; R_f = 0.12


Step e:

[0895] The title compound was prepared according to the procedure described in compound 8, step f: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.22 (s, 1H), 6.88 (s, 2H), 6.81 (d, *J* = 2.1 Hz, 1H), 6.64 (d, *J* = 8.4 Hz, 1H), 6.46 (dd, *J* = 2 Hz and *J* = 8.2 Hz, 1H), 4.08 (d, *J* = 10.2 Hz, 2H), 3.10 (m, 1H), 2.34 (s, 6H), 1.07 (d, *J* = 6.6 H, 6H z); LC-MS m/z = 381 [C₁₈H₂₃O₅PS- H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = IPA/NH₄OH/H₂O [7:1:2]; R_f

= 0.53; HPLC, YMC Pack ODS-AQ, AQ 302, 150mm x 4.6 mm, S 5 μ m, 12nm, flow 2 mL/min, solvent A: 0.05% TFA aqueous, Solvent B: acetonitrile/0.05%TFA, Gradient 20% B to 70% B in 13min – hold 1 min at 70%B – gradient to 100%B in 6 min. Rt=10.23 min.

Example 44:

Compound 44: [3,5-dimethyl-4-[4'-hydroxy-3'-(*iso*-propylsulfonyl)benzyl]-phenoxy]methylphosphonic acid



Step a:

[0896] Triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylsulfanylbenzyl)-phenoxy]silane was synthesized according to the procedure described in example 35, step d using di-*iso*-propyl disulfide as the electrophile. The product of this reaction was carried in the next step as a mixture of desired product and starting material triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxybenzyl)-phenoxy]silane: ^1H NMR (200 MHz, DMSO- d_6): δ 1.15 (d, $J = 6.4$ Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% ethyl acetate in hexane; $R_f = 0.32$

Step b:

[0897] 3,5-Dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylsulfanylbenzyl)-phenol was prepared according to the procedure described in example 35, step e. The product of this reaction was carried on as a mixture of desired product and 3,5-dimethyl-4-(4'-methoxymethoxybenzyl)phenol: ^1H NMR (200 MHz, DMSO- d_6): δ 1.16 (d, $J = 9.9$ Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% ethyl acetate in hexane; $R_f = 0.25$

Step c:

[0898] Diethyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylsulfanylbenzyl)phenoxy]methylphosphonate was prepared according to the procedure described in example 8, step e and carried on as a mixture of desired product and diethyl [3,5-dimethyl 4-(4'-methoxymethoxybenzyl)phenoxy]methylphosphonate: ^1H NMR (200 MHz, DMSO- d_6): δ 4.36 (d, 2H, J = 15 Hz), 4.11 (m, 4H), 1.26 (t, 6H, J = 10.8 Hz), 1.16 (d, 6H, J = 9.9 Hz); LC-MS m/z = 465 [$\text{C}_{23}\text{H}_{36}\text{O}_6\text{PS} + \text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 50% ethyl acetate in hexane; R_f = 0.12

Step d:


[0899] A mixture diethyl [3,5-dimethyl 4-(4'-methoxymethoxy-3'-*iso*-propylsulfanylbenzyl)phenoxy]methylphosphonate (0.200g, 0.402mmol), saturated sodium bicarbonate (1 M) and *m*CPBA 50%-60% (0.173 g, 1.01 mmol) in dichloromethane (5 mL) was stirred overnight at room temperature. The layers were separated and the organics were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (2000 μm , 5% hexanes in ethyl acetate) to give diethyl [3,5-dimethyl-4-[4'-methoxymethoxy-3'-(*iso*-propyl sulfonyl)benzyl]phenoxy]-methylphosphonate (0.090 g, 42%); ^1H NMR (200 MHz, DMSO- d_6): δ 7.42 (s, 1H), 7.24 (s, 2H), 6.77 (s, 2H), 5.32 (s, 2H), 4.36 (d, J = 10 Hz, 2H), 4.11 (m, 4H), 3.96 (s, 2H), 3.69 (m, 1H), 3.39 (s, 3H), 2.16 (s, 6H), 1.26 (t, J = 7 Hz, 6H), 1.12 (d, J = 7 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.28

Step e:

[0900] The title compound was prepared according to the described for example 8, step f (0.057 g, 82); ^1H NMR (200 MHz, DMSO- d_6): δ 10.89 (bs, 1H), 7.31 (s, 1H), 7.12 (dd, J = 5.8, 2.2 Hz, 1H z), 6.93 (d, J = 8 H, 1H z), 6.72 (s, 2H), 4.04 (d, J = 10.2 H, 2H z), 3.89 (s, 2H), 3.64 (m, 1H), 2.15 (s, 6H), 1.11 (d, J = 7 Hz, 6H); LC-MS m/z = 427 [$\text{C}_{19}\text{H}_{25}\text{O}_7\text{PS} - \text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = *iso*-propyl alcohol/ $\text{NH}_4\text{OH}/\text{H}_2\text{O}$ [7:1:2]; R_f = 0.53; Anal. Calcd for ($\text{C}_{18}\text{H}_{23}\text{O}_5\text{PS} + 1 \text{ M H}_2\text{O} + 0.1 \text{ M EtOAc}$) C, 51.18; H, 6.15 . Found: C, 51.01; H, 5.94.

Example 45

Compound 45: [4,6-Dimethyl-5-(4'-hydroxy-3'-*iso*-propyl)benzyl]-benzofuran-2-phosphonic Acid



Step a:

[0901] To a mixture of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol (1.0 g, 3.18 mmol, Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in C₂H₅OH (30.0 mL) and 40% aqueous methylamine (6.20 mL) at 0 °C was added a solution of potassium iodide (2.5 g, 15.0 mmol) and iodine (0.98 g, 3.82 mmol) in H₂O (6.20 mL). The reaction mixture was stirred at 0 °C for 1 h, quenched with water and extracted with ethyl acetate (2x30 mL). The organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 20% ethyl acetate in hexanes to afford 3,5-dimethyl-2-iodo-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol as white solid: ¹H NMR (300 MHz, CD₃OD): δ 6.93 (m, 2 H), 6.65 (m, 2 H), 5.18 (s, 2 H), 4.05 (s, 2 H), 3.48 (s, 3 H), 3.30 (m, 1 H), 2.41 (s, 3 H), 2.19 (s, 3 H), 1.18 (d, *J* = 6.6 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.60.

Step b:

[0902] To a mixture of Cu₂O (0.08 g, 0.57 mmol) in DMF (2.0 mL) was added a solution of diethyl ethynylphosphonate (0.11g, 0.68 mmol) in DMF (0.5 mL) followed by a solution of 3,5-dimethyl-2-iodo-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol in diisopropylethylamine (0.40 mL) and DMF (1.0 mL). The reaction mixture was heated at 90 °C for 48 h, cooled to room temperature and filtered through a Celite plug. The solution


was diluted with water (30 mL) and extracted with ethyl acetate (30 mL). The organic layer was separated, dried over MgSO₄. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with 50% ethyl acetate in hexanes to afford diethyl [4,6-Dimethyl-5-(4'-hydroxy-3'-*iso*-propyl)benzyl]benzofuran-2-phosphonate (0.07 g, 26%) as colorless oil: ¹H NMR (300 MHz, CD₃OD): δ 7.66 (dd, *J* = 8.1, 2.4 Hz, 1 H), 7.35 (s, 1 H), 6.97 (d, *J* = 2.1 Hz, 1 H), 6.92 (d, *J* = 8.1 Hz, 1 H), 6.64 (dd, *J* = 8.1, 2.1 Hz, 1 H), 5.18 (s, 2 H), 4.24 (m, 4 H), 4.14 (s, 2 H), 3.47 (s, 3 H), 3.30 (m, 1 H), 2.49 (s, 3 H), 2.39 (s, 3 H), 1.40 (t, *J* = 6.0 Hz, 6 H), 1.14 (d, *J* = 6.6 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.50.

Step c:

[0903] [4,6-Dimethyl-5-(4'-hydroxy-3'-*iso*-propyl)benzyl]benzofuran-2-phosphonic acid was prepared from diethyl [4,6-Dimethyl-5-(4'-hydroxy-3'-*iso*-propyl)benzyl]benzofuran-2-phosphonate according to the procedure described in example 7, step b: mp: 180-182 °C; ¹H NMR (300 MHz, CD₃OD): δ 7.44 (dd, *J* = 8.1, 2.4 Hz, 1 H), 7.30 (s, 1 H), 6.85 (d, *J* = 2.1 Hz, 1 H), 6.61 (d, *J* = 8.1 Hz, 1 H), 6.55 (d, *J* = 8.1 Hz, 1 H), 4.08 (s, 2 H), 3.24 (m, 1 H), 2.46 (s, 3 H), 2.37 (s, 3 H), 1.14 (d, *J* = 6.6 Hz, 6 H); LC-MS m/z = 375 [C₂₀H₂₃O₅P + H]⁺; Anal. Calcd for (C₂₀H₂₃O₅P+0.7 H₂O+0.1 CH₃OH): C, 61.87; H, 6.41. Found: C, 61.80; H, 6.60.

Example 46


Compound 46: [3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-2-iodophenoxy]methylphosphonic Acid



[0904] The title compound was prepared from 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxy)benzyl-2-iodophenol (compound 45, step a) according to the procedure described in example 7: ^1H NMR (300 MHz, DMSO- d_6): δ 9.00 (s, 1 H), 6.87 (d, J = 3.9 Hz, 1 H), 6.61 (d, J = 12.0 Hz, 1 H), 6.40 (d, J = 12.6 Hz, 1 H), 4.32 (d, J = 10.2 Hz, 2 H), 3.94 (s, 2 H), 3.12 (m, 1 H), 2.36 (s, 3 H), 2.21 (s, 3 H); LC-MS m/z = 491 [C₁₉H₂₄IO₅P + H]⁺; Anal Calcd for C₁₉H₂₄IO₅P: C, 46.55; H, 4.93. Found: C, 46.93; H, 4.99.

Example 47

Compound 47: [3,5-Dimethyl 4-(4'-hydroxy-3'-*iso*-propylbenzyl)-phenylamino]methylphosphonic Acid



Step a:

[0905] A solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-trifluoromethanesulfonyloxyphenyl (2.04 g, 4.57 mmol, intermediate for the synthesis of compound 24-1), triethylamine (1.27 mL, 9.14 mmol), 1,3-bis(diphenylphosphino)propane (0.19 mL, 0.45 mmol), MeOH (3.71 mL, 91.40 mmol), and Pd(OAc)₂ (0.102 g, 0.46 mmol) in DMF (25 mL) was heated at 90 °C under 60 psi of CO in a Parr reactor for 16 h. The reaction mixture was cooled to 0 °C, diluted with ethyl acetate (25 mL) and washed with H₂O (25 mLx2). The organic solution was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford methyl 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoate as an oil (1.52 g, 93%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.68 (s, 2 H), 6.97 (m, 1 H), 6.91 (m, 2 H), 6.20 (m, 1 H), 5.16 (s, 2 H), 4.01 (s, 3 H), 3.85 (s, 3 H), 3.21 (m, 1 H), 2.28 (s, 6 H), 1.14 (d, J =

6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:4); $R_f = 0.42$.

Step b:

[0906] To a stirring solution of methyl 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoate (0.750 g, 2.11 mmol) in MeOH (20.0 mL) at 0 °C was added 1 M NaOH (12.64 mL, 12.64 mmol). The reaction mixture was heated at 50 °C for 16 h, cooled to 0 °C and acidified with 2 N HCl. The mixture was extracted with ethyl acetate (20 mL) and washed with H₂O (10 mLx2). The solvent was removed under reduced pressure to afford 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoic acid as white solid (0.71 g, 98%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.76 (s, 1 H), 7.65 (s, 2 H), 6.98 (m, 1 H), 6.91 (m, 1 H), 6.60 (m, 1 H), 5.17 (s, 2H), 4.00 (s, 2 H), 3.37 (s, 3 H), 3.23 (m, 1 H), 2.27 (s, 6 H), 1.14 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); $R_f = 0.00$.

Step c:

[0907] To a suspension of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoic acid (0.70 g, 2.04 mmol), *tert*-butanol (0.756 mg, 10.22 mmol) and triethylamine (0.71 g, 5.11 mmol) in toluene (30 mL) was added diphenylphosphoryl azide (0.44 mL, 2.04 mmol). The reaction mixture was heated under reflux for 16 h, cooled to room temperature and poured into a cold solution of 0.25 M HCl (30 mL). The mixture was diluted with ethyl acetate and washed with H₂O (30 mL). The organic layer was separated and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford *t*-butyl *N*-3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)carbamate as a yellow oil (0.63 g, 75%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.16 (s, 1 H), 7.16 (s, 2 H), 6.96 (m, 1 H), 6.90 (m, 1 H), 6.62 (m, 1 H), 5.16 (s, 2 H), 3.86 (s, 2 H), 3.37 (s, 3 H), 3.22 (m, 1 H), 2.15 (s, 6 H), 1.48 (m, 9 H), 1.23 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:7); $R_f = 0.72$.

Step d:

[0908] To a mixture of *t*-butyl *N*-3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)carbamate (0.315 g, 0.76 mmol) in THF (8.0 mL) at -78 °C was added lithium diisopropylamide (0.46 g, 0.91 mmol, 2.0 M solution in THF/heptane/ethylbenzene). The reaction mixture was stirred at -78 °C for 20 min and trifluoromethanesulfonic acid diethoxyphosphorylmethyl ester (0.16 g, 0.76 mmol) was added. The reaction mixture was stirred at -78 °C for 1 h, allowed to warm to room temperature and stirred for 4 h. The reaction mixture was quenched with 2.5 M aqueous ammonium chloride and diluted with ethyl acetate. The organic layer was washed with saturated aqueous ammonium chloride (8.0 mL), H₂O (8.0 mL) and brine (8.0 mL). The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl *N*-*t*-butoxycarbonyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenylamino]methyl phosphonate as an oil (0.21 g, 49%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.00 (s, 2 H), 6.94 (m, 1 H), 6.90 (m, 1 H), 6.64 (m, 1 H), 5.16 (s, 2 H), 4.09 (d, *J*=6.0 Hz, 2 H), 4.00 (m, 4 H), 3.8 (m, 2 H), 3.37 (s, 3 H), 3.22 (m, 1 H), 2.20 (s, 6 H), 1.40 (s, 9 H), 1.27 (m, 6 H), 1.13 (m, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:2); R_f = 0.20

Step e:

[0909] To a stirring solution of diethyl *N*-*t*-butoxycarbonyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenylamino]methylphosphonate (0.19 g, 0.34 mmol) in MeOH (4.0 mL) at 0 °C was added 2 M HCl (1.68 mL, 3.37 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 48 h. The reaction mixture was cooled to 0 °C, neutralized with NaHCO₃, diluted with ethyl acetate (20 mL) and washed with H₂O (10 mL×2). The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:2) to afford diethyl [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenylamino]methylphosphonate


as a white solid (0.07 g, 51%): ^1H NMR (300 MHz, DMSO- d_6): δ 8.95 (s, 1 H), 6.84 (m, 1 H), 6.63 (m, 1 H), 6.50 (m, 1 H), 6.45 (s, 2 H), 5.39 (m, 1 H), 4.06 (s, 6 H), 3.74 (s, 2 H), 3.51 (m, 2 H), 3.13 (m, 1 H), 2.09 (s, 6 H), 1.20 (m, 6 H), 1.11 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.29.

Step f:

[0910] To a solution of diethyl [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenylamino]methylphosphonate (0.070 g, 0.17 mmol) in CH₂Cl₂ (3.0 mL) at -30 °C was added bromotrimethylsilane (0.28 mL, 2.08 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile-water (4:1, 5.0 mL) and stirred at 38 °C for 30 min. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with H₂O. The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure to afford the title compound as an off-white powder (0.050 g, 79%); mp: 147-150 °C; ^1H NMR (300 MHz, DMSO- d_6): δ 8.97 (s, 1 H), 6.86 (m, 1 H), 6.59 (m, 1 H), 6.49 (m, 1 H), 6.45 (s, 2 H), 3.74 (s, 2 H), 3.20 (d, J = 12.0 Hz, 2 H), 3.13 (m, 1 H), 2.10 (s, 6 H), 1.12 (d, J = 6.0 Hz, 6 H); LC-MS m/z = 364 [C₁₉H₂₆NO₄P - H]⁺; Anal. Calcd for (C₁₉H₂₆NO₄P + 1.0 H₂O + 0.2 HBr + 0.2 CH₃CO₂CH₂CH₃): C, 57.28; H, 7.23; N, 3.37; Br, 3.85. Found: C, 57.60; H, 7.33; N, 3.12; Br, 3.48.

Example 48

Compound 48: [4-(3'-cyclopropyl-4'-hydroxybenzyl)-3,5-dimethylphenoxy]-methylphosphonic acid



Step a:

[0911] To a suspension of methyltriphenonium bromide (4.81 g, 13.46 mmol) in THF (10.0 mL) at 0 °C was added n-butyllithium (4.30 g, 10.76 mmol, 2.5 M solution in hexane). The reaction mixture was stirred at 0 °C for 1 h and to it was added a solution of 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxy-benzaldehyde (1.23 g, 2.69 mmol, intermediate for the synthesis of Example 35, step d) in THF (5.0 mL). The reaction mixture was stirred at room temperature for 2.5 h, cooled to 0 °C and quenched with saturated ammonium chloride (15.0 mL). The mixture was extracted with ethyl acetate (20 mL), washed with H₂O (25 mLx2) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:50) to afford triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-vinylbenzyl)phenoxy]silane as oil (1.19 g, 97%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.12 (m, 1 H), 7.00-6.93 (m, 2 H), 6.80 (m, 1 H), 6.59 (s, 2 H), 5.62 (d, *J* = 18.0 Hz, 1 H), 5.24 (d, *J* = 12.0 Hz, 1 H), 5.19 (s, 2 H), 3.88 (s, 2 H), 3.37 (s, 3 H), 2.15 (s, 6 H), 1.37 (s, 1 H), 1.21 (m, 3 H), 1.08 (d, *J* = 4.5 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.74.

Step b:

[0912] A mixture of copper powder (0.094 g, 1.48 mmol) and iodine (0.005 g, 0.016 mmol) in benzene (2.3 mL) was stirred at room temperature for 10 min. To it was added a solution of triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-vinylbenzyl)phenoxy]silane (0.15 g, 0.33 mmol) in benzene (1.0 mL) followed by diiodomethane (0.053 mL, 0.66 mmol). The reaction mixture was heated at 70 °C for 144 h, cooled to room temperature and filtered through a Celite plug. The solvent was removed under reduced pressure to afford triisopropyl-[4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]silane as oil (0.14 g, 91%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.92 (m, 1 H), 6.67 (m, 1 H), 6.58 (s, 2 H), 6.43 (s, 1 H), 5.18 (s, 2 H), 3.82 (s, 2 H), 3.39 (s, 3 H), 2.14 (s, 6 H), 1.26 (m, 3 H), 1.08 (d, *J* = 4.5 Hz, 18 H), 0.87 (m, 2 H), 0.46 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.74.

Step c:

[0913] To a mixture of triisopropyl-[3,5-dimethyl-4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)phenoxy]silane (0.38 g, 0.81 mmol) in THF (10.0 mL) at 0 °C was added TBAF (1.22 mL, 0.81 mmol, 1.0 M in THF). The reaction mixture was stirred at room temperature for 1 h, diluted with diethyl ether (20 mL) and washed with H₂O (20 mLx2). The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenol as an oil (0.18 g, 71%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.01 (s, 1 H), 6.90 (m, 1 H), 6.61 (m, 1 H), 6.58 (s, 1 H), 6.46 (s, 2 H), 5.17 (s, 2 H), 3.77 (s, 2 H), 3.39 (s, 3 H), 2.11 (s, 6 H), 0.87 (m, 2 H), 0.51 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.47.

Step d:


[0914] To a mixture of 4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenol (0.16 g, 0.53 mmol) and Cs₂CO₃ (0.859 g, 2.64 mmol) in DMF (6.0 mL) at 0 °C was added trifluoromethanesulfonic acid diethoxyphosphorylmethyl ester (0.11 g, 0.53 mmol). The reaction mixture was stirred at 0 °C for 5 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was cooled to 0 °C, quenched with cold 1 N HCl and extracted with ethyl acetate (8.0 mL). The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl [4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate as oil (0.10 g, 28%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.90 (m, 1 H), 6.75 (s, 2 H), 6.59 (m, 2 H), 5.17 (s, 2 H), 4.39 (d, *J* = 9.0 Hz, 2 H), 4.15 (m, 4 H), 3.83 (s, 2 H), 3.39 (s, 3 H), 2.19 (s, 6 H), 2.09 (m, 1 H), 1.24 (m, 6 H), 0.87 (m, 2 H), 0.52 (m, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.25

Step e:

[0915] To a solution of diethyl [4-(3'-cyclopropyl-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate (0.090 g, 0.19 mmol) in CH₂Cl₂ (3.0 mL) at -30 °C was added bromotrimethylsilane (0.26 mL, 1.94 mmol). The reaction mixture was stirred at room temperature 16 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile-water (4:1, 5.0 mL), stirred at 38 °C for 30 min and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and washed with H₂O. The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure to afford the title compound as an off-white powder (0.040 g, 57%); mp: 153-156 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.02 (s, 1 H), 6.67 (s, 2 H), 6.58 (m, 1 H), 6.41 (m, 2 H), 4.00 (d, *J* = 10.5 Hz, 2 H), 3.75 (s, 2 H), 2.13 (s, 6 H), 1.98 (m, 1 H), 0.81 (m, 2 H), 0.47 (m, 2 H); LC-MS *m/z* = 362 [C₁₉H₂₃O₅P - H]⁺; Anal. Calcd for (C₁₉H₂₃O₅P + 0.9 H₂O): C, 60.28; H, 6.60. Found: C, 60.40; H, 6.92.

Example 49

Compound 49: [4-(3'-Dimethylamino-4'-hydroxybenzyl)-3,5-dimethyl-phenoxy]methylphosphonic acid



Step a:

[0916] To a stirring solution of 4-bromo-2-nitro-phenol (6 g, 27.52 mmol) in MeOH (150 mL) at room temperature was added a suspension of Na₂S₂O₄ (29 g, 165.13 mmol). The mixture was stirred at room temperature for 3 hrs, filtered and concentrated down. The residue was partitioned between EtOAc and water. The organic layer was collected and dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude 2-amino-4-bromo-phenol

as a yellow solid (3.9 g, 75%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.27 (s, 1 H), 6.70 (d, J = 2.2 Hz, 1 H), 6.50 (m, 2 H), 4.79 (s, 2 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; R_f = 0.35.

Step b:

[0917] 2-Amino-4-bromo-phenol (3.9 g, 20.74 mmol) was dissolved into AcOH (120 mL) and heated to 40 °C. To this stirring solution at 40 °C was added (HCHO) n (1.9 g, 62.23 mmol), followed by NaBH₃CN (3.9 g, 62.23 mmol). The reaction mixture was stirred for 1 hr at 40 °C, then another (HCHO) n (1.9 g, 62.23 mmol) and NaBH₃CN (3.9 g, 62.23 mmol) were added. The mixture was stirred for 16 hrs at 40 °C. The solvent was removed under reduced pressure. The residues were partitioned between EtOAc and water. The organic layer was collected and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (30:70) to afford 4-bromo-2-dimethylamino-phenol as a light yellow solid (3.7 g, 83%): ^1H NMR (300 MHz, DMSO- d_6): δ 9.44 (s, 1 H), 6.92 (m, 2 H), 6.71 (d, J = 8.4 Hz, 1 H), 2.69 (s, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; R_f = 0.57.

Step c:

[0918] To a stirring solution of 4-bromo-2-dimethylamino-phenol (3.7 g, 17.13 mmol) in CH₂Cl₂ (100 mL) at room temperature was added ethyl-diisopropyl-amine (4.47 mL, 25.7 mmol) and chloro-methoxy-methane (1.69 mL, 22.27 mmol). The mixture was refluxed for 16 hrs, added water. The organic layer was collected and dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude *N*-(5-bromo-2-methoxymethoxyphenyl)dimethylamine as a red oil (4.4 g, 99%): ^1H NMR (200 MHz, DMSO- d_6): 6.96 (m, 3 H), 5.17 (s, 2 H), 3.40 (s, 3 H), 2.72 (s, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.59.

Step d:

[0919] To a stirring solution of *N*-(5-bromo-2-methoxymethoxy-phenyl)dimethylamine (3.4 g, 13.07 mmol) in THF (80 mL) at -78 °C was added *n*-BuLi (5.22 mL, 2.5 M in hexanes). The mixture was stirred at -78 °C for 1 hr and a solution of 2,6-dimethyl-4-triisopropylsilanyloxy-benzaldehyde (3.6 g, 11.77 mmol) was added. The reaction mixture was stirred at -78 °C for 1 hr, allowed to warm to room temperature and stirred for 1 hr. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (30:70) to afford (3-dimethylamino-4-methoxymethoxy-phenyl)-(2,6-dimethyl-4-triisopropylsilanyloxyphenyl)methanol as a yellow oil (4 g, 63%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.89 (d, *J* = 8.4 Hz, 1 H), 6.79 (s, 1 H), 6.61 (m, 1 H), 6.51 (s, 2 H), 6.01 (d, *J* = 4.0 Hz, 1 H), 5.65 (d, *J* = 4.0 Hz, 1 H), 5.14 (s, 2 H), 3.41 (s, 3 H), 2.64 (s, 6 H), 2.17 (s, 6 H), 1.24 (m, 3 H), 1.08 (d, *J* = 7.2 Hz, 18 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 25% ethyl acetate in hexanes; R_f = 0.27.

Step e:

[0920] To a stirring solution of (3-dimethylamino-4-methoxymethoxy-phenyl)-(2,6-dimethyl-4-triisopropylsilanyloxy-phenyl)-methanol (3.4 g, 6.97 mmol) in CH₂Cl₂ (150 mL) at room temperature was added Et₃SiH (5.6 mL, 34.85 mmol) and TFA (2.6 mL, 34.85 mmol). The reaction mixture was stirred at room temperature for 6 hrs. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:7) to afford *N*-[5-(2',6'-dimethyl-4'-triisopropylsilanyloxybenzyl)-2-methoxymethoxyphenyl]dimethylamine as a yellow oil (3 g, 91%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.68 (d, *J* = 8.1 Hz, 1 H), 6.59 (s, 2 H), 6.54 (d, *J* = 2.1 Hz, 1 H), 6.41 (m, 1 H), 5.12 (s, 2 H), 3.85 (s, 2 H), 3.40 (s, 3 H), 2.64 (s, 6 H), 2.15 (s, 6 H), 1.26 (m, 3 H), 1.08 (d, *J* = 7.2 Hz, 18 H); TLC conditions:

Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (25:75); R_f = 0.54.

Step f:

[0921] To a stirring solution of *N*-[5-(2',6'-dimethyl-4'-triisopropylsilyloxybenzyl)-2-methoxymethoxyphenyl]dimethylamine (3 g, 6.36 mmol) in THF (60 mL) at room temperature was added tetrabutylammonium fluoride (9.54 mL, 1.0 M in THF). The reaction mixture was stirred at room temperature for 2 hr, diluted with diethyl ether and washed with water (30 mLx2). The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford 4-(3'-dimethylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenol as a light yellow oil (1.8 g, 90%): ^1H NMR (300 MHz, DMSO-*d*₆): δ 9.01 (s, 1 H), δ 6.85 (d, *J*= 8.1 Hz, 1 H), 6.63 (d, *J*= 2.1 Hz, 1 H), 6.47 (s, 2 H), 6.35 (m, 1 H), 5.12 (s, 2 H), 3.80 (s, 2 H), 3.40 (s, 3 H), 2.67 (s, 6 H), 2.17 (s, 6 H), TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 30% ethyl acetate in hexanes; R_f = 0.28.

Step g:

[0922] To a stirring solution of 4-(3'-dimethylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenol (0.525 g, 1.66 mmol) in DMF (18 mL) at 0 °C was added NaH (80 mg, 1.99 mmol, 60%) and stirred for 1 hr at room temperature. Diethyl tosyloxymethylphosphonate (0.7 g, 2.16 mmol) was added and the mixture was stirred for 16 hrs at room temperature. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (8:2) to afford diethyl [4-(3'-dimethylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate as a light yellow oil (0.5 g, 65%): ^1H NMR (300 MHz, DMSO-*d*₆): δ 6.85 (d, *J*= 8.1 Hz, 1 H), 6.76 (s, 2 H), 6.64 (d, *J*= 2.1 Hz, 1 H), 6.34 (m, 1 H), 5.12 (s, 2 H),

4.38 (d, $J = 9.8$ Hz, 2 H), 4.14 (m, 4 H), 3.86 (s, 2 H), 3.40 (s, 3 H), 2.67 (s, 6 H), 2.19 (s, 6 H), 1.25 (t, $J = 7.0$ Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (6:4); $R_f = 0.43$.

Step h:


[0923] To a stirring solution of diethyl [4-(3'-dimethylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate (0.48 g, 1.03 mmol) in MeOH (6 mL) and water (1 mL) at room temperature was added HCl (1.03 mL, 10 N), and heated at 100 °C for 5 min by microwave. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-CH₂Cl₂ (3:1) to afford diethyl [4-(3'-dimethylamino-4'-hydroxybenzyl)-3,5-dimethyl-phenoxy]methylphosphonate as a light yellow oil (0.29 g, 67%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 8.77 (s, 1 H), 8.672 (s, 2 H), 6.57 (m, 2 H), 6.26 (m, 1 H), 4.35 (d, $J = 9.8$ Hz, 2 H), 4.13 (m, 4 H), 3.79 (s, 2 H), 2.60 (s, 6 H), 2.17 (s, 6 H), 1.25 (t, $J = 7.0$ Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-CH₂Cl₂ (1:3); $R_f = 0.49$.

Step i:

[0924] The title compound was prepared according to the procedure described for the synthesis of compound 8, step f. ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.34 (s, 1 H), 6.92 (d, $J = 8.7$ Hz, 1 H), 6.79 (m, 1 H), 6.73 (s, 2 H), 4.03 (d, $J = 10.2$ Hz, 2 H), 3.88 (s, 2 H), 3.13 (s, 6 H), 2.17 (s, 6 H); mp: degasses at 90 °C; LC-MS *m/z* = 366 [C₁₈H₂₄NO₅P + H]⁺; Anal Calcd for (C₁₈H₂₄NO₅P + 1.4HBr + 0.4H₂O + 0.1MeOH): C, 44.45; H, 5.48; N, 2.86; Br, 22.87. Found: C, 44.64; H, 5.67; N, 2.65; Br, 22.74.

Example 50

Compound 50: [4-(3'-Benzoyloxycarbonylamino-4'-hydroxybenzyl)-3,5-dimethyl-phenoxy]methylphosphonic acid



Step a:

[0925] To a stirring solution of diethyl [3,5-dimethyl-4-(3'-carboxyl-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (0.36 g, 0.77 mmol) in toluene (20 mL) at room temperature was added diphenylphosphoryl azide (0.17 mL, 0.77 mmol), triethylamine (0.2 mL, 1.4 mmol) and benzyl alcohol (0.4 mL, 3.85 mmol). The mixture was refluxed for 16 hrs. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NH₄Cl. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [4-(3'-benzoyloxycarbonylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate as a light yellow oil (0.4 g, 91%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.60 (s, 1 H), 7.38 (m, 6 H), 6.99 (d, *J* = 8.4 Hz, 1 H), 6.76 (s, 2 H), 6.65 (m, 1 H), 5.13 (s, 2 H), 5.12 (s, 2 H), 4.37 (d, *J* = 9.6 Hz, 2 H), 4.13 (m, 4 H), 3.87 (s, 2 H), 3.37 (s, 3 H), 2.19 (s, 6 H), 1.27 (t, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 75% ethyl acetate in hexanes; R_f = 0.45.

Step b:

[0926] To a stirring solution of diethyl [4-(3'-benzoyloxycarbonylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonic (0.1 g, 0.175 mmol) in MeOH (2 mL) at room temperature was added HCl (0.18 mL, 10 N), and the reaction mixture was heated at 100 °C for 5 min by microwave.


The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [4-(3'-benzyloxycarbonylamino-4'-hydroxybenzyl)-3,5-dimethylphenoxy]methylphosphonate as a light yellow oil (0.076 g, 82%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (s, 1 H), 8.34 (s, 1 H), 7.38 (m, 6 H), 6.71 (m, 3 H), 6.53 (m, 1 H), 5.11 (s, 2 H), 4.37 (d, *J* = 9.6 Hz, 2 H), 4.13 (m, 4 H), 3.82 (s, 2 H), 2.19 (s, 6 H), 1.27 (t, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 75% ethyl acetate in hexanes; R_f = 0.40.

Step c:

[0927] To a stirring solution of diethyl [4-(3'-benzyloxycarbonylamino-4'-hydroxybenzyl)-3,5-dimethylphenoxy]methylphosphonic (0.076 g, 0.144 mmol) in CH₂Cl₂ (8 mL) at room temperature was added hexamethyldisilazane (0.28 mL, 1.27 mmol) and bromotrimethylsilane (0.15 mL, 1.15 mmol). The reaction mixture was stirred at room temperature for 16 hrs. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was washed by CH₂Cl₂ to afford the title compound as a white amorphous solid (0.03 g, 44%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.41 (s, 1 H), 8.30 (s, 1 H), 7.33 (m, 6 H), 6.66 (m, 3 H), 6.48 (m, 1 H), 5.08 (s, 2 H), 3.97 (d, *J* = 10.2 Hz, 2 H), 3.77 (s, 2 H), 2.13 (s, 6 H). mp: shrink at 180 °C. LC-MS *m/z* = 472 [C₂₄H₂₆NO₇P + H]⁺; Anal Calcd for (C₂₄H₂₆NO₇P + 1.1H₂O): C, 58.68; H, 5.79; N, 2.85. Found: C, 58.44; H, 5.89; N, 2.77.

Example 51:

Compound 51-1: [3,5-dimethyl-4-(4'-Hydroxy-3'-methanesulfonylamino-benzyl)phenoxy]methylphosphonic acid



Step a:

[0928] To a solution of diethyl [4-(3'-benzyloxycarbonylamino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonic (0.33 g, 0.58 mmol) in EtOH (20 mL) at room temperature was added Pd/C (50 mg). The reaction mixture was stirred at room temperature under 50 psi H₂ for 16 hrs then filtered through Celite®. The solvent was removed under reduced pressure to afford diethyl [4-(3'-amino-4'-methoxymethoxybenzyl)-3,5-dimethylphenoxy]methylphosphonate as a colorless oil (0.25 g, 99%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.76 (m, 3 H), 6.29 (d, *J* = 2.4 Hz, 1 H), 6.12 (m, 1 H), 5.07 (s, 2 H), 4.69 (s, 2 H), 4.35 (d, *J* = 10.2 Hz, 2 H), 4.12 (m, 4 H), 3.76 (s, 2 H), 3.39 (s, 3 H), 2.19 (s, 6 H), 1.27 (t, *J* = 7 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 75% ethyl acetate in hexanes; R_f = 0.51.

Step b:

[0929] To a stirring solution of diethyl [4-(3'-amino-4'-methoxymethoxybenzyl)-3,5-dimethyl-phenoxy]methylphosphonic (0.13 g, 0.3 mmol) in CH₂Cl₂ (10 mL) at room temperature was added pyridine (0.037 mL, 0.45 mmol) and methanesulfonyl chloride (0.026 mL, 0.33 mmol). The reaction mixture was stirred at room temperature for 16 hrs. then partitioned between CH₂Cl₂ and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [3,5-dimethyl-4-(3'-methanesulfonylamino-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate as a light yellow oil (0.12 g, 77%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.91 (s, 1 H), 7.02 (d, *J* = 8.4 Hz, 1 H), 6.96 (d, *J* = 2.1 Hz, 1 H), 6.76 (m, 3 H), 5.18 (s, 2 H), 4.37 (d, *J* = 9.9 Hz, 2 H),

4.16 (m, 4 H), 3.87 (s, 2 H), 3.41 (s, 3 H), 2.93 (s, 3 H), 2.19 (s, 6 H), 1.27 (t, J = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 75% ethyl acetate in hexanes; R_f = 0.42.

Step c:


[0930] To a stirring solution of diethyl[3,5-dimethyl-4-(3'-methanesulfonylamino-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (0.12 g, 0.23 mmol) in MeOH (2 mL) at room temperature was added HCl (1.2 mL, 2 N), and the reaction mixture was heated at 100 °C for 5 min by microwave. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl[3,5-dimethyl-4-(4'-hydroxy-3'-methanesulfonylaminobenzyl) phenoxy]methylphosphonate as a white solid (0.08g, 74%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.85 (d, J = 1.8 Hz, 1 H), 6.76 (m, 3 H), 6.63 (m, 1 H), 4.37 (d, J = 9.9 Hz, 2 H), 4.14 (m, 4 H), 3.82 (s, 2 H), 2.89 (s, 3 H), 2.18 (s, 6 H), 1.27 (t, J = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.42.

Step d:

[0931] The title compound was prepared according to the procedure described in example 8, step f, (60 mg, 85%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.61 (s, 1 H), 8.61 (s, 1 H), 6.74 (m, 5 H), 4.02 (d, J = 10.2 Hz, 2 H), 3.80 (s, 2 H), 2.88 (s, 3 H), 2.16 (s, 6 H); mp: shrinks at 200 °C; LC-MS *m/z* = 416 [C17H22NO7PS + H]⁺; Anal Calcd for (C17H22NO7PS + 0.1MeOH + 0.8H₂O): C, 47.43; H, 5.59; N, 3.23. Found: C, 47.57; H, 5.68; N, 3.10.


[0932] Using the appropriate starting materials, compounds 51-2 was prepared in an analogous manner to that described for the synthesis of compound 51-1

Compound 51-2: [3,5-Dimethyl-4-(4'-hydroxy-3'-trifluoroacetyl-aminobenzyl)phenoxy]methylphosphonic acid



[0933] ^1H NMR (200 MHz, DMSO-*d*₆): δ 10.41 (s, 1 H), 9.71 (s, 1 H), 6.95 (s, 1 H), 6.74 (m, 4 H), 4.03 (d, *J* = 10.2 Hz, 2 H), 3.83 (s, 2 H), 2.16 (s, 6 H); mp: 170 - 172 °C; LC-MS *m/z* = 434 [C₁₈H₁₉F₃NO₆P + H⁺]; Anal Calcd for (C₁₈H₁₉F₃NO₆P + 0.4H₂O): C, 49.08; H, 4.53; N, 3.18. Found: C, 49.26; H, 4.75; N, 2.83.

Compound 51-3: [3,5-dimethyl-4-(4'-Hydroxy-3'-isobutyrylaminobenzyl)phenoxy]methylphosphonic acid



Step a:

[0934] Diethyl (3'-amino-4'-hydroxybenzyl)-3,5-dimethylphenoxy]-methylphosphonate was prepared according to the procedure described for the synthesis of example 51-1, step c: ^1H NMR (200 MHz, DMSO-*d*₆): δ 8.70 (s, 1 H), 6.71 (s, 2 H), 6.48 (d, *J* = 7.6 Hz, 1 H), 6.19 (s, 1 H), 6.01 (m, 1 H), 4.38 (s, 2 H), 4.33 (d, *J* = 9.6 Hz, 2 H), 4.12 (m, 4 H), 3.70 (s, 2 H), 2.16 (s, 6 H), 1.23 (t, *J* = 7.4 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 75% ethyl acetate in hexanes; R_f = 0.46.

Step b:

[0935] To a stirring solution of diethyl (3'-amino-4'-hydroxybenzyl)-3,5-dimethylphenoxy]methylphosphonate (0.046 g, 0.12 mmol) in THF (5 mL) at 0 °C was added pyridine (0.015 mL, 0.18 mmol) and isobutyric anhydride (0.021 mL, 0.13 mmol). The reaction mixture was stirred at 50 °C for 16 hrs. It


was added EtOAc and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford diethyl [3,5-dimethyl-4-(4'-hydroxy-3'-isobutyrylaminobenzyl)phenoxy]methylphosphonate as a yellow oil (0.046 g, 83%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.55 (s, 1 H), 9.22 (s, 1 H), 7.36 (s, 1 H), 6.73 (m, 3 H), 6.58 (m, 1 H), 4.36 (d, *J* = 9.6 Hz, 2 H), 4.13 (m, 4 H), 3.82 (s, 2 H), 2.73 (m, 1 H), 2.19 (s, 6 H), 1.27 (t, *J* = 6.9 Hz, 6 H), 1.07 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 80% ethyl acetate in hexanes; R_f = 0.37.

Step c:

[0936] The title compound was prepared according to the procedure described for the synthesis of example 8, step f: ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.51 (s, 1 H), 9.22 (s, 1 H), 7.33 (s, 1 H), 6.72 (m, 3 H), 6.58 (m, 1 H), 4.03 (d, *J* = 10.2 Hz, 2 H), 3.80 (s, 2 H), 2.71 (m, 1 H), 2.17 (s, 6 H), 1.06 (d, *J* = 7.0 Hz, 6 H); LC-MS *m/z* = 408 [C₂₀H₂₆NO₆P + H]⁺; Anal Calcd for (C₂₀H₂₆NO₆P + 0.9H₂O + 0.45HBr): C, 52.22; H, 6.19; N, 3.04; Br, 7.82. Found: C, 52.31; H, 6.42; N, 2.66; Br, 7.60.

Example 52:

Compound 52: [3,5-dimethyl-4-(4'-Hydroxy-3'-*iso*-propylbenzyl)-benzenesulfonyl]methylphosphonic acid



Step a:

[0937] To a stirring solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenylamine (0.5 g, 1.6 mmol) at 80 °C in dimethyldisulfide (5 mL) was added isoamylnitrite (0.86 mL, 6.4 mmol). The reaction mixture was

stirred at 80 °C for 1 h. The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:3) to afford 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)methylsulfanylbenzene as a light yellow oil (0.24 g, 44%): ¹H NMR (300 MHz, CDCl₃-*d*₇): δ 6.90 - 6.94 (m, 4 H), 6.62 (m, 1 H), 5.19 (s, 2 H), 3.97 (s, 2 H), 3.50 (s, 3 H), 3.31 (m, 1 H), 2.52 (s, 3 H), 2.25 (s, 6H) 1.20 (d, *J* = 6.9 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:2); R_f = 0.73.

Step b:

[0938] To a stirring solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)methylsulfanylbenzene (0.24 g, 0.7 mmol) at room temperature in CH₂Cl₂ (10 mL) was added *m*-CPBA (0.42 g, 2.45 mmol). The reaction mixture was stirred at room temperature for 16 hrs. It was quenched by sat. Na₂SO₃. The organic layer was washed by sat. NaHCO₃ and dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)methylsulfonylbenzene as a light yellow oil (0.23 g, 87%): ¹H NMR (200 MHz, CDCl₃-*d*₇): δ 7.62 (s, 2 H), 6.88 (m, 2 H), 6.55 (m, 1 H), 5.16 (s, 2 H), 4.10 (s, 2 H), 3.46 (s, 3 H), 3.28 (m, 1 H), 3.06 (s, 3 H), 2.33 (s, 6H) 1.17 (d, *J* = 6.9 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:2); R_f = 0.46.

Step c:

[0939] To a stirring solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)methylsulfonylbenzene (0.23 mL, 0.61 mmol) in THF (10 mL) at -78 °C was added *n*-BuLi (2.5 M in hexanes, 0.29 mL), the reaction mixture was stirred at -78 °C for 1 hr and at 0 °C for 40 min, then diethyl phosphorochloridate (0.11 mL, 0.73 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 1 hr. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel,


eluting with ethyl acetate to afford diethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenylsulfonyl]methylphosphonate as a light yellow oil (130 mg, 42%): ^1H NMR (200 MHz, DMSO- d_6): δ 7.63 (s, 2 H), 7.00 (d, J = 3.0 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 1 H), 6.60 (dd, J = 3.0, 8.4 Hz, 1 H), 5.15 (s, 2 H), 4.36 (d, J = 17.2 Hz, 2 H), 3.97 (m, 6 H), 3.36 (s, 3H), 3.22 (m, 1 H), 2.31 (s, 6H), 1.19 (m, 12 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:1); R_f = 0.43.

Step d:

[0940] The title compound was prepared by the procedure described for the synthesis of example 8, step f: ^1H NMR (200 MHz, DMSO- d_6): δ 9.08 (s, 1 H), 7.61 (s, 2 H), 6.89 (d, J = 3.0 Hz, 1 H), 6.62 (d, J = 8.0 Hz, 1 H), 6.43 (d, J = 3.0, 8.0 Hz, 1 H), 3.96 (s, 2 H), 3.85 (d, J = 16.6 Hz, 2 H), 3.13 (m, 1 H), 2.28 (s, 6 H), 1.10 (d, J = 6.8 Hz, 6 H); LC-MS m/z = 413 [C₁₉H₂₅O₆PS + H]⁺; Anal Calcd for (C₁₉H₂₅O₆PS + 1.0H₂O + 0.15HBr + 0.2Et₂O): C, 51.99; H, 6.42; Br, 2.62. Found: C, 51.67; H, 6.50; Br, 2.62.

Example 53

Compound 53: [3,5-dimethyl-4-(4'-Hydroxy-3'-*iso*-propylphenoxy)-benzenesulfonyl]methylphosphonic acid



Step a:

[0941] To a stirring solution of 4-bromo-2,6-dimethylphenol (6 g, 29.85 mmol) in CH₂Cl₂ (80 mL) at 0 °C was added imidazole (4.1 g, 59.70 mmol) and triisopropylsilyl chloride (7.1 mL, 32.84 mmol). The reaction mixture was stirred at room temperature for 16 hrs. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated

under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford (4-bromo-2,6-dimethylphenoxy)triisopropylsilane as a colorless oil (1.6 g, 15%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.19 (s, 2 H), 2.20 (s, 6 H), 1.29 (m, 3 H), 1.10 (d, $J = 7.2$ Hz, 18 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (5:95); $R_f = 0.70$.

Step b:

[0942] To a stirring solution of (4-bromo-2,6-dimethylphenoxy)-triisopropylsilane (0.5 g, 1.4 mmol) in THF (15 mL) at -78 °C was added *n*-BuLi (2.5 M in hexanes, 0.56 mL), the reaction mixture was stirred at -78 °C for 1 hr, then dimethyldisulfide (0.16 mL, 1.82 mmol) was added at -78 °C. The reaction mixture was stirred at room temperature for 1 h and quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude (2,6-dimethyl-4-methylsulfanylphenoxy)triisopropyl-silane as an oil (0.46 g, 100%): ^1H NMR (300 MHz, DMSO- d_6): δ 6.92 (s, 2 H), 2.41 (s, 3 H), 2.20 (s, 6 H), 1.29 (m, 3 H), 1.10 (d, $J = 7.2$ Hz, 18 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (2:98); $R_f = 0.57$.

Step c:

[0943] To a stirring solution of (2,6-dimethyl-4-methylsulfanylphenoxy)triisopropyl-silane (0.46 g, 1.4 mmol) in CH₂Cl₂ (15 mL) at room temperature was added *m*-CPBA (0.85 g, 4.9 mmol). The reaction mixture was stirred at room temperature for 16 hrs. It was quenched by sat. Na₂SO₃. The organic layer was washed by sat. NaHCO₃ and dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude (2,6-dimethyl-4-methanesulfonylphenoxy)triisopropylsilane as an oil (0.47 g, 94%): ^1H NMR (200 MHz, DMSO- d_6): δ 7.57 (s, 2 H), 3.14 (s, 3 H), 2.28 (s, 6 H), 1.19 (m, 3 H), 1.10 (d, $J = 7.2$ Hz, 18 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (5:95); $R_f = 0.49$.

Step d:

[0944] To a stirring solution of (2,6-dimethyl-4-methanesulfonylphenoxy)triisopropylsilane (0.47 g, 1.32 mmol) in THF (15 mL) at -78 °C was added *n*-BuLi (2.5 M in hexanes, 0.58 mL), the reaction mixture was stirred at -78 °C for 1 hr, then diethyl phosphorochloridate (0.25 mL, 1.72 mmol) was added at -78 °C. The reaction mixture was stirred at room temperature for 16 hrs. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl (3,5-dimethyl-4-triisopropylsilanyloxybenzenesulfonyl)methylphosphonate as a colorless oil (0.1 g, 15%): ¹H NMR (200 MHz, CDCl₃-d₆): δ 7.57 (s, 2 H), 4.17 (m, 4 H), 3.71 (d, *J* = 17.2 Hz, 2 H), 2.29 (s, 6 H), 1.33 (m, 9 H), 1.10 (d, *J* = 7.2 Hz, 18 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.45.

Step e:

[0945] To a stirring solution diethyl (3,5-dimethyl-4-triisopropylsilanyloxybenzenesulfonyl)methylphosphonate in THF (3 mL) at room temperature was added TBAF (0.3 mL, 1 M in THF). It was stirred at room temperature for 2 hrs. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (5:1) to afford diethyl (3,5-dimethyl-4-hydroxybenzenesulfonyl)methylphosphonate as a light yellow oil (70 mg, 100%): ¹H NMR (300 MHz, CDCl₃-d₆): δ 7.54 (s, 2 H), 4.12 (m, 4 H), 3.65 (d, *J* = 16.8 Hz, 2 H), 2.22 (s, 6 H), 1.22 (d, *J* = 7.2 Hz, 6 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (5:1); R_f = 0.44.

Step f:


[0946] To a stirring mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (0.15 g, 0.3 mmol) and copper powder (16 mg, 0.26 mmol) in CH₂Cl₂ (5 mL) at 0 °C was added a solution of triethylamine (0.031 mL, 0.22 mmol) and diethyl (3,5-dimethyl-4-hydroxybenzenesulfonyl)methylphosphonate (70 mg, 0.2 mmol) in CH₂Cl₂ (2 mL). The reaction mixture was stirred at room temperature for 16 hrs and filtered through a Celite plug. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (5:1) to afford diethyl[3,5-dimethyl-4-(4'-methoxy-3'-*iso*-propylphenoxy)benzenesulfonyl]methylphosphonate as a light yellow oil (40 mg, 41%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.76 (s, 2 H), 6.79 (m, 2 H), 6.35 (m, 1 H), 4.44 (d, *J* = 16.8 Hz, 2 H), 4.02 (m, 4 H), 3.73 (s, 3 H), 3.18 (m, 1 H), 2.14 (s, 6 H), 1.15 (m, 12 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:2); R_f = 0.49.

Step g:

[0947] The title compound was prepared according to the procedure described for the synthesis of example 22, step d, (40 mg, 0.083 mmol): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.02 (s, 1 H), 7.70 (s, 2 H), 6.67 (m, 2 H), 6.19 (dd, *J* = 3.0, 8.4 Hz, 1 H), 3.72 (d, *J* = 15.8 Hz, 2 H), 3.14 (m, 1 H), 2.09 (s, 6 H), 1.11 (d, *J* = 6.6 Hz, 6 H); LC-MS *m/z* = 415 [C₁₈H₂₃O₇PS + H]⁺; Anal Calcd for (C₁₈H₂₃O₇PS + 1.3H₂O + 0.1EtOAc): C, 49.48; H, 5.96. Found: C, 49.18; H, 5.67.

Example 54:

Compound 54: [3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)benzenesulfanyl]methylphosphonic acid



Step a:


[0948] To a stirring solution of (2,6-dimethyl-4-methylsulfanyl-phenoxy)triisopropylsilane (2.18 g, 6.72 mmol) in CCl_4 (25 mL) at room temperature was added *N*-chlorosuccinimide (0.99 g, 7.39 mmol). The reaction mixture was stirred at room temperature for 16 hrs and filtered through a Celite plug. The solvent was removed under reduced pressure to afford crude (4-chloromethylsulfanyl-2,6-dimethylphenoxy)triisopropylsilane as an oil (2.4 g, 100%). This crude oil was dissolved into phosphorous acid triethyl ester (1.5 mL). It was heated at 180 °C for 30 min by microwave. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl (3,5-dimethyl-4-triisopropylsilyloxy-phenylsulfanyl)methylphosphonate as a yellow oil (1.6 g, 52%): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): δ 7.09 (s, 2 H), 4.98 (m, 4 H), 3.31 (d, J = 13.8 Hz, 2 H), 2.17 (s, 6 H), 1.25 (m, 9 H), 1.09 (d, J = 7.0 Hz, 18 H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate/Hexanes (2:3); R_f = 0.45.

Step b:

[0949] The title compound was prepared according to the procedure described for the synthesis of example 53, steps e, f and g: ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 8.91 (s, 1 H), 7.16 (s, 2 H), 6.64 (m, 2 H), 6.21 (dd, J = 3.3, 8.7 Hz, 1 H), 4.13 (m, 3 H), 2.02 (s, 6 H), 1.11 (d, J = 6.9 Hz, 6 H); LC-MS m/z = 383 [C₁₈H₂₃O₅PS + H]⁺; Anal Calcd for (C₁₈H₂₃O₅PS + 0.15TFA + 0.2Et₂O): C, 55.00; H, 5.98. Found: C, 54.88; H, 5.76.

Example 55

Compound 55: [3,5-Dimethyl-4-(4'-hydroxy-3'-methylsulfanyl-benzyl)-phenoxy]methylphosphonic acid



Step a:


[0950] To a stirring solution of diethyl [3,5-dimethyl-4-(3'-amino-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (Example 51, step a; 0.29g, 0.66 mmol) at 80 °C in dimethyldisulfide (3 mL) was added isoamyl nitrite (0.4 mL, 2.64 mmol). The reaction mixture was stirred at 80 °C for 1 h. The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl [3,5-dimethyl-4-(3'-methylsulfanyl-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate as a red oil (0.12 g, 39%): ^1H NMR (200 MHz, DMSO- d_6): δ 6.91 (d, J = 8.4 Hz, 1 H), 6.86 (d, J = 2.1 Hz, 1 H), 6.75 (s, 2 H), 6.58 (dd, J = 2.2, 8.4 Hz, 1 H), 5.16 (s, 2 H), 4.36 (d, J = 10.0 Hz, 2 H), 4.11 (m, 4 H), 3.89 (s, 2 H), 3.37 (s, 3 H), 2.30 (s, 3 H), 2.17 (s, 6 H), 1.25 (t, J = 7.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 50% ethyl acetate in hexanes; R_f = 0.61.

Step b:

[0951] The title compound was prepared according to the procedure described for the synthesis of example 8, step f as a yellow foam (40 mg, 42%). ^1H NMR (300 MHz, DMSO- d_6): δ 9.58 (s, 1 H), 6.80 (d, J = 2.1 Hz, 1 H), 6.72 (s, 2 H), 6.66 (d, J = 8.4 Hz, 1 H), 6.50 (dd, J = 2.1, 8.4 Hz, 1 H), 4.06 (d, J = 10.2 Hz, 2 H), 3.84 (s, 2 H), 2.28 (s, 3 H), 2.18 (s, 6 H); LC-MS m/z = 369 [$\text{C}_{17}\text{H}_{21}\text{O}_5\text{PS} + \text{H}^+$]; Anal Calcd for ($\text{C}_{17}\text{H}_{21}\text{O}_5\text{PS} + 0.1\text{EtOAc} + 0.1\text{TFA}$): C, 54.40; H, 5.68. Found: C, 54.65; H, 5.33.

Example 56:

Compound 56: 3,5-Dicyano-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy]-methylphosphonate



Step a:

[0952] To a solution of 4-benzyloxyphenol (0.2 g, 0.93 mmol) in dichloromethane (9.3 mL) at 0 °C was added bis(pyridine)iodonium tetrafluoroborate (0.76 g, 2.06 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 4-benzyloxy-3,5-diiodophenol as an off-white solid (0.22 g, 50%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.60 (s, 1 H), 8.06 (m, 2 H), 7.72 (s, 2 H), 7.59 (m, 3 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (4:1); R_f = 0.45.

Step b:

[0953] To a mixture of bis(4-methoxy-3-*iso*-propylphenyl)iodonium tetrafluoroborate (0.77 g, 1.51 mmol) and copper powder (0.13 g, 2.01 mmol) in CH₂Cl₂ (4.4 mL) at 0 °C was added a solution of TEA (0.15 mL, 1.10 mmol) and 4-benzyloxy-3,5-diiodophenol (0.47 g, 1.00 mmol) in dichloromethane (4.0 mL). The reaction mixture was stirred at room temperature for 24 h and filtered through a Celite plug. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with acetone-hexanes (1:9) to afford 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenyl benzoate as an off-white solid (0.61 g, 98%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.10 (m, 2 H), 7.96 (s, 2 H), 7.73 (m, 1 H), 7.60 (m, 2 H), 6.85 (d, J = 9.0 Hz, 1H), 6.73 (d, J = 3.0 Hz, 1H), 6.35 (m, 1 H), 3.74 (s, 3 H), 3.21 (m, 1 H), 1.13 (d, J = 6.0

Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-acetone (1:9); R_f = 0.42.

Step c:

[0954] To a stirred solution of 3,5-diido-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenyl benzoate (0.4 g, 0.76 mmol) in DMF(5.0 mL) at rt was added CuCN (0.27 g, 3.0 mmol). The reaction mixture was heated at 160 °C for 5 min under microwave irradiation, the reaction mixture was cool to room temperature and poured into 1N HCl (50 mL) and extracted with ethyl acetate (100 mLx2). The organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:7) to afford 3,5-dicyano-4-(4'-methoxy-3'-*iso*-propylphenoxy)phenol as a viscous oil (105 mg, 35%): ¹H NMR (300 MHz, CDCl₃) δ 7.35 (s, 2 H), 6.99 (d, *J*= 3.0 Hz, 1 H), 6.78 (d, *J*= 8.7 Hz, 1 H), 6.99 (dd, *J*= 3.0, 8.7 Hz, 1 H), 3.84 (s, 3 H), 3.38 - 3.30 (m, 1 H), 1.21 (d, *J*= 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (7:3); R_f = 0.38.

Step d:

[0955] 3,5-dicyano-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenol was prepared according to the procedure described for the synthesis of compound 54, step d (132 mg, 32%): ¹H NMR (300 MHz, CD₃OD) δ 7.38 (s, 2H), 6.81 (d, *J*= 3.0 Hz, 1H), 6.70 (d, *J*= 9.0 Hz, 1H), 6.52 (dd, *J*= 9.0, 3.0 Hz, 1H), 3.26 (heptuplet, *J*= 7.0 Hz, 1H), 1.18 (d, *J*= 7.0 Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1), R_f = 0.35.

Step e:

[0956] Diethyl trifluoromethanesulfonyloxyethylphosphonate (148 mg, 0.5 mmol) was added to an heterogeneous mixture of 3,5-dicyano-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenol (132 mg, 0.45 mmol) and cesium carbonate (440 mg, 1.35 mmol) in DMF at rt. After stirring at rt for 1 week, the reaction mixture was diluted with ethyl acetate and the pH lowered to 1 with 1 N hydrochloric acid. The organics were washed with water then brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was


purified by column chromatography (silica gel, hexanes/ethyl acetate 50/50 to 0/100) to give diethyl 3,5-dicyano-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy)methylphosphonate (44 mg, 22%): ¹H NMR (300 MHz, CDCl₃) δ 7.42 (s, 2H), 6.73 (d, *J* = 3.0 Hz, 1H), 6.68 (d, *J* = 9.0 Hz, 1H), 6.57 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.35-4.20 (m, 6H), 3.23 (heptuplet, *J* = 7.0 Hz, 1H), 1.38 (t, *J* = 7.0 Hz, 6H), 1.18 (d, *J* = 7.0 Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1), R_f = 0.2.

Step f:

[0957] The title compound was prepared by the procedure described for the synthesis of compound 8, step f (18 mg, 47%): ¹H NMR (300 MHz, CD₃OD) δ 7.74 (s, 2H), 6.85 (d, *J* = 3.0 Hz, 1H), 6.72 (d, *J* = 9.0 Hz, 1H), 6.56 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.35 (d, *J* = 6.8 Hz 2H), 3.27 (heptuplet, *J* = 7.0 Hz, 1H), 1.18 (d, *J* = 7.0 Hz, 6H); Anal. Calcd for (C₁₈H₁₇N₂O₆P + 1.4 H₂O): C, 52.28; H, 4.83; N, 6.77. Found: C, 52.55; H, 4.90; N, 6.12.

Example 57

Compound 57: [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-yloxy]methyl phosphonic acid



Step a:

[0958] To a stirring solution of 3,5-dichloro-2,6-difluoro-4-(4'-methoxymethoxy-3'-*iso*-propyl-phenoxy)-pyridine (0.11 g, 0.29 mmol) and diethyl hydroxymethyl-phosphonate (0.045 mL, 0.31 mmol) in THF (3 mL) at 0 °C was added NaH (13 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 16 hrs, diluted with EtOAc and washed with water (30 mLx2). The solvent was removed under reduced pressure. The crude product


was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:1) to afford diethyl [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-*iso*-propylphenoxy)-pyrid-2-yl]methyl phosphonate as a yellow oil (43 mg, 28%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.00 (d, J = 9.0 Hz, 1 H), 6.96 (d, J = 3.3 Hz, 1 H), 6.67 (dd, J = 3.3, 9.0 Hz, 1 H), 5.19 (s, 2 H), 4.77 (d, J = 8.1 Hz, 2 H), 4.15 (m, 4 H), 3.40 (s, 3 H), 3.28 (m, 1 H), 1.27 (t, J = 7.2 Hz, 6 H), 1.17 (d, J = 6.6 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 66% ethyl acetate in hexanes; R_f = 0.31.

Step b:

[0959] The title compound was prepared according to the procedure described for the synthesis of example 8, step f as a white solid (30 mg, 71%): mp: 139–141 °C; ^1H NMR (200 MHz, DMSO- d_6): δ 9.22 (s, 1 H), 6.84 (d, J = 2.8 Hz, 1 H), 6.68 (d, J = 8.8 Hz, 1 H), 6.47 (dd, J = 2.8, 8.8 Hz, 1 H), 4.46 (d, J = 8.8 Hz, 2 H), 3.17 (m, 1 H), 1.13 (d, J = 6.6 Hz, 6 H); LC-MS m/z = 427 [$\text{C}_{15}\text{H}_{15}\text{Cl}_2\text{FNO}_6\text{P} + \text{H}^+$] $^+$; Anal Calcd for ($\text{C}_{15}\text{H}_{15}\text{Cl}_2\text{FNO}_6\text{P} + 0.5\text{H}_2\text{O}$): C, 41.40; H, 3.71; N, 3.22. Found: C, 41.09; H, 3.87; N, 2.89.

Example 58:

Compound 58: [4-(4'-Acetoxy-3'-*iso*-propylbenzyl)-3,5-dimethylphenoxy]-methylphosphonic acid:




[0960] A mixture of [3,5-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)]phenoxy)methyl phosphonic acid (5.0 g, 13.7 mmol) and acetic anhydride (5.0 g, 48.9 mmol) in toluene (70 mL) was stirred at 20 °C for 3 hrs. Water (5 mL) was added and the mixture was stirred 1 hr. The solvent was removed under reduced pressure. Toluene (50 mL) was added to the residue then removed under reduced pressure. Toluene addition and evaporation was repeated twice

more. The resulting solid was dried under vacuum at 45 °C to give the title compound (5.6 g, 100%). A purified sample (420 mg) was obtained by stirring the crude product in boiling isopropyl ether, cooling to 20 °C, collecting the solid by filtration, and drying under vacuum. mp: 169-172 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.06 (d, *J* = 2.1 Hz, 1H), 6.85 (d, *J* = 8.4 Hz, 1H), 6.70 (s, 2H), 6.65 (dd, *J* = 9.0 and 2.4 Hz, 1H), 4.02 (d, *J* = 10.2 Hz, 2H), 3.90 (s, 2H), 2.94-2.84 (m, 1H), 2.25 (s, 3H), 2.15 (s, 6H), 1.07 (d, *J* = 6.9 Hz, 6H). Anal. Calcd for (C₂₁H₂₇O₆P): C, 62.06; H, 6.70. Found: C, 62.22; H, 6.82.

Example 59

Cis and *Trans* (*S*)-2-[(4-(4'-Acetoxy-3'-*iso*-propylbenzyl)-3,5-dimethylphenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2*λ*⁵-[1,3,2]-dioxaphosphonane:



[0961] A solution of oxalyl chloride (3.0 g, 23.6 mmol) in dichloromethane (14 mL) was added over 20 minutes to a stirring suspension of [4-(4'-acetoxy-3'-*iso*-propylbenzyl)-3,5-dimethylphenoxy]methylphosphonic acid (3.2 g, 7.88 mmol) in dichloromethane (50 mL). The resulting solution was stirred at 20 °C for 1hr. then the solvent was removed under reduced pressure. Dichloromethane (30 mL) was added to the residue then evaporated under reduced pressure. The resulting oil was dissolved in THF (32 mL) and the solution was added over 40 minutes to a stirring solution of (*S*)-1-(3-chlorophenyl)-1,3-propanediol (1.5 g, 7.88 mmol) and triethylamine (2.4 g, 23.6 mmol) in THF (32 mL) while keeping the temperature below -70 °C. The reaction mixture was stirred at -70 °C for 2 hrs. then warmed to 15 °C. To the reaction mixture was added 0.5 M aqueous HCl (32 mL) and ethyl acetate (32 mL). The phases were separated and the aqueous layer was


extracted with ethyl acetate (32 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, and filtered. The solvent was removed under reduced pressure. The crude product was purified by chromatography on silica gel, eluting with ethyl acetate-hexanes (50%-100%) to afford:

Compound 59-trans: (610 mg, 14%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.48-7.36 (m, 4H), 7.07 (d, J = 2.1 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.83 (s, 2H), 6.64 (dd, J = 9.0 and 2.0 Hz, 1H), 5.85-5.82, (m, 1H), 4.74-4.68 (m, 1H), 4.61 (d, J = 9.3 Hz, 2H), 4.52-4.42 (m, 1H), 3.92 (s, 2H), 2.94-2.85 (m, 1H), 2.25 (s, 3H), 2.24-2.20 (m, 2H), 2.17 (s, 6H), 1.07 (d, J = 6.9 Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane-acetone (9:1); R_f = 0.5.

Compound 59-cis: (2.5g, 57%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.47 (m, 1H), 7.38-7.26 (m, 3H), 7.06 (d, J = 2.1 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 6.76 (s, 2H), 6.67 (dd, J = 8.1 and 2.1 Hz, 1H), 5.76-5.72 (m, 1H), 4.61-4.36 (m, 4H), 3.92 (s, 2H), 2.94-2.85 (m, 1H), 2.25 (s, 3H), 2.20-2.19 (m, 2H), 2.16 (s, 6H), 1.07 (d, J = 6.9 Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = dichloromethane-acetone (9:1); R_f = 0.35; Anal Calcd for (C₃₀H₃₄ClO₆P + 0.13 H₂O): C, 64.42; H, 6.17. Found: C, 64.12; H, 6.07.

Example 60

Compound 60: [4-(4'-Hydroxy-3'-*iso*-propyl-2'-methylbenzyl)-3-methylphenoxy]methylphosphonic acid



Step a:

[0962] To a stirring solution of 1-bromo-3-*iso*-propyl-4-methoxy-2-methylbenzene (compound 7-16, step c; 0.7 g, 2.88 mmol) in THF (20 mL) at -78 °C was added *n*-BuLi (1.6 mL, 2.5 M in hexanes). The mixture was stirred at -78 °C for 1 hr and 4-methoxy-2-methyl-benzaldehyde (0.37 mL, 2.74 mmol) was added. The reaction mixture was stirred at -78 °C for 1 hr, allowed to warm to room temperature and stirred for 1 hr. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude (4'-methoxy-3'-*iso*-propyl-2'-methylphenyl)-(4-methoxy-2-methylphenyl)-methanol as a light yellow oil (1.0 g, 100%). This crude oil was dissolved into EtOAc (25 mL) and AcOH (5 mL) and Pd/C (0.1 g) was added. After stirring at rt for 6 hours, the reaction mixture was filtered through the Celite and concentrated under reduced pressure to afford crude 4-(4'-methoxy-2'-methyl-3'-*iso*-propylbenzyl)-3-methyl-anisole as a yellow oil (0.8 g, 93%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.88–6.80 (m, 5 H), 3.77 (s, 2 H), 3.74 (s, 3 H), 3.71 (s, 3 H), 3.34 (m, 1 H), 2.22 (s, 3 H), 2.14 (s, 3 H), 1.28 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 8% ethyl acetate in hexanes; R_f = 0.56.

Step b:

[0963] To a stirring solution of 4-(4'-methoxy-2'-methyl-3'-*iso*-propylbenzyl)-3-methyl-anisole (0.8 g, 2.68 mmol) in CH₂Cl₂ (10 mL) at -20 °C was added BBr₃ (10.7 mL, 1M in CH₂Cl₂). The reaction mixture was stirred at room temperature for 16 hrs. Ice was add and the mixture was diluted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate/hexanes (1:1) to afford 4-(4'-hydroxy-2'-methyl-3'-*iso*-propylbenzyl)-3-methylphenol as a yellow solid (0.54 g, 75%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.03 (s, 1 H), 8.84 (s, 1 H), 6.41–6.60 (m, 5 H), 3.65 (s, 2 H), 3.33 (m, 1 H), 2.12 (s, 3 H), 2.08 (s, 3 H), 1.27 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 20% ethyl acetate in hexanes; R_f = 0.31.

Step c:


[0964] To a solution of 44-(4'-hydroxy-2'-methyl-3'-*iso*-propylbenzyl)-3-methylphenol (0.54 g, 2 mmol) in DMF (15 mL) at room temperature was added Cs₂CO₃ (2.6 g, 8 mmol) and diethyl trifluoromethanesulfonyloxymethylphosphonate (0.66 g, 2.2 mmol). The reaction mixture was stirred at room temperature for 1 hr. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (4:1) to afford diethyl [4-(4'-hydroxy-3'-*iso*-propyl-2'-methylbenzyl)-3-methylphenoxy]methylphosphonate as a colorless oil (0.14 g, 17%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.89 (s, 1 H), 6.86 (d, *J* = 2.7 Hz, 1 H), 6.76 (dd, *J* = 2.7, 9.0 Hz, 1 H), 6.67 (d, *J* = 9.0 Hz, 1 H), 6.51 (m, 2 H), 4.36 (d, *J* = 9.6 Hz, 2 H), 4.11 (m, 4 H), 3.73 (s, 2 H), 3.34 (m, 1 H), 2.22 (s, 3 H), 2.09 (s, 3 H), 1.27 (m, 12 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 66% ethyl acetate in hexanes; R_f = 0.45.

Step d:

[0965] The title compound was prepared according to the procedure described for the synthesis of example 8, step f as a white solid (80 mg, 67%): ¹H NMR (300 MHz, DMSO-*d*₆): 8.88 (s, 1 H), 6.85 (d, *J* = 2.1 Hz, 1 H), 6.73 (dd, *J* = 2.1, 8.7 Hz, 1 H), 6.66 (d, *J* = 8.7 Hz, 1 H), 6.51 (m, 2 H), 4.02 (d, *J* = 10.2 Hz, 2 H), 3.73 (s, 2 H), 3.34 (m, 1 H), 2.22 (s, 3 H), 2.10 (s, 3 H), 1.30 (d, *J* = 6.9 Hz, 6 H); mp: 166 – 168 °C; LC-MS *m/z* = 363 [C₁₉H₂₅O₅P - H]; Anal Calcd for (C₁₉H₂₅O₅P + 0.13HBr): C, 60.87; H, 6.76; Br, 2.77. Found: C, 61.19; H, 6.84; Br, 3.10.

Example 61:

Compound 61-1: [4-(4'-hydroxy-3'-*iso*-propylbenzyl)-2,3,5-trimethylphenoxy]methylphosphonic Acid



Step a:

[0966] A mixture of 3,5-dimethyl-2-iodo-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol (compound 47, step a; 1.0 g, 2.27 mmol) and PdCl₂(PPh₃)₂ (0.10 g, 0.14 mmol) in TEA (1.6 mL) and methanol (8.0 mL) was heated under a CO atmosphere (60 psi) at 80 °C for 72 h. The reaction mixture was cooled to room temperature and filtered through a Celite plug. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in hexanes to afford methyl 2,4-dimethyl-6-hydroxy-3-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoate (0.32 g, 38 %): ¹H NMR (300 MHz, CD₃OD): δ 6.93 (m, 2 H), 6.67 (s, 2 H), 5.18 (s, 1 H), 3.98 (s, 2 H), 3.92 (s, 3 H), 3.48 (s, 3 H), 3.30 (m, 1 H), 2.22 (m, 6 H), 1.18 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.60.

Step b:

[0967] To a solution of methyl 2,4-dimethyl-6-hydroxy-3-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzoate in ethanol-water (3.0 mL, 95:5) at room temperature was added NaBH₄. The reaction mixture was heated at 80 °C for 4 h and cooled to room temperature. The reaction mixture was quenched with aqueous NH₄Cl and extracted with ether. The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 30% acetone in hexanes to afford 2,4-dimethyl-6-hydroxy-3-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzyl alcohol: ¹H NMR (300 MHz, CD₃OD): δ 6.97 (d, *J* = 2.4 Hz, 1 H), 6.92 (d, *J* = 13.2 Hz, 1 H), 6.68 (dd, *J* = 13.2, 2.4 Hz, 1 H), 6.59 (s, 1 H), 5.17 (s, 2 H), 4.78 (s, 2 H), 3.96 (s, 2 H), 3.47 (s, 3 H), 3.30 (m, 1 H), 2.24 (s, 3 H), 2.19 (s, 3 H), 1.18 (d, *J* = 10.8 Hz, 6 H).

Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.40.


Step c:

[0968] A mixture of 2,4-dimethyl-6-hydroxy-3-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)benzyl alcohol ((0.20 g, 0.58 mmol) and Pd-C (0.08 g, 10%) in ethyl acetate-acetic acid (3.5 mL, 95:5) was stirred at room temperature under a H₂ atmosphere for 6 h. The reaction mixture was filtered through a Celite plug and the solvent was removed under reduced pressure to afford 4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-2,3,5-trimethylphenol (0.19 g, 100%) as colorless oil: ¹H NMR (300 MHz, CD₃OD): δ 6.94 (m, 1 H), 6.91 (d, J = 13.2 Hz, 1 H), 6.68 (dd, J = 13.2, 2.4 Hz, 1 H), 6.55 (s, 1 H), 5.17 (s, 2 H), 3.95 (s, 2 H), 3.47 (s, 3 H), 3.30 (m, 1 H), 2.19 (s, 3 H), 2.16 (s, 3 H), 2.11 (s, 3 H), 1.17 (d, J = 10.8 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (3:7); R_f = 0.60.

[0969] The title compound was prepared according to the procedure described for the synthesis of compound 7: mp: 56.0-58.0 °C; ¹H NMR (300 MHz, CD₃OD): δ 6.85 (d, J = 2.4 Hz, 1 H), 6.76 (s, 1 H), 6.60 (d, J = 12.0 Hz, 1 H), 6.52 (dd, J = 12.6, 2.4 Hz, 1 H), 4.22 (d, J = 10.2 Hz, 2 H), 3.94 (s, 2 H), 3.23 (m, 1 H), 2.25 (s, 3 H), 2.24 (s, 3 H), 2.15 (s, 3 H), 1.17 (d, J = 10.8 Hz, 6 H); LC-MS *m/z* = 379 [C₂₀H₂₇O₅P + H]⁺; Anal Calcd for [C₂₀H₂₇O₅P + 1.1 H₂O]: C, 60.32; H, 7.39. Found: C, 60.05; H, 7.14.

Example 62


Compound 62: [6-iodo-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-2,3,5-trimethylphenoxy]methylphosphonic Acid



[0970] [6-Iodo-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-2,3,5-trimethylphenoxy] methylphosphonic acid was prepared from 4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)-2,3,5-trimethylphenol (compound 61-1, step c) was prepared according to the procedure described for the synthesis of compound 45, step a and transformed into the title compound according to the procedure described for the synthesis of compound 7-1: mp: 185-187 °C; ¹H NMR (300 MHz, CD₃OD): δ 6.88 (d, *J* = 2.4 Hz, 1 H), 6.61 (d, *J* = 12.3 Hz, 1 H), 6.50 (d, *J* = 2.4 Hz, 1 H), 4.14 (d, *J* = 10.5 Hz, 1 H), 4.09 (s, 2 H), 3.24 (m, 1 H), 2.46 (s, 3 H), 2.39 (s, 3 H), 2.19 (s, 3 H), 1.18 (d, *J* = 6.9 Hz, 6 H); LC-MS *m/z* = 504 [C₂₀H₂₇O₅P]⁺; Anal. Calcd for (C₂₀H₂₆IOP+0.8 H₂O): C, 46.26; H, 5.41. Found: C, 46.48; H, 5.78.

Example 63

Compound 63: [3-Bromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-5-trifluoromethyl-phenylamino]methylphosphonic acid



Step a:

[0971] Intermediate 1,5-dibromo-2-(3'-*iso*-propyl-4'-methoxy-phenoxy)-3-trifluoromethyl-benzene was prepared from 2,4-dibromo-6-trifluoromethyl-phenol (*J. Amer. Chem. Soc.*, 1947, 2346) according to the procedure described for the synthesis of compound 4, step a: ¹H NMR (200 MHz, DMSO-*d*₆): δ 8.39 (m, 1 H), 8.07 (m, 1 H), 6.85 (m, 2 H), 6.45 (m, 1 H), 3.73 (s, 3 H), 3.15 (m, 1 H), 1.08 (d, *J* = 10.5 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes; R_f = 0.54.

Step b:


[0972] To a mixture of Pd(OAc)₂ (0.031 g, 0.14 mmol) in toluene (40 mL) at rt was added (+/-)2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.13 mL, 0.21 mmol). The reaction mixture was stirred at rt for several minutes and Cs₂CO₃ (3.62 g, 11.10 mmol), 1,5-dibromo-2-(3'-iso-propyl-4'-methoxyphenoxy)-3-trifluoromethyl-benzene (1.30 g, 2.77 mmol, dissolved in 10 mL toluene), and diethyl aminomethylphosphonate oxalate (0.76 g, 2.97 mmol) were added. The reaction mixture was stirred at 100 °C for 16 h. The solution was cooled to rt, diluted with diethyl ether (25 mL), filtered and concentrated. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl [3-bromo-4-(4'-methoxy-3'-iso-propyl-phenoxy)-5-trifluoromethylphenylamino]methylphosphonate as an oil (0.28 g, 18%): ¹H NMR (300 MHz, DMSO-d₆): δ 7.33 (m, 1 H), 7.16 (m, 1 H), 6.85 (m, 1 H), 6.65 (m, 1 H), 6.55 (m, 1 H), 6.39 (m, 1 H), 4.08 (m, 4 H), 3.74 (s, 3 H), 3.68 (m, 2 H), 3.21 (m, 1 H), 1.19 (m, 6 H), 1.11 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.25.

Step c:

[0973] The title compound was prepared according to the procedure described for the synthesis of Example 19, step e: mp: 98-102 °C; ¹H NMR (300 MHz, CD₃OD): δ 7.11 (m, 1 H), 6.95 (m, 2 H), 6.48 (m, 1 H), 6.45 (m, 1 H), 6.20 (m, 1 H), 3.41 (d, J = 12.0 Hz, 2 H), 3.12 (m, 1 H), 1.17 (m, 18 H), 1.04 (d, J = 6.0 Hz, 6 H); LC-MS m/z = 484 [C₁₇H₁₈BrF₃NO₅P - H]⁺; HPLC conditions: Column = Shimadzu LC-A8, SPD-10A; YMC Pack RP-18 filter, 150×4.6; Mobile phase = Solvent A Acetonitrile/0.05% TFA; Solvent B = H₂O/0.05% TFA. Gradient: 0min: 20% B; 13 min: 70% B; 16min: 100% B; 18min: 20% B. Flow rate = 2.0 mL/min; UV@ 254 nm. rt = 9.16min.

Example 64

Compound 64: [3,5-Dimethyl-4-[4'-hydroxy-3'-(3-trifluoromethylphenoxy)-benzyl]phenoxy]methylphosphonic acid



Step a:

[0974] To 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxy-methoxy-benzaldehyde (compound 15, step e; 0.460 g, 1.01mmol) in dichloromethane 30 mL was add mCPBA (0.870 g, 2.52 mmol) and saturated sodium bicarbonate solution (2 mL). After stirring at rt overnight, the reaction mixture was poured into dichloromethane 50 mL and washed 3 x with 10 mL of saturated aqueous sodium bicarbonate. The dichloromethane was dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was combined with methanol (10 mL) and 2 mL of 1 N NaOH and stirred for 1.5 hours at room temperature. The reaction was acidified with 12 N HCl (pH<3) and poured into 50 mL ethyl acetate. The layers were separated and the organics were dried over sodium sulfate, filtered and concentrated. Flash column chromatography using silica and a step gradient of hexane/ethyl acetate [20:1], hexane/ethyl acetate [9:1] provided 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxy-phenol (0.189 g, 42%): ^1H NMR (300 MHz, DMSO- d_6): δ 8.95(s, 1H), 6.86(d, 1H, J = 8.1 Hz), 6.56(s, 2H), 6.41(d, 1H, J = 2.1 Hz), 6.34(dd, 1H, J = 2.1 Hz and J = 8.7 Hz), 5.05(s, 2H), 3.78(s, 2H), 3.38(s, 3H), 2.13(s, 6H), 1.11(m, 3H), 1.00(m, 18H); Uniplate silica gel, 250 microns; Mobile phase = 10% ethyl acetate in hexane: Rf = 0.15

Step b:

[0975] (2,6-Dimethyl-4-triisopropylsilyloxybenzyl)-4-methoxymethoxy-3-(3-trifluoromethylphenoxy)benzene was prepared from 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-2-methoxymethoxy-phenol according to the procedure described in Dominic M. T. Chan *et al.* *Tetrahedron Lett.* 39:2933-2936 (1998), (0.070 g, 37%) ^1H NMR (300 MHz, DMSO- d_6): δ 7.53(t, 1H, J = 7.8 Hz), 7.35(d, 1H, J = 7.8 Hz), 7.21-7.10(m, 2H), 6.98(s, 1H), 6.89(m, 1H),

6.59(m, 1H), 6.64(s, 2H), 5.09(s, 2H), 3.89(s, 2H), 3.18(s, 3H), 2.11(s, 6H), 1.16(m, 3H), 1.01(m, 18H); Uniplate silica gel, 250 microns; Mobile phase = 10% ethyl acetate in hexane: R_f = 0.47

Step c:

[0976] 3,5-Dimethyl-4-[4'-methoxymethoxy-3'-(3-trifluoromethylphenoxy)-benzyl]phenol was synthesized according to the procedure described for the synthesis of compound 35, step e, (0.059 g, 100%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.02(s, 1H), 7.55(t, 1H, *J* = 7.8 Hz), 7.38(1H, d, *J* = 8.4 Hz), 7.14(m, 2H), 7.02(s, 1H), 6.88(dd, 1H, *J* = 1.5 Hz and *J* = 6.6 Hz), 6.72(d, 1H, 2.1 Hz), 6.44(s, 2H), 5.08(s, 2H), 3.85(s, 2H), 3.18(s, 3H), 2.08(s, 6H); (Uniplate silica gel, 250 microns; Mobile phase = 25% ethyl acetate in hexane: R_f = 0.28

Step d:

[0977] Diethyl[3,5-dimethyl-4-[4'-methoxymethoxy-3'-(3-trifluoromethylphenoxy)benzyl]phenoxy]methylphosphonate was prepared according to the procedure described for the synthesis of compound 8, steps e (0.015 g, 15%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.55(t, 1H, *J* = 8.4 Hz), 7.37(d, 1H, *J* = 7.5 Hz), 7.14(m, 2H), 7.02(s, 1H), 6.86(dd, 1H, *J* = 1.7Hz and *J* = 7 Hz), 6.73(s, 2H), 5.08(s, 2H), 4.34(d, 2H, *J* = 9.9 Hz), 4.09(m, 4H), 3.91(s, 2H), 3.18(s, 3H), 2.18(s, 6H), 1.24(t, 6H, *J* = 7 Hz); Uniplate silica gel, 250 microns; Mobile phase = 25% hexane in ethyl acetate: R_f = 0.2


Step e:

[0978] The title compound was prepared according to the procedure described for the synthesis of compound 8, steps f, (0.022g, 90%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48(s, 1H), 7.53(t, 1H, *J* = 7.8 Hz), 7.34(d, 1H, *J* = 7.2 Hz), 7.07(d, 1H, *J* = 9 Hz), 7.01(s, 1H), 6.90(d, 1H, *J* = 8.4 Hz), 6.71(m, 4H), 4.00(d, 2H, *J* = 10.2 Hz), 3.84(s, 2H), 2.15(s, 6H); LC-MS m/z = 481 [C₂₃H₂₂F₃O₆P - H]⁺; Uniplate silica gel, 250 microns; Mobile phase = isopropyl alcohol /water/ ammonium hydroxide [7:2:1]; R_f = 0.47; HPLC, zorbax, XDB-C8, 150mm x 4.6 mm, 5um, flow 1 mL/min, solvent A: 0.05 M KH₂PO₄ aqueous pH 6.2, Solvent B: acetonitrile, Gradient 40% B to 60% B

over 11min then 60% B. total run time 12 min. RT 1.87 min; Anal Calcd for (C₂₃H₂₂F₃O₆P + 0.3 M H₂O + 0.1 M EtOAc) C, 56.60; H, 4.70. Found: C, 56.68; H, 3.97.

Example 65

Compound 65-1: 2,6-diido-3,5-dimethyl-[4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methyl phosphonic acid



Step a:

[0979] To a stirred solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol (0.22 g, 0.70 mmol), (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in EtOH (6.2 mL) and CH₃NH₂ 40% in water (2.5 mL) was added iodine (0.39 g, 1.54 mmol) and KI (0.25 g 1.54 mmol) in H₂O (3 mL) at 0° C. The reaction mixture was stirred at room temperature for 16 h, quenched with brine (50 mL) and extracted with ethyl acetate (50 mLx2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 2,6-diido-3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol as a colorless oil (198 mg, 50%): ¹H NMR (300 MHz, CDCl₃): δ 6.97 (d, *J* = 2.1 Hz, 1 H), 6.92 (d, *J* = 5.6 Hz, 1 H), 6.59 (dd, *J* = 2.4, 8.4 Hz, 1 H), 6.0 (s, 1 H), 5.19 (s, 2 H), 4.16 (s, 2 H), 3.50 (s, 3 H), 3.35 - 3.30 (m, 1 H), 2.48 (s, 6 H), 1.21 (d, *J* = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.62.

Step b:

[0980] To a stirred solution of 2,6-diiodo-3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (0.2 g, 0.35 mmol) in DMF (3.0 mL) at 0 °C was added Cs₂CO₃ (0.34 g, 1.05 mmol). After 10-min, diethyl trifluoromethanesulfonyloxymethyl phosphonate (0.1 g, 0.35 mmol) was added. The reaction mixture was stirred at 0 °C for 1 h, allowed to warm to room temperature and stirred for 16 h. The reaction mixture was quenched with 1 N HCl, diluted with ethyl acetate, and washed with water (10 mLx4) and brine. The organic layer was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:3) as mobile phase to afford diethyl [2,6-diiodo-3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenoxy]methyl-phosphonate as an oil (0.21 g, 85%): ¹H NMR (300 MHz, CDCl₃): δ 6.96 (d, J = 2.4 Hz, 1 H), 6.92 (d, J = 8.4 Hz, 1 H), 6.56 (dd, J = 2.1, 8.4 Hz, 1 H), 5.18 (s, 2 H), 4.45 - 4.35 (m, 6 H), 4.18 (s, 2H), 3.50 (s, 3H), 3.39 - 3.25 (m, 1 H), 2.49 (s, 6 H), 1.47 (t, J = 6.9 Hz, 6 H), 1.20 (d, J = 6.9 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:1); R_f = 0.35.


Step c:

[0981] To a solution of diethyl [2,6-diiodo-3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (0.14 g, 0.19 mmol) in CH₂Cl₂ (4.0 mL) at 0 °C was added bromotrimethylsilane (0.31 mL, 1.9 mmol). The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was treated with methanol and water (4:1, 5.0 mL) and the solvents were removed under reduced pressure. The residue was treated with acetonitrile and filtered to afford 2,6-diiodo-3,5-dimethyl-[4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]-methyl phosphonic acid as white solid (97 mg, 80%): mp 236 °C; ¹H NMR (300 MHz, CD₃OD): δ 6.87 (s, 1 H), 6.62 (d, J = 7.8 Hz, 1 H), 6.46 (d, J = 8.7 Hz, 1 H), 4.31 (d, J = 10.8 Hz, 2 H), 4.19 (s, 2 H), 3.35 - 3.18 (m, 1 H), 2.50 (s, 6 H), 1.17 (d, J = 6.9 Hz, 6 H); LC-MS m/z = 616 [C₁₉H₂₃I₂O₃P]⁺; HPLC conditions: ODSAQ AQ-303-5 column; mobile phase = CH₃OH:0.05%TFA(7:3) flow rate = 1.0 mL/min; detection = UV @ 280 nm

retention time in min: 13.82; Anal Calcd for (C₂₀H₂₅O₆P + 0.9 H₂O): C, 36.09; H, 3.95. Found: C, 35.80; H, 4.22.

[0982] Using the appropriate starting material, compounds 65-2 was prepared in an analogous manner to that described for the synthesis of compound 65-1.

Compound 65-2: 2,6-dibromo-3,5-dimethyl-[4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methyl phosphonic acid



Step a

[0983] To a stirred solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol (0.2 g, 0.63 mmol), (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000)) in EtOH (6.0 mL) and CH₃NH₂ 40% in water (2.5 mL) was added bromine (0.25 g, 1.59 mmol) and KBr (0.11 g 1.59 mmol) in H₂O (2 mL) at 0° C. The reaction mixture was stirred at room temperature for 16 h, quenched with water (50 mL) and extracted with ethyl acetate (50 mLx2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 2,6-dibromo-3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenol as a white solid (0.18 g, 60%): ¹H NMR (300 MHz, CDCl₃): δ 6.97 (d, *J* = 2.1 Hz, 1 H), 6.92 (d, *J* = 8.4 Hz, 1 H), 6.60 (dd, *J* = 2.4, 8.7 Hz, 1 H), 6.0 (s, 1 H), 5.19 (s, 2 H), 4.08 (s, 2 H), 3.50 (s, 3 H), 3.35 - 3.30 (m, 1 H), 2.38 (s, 6 H), 1.21 (d, *J* = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (4:1); R_f = 0.62.

Step b:


[0984] The title compound was prepared according to the procedure described for the synthesis of example 45, step b and c: as a white solid (0.15 g, 80%)

mp 190 °C; ^1H NMR (300 MHz, CD₃OD): δ 6.88 (d, $J = 2.1$ Hz, 1 H), 6.62 (d, $J = 8.4$ Hz, 1 H), 6.46 (dd, $J = 2.4, 8.7$ Hz, 1 H), 4.27 (d, $J = 10.5$ Hz, 2 H), 4.12 (s, 2 H), 3.35 - 3.18 (m, 1 H), 2.40 (s, 6 H), 1.17 (d, $J = 6.9$ Hz, 6 H); LC-MS $m/z = 523$ [C₁₉H₂₃I₂O₅P+H]⁺; HPLC conditions: ODSAQ AQ-12505146W column; mobile phase = 0.05%TFA/CH₃CN:0.05%TFA/H₂O

[0985] (1:1) flow rate = 1.0 mL/min; detection = UV @ 254 nm retention time in min: 10.45; Anal Calcd for (C₂₀H₂₃Br₂O₅P): C, 43.70; H, 4.44. Found: C, 43.78; H, 4.46.

Example 66

Compound 66: 4,6-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-indolephosphonic acid



Step a:

[0986] A solution of sodium nitrite (155 mg, 2.24 mmol) in water (1 mL) was added to a suspension of 3,5-dimethyl-4-(4'-methoxy-3'-*iso*-propylphenoxy)-aniline (*J. Med. Chem.* 38:695 (1995), 640 mg, 2.24 mmol) in ethanol (3mL) and concentrated hydrochloric acid (12 M, 1.12 mL, 13.44 mmol) at 0 °C. The yellow heterogeneous solution slowly turns to an orange clear solution. After stirring at 0 °C for 30 minutes, a solution of tin dichloride (1.53 g, 8.06 mmol) in hydrochloric acid (12 M, 1.3 mL, 15.68 mmol) was added. The orange solution turned green and a white precipitate formed. Ethanol (3 mL) was added to dissolve most of the precipitate and the heterogeneous reaction mixture was stirred at 0 °C. After 2 hours, water was added and the precipitate collected by filtration. The sticky solid was dissolved in ethyl acetate and washed with water, 1 N sodium hydroxide then brine. The organics were dried over sodium sulfate, concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, dichloromethane/methanol

95/5 to 90/10) to give 3,5-dimethyl-4-(4'-methoxy-3'-*iso*-propylphenoxy)-phenyl hydrazine (305 mg, 45%): ^1H NMR (300 MHz, CDCl_3) δ 6.77 (d, J = 3.0 Hz, 1H), 6.67 (d, J = 9.0 Hz, 1H) 6.58 (s, 2H), 6.37 (dd, J = 9.0, 3.0 Hz, 1H), 3.77 (s, 3H), 3.27 (heptuplet, J = 6.9 Hz, 1H), 2.09 (s, 3H), 1.18 (d, J = 6.9 Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = dichloromethane-methanol (9:1); R_f = 0.6.

Step b:

[0987] Diethyl acetylphosphonate (183 mg, 1.02 mmol) was added to a yellow solution of hydrazine in toluene at rt. After stirring 10 minutes at rt, polyphosphoric acid (PPA, 0.4 g) was added and the turbid reaction mixture was placed in an oil bath at 115 °C. After refluxing for 5 minutes, the cooled brown biphasic solution was partitioned between ethyl acetate and water and the organic layer was washed with water then brine, dried over sodium sulfate, concentrated under reduced pressure and the residue purified by column chromatography (silica gel, hexanes/ethyl acetate 70/30 to 20/80) to give diethyl 5,6-dimethyl-4-(4'-methoxy-3'-*iso*-propylphenoxy)indolephosphonate (276 mg, 61%): ^1H NMR (300 MHz, CDCl_3) δ (s, 1H, exchangeable with D_2O), 7.17 (s, 1H), 7.07 (m, 1H), 6.83 (d, J = 3.0 Hz, 1H), 6.65 (d, J = 9.0 Hz, 1H), 6.34 (dd, J = 9.0, 3.0 Hz, 1H), 4.30-4.08 (m, 4H), 3.77 (s, 3H), 3.28 (heptuplet, J = 6.9 Hz, 1H), 2.35 (s, 3H), 2.24 (s, 3H), 1.37 (t, J = 7.1 Hz, 6H), 1.18 (d, J = 6.9 Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = dichloromethane-methanol (9:1); R_f = 0.55.

Step c:


[0988] 5,6-Dimethyl-4-(4'-hydroxy-3'-*iso*-propylphenoxy)indolephosphonic acid was prepared according to the procedure described for the synthesis of example 8, step f (100 mg, 51%): ^1H NMR (300 MHz, CD_3OD) δ 7.14 (s, 1H), 6.97 (s, 1H), 6.75 (d, J = 9.0 Hz, 1H), 6.68 (d, J = 3.0 Hz, 1H), 6.35 (dd, J = 9.0, 3.0 Hz, 1H), 3.75 (s, 3H), 3.25 (heptuplet, J = 6.9 Hz, 1H), 2.27 (s, 3H), 2.16 (s, 3H), 1.11 (d, J = 6.9 Hz, 6H); LC-MS m/z = 390.4 [$\text{C}_{20}\text{H}_{24}\text{NO}_5\text{P} + \text{H}]^+$.

Step d:

[0989] A solution of boron tribromide (1 M in dichloromethane, 1.3 mL, 1.3 mmol) was added to a solution of 5,6-dimethyl-4-(4'-methoxy-3'-*iso*-propylphenoxy)indolephosphonic acid (100 mg, 0.26 mmol) in dichloromethane (10 mL) at -78 °C. The ice bath was removed and the reaction mixture was warmed to rt. After stirring at rt overnight, the reaction mixture was quenched with ice, diluted with ethyl acetate and washed with water then brine, dried over sodium sulfate and concentrated under reduced pressure to give the title compound (86.3 mg, 80%): ¹H NMR (300 MHz, CD₃OD) δ 7.18 (s, 1H), 6.97 (d, *J* = 3.0 Hz, 1H), 6.60 (s, 1H), 6.57 (d, *J* = 9.0 Hz, 1H), 6.26 (dd, *J* = 9.0, 3.0 Hz, 1H), 3.22 (heptuplet, *J* = 6.9 Hz, 1H), 2.28 (s, 3H), 2.18 (s, 3H), 1.12 (d, *J* = 6.9 Hz, 6H); Anal. Calcd for (C₁₉H₂₂NO₃P + 1.5 H₂O + 0.1 C₃H₆O): C, 56.79; H, 6.32; N, 3.43. Found: C, 56.61; H, 5.92; N, 3.22.

Example 67

Compound 67: 2-[3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)phenyl]-ethylphosphonic Acid



Step a:

[0990] To a solution of dimethyl methylphosphonate (0.06 g, 0.48 mmol) in THF (3.0 mL) at -78 °C was slowly added LDA (0.25 mL, 2 M in THF). After 30 min, a solution of 3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl bromide (0.20 g, 0.40 mmol, intermediate for the synthesis of compound 19-1) in THF was added. The reaction mixture was stirred at -78 °C for 5 min, allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with aqueous NH₄Cl (10.0 mL) and extracted with ether (10.0 mL). The organic layer was dried over MgSO₄,


filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford dimethyl 2-[3,5-dibromo-4-(4'-methoxy-3'-isopropylphenoxy)phenyl]ethylphosphonate (0.09 g, 43%) as a colorless oil: ^1H NMR (300 MHz, CD₃OD): δ 7.64 (s, 2H), 6.82 (d, J = 10.0 Hz, 1H), 6.75 (d, J = 4.2 Hz, 1H), 6.44 (dd, J = 2.8, 10.2 Hz, 1H), 3.79 (d, J = 2.8 Hz, 6H), 3.76 (s, 3H), 3.30 (m, 1H), 2.94 (m, 2H), 2.23 (m, 2H), 1.17 (d, J = 7.0 Hz, 6H); LC-MS m/z = 537 [C₂₀H₂₅Br₂O₃P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.50.

Step b:

[0991] The title compound was prepared from dimethyl 2-[3,5-dibromo-4-(4'-methoxy-3'-isopropylphenoxy)phenyl]ethylphosphonate according to the procedure described for the synthesis of compound 4, step b: mp: 56-59 °C; ^1H NMR (200 MHz, DMSO-*d*₆): δ 9.02 (s, 1H), 7.65 (s, 2H), 6.64 (m, 2H), 6.21 (dd, J = 2.8, 10.2 Hz, 1H), 3.14 (m, 1H), 2.79 (m, 2H), 1.87 (m, 2H), 1.11 (d, J = 7.0 Hz, 6H); LC-MS m/z = 495 [C₁₇H₁₉Br₂O₃P + H]⁺; Anal. Calcd for (C₁₇H₁₉Br₂O₃P + 0.5 H₂O): C, 40.58; H, 4.01. Found: C, 40.26; H, 4.22.

Example 68

Compound 68: [3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzyl]-phosphonic Acid



Step a:

[0992] To a solution of methyl 3,5-methyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)benzoate 1.80 g, 5.0 mmol, Example 47, step a) in THF (30.0 mL) at 0 °C was slowly added DIBAL (12.6 mL, 12.6 mmol). The reaction mixture was stirred at 0 °C for 2 h and quenched with potassium

sodium tartrate. The reaction mixture was diluted with hexanes and stirred at room temperature for 2 h. The organic layer was separated, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was dissolved in ether (95.0 mL) and slowly added to a solution of carbon tetrabromide and PPh₃ in ether (20.0 mL). The reaction mixture was stirred at room temperature for 16 h and filtered through a Celite plug. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in hexanes to afford 3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)-benzyl bromide (1.82 g, 93%) as white solid: ¹H NMR (300 MHz, CD₃OD): δ 7.13 (s, 2H), 6.93 (m, 2H), 6.67 (d, *J* = 7.2 Hz, 1H), 5.17 (s, 2H), 4.54 (s, 2H), 4.02 (s, 2H), 3.48 (s, 3H), 3.31 (m, 1H), 2.25 (s, 6H), 1.17 (d, *J* = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.8.

Step b:


[0993] To a solution of 3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)benzyl bromide (0.60 g, 1.53 mmol) in DMF (5.0 mL) at room temperature was slowly added a solution of trimethylphosphite (0.57 g, 4.60 mmol) in DMF (1.0 mL). The reaction mixture was stirred at 140 °C for 3 h and cooled to room temperature. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford dimethyl 2-[3,5- dibromo-4-(4'-methoxymethoxy-3'-isopropylphenoxy)]benzylphosphonate (0.20 g, 31%) as colorless oil: ¹H NMR (300 MHz, CD₃OD): δ 7.04 (d, *J* = 2.4 Hz, 2H), 6.93 (m, 2H), 6.69 (d, *J* = 7.2 Hz, 1H), 5.17 (s, 2H), 4.01 (s, 2H), 3.72 (d, *J* = 10.2 Hz, 6H), 3.28 (m, 1H), 3.22 (d, *J* = 21.3 Hz, 2H), 2.25 (s, 6H), 1.17 (d, *J* = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.5.

Step c:

[0994] The title compound was prepared from dimethyl [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]phosphonate according to the procedure described for the synthesis of compound 7, step b: mp: 60-63; ¹H NMR (300 MHz, CD₃OD): δ 7.03 (s, 2H), 6.93 (m, 2H), 6.09 (s, 1H), 6.58 (m, 2H), 3.95 (s, 2H), 3.23 (m, 1H), 3.08 (d, *J* = 21.0 Hz, 2H), 2.24 (s, 6H), 1.17 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 349 [C₁₉H₂₅O₄P + H]⁺; Anal. Calcd for (C₁₉H₂₅O₄P + 0.6H₂O): C, 63.47; H, 7.55. Found: C, 63.53; H, 7.35.

Example 69

Compound 69: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]-methylphosphonic acid monomethyl ester



Step a:


[0995] A solution of [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonic acid (compound 7, 105 mg, 0.29 mmol), oxalyl chloride (0.5 mL) and DMF (2 drops) in dichloromethane was refluxed for 2 hours then concentrated under reduced pressure and azeotroped twice with dichloromethane. The residue was taken in dichloromethane and triethylamine (0.16 mL, 1.2 mmol) followed by methanol (1 mL) were added at rt. After stirring at rt for 2 hours, the reaction mixture was quenched with brine, diluted with ethyl acetate, washed with 1 N sodium hydroxide, then brine. The organics were dried over sodium sulfate, concentrated under reduced pressure and the residue purified by column chromatography (silica gel, dichloromethane/methanol 96/4 to 92/8) to give dimethyl [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate (75 mg, 70%): ¹H NMR (200 MHz, CDCl₃) δ 6.92 (d, *J* = 3.0 Hz, 1H), 6.68 (s, 2H), 6.66 (d, *J* = 9.0 Hz, 1H), 6.52 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.31 (d, *J* = 10.2 Hz, 2H), 3.89 (d,

J = 11.0 Hz, 6H), 3.15 (heptuplet, *J* = 7.0 Hz, 1H), 2.19 (s, 6H), 1.21 (d, *J* = 7.0 Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = dichloromethane-methanol (9:1); *R*_f = 0.65.

Step b:

[0996] A 1 N solution of sodium hydroxide (1 mL, 1 mmol) was added to a solution of dimethyl [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate (75 mg, 0.19 mmol) in THF at rt. The biphasic solution was stirred at rt for 24 hours then diluted with ethyl acetate and extracted twice with 1 N sodium hydroxide. The combined aqueous extracts were acidified to pH 1 with concentrated hydrochloric acid and extracted twice with ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure to give the title compound (55 mg, 76%): ¹H NMR (200 MHz, CDCl₃) δ 6.92 (d, *J* = 3.0 Hz, 1H), 6.68 (s, 2H), 6.60-6.4 (m, 2H), 4.31 (d, *J* = 10.2 Hz, 2H), 3.89 (d, *J* = 11.0 Hz, 3H), 3.15 (heptuplet, *J* = 7.0 Hz, 1H), 2.19 (s, 6H), 1.21 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 379.4 [C₂₀H₂₇O₂P + H]⁺; Anal. Calcd for (C₂₀H₂₇O₂P + 0.4 H₂O): C, 62.30; H, 7.27. Found: C, 62.20; H, 7.51.

Compound 69-1: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonic acid monoethyl ester



Step a:

[0997] Diethyl[3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate was prepared from diethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate (Example 7, step a) according to the procedure described for the synthesis of compound 7-14, step a: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 6.85 (m, 1H), 6.74 (s, 2H), 6.63 (m, 1H), 6.48 (m, 1H), 4.36 (d, *J* = 9.0 Hz, 2H),


- 486 -

4.13 (m, 4H), 3.81 (s, 2H), 3.14 (m, 1H), 2.18 (s, 6H), 1.27 (m, 6H), 1.12 (d, *J* = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (1:4); R_f = 0.40.

Step b:

[0998] The title compound was prepared according to the procedure described for the synthesis of compound 69, step b: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 6.85 (m, 1H), 6.73 (s, 2H), 6.61 (m, 1H), 6.48 (m, 1H), 4.21 (d, *J* = 9.0 Hz, 2H), 4.06 (m, 2H), 3.81 (s, 2H), 3.14 (m, 1H), 2.18 (s, 6H), 1.24 (m, 3H), 1.12 (d, *J* = 6.0 Hz, 6H); LC-MS m/z = 393 [C₂₁H₂₉O₅P - H]⁺; Anal. Calcd for (C₂₁H₂₉O₅P + 0.1 H₂O): C, 63.98; H, 7.47. Found: C, 63.93, H, 7.07. HPLC conditions: Column = Agilent zorbax RP18, 150×3.0 mm; Mobile phase = Solvent B (Acetonitrile) = HPLC grade acetonitrile; Solvent A (buffer) = 20 mM potassium phosphate buffer (pH 4.7). Flow rate = 0.75 mL/min; UV@ 254 nm. rt = 13.98 min).

Compound 69-2: [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]-phosphonic Acid Monomethyl Ester



Step a:

[0999] To a solution of [3,5-dimethyl-4-(3'-isopropyl-4'-methoxyphenoxy)]benzyl bromide (intermediate for the synthesis of compound 19-1, 0.20 g, 0.40 mmol) in DMF (2.5 mL) at room temperature was slowly added a solution of trimethylphosphite (0.57 g, 4.60 mmol) in DMF (0.5 mL). The reaction mixture was stirred at 140 °C for 3 h and cooled to room temperature. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50%

acetone in hexanes to afford dimethyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl]phosphonate (0.10 g, 49%) as colorless oil: ^1H NMR (300 MHz, CD₃OD): δ 7.68 (s, 2H), 6.83 (d, J = 7.2 Hz, 1H), 6.72 (s, 1H), 6.45 (d, J = 7.2 Hz, 1H), 3.81 (s, 6H), 3.77 (s, 3H), 3.38 (d, J = 10.2 Hz, 2H), 3.28 (m, 1H), 1.17 (d, J = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.5.


Step b

[1000] To a solution dimethyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl]phosphonate (0.22 g, 0.42 mmol) in CH₂Cl₂ (3.0 mL) at -78 °C was slowly added BBr₃ (0.63 mL, 0.63 mmol). After 5 min, the reaction mixture was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was quenched with ice-water and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford dimethyl [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)-benzyl]phosphonate (0.06 g, 28%) as white solid: ^1H NMR (200 MHz, DMSO-*d*₆): δ 9.07 (s, 1H), 7.67 (d, J = 2.2 Hz, 1H), 6.65 (m, 2H), 6.22 (dd, J = 2.8, 10.2 Hz, 1H), 3.64 (d, J = 11.0 Hz, 6H), 3.40 (d, J = 15.0, 2H), 3.18 (m, 1H), 1.10 (d, J = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.3.

Step c


[1001] The title compound was prepared according to the procedure described for the synthesis of compound 69, step b: mp: 56-59 °C; ^1H NMR (200 MHz, DMSO-*d*₆): δ 9.05 (s, 1H), 6.75 (s, 2H), 7.66 (d, J = 2.2 Hz, 1H), 6.66 (m, 2H), 6.22 (dd, J = 2.8, 10.2 Hz, 1H), 3.57 (d, J = 11.0 Hz, 3H), 3.12-3.23 (m, 3H), 1.10 (d, J = 7.0 Hz, 6H); LC-MS *m/z* = 495 [C₁₇H₁₉ Br₂O₃P + H]⁺; Anal. Calcd for (C₁₇H₁₉ Br₂O₃P): C, 41.32; H, 3.88. Found: C, 41.55; H, 4.02.

Compound 69-3: [3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzyl]-phosphonic Acid Monomethyl ester



[1002] The title compound was prepared from dimethyl 2-[3,5- dibromo-4-(4'-methoxymethoxy-3'-isopropylphenoxy)]benzylphosphonate (compound 68, step b) according to the procedure described for the synthesis of compound 7-14, step a followed by compound 69, step b: mp: 72-75; ¹H NMR (300 MHz, CD₃OD): δ 7.01 (d, *J* = 2.1 Hz, 2 H), 6.84 (d, *J* = 2.1 Hz, 1 H), 6.54 (m, 2 H), 3.94 (s, 2 H), 3.65 (d, *J* = 10.8 Hz, 3 H), 3.21 (m, 1 H), 3.09 (d, *J* = 21.0 Hz, 2 H), 2.23 (s, 6 H), 1.13 (d, *J* = 7.0 Hz, 6 H); LC-MS *m/z* = 361 [C₂₀H₂₇O₄P - H]⁺; Anal. Calcd for (C₂₀H₂₇O₄P + 0.2H₂O): C, 65.63; H, 7.55. Found: C, 65.70; H, 7.44.

Compound 69-4: [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenylamino] -methylphosphonic acid monomethyl ester



Step a:

[1003] To a stirring mixture of *t*-butyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl]carbamate (compound 84, step f, 0.15 g, 0.28 mmol) and acetonitrile (4.0 mL) was added Cs₂CO₃ (0.179 g, 0.55 mmol) followed by dimethyl 4-chloro-benzenesulfonyloxymethylphosphonate (0.087 g, 0.28 mmol). The reaction mixture was stirred at 40 °C for 16 h and the solvent evaporated. The reaction mixture was partitioned with ethyl acetate and H₂O, the organic layer was concentrated and the crude was purified by preparatory thin-layer chromatography on silica gel, eluting with ethyl acetate-hexanes (3:2) to afford dimethyl *N*-*tert*-butoxycarbonyl-[3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenylamino]-

methylphosphonate as an oil (0.040 g, 22%): ^1H NMR (300 MHz, DMSO- d_6): δ 7.88 (s, 2 H), 7.03 (m, 1 H), 6.72 (m, 1 H), 6.46 (m, 1 H), 5.18 (s, 2 H), 4.25 (m, 2 H), 3.64 (d, J = 9.0 Hz, 6 H), 3.41 (s, 3 H), 3.27 (m, 1 H), 1.44 (s, 9 H), 1.15 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.42

Step b:


[1004] To a mixture of *N*-*tert*-butoxycarbonyl-[3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenylamino]methylphosphonate (0.27 g, 0.41 mmol) in methanol (6.0 mL) was added 3 N HCl (0.68 mL, 2.03 mmol). The reaction mixture was heated with microwave radiation at 100 °C in a sealed vial for 5 minutes. The solvent was removed and the residue was partitioned with ethyl acetate and water. The organic layer was coevaporated with methanol and concentrated under reduced pressure to afford *N*-*tert*-butoxycarbonyl-[3,5-dibromo-4-(4'-hydroxy-3'-isopropyl-phenoxy)-phenylamino]methylphosphonate (0.075 g, 87%) as a solid: ^1H NMR (300 MHz, DMSO- d_6): δ 8.90 (s, 1 H), 7.09 (s, 2 H), 6.65 (m, 2 H), 6.28 (m, 2 H), 3.70 (m, 6 H), 3.66 (m, 2 H), 3.19 (m, 1 H), 1.14 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.25

Step c:

[1005] To a stirred solution of *N*-*tert*-butoxycarbonyl-[3,5-dibromo-4-(4'-hydroxy-3'-isopropyl-phenoxy)phenylamino]methylphosphonate (0.075 g, 0.14 mmol) in THF (2.0 mL) was added 1 M NaOH (0.70 mL, 0.86 mmol). The reaction mixture was stirred at rt for 16 h, then heated at 40 °C for 5 hrs. The reaction mixture was cooled to 0 °C, treated 2 N HCl (pH ~ 1), diluted with H₂O. The organic layer was filtered and concentrated to afford the title compound as a grey solid (0.070 g, 96%): ^1H NMR (300 MHz, DMSO- d_6): δ 8.97 (s, 1 H), 7.07 (s, 2 H), 6.65 (m, 2 H), 6.25 (m, 1 H), 3.64 (m, 2 H), 3.42 (s, 3 H), 3.16 (m, 1 H), 1.14 (d, J = 6.0 Hz, 6 H); LC-MS m/z = 510 [C₁₇H₂₀Br₂NO₅P - H]⁺; HPLC conditions: Column = Shimadzu LC-A8, SPD-


10A; YMC Pack RP-18 filter, 150×4.6; Mobile phase = Solvent A Acetonitrile/0.05% TFA; Solvent B = H₂O/0.05% TFA. Flow rate = 2.0 mL/min; UV@ 254 nm. Retention time in minutes. (rt = 8.81/20.00, 93% purity).

Compound 69-5: [(3,5-Dimethyl-4-[3'-(4-fluorobenzyl)-4'-hydroxybenzyl]-phenylamino)methyl]methylphosphonic acid monomethyl ester



[1006] Prepared from benzyl N-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl]carbamate (compound 79, step b) according to the procedure described for the synthesis of compound 69-4: ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.15 (s, 1 H), 7.01 – 7.22 (m, 4 H), 6.76 (s, 1 H), 6.67 (d, *J* = 8.1 Hz, 1 H), 6.58 (d, *J* = 8.1 Hz, 1 H), 6.40 (s, 2 H), 3.79 (s, 2 H), 3.71 (s, 2 H), 3.58 (d, *J* = 10.5 Hz, 3 H), 3.29 (m, 2 H), 2.07 (s, 6 H); LC-MS *m/z* = 444 [C₂₄H₂₇FNO₄P + H]⁺; Anal Calcd for (C₂₄H₂₇FNO₄P + 2.2H₂O): C, 59.67; H, 6.55; N, 2.90. Found: C, 59.40; H, 6.24; N, 3.31.

Compound 69-6: [3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenoxy]methylphosphonic acid monomethyl ester




Step a:

[1007] To a stirring mixture of DMF (20.0 mL) and NaH (0.074 g, 1.86 mmol) at 0 °C was added 3,5-dibromo-4-(3-isopropyl-4-hydroxy-phenoxy)phenol (Intermediate for the synthesis of compound 8-1, 0.75 g, 1.86 mmol) dissolved in DMF (2.0 mL). The reaction mixture was allowed to stir at rt for 1 hr and cooled to 0 °C. Dimethyl 4-chlorobenzenesulfonyloxymethylphosphonate (0.11 g, 0.36 mmol) was added and the reaction mixture was stirred at rt for 16 h. The reaction was quenched with ice H₂O, the pH was adjusted to 1 with 2 M HCl, and the mixture was partitioned with ethyl acetate and H₂O. The organic layer was concentrated and coevaporated with acetone (2X). The residue was treated with a hexane/ethyl acetate mixture and sonicated to afford dimethyl [3,5-dibromo-4-(4-hydroxy-3-*iso*-propyl-phenoxy)phenoxy)methylphosphonate as a white solid precipitate (0.070 g, 34%): ¹H NMR (200 MHz, DMSO-d₆): δ 9.00 (s, 1H), 7.47 (s, 2H), 6.65 (m, 2H), 6.23 (m, 1H), 4.60 (d, *J* = 10.0 Hz, 2H), 3.75 (d, *J* = 10.0 Hz, 6H), 3.12 (m, 1H), 1.09 (d, *J* = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.60

Step b:

[1008] To a stirred solution of dimethyl [3,5-dibromo-4-(4-hydroxy-3-*iso*-propyl-phenoxy)phenoxy)methylphosphonate (0.155 g, 0.30 mmol) in THF (4.0 mL) was added 2 M NaOH (0.89 mL, 1.77 mmol). The reaction mixture was stirred at rt for 48 h, cooled to 0 °C, treated with conc. HCl (pH ~ 1), and partitioned with ethyl acetate and H₂O (1X). The organic layer was extracted with H₂O (1X). The organic layer was concentrated, dissolved in acetone, filtered and concentrated to afford the title compound as an off-white solid (0.110 g, 73%): ¹H NMR (300 MHz, DMSO-d₆): δ 9.03 (s, 1H), 7.47 (s, 2H), 6.66 (m, 2H), 6.27 (m, 1H), 4.41 (d, *J* = 9.0 Hz, 2H), 3.69 (d, *J* = 9.0 Hz, 3H), 3.17 (m, 1H), 1.14 (d, *J* = 6.0 Hz, 6H); LC-MS *m/z* = 510 [C₁₇H₁₉Br₂O₆P-H]⁺.


Compound 69-7: 2-[3,5-Dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]ethylphosphonic Acid Monomethyl Ester



[1009] The title compound was prepared from dimethyl-2-[3,5-dibromo-4-(4'-methoxy-3'-isopropylphenoxy)phenyl]ethylphosphonate (Example 67) according to the procedures described for the synthesis of Example 69-2. MP: 65–68 °C; ^1H NMR (300 MHz, CD_3OD): δ 7.62 (s, 2H), 6.65 (m, 2H), 6.34 (dd, J = 11.2, 2.1 Hz, 1H), 3.73 (d, J = 10.5 Hz, 1H), 3.25 (m, 1H), 2.95 (m, 2H), 2.16 (m, 2H), 1.18 (d, J = 7.0 Hz, 6H); LC-MS m/z = 509 [$\text{C}_{18}\text{H}_{21}\text{Br}_2\text{O}_5\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{18}\text{H}_{21}\text{Br}_2\text{O}_5\text{P}$): C, 42.55; H, 4.17. Found: C, 42.72; H, 3.90.

Example 70

Compound 70: [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)-phenoxy]methyl[methylphosphinic acid



Step a:

[1010] Solid sodium hydroxide (400 mg, 10 mmol) was added to a solution of diethyl[3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenoxy]-methylphosphonate (compound 7, step a, 500 mg, 1.08 mmol) in THF (6 mL) and water (2 mL). The biphasic mixture was stirred at rt for 2 days, then diluted with ethyl acetate and washed with brine then 1 N hydrochloric acid, dried (Na_2SO_4) and concentrated under reduced pressure. The crude material was carried over without purification: ^1H NMR (300 MHz, CDCl_3) δ 6.96 (d, J = 2.1 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.71 (s, 2H), 6.66 (dd, J = 8.1, 2.1 Hz, 1H), 5.12 (s, 2H), 4.4–4.2 (m, 4H), 3.94 (s, 2H), 3.51 (s, 3H), 3.31 (heptuplet,

$J = 7.0$ Hz, 1H), 2.23 (s, 6H), 1.41 (t, $J = 7.0$ Hz, 3H), 1.21 (d, $J = 7.0$ Hz, 6H).

Step b:

[1011] Thionyl chloride (120 μ L, 1.62 mmol) was added to a solution of crude [3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenoxy]-methylphosphonic acid monoethyl ester (1.08 mmol) and pyridine (510 μ L, 6.48 mmol) in dichloromethane at rt. After stirring at rt for 18 hours, the yellow solution was concentrated under reduced pressure. The yellow oil was dissolved in THF (10 mL) and the solution cooled to -78 °C. A solution of MeMgBr in THF (3M, 1.1 mL, 3.3 mmol) was added to the solution of chloridate at -78 °C. After stirring at -78 °C for 15 min, the reaction mixture was quenched at -78 °C with acetic acid (324 μ L, 5.4 mmol), diluted with ethyl acetate and washed successively with saturated solution of sodium bicarbonate, a 10% solution of copper sulfate, brine, dried (Na_2SO_4) and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, ethyl acetate/methanol 99/1 to 95/5) to give ethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-*iso*-propylbenzyl)phenoxy(methyl)methylphosphinate (318 mg, 68%): ^1H NMR (300 MHz, CDCl_3) δ 6.98 (s, 1H), 6.92 (d, $J = 8.4$ Hz, 1H), 6.70 (s, 2H), 6.66 (d, $J = 8.4$ Hz, 1H), 5.19 (s, 2H), 4.4-4.2 (m, 4H), 3.96 (s, 2H), 3.51 (s, 3H), 3.33 (heptuplet, $J = 7.0$ Hz, 1H), 2.26 (s, 6H), 1.68 (d, $J = 15$ Hz, 3H), 1.4 (t, $J = 7.0$ Hz, 3H), 1.22 (d, $J = 7.0$ Hz, 6H); TLC conditions: Merck silica gel, 250 microns; Mobile phase = dichloromethane-methanol (9:1); $R_f = 0.5$.


Step c:

[1012] The title compound was prepared according to the procedure described for the synthesis of compound 7, step b, (225.8 mg): ^1H NMR (300 MHz, DMSO d_6) δ 9.00 (s, 1H), 8.66 (d, $J = 1.8$ Hz, 1H), 6.73 (s, 2H), 6.63 (d, $J = 8.4$ Hz, 2H), 6.46 (dd, $J = 8.4$, 1.8 Hz, 1H), 4.11 (d, $J = 8.4$ Hz, 4H), 3.82 (s, 2H), 3.51 (s, 3H), 3.14 (heptuplet, $J = 7.0$ Hz, 1H), 2.19 (s, 6H), 1.43 (d, $J = 14.7$ Hz, 3H), 1.12 (d, $J = 7.0$ Hz, 6H); LC-MS $m/z = 363.1$ [$\text{C}_{20}\text{H}_{27}\text{O}_4\text{P} + \text{H}]^+$;

Anal. Calcd for (C₂₀H₂₇O₄P + 0.2 H₂O): C, 65.63; H, 7.55. Found: C, 65.47; H, 7.57.

Example 71

Compound 71: [3,5-Dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]-methylphosphinic Acid



Step a:


[1013] To a solution of 3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl bromide (intermediate for the synthesis of compound 19-1, 0.30 g, 0.60 mmol) in DMF (4.0 mL) at room temperature was slowly added a solution of diethyl methylphosphonite (0.25 g, 1.8 mmol) in DMF (0.5 mL). The reaction mixture was stirred at 100 °C for 3 h and cooled to room temperature. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford ethyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl]methylphosphinate (0.29 g, 92%) as a colorless oil: ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.69 (d, *J* = 2.8 Hz, 1H), 6.84 (d, *J* = 10 Hz, 1H), 6.73 (d, *J* = 4.2 Hz, 1H), 6.40 (dd, *J* = 2.8, 10.2 Hz, 1H), 3.98 (m, 2H), 3.73 (s, 3H), 3.20 (m, 1H), 1.38 (d, *J* = 10.2 Hz, 3H), 1.19 (t, *J* = 7.8 Hz, 3H), 1.11 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 521 [C₂₀H₂₅Br₂O₄P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.50.

Step b:

[1014] The title compound was prepared according to the procedure described for the synthesis of compound 4, step b: mp: 61-63 °C; ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.05 (s, 1H), 7.65 (d, *J* = 2.4 Hz, 2H), 6.67 (m, 2H), 6.23 (dd, *J* = 2.8, 10.2 Hz, 1H), 3.36 (d, *J* = 10.2 Hz, 3H), 3.14 (m, 1H), 1.28 (d, *J* = 10.2 Hz, 3H), 1.11 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 479 [C₁₇H₁₉ Br₂O₄P + H]⁺; Anal. Calcd for (C₁₇H₁₉ Br₂O₄P): C, 42.71; H, 4.01. Found: C, 42.45; H, 4.40.

Example 72

Compound 72: [3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-benzyl]methylphosphinic Acid



Step a:

[1015] To a solution of [3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)benzyl bromide (compound 68, step a, 0.25 g, 0.64 mmol) in DMF (4.0 mL) at room temperature was slowly added a solution of diethyl methylphosphite (0.26 g, 1.92 mmol) in DMF (1.0 mL). The reaction mixture was stirred at 110 °C for 2 h and cooled to room temperature. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 80% acetone in hexanes to afford ethyl [3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)benzyl]-methylphosphinate (0.18 g, 70%) as colorless oil: ¹H NMR (300 MHz, CD₃OD): δ 7.04 (d, *J* = 2.4 Hz, 2H), 6.91 (m, 2H), 6.72 (d, *J* = 7.2 Hz, 1H), 5.18 (s, 2H), 4.07 (m, 2H), 4.01 (s, 2H), 3.47 (s, 3H), 3.28 (m, 1H), 3.22 (d, *J* = 21.3 Hz, 2H), 2.25 (s, 6H), 1.45 (d, *J* = 14.1 Hz, 3H), 1.17 (d, *J* = 7.0 Hz,


6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); R_f = 0.3.

Step b:

[1016] The title compound was prepared according to the procedure described for the synthesis of compound 7, step b: mp: 170-173; ^1H NMR (300 MHz, CD₃OD): δ 6.97 (s, 2H), 6.79 (s, 1H), 6.52 (m, 2H), 3.91 (s, 2H), 3.20 (m, 1H), 3.09 (d, J = 17.7 Hz, 2H), 2.20 (s, 6H), 1.37 (d, J = 14.1 Hz, 3H), 1.10 (d, J = 7.0 Hz, 6H); LC-MS m/z = 347 [C₂₀H₂₇O₃P + H]⁺; Anal. Calcd for (C₂₀H₂₇O₃P + 0.3 H₂O): C, 68.28; H, 7.91. Found: C, 68.33; H, 9.11.

Example 73

Compound 73: [3,5-Dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]-ethylphosphinic Acid



Step a:

[1017] To a solution of 3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)benzyl bromide (intermediate for the synthesis of compound 19-1, 0.19 g, 0.39 mmol) in DMF (3.0 mL) at room temperature was slowly added a solution of diethyl ethylphosphite (0.17 g, 1.17 mmol) in DMF. The reaction mixture was stirred at 100 °C for 2 h and cooled to room temperature. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with 50% acetone in hexanes to afford diethyl [3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)benzyl]-ethylphosphinate (0.19 g, 93%) as colorless oil: ^1H NMR (300 MHz, CD₃OD): δ 7.70 (d, J = 2.8 Hz, 2H), 6.84 (d, J = 10 Hz, 1H), 6.71 (d, J = 4.2 Hz, 1H),

6.48 (dd, $J = 2.8, 10.2$ Hz, 1H), 4.09 (m, 2H), 3.81 (s, 3H), 3.30 (m, 3H), 1.84 (m, 2H), 1.13-1.40 (m, 12H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); $R_f = 0.50$.

Step b:

[1018] The title compound was prepared according to the procedure described for the synthesis of compound 4, step b: mp: 80-83 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.68 (d, $J = 2.8$ Hz, 2H), 6.64 (m, 2H), 6.36 (dd, $J = 2.8, 10.2$ Hz, 1H), 3.33 (m, 1H), 3.24 (d, $J = 15.6$ Hz, 2H), 1.76 (m, 2H), 1.19 (m, 9H); LC-MS $m/z = 493$ [C₁₈H₂₁Br₂O₄P + H]⁺; Anal. Calcd for (C₁₈H₂₁Br₂O₄P): C, 43.93; H, 4.30. Found: C, 43.56; H, 4.26.

Example 74

Compound 74: ethyl [(4-methylphenyl)sulfonyloxyethyl]-methylphosphinate

Step a:

[1019] To a stirred solution of diethyl (4-methylphenyl)-sulfonyloxyethylphosphonate (intermediate for the synthesis of compound 7, 2.00 g, 6.21 mmol) in benzene (20.0 mL) was added phosphorous pentachloride (1.55 mL, 7.45 mmol) and the reaction mixture was refluxed until homogenous, then stirred at rt overnight. The solvents were removed and the residue was coevaporated with toluene (2X). The crude was used as is in the next step.


Step b:

[1020] To the crude ethyl (4-methylphenyl)sulfonyloxyethylphosphinate monochloride (2.00 g, 6.39 mmol) in dry THF (30.0 mL) at -78 °C was added MeMgBr (2.20 mL, 6.97 mmol, 3.0 M in diethyl ether). The reaction was quenched immediately after the MeMgBr addition with 1 mL of acetic acid. The reaction mixture was diluted with ethyl acetate and H₂O and the organic layer was washed twice with saturated aqueous NaHCO₃ and once with H₂O. The organic layer was concentrated and coevaporated with MeOH. The product was obtained by precipitation from hexanes to afford the title

compound as a white solid (1.40 g, 77% over two steps): ^1H NMR (200 MHz, DMSO- d_6): δ 7.85 (m, 2H), 7.52 (m, 2H), 4.30 (d, J = 12.0 Hz, 2H), 3.90 (m, 2H), 2.40 (s, 3H), 1.45 (d, J = 21.0 Hz, 3H), 1.15 (m, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-methanol (9:1); R_f = 0.27.

Example 75

Compound 75: [3,5-Dimethyl-4-(4'-hydroxy-3'-methylsulfanylbenzyl)phenoxy]methylphosphonic acid monomethyl ester



Step a:

[1021] To a stirring solution of triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxybenzyl)phenoxy]silane (1.2 g, 2.8 mmol) and TMEDA (0.51 mL, 3.42 mmol) in ether (25 mL) at -20 °C was added *n*-BuLi (1.37 mL, 2.5 M in hexanes). The mixture was stirred at -20 °C for 1 h and methyldisulfanylmethane (0.5 mL, 5.6 mmol) was added. The reaction mixture was stirred at -20 °C for 1 h, allowed to warm to room temperature and stirred for 4 h. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy]silane as a yellow oil (1.3 g, 98%): ^1H NMR (300 MHz, DMSO- d_6): δ 6.95 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 2.1 Hz, 1H), 6.4 (dd, J = 2.1, 8.1 Hz, 1H), 6.60 (s, 2H), 5.19 (s, 2H), 3.90 (s, 2H), 3.35 (s, 3H), 2.27 (s, 3H), 2.14 (s, 6H), 1.25 (m, 3H), 1.09 (d, J = 6.9 Hz, 18H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.46.

Step b:

[1022] To a stirring solution of triisopropyl-[3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy]silane (1.3 g, 2.74 mmol) in THF (20 mL) at room temperature was added tetrabutylammonium fluoride (3.4 mL, 1.0 M in THF). The reaction mixture was stirred at room temperature for 2 h, diluted with diethyl ether and washed with water (30 mLx2). The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (4:6) to afford 3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenol as a white solid (0.75 g, 86%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.04 (s, 1H), 6.93 (d, *J* = 8.4 Hz 1H), 6.86 (d, *J* = 1.2 Hz 1H), 6.61 (dd, *J* = 1.2, 8.4 Hz, 1H), 6.49 (s, 2H), 5.19 (s, 2H), 3.86 (s, 2H), 3.40 (s, 3H), 2.32 (s, 3H), 2.12 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 30% ethyl acetate in hexanes; R_f = 0.45.

Step c:

[1023] To a solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenol (0.54 g, 1.7 mmol) in CH₃CN (20 mL) at room temperature was added Cs₂CO₃ (0.82 g, 2.54 mmol) and dimethyl (4-chlorophenylsulfonyloxy)methylphosphonate (0.54 g, 1.7 mmol). The reaction mixture was refluxed for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (4:1) to afford dimethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy]methylphosphonate as a colorless oil (0.3 g, 40%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 6.89 (m, 2H), 6.75 (s, 2H), 6.58 (m, 1H), 5.16 (s, 2H), 4.42 (d, *J* = 10.0 Hz, 2H), 3.89 (s, 2H), 3.73 (d, *J* = 10.6 Hz, 6H), 3.37 (s, 3H), 2.30 (s, 3H), 2.17 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 80% ethyl acetate in hexanes; R_f = 0.31.

Step d:

- 500 -


[1024] To a stirring solution of dimethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy]methylphosphonate (0.051 g, 0.12 mmol) in MeOH (1.5 mL) at room temperature was added HCl (0.93 mL, 1 N), and heated at 100 °C for 5 min by microwave. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford dimethyl[3,5-dimethyl-4-(4'-hydroxy-3-methylsulfanylbenzyl)phenoxy]-methylphosphonate as a colorless oil (0.037 g, 80%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.57 (s, 1H), δ 6.74 (m, 3H), 6.63 (d, *J* = 8.0 Hz, 1H), 6.49 (m, 1H), 4.42 (d, *J* = 9.8 Hz, 2H), 3.83 (s, 2H), 3.72 (d, *J* = 10.3 Hz, 6H), 2.26 (s, 3H), 2.16 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.45.

Step e:

[1025] To a stirring solution of dimethyl [3,5-dimethyl-4-(4'-hydroxy-3-methylsulfanylbenzyl)phenoxy]methylphosphonate (0.037 g, 0.093 mmol) in THF (3 mL) at room temperature was added NaOH (0.37 mL, 1 N), and stirred for 48 h at room temperature. It was acidified by 1 N HCl to pH = 2, and the mixture was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the title compound as a light brown foam (0.030g, 84%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.61 (s, 1H), 6.78 (s, 1H), 6.64 (m, 3H), 6.46 (d, *J* = 8.0 Hz, 1H), 3.96 (d, *J* = 9.2 Hz, 2H), 3.81 (s, 2H), 3.51 (d, *J* = 9.8 Hz, 3H), 2.26 (s, 3H), 2.14 (s, 6H); LC-MS *m/z* = 383 [C₁₈H₂₃O₅PS + H]⁺; Anal Calcd for (C₁₈H₂₃O₅PS + 0.1H₂O + 0.4CH₂Cl₂): C, 52.85; H, 5.78. Found: C, 52.68; H, 5.45.

Example 76

Compound 76: [3,5-Dimethyl-4-(4'-hydroxy-3'-methanesulfonylbenzyl)-phenoxy]methylphosphonic acid monomethyl ester



Step a:

[1026] To a stirring solution of dimethyl [3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy]methylphosphonate (compound 75, step c, 0.25 g, 0.57 mmol) in CH₂Cl₂ (15 mL) at room temperature was added m-CPBA (0.34 g, 2 mmol). The mixture was stirred for 16 h at room temperature, quenched with saturated Na₂SO₃ and diluted with CH₂Cl₂. The organic layer was collected and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford dimethyl [3,5-dimethyl-4-(3'-methanesulfonyl-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate as a colorless oil (0.14 g, 53%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.43 (s, 1H), 7.25 (s, 2H), 6.77 (s, 2H), 5.35 (s, 2H), 4.43 (d, *J* = 10.0 Hz, 2H), 3.95 (s, 2H), 3.73 (d, *J* = 10.6 Hz, 6H), 3.41 (s, 3H), 3.25 (s, 3H), 2.17 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.31.

Step b:

[1027] To a stirring solution of dimethyl [3,5-dimethyl-4-(3'-methanesulfonyl-4'-methoxymethoxybenzyl)phenoxy]methylphosphonate (0.14 g, 0.3 mmol) in MeOH (2 mL) at room temperature was added HCl (0.3 mL, 10 N), and heated at 100 °C for 5 min by microwave. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by

- 502 -


column chromatography on silica gel, eluting with methanol-ethyl acetate (5:95) to afford dimethyl [3,5-dimethyl-4-(4'-hydroxy-3'-methanesulfonylbenzyl)phenoxy]methylphosphonate as a colorless oil (0.042 g, 33%): ^1H NMR (200 MHz, DMSO- d_6): δ 10.87 (s, 1H), 7.30 (d, J = 1.8 Hz, 1H), 7.13 (dd, J = 1.8, 8.4 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.76 (s, 2H), 4.42 (d, J = 10.0 Hz, 2 Hz), 3.89 (s, 2H), 3.74 (d, J = 10.6 Hz, 6H), 3.19 (s, 3H), 2.16 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% methanol in ethyl acetate; R_f = 0.42.

Step c:

[1028] To a stirring solution of dimethyl [3,5-dimethyl-4-(4'-hydroxy-3'-methanesulfonylbenzyl)phenoxy]methylphosphonate (0.042 g, 0.098 mmol) in THF (3 mL) at room temperature was added NaOH (0.39 mL, 1 N), and stirred for 48 h at room temperature. It was acidified by 1 N HCl to pH = 2, and the mixture was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the title compound as a light yellow foam (0.016g, 39%): ^1H NMR (200 MHz, DMSO- d_6): δ 10.96 (s, 1H), 7.34 (d, J = 1.8 Hz, 1H), 7.11 (dd, J = 1.8, 8.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.71 (s, 2H), 4.07 (d, J = 9.6 Hz, 2H), 3.88 (s, 2H), 3.58 (d, J = 10.4 Hz, 3H), 3.19 (s, 3H), 2.15 (s, 6H); LC-MS m/z = 415 [C₁₈H₂₃O₇PS + H]⁺; Anal Calcd for (C₁₈H₂₃O₇PS + 1.1H₂O): C, 49.79; H, 5.86. Found: C, 49.47; H, 5.73.

Example 77

Compound 77: [(3,5-dimethyl-4-(4-hydroxy-3-methanesulfonylbenzyl)phenoxy)methyl]methylphosphinic acid



Step a:

[1029] To a solution of 3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenol (compound 75, step b, 0.11 g, 0.35 mmol) in CH₃CN (5 mL) at room temperature was added Cs₂CO₃ (0.17 g, 0.52 mmol) and ethyl [(4-methylphenyl)sulfonyloxymethyl]methylphosphinate (compound 74, 0.1 g, 0.35 mmol). The reaction mixture was refluxed for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford ethyl [(3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy)methyl]methylphosphinate as a colorless oil (0.3 g, 91%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 6.89 (m, 2H), 6.76 (s, 2H), 6.56 (dd, *J* = 1.8, 8.4 Hz, 1H), 5.16 (s, 2H), 4.27 (m, 2H), 4.04 (m, 2H), 3.89 (s, 2H), 3.37 (s, 3H), 2.30 (s, 3H), 2.17 (s, 6H), 1.51 (d, *J* = 14.6 Hz, 3H), 1.23 (t, *J* = 7.0 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.32.

Step b:


[1030] To a stirring solution of ethyl [(3,5-dimethyl-4-(4'-methoxymethoxy-3'-methylsulfanylbenzyl)phenoxy)methyl]methylphosphinate (0.14 g, 0.32 mmol) in CH₂Cl₂ (10 mL) at room temperature was added m-CPBA (0.19 g, 1.12 mmol). The mixture was stirred for 16 h at room temperature, quenched with saturated Na₂SO₃ and diluted with CH₂Cl₂. The organic layer was collected and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford ethyl [(3,5-dimethyl-4-(3'-methanesulfonyl-4'-methoxymethoxybenzyl)phenoxy)methyl]methylphosphinate as a colorless oil (0.07 g, 47%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 7.42 (s, 1H), 7.25 (s, 2H), 6.78 (s, 2H), 5.35 (s, 2H), 4.27 (m, 2H), 4.04 (m, 2H), 3.95 (s, 2H), 3.41 (s, 3H), 3.25 (s, 3H), 2.17 (s, 6H), 1.51 (d, *J* = 14.6 Hz, 3H), 1.23 (t, *J* = 7.0 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 5% methanol in ethyl acetate; R_f = 0.32.

Step c:

[1031] To a stirring solution of ethyl [(3,5-dimethyl-4-(3'-methanesulfonyl-4'-methoxymethoxybenzyl)phenoxy)methyl]methylphosphinate (0.07 g, 0.15 mmol) in CH₂Cl₂ (6 mL) at -20 °C was added TMSBr (0.2 mL, 1.5 mmol). The mixture was stirred for 16 h at room temperature and concentrated under reduced pressure. The residue was added MeOH and stirred for 1 h at room temperature. The solution was concentrated under reduced pressure to afford the title compound as a light pink foam (0.04 g, 67%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 10.84 (s, 1H), 7.31 (d, *J* = 1.8 Hz, 1H), 7.17 (dd, *J* = 1.8, 8.4 Hz, 1H), 6.95 (d, *J* = 8.4 Hz, 1H), 6.74 (s, 2H), 4.08 (d, *J* = 8.4 Hz, 2H), 3.89 (s, 2H), 3.19 (s, 3H), 2.16 (s, 6H), 1.39 (d, *J* = 14.6 Hz, 3H); LC-MS *m/z* = 399 [C18H23O6PS + H]⁺; Anal Calcd for (C18H23O6PS + 0.2CH₂Cl₂ + 1.8H₂O): C, 48.81; H, 6.08. Found: C, 48.52; H, 6.22.

Example 78

Compound 78: 2-[3,5-Dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)-phenyl]ethylphosphonic acid monomethyl ester



Step a:

[1032] To a solution of 4-bromophenol (13.84 gm, 0.08 Mol), 4-fluorobenzyl alcohol (8.68 gm, 0.08 Mol), and 120 mL of dichloroethane was added zinc bromide (21 gm, 0.09 Mol). The reaction mixture was stirred at 60 °C for 24 h, filtered and concentrated under reduced pressure. Pure product was obtained by flash chromatography using SiO₂, dichloromethane/hexane [1:1] as eluant to give 4-bromo-2-(4-fluorobenzyl)phenol (9.25 g, 41%) as colorless oil: ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.79 (s, 1H), 7.16 (m, 5H), 6.74 (d, *J* =

8.8 Hz, 1H), 3.82 (s, 2H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methylene chloride-hexanes (1:1); R_f = 0.38.

Step b:

[1033] To a stirring solution of 4-bromo-2-(4-fluorobenzyl)phenol (16 g, 59.9 mmol) in CH_2Cl_2 (200 mL) at room temperature was added ethyl-diisopropylamine (15.6 mL, 89.85 mmol) and chloro-methoxy-methyl ether (6.1 mL, 79.67 mmol). After stirring at reflux for 16 h, water was added and the mixture was partitioned with ethyl acetate. The organic layer was collected and dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 4-bromo-2-(4-fluorobenzyl)methoxymethoxybenzene as a light yellow oil (16.4 g, 88%): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): 6.96 – 7.40 (m, 7H), 5.20 (s, 2H), 3.89 (s, 2H), 3.26 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 6% ethyl acetate in hexanes; R_f = 0.79.

Step c:

[1034] To a stirring solution of 4-bromo-2-(4-fluorobenzyl)methoxymethoxybenzene (6.2 g, 19.93 mmol) in THF (80 mL) at -78°C was added *n*-BuLi (8.8 mL, 2.5 M in hexanes). The mixture was stirred at -78°C for 1 h and 2,6-dimethyl-4-triisopropylsilyloxy-benzaldehyde (6.11 g, 19.93 mmol) was added. The reaction mixture was stirred at -78°C for 1 h, allowed to warm to room temperature and stirred for 1 h. The reaction mixture was quenched with saturated NH_4Cl and diluted with diethyl ether. The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-[3-(4-fluorobenzyl)-4-methoxymethoxyphenyl]methanol as a light yellow oil (8.3 g, 75%): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): δ 6.88 – 7.20 (m, 7H), 6.47 (s, 2H), 5.97 (d, J = 4.0 Hz, 1H), 5.65 (d, J = 4.0 Hz, 1H), 5.14 (s, 2H), 3.85 (s, 2H), 3.25 (s, 3H), 2.11 (s, 6H), 1.24 (m, 3H), 1.08

(d, $J = 7.2$ Hz, 18H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 10% ethyl acetate in hexanes; $R_f = 0.47$.

Step d:

[1035] To a stirring solution of (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-[3-(4-fluorobenzyl)-4-methoxymethoxyphenyl]methanol (8.3 g, 15.01 mmol) in CH_2Cl_2 (150 mL) at room temperature was added Et_3SiH (9.6 mL, 60.04 mmol) and TFA (4.5 mL, 60.04 mmol). The reaction mixture was stirred at room temperature for 6 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO_3 . The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. Then to this stirring solution of crude product in CH_2Cl_2 (150 mL) at room temperature was added ethyl-diisopropyl-amine (2.6 mL, 15.01 mmol) and chloro-methoxy-methyl ether (1 mL, 13.51 mmol). The mixture was refluxed for 16 h, added water. The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford [3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenoxy]triisopropylsilane as a light yellow oil (7 g, 87%): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): δ 6.66 – 7.19 (m, 7H), 6.54 (s, 2H), 5.12 (s, 2H), 3.82 (s, 4H), 3.25 (s, 3H), 2.11 (s, 6H), 1.23 (m, 3H), 1.06 (d, $J = 7.2$ Hz, 18H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); $R_f = 0.68$.

Step e:

[1036] To a stirring solution of [3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenoxy]triisopropylsilane (7 g, 13.04 mmol) in THF (100 mL) at room temperature was added tetrabutylammonium fluoride (16.3 mL, 1.0 M in THF). The reaction mixture was stirred at room temperature for 2 h, diluted with diethyl ether and washed with water (30 mLx2). The solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (3:7) to afford 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]-

phenol as a colorless oil (4.6 g, 93%): ^1H NMR (200 MHz, DMSO- d_6): δ 6.99 (s, 1H), δ 7.13 (m, 4H), 6.85 (m, 2H), 6.67 (m, 1H), 6.43 (s, 2H), 5.12 (s, 2H), 3.84 (s, 2H), 3.76 (s, 2H), 3.24 (s, 3H), 2.07 (s, 6H), TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:85); R_f = 0.45.

Step f:

[1037] To a solution of 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]phenol (4.6 g, 12.09 mmol) and DMAP (4.4 g, 36.27 mmol) in CH_2Cl_2 (100 mL) at 0 °C was slowly added trifluoromethanesulfonyl anhydride (3.1 mL, 18.14 mmol). The reaction mixture was stirred at 0 °C for 2 h and quenched with water (60 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (15:85) to afford 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]phenyl trifluoromethanesulfonate as a colorless oil (5.8 g, 94%): ^1H NMR (200 MHz, DMSO- d_6): δ 6.91 – 7.28 (m, 7H), 6.80 (s, 1H), 6.69 (d, J = 8.4 Hz, 1H), 5.15 (s, 2H), 3.91 (s, 2H), 3.84 (s, 2H), 3.25 (s, 3H), 2.22 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:85); R_f = 0.65.

Step g:

[1038] To a solution of 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]phenyl trifluoromethanesulfonate (5.8 g, 11.32 mmol) in DMF (80 mL) in a bomb apparatus was added MeOH (9.2 mL, 226.4 mmol), $\text{Pd}(\text{OAc})_2$ (0.25 g, 1.13 mmol), DPPP (0.47 g, 1.13 mmol) and TEA (3.2 mL, 22.64 mmol). 60 psi of CO was then infused and the reaction mixture was stirred at 90 °C for 16 h. The bomb was cooled to 0 °C, vented, its content poured into cold 1 N HCl and extracted with EtOAc twice. The combined EtOAc extracts were washed with brine, dried over MgSO_4 , filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (15:85) to afford methyl 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzoate as a colorless oil

(4.8 g, 100%): ^1H NMR (200 MHz, DMSO-*d*₆): δ 7.64 (s, 2H), 6.68 – 7.25 (m, 7H), 5.13 (s, 2H), 3.97 (s, 2H), 3.83 (s, 5H), 3.24 (s, 3H), 2.23 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:75); R_f= 0.52.

Step h:

[1039] To a stirring solution of dimethyl methylphosphonate (1.44 mL, 13.26 mmol) in THF (60 mL) at -78 °C was added *n*-BuLi (2.5 M in hexanes, 5.3 mL), the reaction mixture was stirred at -78 °C for 1 h, then 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzoate (1.4 g, 3.31 mmol) in THF (10 mL) was added at the same temperature. The reaction mixture was stirred at -78 °C for 1.5 h, then at room temperature for 1 h. The reaction mixture was quenched with saturated NH₄Cl and diluted with diethyl ether. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate to afford dimethyl [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-2-oxo-ethyl]phosphonate as a light yellow oil (1.53 g, 90%): ^1H NMR (200 MHz, DMSO-*d*₆): δ 7.70 (s, 2H), 6.66 – 7.22 (m, 7H), 5.14 (s, 2H), 3.97 (s, 2H), 3.84 (s, 2H), 3.82 (d, *J*= 22.4 Hz, 2H), 3.65 (d, *J*= 11.0 Hz, 6H), 3.24 (s, 3H), 2.25 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f= 0.35.

Step i:

[1040] To a stirring solution of dimethyl [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-2-oxo-ethyl]phosphonate (1.34 g, 2.6 mmol) in MeOH (60 mL) at 0 °C was added NaBH₄ (0.49 g, 13.02 mmol). The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford crude dimethyl [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-2-hydroxy-ethyl]phosphonate as a light yellow oil (1.4 g, 100%): ^1H NMR (200

MHz, DMSO-*d*₆): δ 7.11 (m, 6H), 6.89 (m, 2H), 6.67 (m, 1H), 5.44 (d, *J* = 4.2 Hz, 1H), 5.12 (s, 2H), 4.80 (m, 1H), 3.87 (s, 2H), 3.84 (s, 2H), 3.55 (m, 8H), 3.22 (s, 3H), 2.17 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f= 0.41.

Step j:

[1041] To a stirring solution of [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-2-hydroxy-ethyl]phosphonate (1.4 g, 2.7 mmol) in CH₂Cl₂ (80 mL) at room temperature in EtOAc (20 mL) and AcOH (2 mL) was added Pd/C (0.2 g), and the reaction mixture was stirred under 50 PSI H₂ at room temperature for 16 h. The mixture was filtered through a celite plug. The solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate to afford dimethyl 2-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl]ethylphosphonate as a colorless oil (0.37 g, 27%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 6.81 – 7.22 (m, 8H), 6.69 (m, 1H), 5.12 (s, 2H), 3.84 (s, 4H), 3.62 (d, *J* = 10.6 Hz, 6H), 3.24 (s, 3H), 2.65 (m, 2H), 2.14 (s, 6H), 2.02 (m, 2H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f= 0.49.

Step k:

[1042] To a stirring solution of dimethyl 2-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl]ethylphosphonate (0.32 g, 0.64 mmol) in MeOH (4 mL) at room temperature was added HCl (2.1 mL, 3 N), and heated at 100 °C for 5 min by microwave. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford dimethyl 2-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenyl]ethylphosphonate as a colorless oil (0.27 g, 92%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.19 (s, 1H), 6.98 – 7.22 (m, 4H), 6.89 (s, 2H), 6.63 (m, 3H), 3.79 (s, 2H), 3.76 (s, 2H), 3.62 (d, *J* = 10.8 Hz, 6H), 2.65 (m, 2H), 2.13 (s,

- 510 -


6H), 2.02 (m, 2H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.44.

Step 1:

[1043] To a stirring solution of dimethyl 2-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenyl]ethylphosphonate (0.27 g, 0.59 mmol) in THF (10 mL) at room temperature was added NaOH (2.4 mL, 1 N), and the reaction mixture was brought to reflux. After 48 h, 1 N HCl was added to pH = 2, and the mixture was partitioned between EtOAc and sat. NaHCO_3 . The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford the title compound as a light yellow solid (0.2 g, 77%): ^1H NMR (300 MHz, DMSO- d_6): 9.18 (s, 1H), 6.88 – 7.22 (m, 4H), 6.86 (s, 2H), 6.71 (d, J = 2.1 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 6.55 (dd, J = 2.1, 8.1 Hz, 1H), 3.78 (s, 2H), 3.76 (s, 2H), 3.52 (d, J = 11.1 Hz, 3H), 2.65 (m, 2H), 2.11 (s, 6H), 1.84 (m, 2H); mp: 125 – 127 °C; LC-MS m/z = 443 [C₂₅H₂₈FO₄P + H]⁺; Anal Calcd for (C₂₅H₂₈FO₄P + 0.5H₂O): C, 66.51; H, 6.47. Found: C, 66.23; H, 6.61.

Example 79

Compound 79: [(3,5-Dimethyl-4-[3'-(4-fluorobenzyl)-4'-hydroxybenzyl]-phenylamino)methyl]methylphosphinic acid



Step a:

[1044] To a stirring solution of afford methyl 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzoate (compound 78, step f, 2.8 g, 6.63 mmol) in MeOH (80 mL) at 0 °C was added NaOH (27 mL, 1 N).

After heating at 50 °C for 16 h, the solvent was removed under reduced pressure and the residue was acidified with 1 N HCl to pH = 1, and the mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzoic acid as white solid (2.7 g, 100%): ¹H NMR (300 MHz, DMSO-*d*₆): 12.71 (s, 1H), 7.64 (s, 2H), 7.01 - 7.22 (m, 4H), 6.95 (d, *J* = 8.4 Hz, 1H), 6.85 (d, *J* = 2.1 Hz, 1H), 6.73 (dd, *J* = 2.1, 8.4 Hz, 1H), 5.15 (s, 2H), 3.98 (s, 2H), 3.86 (s, 2H), 3.27 (s, 3H), 2.25 (s, 6H).

Step b

[1045] To a solution of 3,5-dimethyl-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzoic acid (2.3 g, 5.63 mmol) in toluene (80 mL) was added diphenylphosphoryl azide (1.22 mL, 5.63 mmol), triethylamine (1.57 mL, 11.26 mmol) and BnOH (2.9 mL, 28.15 mmol) at room temperature. The mixture was refluxed for 16 h. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and sat. NH₄Cl. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford benzyl *N*-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl]carbamate as a yellow oil (2.9 g, 100%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.59 (s, 1H), 7.01 - 7.44 (m, 11H), 6.92 (d, *J* = 8.7 Hz, 1H), 6.86 (d, *J* = 1.8 Hz, 1H), 6.76 (dd, *J* = 1.8, 8.7 Hz, 1H), 5.15 (s, 2H), 5.14 (s, 2H), 3.87 (s, 2H), 3.85 (s, 2H), 3.27 (s, 3H), 2.14 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = 15% ethyl acetate in hexanes; R_f = 0.55.

Step c:

[1046] To a solution of benzyl *N*-[3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl]carbamate (0.62 g, 1.21 mmol) in CH₃CN (10 mL) at room temperature was added Cs₂CO₃ (0.79 g, 2.42 mmol) and ethyl [(4-methylphenyl)sulfonyloxy)methyl]methylphosphinate (compound 74, 0.35


g, 1.21 mmol). The reaction mixture was refluxed for 16 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and saturated NaHCO₃. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate to afford ethyl [(N-benzyloxycarbonyl-3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenylamino)methyl]methylphosphinate as a colorless oil (0.065 g, 8.5%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.01–7.44 (m, 11H), 6.92 (d, *J* = 8.4 Hz, 1H), 6.89 (d, *J* = 2.1 Hz, 1H), 6.73 (dd, *J* = 2.1, 8.4 Hz, 1H), 5.15 (s, 2H), 5.14 (s, 2H), 4.08 (d, *J* = 6.9 Hz, 2H), 3.91 (s, 2H), 3.85 (m, 3H), 3.63 (m, 1H), 3.27 (s, 3H), 2.18 (s, 6H), 1.32 (d, *J* = 14.4 Hz, 3H), 1.01 (t, *J* = 7.0 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.39.

Step d:

[1047] To a solution of ethyl [(N-benzyloxycarbonyl-3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenylamino)methyl]methylphosphinate (0.065 g, 0.1 mmol) in EtOH (30 mL) at room temperature was added Pd/C (0.04 g) and the reaction mixture was stirred under 50 PSI H₂ at room temperature for 16 h. The mixture was filtered through a Celite plug. The solvent was removed under reduced pressure and the residue (0.045 g, 0.09 mmol) was dissolved into CH₂Cl₂ (8 mL). TMSBr (0.12 mL, 0.9 mmol) was then added at – 20 °C. The reaction mixture was stirred at room temperature for 16 h and concentrated under reduced pressure. MeOH was added to the residue and the solution was stirred at room temperature. After 1h, the solution was concentrated under reduced pressure and purified by Prep. LC-MS to afford the title compound as a white solid (0.014 g, 36%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.15 (s, 1H), 7.01 – 7.22 (m, 4H), 6.77 (d, *J* = 2.1 Hz, 1H), 6.67 (d, *J* = 8.1 Hz, 1H), 6.59 (dd, *J* = 2.1, 8.1 Hz, 1H), 6.41 (s, 2H), 3.79 (s, 2H), 3.71 (s, 2H), 3.25 (d, *J* = 10.2 Hz, 2H), 2.16 (s, 6H), 1.37 (d, *J* = 14.1 Hz, 3H); LC-MS m/z = 428 [C₂₄H₂₇FNO₃P + H]⁺; Anal Calcd for (C₂₄H₂₇FNO₃P + 1.6H₂O): C, 63.18; H, 6.67; N, 3.07. Found: C, 62.87; H, 6.50; N, 2.96.

Example 80

Compound 80: [(3,5-Dichloro-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)-phenoxy)methyl]methylphosphonic acid



Step a:

[1048] 4-[(4-Benzyloxy-2,6-dichlorophenyl)[3-(4-fluorobenzyl)-4-methoxy-methoxyphenyl]methanol was prepared from 2,6-dichloro-4-benzyloxybenzaldehyde (*Organic Letters* 4:2833 (2002)) according to the procedure described for the synthesis of compound 78, step c. (0.58 gm, 20%); ^1H NMR (200 MHz, DMSO- d_6): δ 7.38 (m, 5H), 7.13 (m, 7H), 6.95 (s, 2H), 6.32 (d, $J = 4.8$ Hz, 1H), 5.97 (d, $J = 4.4$ Hz, 1H), 5.15 (s, 4H), 3.88 (s, 2H), 3.26 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:1); $R_f = 0.45$.

Step b:

[1049] 5-Benzyl-1,3-dichloro-2-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]benzene was synthesized by combining (1.21 gm, 2.48 mmol) starting material, with dichloromethane 30 mL, TFA (0.92 mL, 12.4 mmol), and triethylsilane (2 mL, 12.4 mmol). The reaction was stirred at r.t for 1.5 h in an ice/water bath, poured into dichloromethane 50 mL, washed 1 x with 50 mL NaHCO₃, 1 x with 25 mL H₂O, 1 x with 25 mL HCl. The organics were dried over Na₂SO₄, filtered and concentrated under reduced pressure. (1.172 gm, 100 %); NMR (300 MHz, DMSO- d_6): δ 7.37 (m, 5H), 7.15 (m, 4H), 7.08 (m, 4H), 6.94 (m, 2H), 5.14 (s, 4H), 4.06 (s, 2H), 3.85 (s, 2H), 3.25 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (3:1); $R_f = 0.40$.

Step c:

[1050] 3,5-Dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]-phenol

phenol was prepared according to the procedure described for the synthesis of compound 35, step c. (0.183 gm, 40%); ^1H NMR (300 MHz, DMSO- d_6): δ 10.27 (bs, 1H), 7.23 (m, 4H), 7.10 (m, 4H), 6.86 (m, 2H), 6.84 (m, 3H), 5.14 (s, 2H), 4.02 (s, 2H), 3.85 (s, 2H), 3.25 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = hexanes-ethyl acetate (3:1); R_f = 0.32.

Step d:


[1051] To a solution of 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl]phenol (0.08 gm, 0.19 mmol), acetonitrile (3 mL), ethyl [(4-methylphenyl)sulfonyloxymethyl]methylphosphinate (compound 74, 0.105 gm, 0.38 mmol), was added cesium carbonate (0.153 gm, 0.47 mmol). The reaction was heated at reflux for 2 hours, then stirred over night at r.t. The reaction was filter into 25 ml ethyl acetate, washed 1 x with brine, dried over Na_2SO_4 , filtered and concentrated. Ethyl [(3,5-dichloro-4-(3-(4-fluorobenzyl)-4-hydroxybenzyl)phenoxy)methyl]methylphosphinate was obtained by prep plate TLC using a 2mm x 20 x 20 cm SiO_2 plate eluted with ethyl acetate. (0.06gm, 60%); ^1H NMR (300 MHz, DMSO- d_6): δ 7.23 (s, 2H), 7.17 (m, 2H), 7.07 (t, J = 8.7 Hz, 2H), 6.95 (m, 2H), 6.86 (m, 1H), 5.14 (s, 2H), 4.41 (m, 2H), 4.07 (s, 2H), 4.04 (m, 2H), 3.86 (s, 2H), 3.25 (s, 3H); ^{31}P NMR (121.4 MHz, DMSO- d_6): δ 46.13; TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate; R_f = 0.22.

Step e:

[1052] Title compound was prepared according to the procedure described for the synthesis of compound 7, step b (0.032gm, 62%); ^1H NMR (300 MHz, DMSO- d_6): δ 9.27 (s, 1H), 7.18 (m, 4H), 7.06 (t, J = 8.7 Hz, 2H), 6.84 (d, J = 1.8 Hz, 1H), 6.71 (m, 2H), 4.20 (d, J = 8.1 Hz, 2H), 4.01 (s, 2H), 3.78 (s, 2H), 1.39 (d, J = 14.7 Hz, 3 H); TLC conditions: Uniplate silica gel, 250 microns; isopropanol/AcOH/H₂O [7:2:1]; R_f = 0.65; LC-MS m/z = 467 [$\text{C}_{22}\text{H}_{20}\text{Cl}_2\text{FO}_4\text{P} + \text{H}^+$]; Anal Calcd for ($\text{C}_{22}\text{H}_{20}\text{Cl}_2\text{FO}_4\text{P} + 0.1 \text{ H}_2\text{O}$): C, 56.09; H, 4.32. Found: C, 55.94; H, 4.15.

Example 81:

Compound 81: [3,5-Dichloro-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)-phenoxy]methyl phosphonic acid monomethyl ester



Step a:

[1053] Dimethyl[3,5-dichloro-4-(3'-(4-fluorobenzyl)-4'-methoxymethyl-benzyl)phenoxy]methylphosphonate was prepared from 3,5-dichloro-4-[3'-(4-fluorobenzyl)-4'-hydroxybenzyl]phenol according to the procedure described for the synthesis of compound 75, step b (0.091 gm, 69%); ^1H NMR (200 MHz, DMSO- d_6): δ 7.26 (s, 2H), 7.10 (m, 2H), 6.92 (m, 5H), 5.10 (s, 2H), 4.25 (d, $J = 10.6$ Hz, 2H), 4.07 (s, 2H), 3.85 (s, 3H), 3.74 (d, $J = 11$ Hz, 2H), 3.25 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate-hexane [3:1]; $R_f = 0.32$.

Step b

[1054] Dimethyl[3,5-dichloro-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)-phenoxy]methylphosphonate was prepared according to the procedure described for the synthesis of compound 7-14, step a (0.093 gm, 81%); ^1H NMR (300 MHz, DMSO- d_6): δ 9.27 (s, 1H), 7.18 (m, 4H), 7.06 (t, $J = 9$ Hz, 2H), 6.84 (s, 1H), 6.69 (m, 2H), 4.57 (d, $J = 10$ Hz, 2H), 4.02 (s, 2H), 3.78 (s, 2H), 3.73 (d, $J = 11$ Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate-hexane [3:1]; $R_f = 0.23$.


Step c:

[1055] A solution of dimethyl [3,5-dichloro-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenoxy]methyl phosphonate (compound 80, step , 0.093 gm, 0.18 mmol), THF (3mL), and 1 N NaOH (0.75 mL) was heated at reflux for 12 h. The reaction was allowed to cool, concentrated under reduced pressure

and diluted to a volume of 20 mL with H₂O. The liquor was washed with 2 x with 10 mL of ethyl acetate, then acidified using conc. HCl to pH 3. The acidic solution was extracted with 2 x 10 mL of diethyl ether. The ether was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the title compound (0.063 gm, 72%); ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.28 (s, 1H), 7.10 (m, 4H), 6.85 (s, 1H), 6.70 (s, 2H), 4.36 (d, *J* = 10 Hz, 2H), 4.01 (s, 2H), 3.77 (s, 2H), 3.64 (d, *J* = 10.5 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; isopropanol/AcOH/H₂O [7:2:1]; R_f = 0.72; LC-MS *m/z* 485 [C₂₂H₂₀Cl₂FO₅P + H]⁺; Anal Calcd for (C₂₂H₂₀Cl₂FO₅P): C, 54.45; H, 4.15. Found: C, 54.45; H, 4.12.

Example 82

Compound 82: [3,5-Dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)-methylphosphonic acid monomethyl ester.



Step a:

[1056] A mixture of 4-bromo-2-(4-fluorobenzyl)phenol (compound 78, step a, 6.0 gm, 21.4 mmol), 1.2 g of palladium on activated carbon (10%) and 100 mL of methanol in a glass reaction vessel was shaken at 50 psi H₂ over night, filtered and concentrated under reduced pressure. The resulting light orange oil was dissolved in 180 mL dichloromethane and washed 1 x with NaHCO₃ saturated solution. The organic was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-(4-fluorobenzyl)phenol (4.52 gm, 100%); ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.39 (s, 1H), 7.22 (m, 2H), 7.02 (m, 3H), 6.74 (m, 2H), 3.84 (s, 2H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methylene chloride-hexanes (1:1); R_f = 0.32.

Step b:

[1057] A mixture of 2-(4-fluorobenzyl)phenol (4.51 gm, 22.41 mmol), DMF (60 mL), potassium carbonate (7.78 gm, 56.02 mmol) and methyl iodine (1.67 mL, 26.81 mmol) was stirred at rt for 16 h. The reaction was poured into 150 mL ethyl acetate, filtered, washed 3x with 50 mL H₂O, 1x with 100 mL brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-(4-fluorobenzyl)anisole (4.27 gm, 88%); ¹H NMR (200 MHz, DMSO-d₆): δ 7.11(m, 7H), 3.88(s, 2H), 3.76(s, 3H); TLC conditions: Uniplate silica gel, 250 microns; methylene chloride-hexanes (1:1); R_f = 0.64.

Step c:

[1058] Bis[3-(4-fluorobenzyl)-4-methoxy]iodonium tetrafluoroborate was prepared from 2-(4-fluorobenzyl)anisole using the procedure from (Yokoyama et al. *J. Med. Chem.* 38:695 (1995)). (5.49gm, 40%); ¹H NMR (200 MHz, DMSO-d₆): δ 7.94 (m, 4H), 7.15 (m, 12H), 3.86 (s, 4H), 3.25 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; dichloromethane-methanol [10:1]; R_f = 0.53.

Step d:

[1059] 3,5-Dibromo-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]phenyl benzoate was prepared from bis[3-(4-fluorobenzyl)-4-methoxy]iodonium tetrafluoroborate and 3-benzyloxy-2,6-dibromophenol according to the procedure described for the synthesis of compound 4, step a (2.15gm, 63%); ¹H NMR (200 MHz, DMSO-d₆): δ 8.13(dd, J = 6.8, 1 Hz, 2 H z), 7.90(s, 2H), 7.75(d, J = 7.2 Hz, 1H), 7.63(t, J = 7 Hz, 2H), 7.19(m, 4H), 6.92(d, J = 8.8 Hz, 1H), 6.76(d, J = 3 Hz, 1H), 6.51(dd, J = 6, 2.2 Hz, 1H), 3.87(s, 2H), 3.74(s, 3H); TLC conditions: Uniplate silica gel, 250 microns; hexane-acetone [20:1]; R_f = 0.24.

Step e:

[1060] To a mixture of 3,5-dibromo-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]phenyl benzoate (2.14 gm, 3.75 mmol) in THF 60 mL was added 1 N NaOH 20 mL. The reaction was stirred at r.t overnight, then poured into 120 mL ethyl acetate. The aqueous layer was removed and the

organic was washed 2 x with aqueous NaHCO₃, 1 x with 1 N HCl 30 mL. The ethyl acetate was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 3,5-dibromo-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]phenol (1.68 gm, 93%); ¹H NMR (300 MHz, DMSO-d₆): δ 10.27 (s, 1H), 7.20 (m, 2H), 7.05 (m, 4H), 6.87 (d, J = 9 Hz, 1H), 6.65 (d, J = 3.3 Hz, 1H), 6.46 (dd, J = 9, 3 Hz, 1H), 3.84 (s, 2H), 3.71 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; hexane-ethyl acetate [3:1]; R_f = 0.65.

Step f:

[1061] To a stirred solution of 3,5-dibromo-4-[3'-(4-fluorobenzyl)-4'-methoxyphenoxy]phenol (1.66 gm, 3.44 mmol), dichloromethane 100mL, was added boron tribromide (8.6 mL, 8.60 mmol) in an ice / water bath. The reaction was stirred overnight under a nitrogen atmosphere. The reaction was diluted with ethyl acetate 60 mL, filtered and washed with water 2 x with 10 mL and brine 3 x 10 mL. The ethyl acetate was dried over Na₂SO₄, filtered and concentrated under reduced pressure. 3,5-Dibromo-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy]phenol (1.06 gm, 66%) was obtained by flash chromatography using SiO₂ eluted with a step gradient of hexane-ethyl acetate[3:1] 2L and hexane-ethyl acetate [3:2]; ¹H NMR (300 MHz, DMSO-d₆): δ 10.24 (s, 1H), 9.14 (s, 1H), 7.22 (m, 2H), 7.08 (m, 4H), 6.69 (td, J = 8.7 Hz, 1H), 6.54 (d, J = 3.3 Hz, 1H), 6.55 (dd, J = 8.4, 3.3 Hz, 1H), 6.35 (dd, J = 9, 3 Hz, 1H), 3.80 (s, 2H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methylene chloride-hexanes (1:1); R_f = 0.55.

Step g:

[1062] To a stirred solution of 3,5-dibromo-4-[3'-(4-fluorobenzyl)-4'-hydroxyphenoxy] phenol (0.237 gm, 0.51 mmol), DMF 8mL, cesium carbonate (0.824, 2.53 mmol) in an ice / water bath was added diethyl trifluoromethylsulfonyloxyethylphosphonate (0.122 gm, 0.41 mmol). The reaction was stir overnight under a nitrogen atmosphere. The reaction was diluted with ethyl acetate 60 mL, filtered and washed with water 2 x with 10 mL and brine 3 x 10 mL. The ethyl acetate was dried over Na₂SO₄, filtered

and concentrated under reduced pressure. Diethyl [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)methylphosphonate (0.124 g, 39%) was obtained by prep plate TLC using a 2mm x 20 cm x 20 cm prep plate eluted with ethyl acetate; ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.18 (s, 1H), 7.47 (s, 2H), 7.22 (t, *J* = 5.7 Hz, 2H), 7.07 (t, *J* = 9 Hz, 2H), 6.70 (d, *J* = 8.7 Hz, 1H), 6.55 (d, *J* = 3.3 Hz, 1H), 6.35 (dd, *J* = 9 Hz and *J* = 3 Hz, 1H), 4.54 (d, *J* = 8.7 Hz, 2H), 4.11 (q, *J* = 7.2 Hz, 4H), 3.80 (s, 2H), 1.26 (t, *J* = 7.2 Hz, 6H); ³¹P NMR (121 MHz, DMSO-*d*₆): δ 18.87 (s, 1P); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.42.

Step h:

[1063] To a stirred solution of diethyl [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)phenoxy)methylphosphonate (0.134 g, 0.22 mmol) in CH₂Cl₂ (5 mL) at 0 °C was added TMSBr (0.24 g, 0.2 mL). The reaction mixture was stirred at 0 °C for 30 min, allowed to warm to room temperature. The reaction mixture was stirred at room temperature for 16 h and the solvent was removed under reduced pressure. The residue was co-evaporated 3 x 5 mL dichloromethane and 1 x 5 mL methanol to give [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)phenoxy)methylphosphonic acid as a white foam (0.124 g, 100%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.35 (s, 2H), 7.23 (m, 2H), 7.06 (t, *J* = 9 Hz, 2H), 6.70 (d, *J* = 8.4 Hz, 1H), 6.58 (d, *J* = 3.3 Hz, 1H), 6.32 (dd, *J* = 9 Hz and *J* = 3 Hz 1H), 3.92 (d, *J* = 8.7 Hz), 3.79 (s, 2H); LC-MS *m/z* = 561 [C₂₀H₁₆Br₂FO₆P-H]⁺.

Step i:

[1064] Dimethyl [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)phenoxy)methylphosphonate was prepared from [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)phenoxy)methylphosphonic acid according to the procedure described for the synthesis of compound 69, step a (0.089 gm, 66%); ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.19 (s, 1H), 7.48 (s, 2H), 7.22 (m, 2H), 7.07 (t, *J* = 9 Hz, 2H), 6.70 (d, *J* = 9 Hz, 1H), 6.55 (dd, *J* = 3.3 Hz, 1H), 6.34 (dd, *J* = 3 Hz and *J* = 9 Hz, 1H), 4.59 (d, *J* = 9.9 Hz, 2H), 3.80 (s,

- 520 -


2H), 3.75 (d, J = 10.5 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.40.

Step j:

[1065] Title compound was prepared from dimethyl [3,5-dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)phenoxy]methylphosphonate according to the procedure described for the synthesis of compound 81, step c (0.064 gm, 80%); ^1H NMR (200 MHz, DMSO- d_6): δ 9.19 (s, 1H), 7.44 (s, 2H), 7.22 (t, J = 8 Hz, 2H), 7.07 (t, J = 8 Hz, 2H), 6.70 (d, J = 8.8 Hz, 1H), 6.57 (d, J = 3 Hz, 1H), 6.34 (dd, J = 8.8, 3 Hz, 1H), 4.33 (d, J = 10 Hz, 2H), 3.80 (s, 2H), 3.63 (d, J = 11 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; isopropanol/AcOH/H₂O [7:2:1]; R_f = 0.74; LC-MS m/z 575 [C₂₁H₁₈Br₂FO₆P - H]⁺; Anal Calcd for (C₂₁H₁₈Br₂FO₆P): C, 43.78; H, 3.15. Found: C, 43.66; H, 3.09.

Example 83:

Compound 83: [3,5-dimethyl-4-(5'-iodo-4'-hydroxy-3'-*iso*-propylbenzyl)-phenoxy]methylphosphonic acid



Step a:

[1066] Diethyl [3,5-dimethyl-4-(5'-iodo-4'-hydroxy-3'-*iso*-propylbenzyl)-phenoxy]methylphosphonate was prepared from diethyl [3,5-dimethyl-4-(4'-hydroxy-3'-*iso*-propylbenzyl)phenoxy]methylphosphonate (compound 69-1, step a) was prepared according to the procedure described for the synthesis of compound 13-15-*cis*: ^1H NMR (300 MHz, CD₃OD): δ 7.06 (d, J = 2.4 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.77 (s, 2H), 4.42 (d, J = 11.2 Hz, 2H), 4.28 (m, 4H), 3.93 (s, 2H), 3.28 (m, 1H), 2.24 (s, 6H), 1.40 (t, J = 7.2 Hz, 6H),

- 521 -


1.17 (d, $J = 7.0$ Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:1); $R_f = 0.6$.

Step b:

[1067] The title compound was prepared according to the procedure described for the synthesis of compound 7, step b: mp: 195-198 °C; 7.06 (d, $J = 2.4$ Hz, 1H), 6.89 (d, $J = 2.4$ Hz, 1H), 6.77 (s, 2H), 4.24 (d, $J = 11.2$ Hz, 2H), 3.92 (s, 2H), 3.25 (m, 1H), 2.23 (s, 6H), 1.17 (d, $J = 7.0$ Hz, 6H); LC-MS $m/z = 491$ [$C_{19}H_{24}IO_5P + H^+$]; Anal. Calcd for ($C_{19}H_{24}IO_5P$): C, 46.55; H, 4.93. Found: C, 46.66; H, 5.26.

Example 84

Compound 84: [(3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenylamino)methyl]methylphosphinic acid



Step a:

[1068] To a stirred solution of bis(4-methoxyphenyl)iodonium tetrafluoroborate (3.14 g, 6.12 mmol, Yokoyama *et al.* *J. Med. Chem.* 38:695 (1995)) and copper powder (0.52 g, 8.12 mmol) in CH_2Cl_2 (12.0 mL) at 0 °C was added a solution of 2,6-dibromo-4-nitrophenol (1.20 g, 4.04 mmol) and Et₃N (0.62 mL, 4.48 mmol) in CH_2Cl_2 (8.0 mL). The reaction was wrapped in aluminum foil (darkness), stirred at room temperature for 216 h and filtered through a Celite plug. The filtrate was concentrated and purified by column chromatography on silica gel, eluting with acetone-hexanes (3: 97) to afford 3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)nitrobenzene as an orange solid (1.95 g, 100%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.60 (s, 2H), 6.82 (m, 2H), 6.44 (m, 1H), 3.73 (s, 3H), 3.12 (m, 1H), 1.13 (d, $J = 6.0$ Hz, 6H); TLC

- 522 -

conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (3:47); R_f = 0.45.

Step b:

[1069] To a stirred solution of 3,5-dibromo-4-(3'-isopropyl-4'-methoxyphenoxy)-nitrobenzene (1.37 g, 2.98 mmol) in CH_2Cl_2 (30.0 mL) at -78 °C was added BBr_3 (8.93 mL, 8.93 mmol, 1 M solution in CH_2Cl_2). The reaction mixture was stirred at room temperature for 2.5 h, quenched with ice/water, and stirred cold for several minutes. The reaction mixture was diluted with CH_2Cl_2 and H_2O , partitioned, and the aqueous solution was extracted with CH_2Cl_2 . The combined organic layers were concentrated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1: 10) to afford 3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)nitrobenzene as a solid (1.20 g, 90%): ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 9.19 (s, 1H), 8.64 (s, 2H), 6.73 (m, 2H), 6.37 (m, 1H), 3.12 (m, 1H), 1.16 (d, J = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.46.

Step c:

[1070] To a stirred solution of 3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)nitrobenzene (0.43 g, 0.96 mmol) in CH_2Cl_2 (9.0 mL) at 0 °C was added diisopropylethylamine (0.50 mL, 2.89 mmol) and the reaction mixture was stirred for several minutes. Chloromethylmethyl ether (0.15 mL, 1.92 mmol) was added and the solution was refluxed for 16 h, cooled to 0 °C, quenched with H_2O and partitioned between CH_2Cl_2 and H_2O . The organic layer was concentrated under reduced pressure and coevaporated with methanol and toluene to afford 3,5-dibromo-2-(3'-isopropyl-4'-methoxymethoxyphenoxy)nitrobenzene as a glass (0.430 g, 91%): ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 8.65 (s, 2H), 7.00 (m, 1H), 6.86 (m, 1H), 6.48 (m, 1H), 5.19 (s, 2H), 3.41 (s, 3H), 3.14 (m, 1H), 1.17 (d, J = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.50.

Step d:

- 523 -

[1071] To a stirred suspension of 3,5-dibromo-2-(3'-isopropyl-4'-methoxymethoxyphenoxy)nitrobenzene (0.72 g, 1.47 mmol) in MeOH/H₂O (15.0 mL/3.0 mL) was added Na₂S₂O₄ (2.56 g, 14.68 mmol). The reaction mixture was stirred at room temperature for 20 min and the methanol was evaporated under reduced pressure. The reaction mixture was diluted with diethyl ether and H₂O, partitioned, and the aqueous solution was treated with 1:1 saturated aqueous NaHCO₃ /brine. The treated aqueous layer was then extracted with ethyl acetate. The organic layers were then combined, washed with H₂O (2X), concentrated, then coevaporated with MeOH (2X) to afford 3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)aniline as a solid (0.60 g, 89%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.93 (m, 3H), 6.72 (m, 1H), 6.40 (m, 1H), 5.16 (s, 2H), 3.40 (s, 3H), 3.21 (m, 1H), 1.15 (d, J = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.27.

Step e:

[1072] To a stirred suspension of 3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)aniline (0.50 g, 1.12 mmol) in THF (12.0 mL) was added *t*-BOC anhydride (0.61 g, 2.80 mmol), dimethylaminopyridine (0.025 g, 5% wt/wt), and *t*-BuOH (0.25 g, 3.36 mmol). The reaction mixture was stirred at reflux for 1 h and the solvent was evaporated under reduced pressure. The reaction mixture was diluted with ethyl acetate and H₂O, partitioned, and the organic layer was concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1: 10) to afford *t*-butyl *N*-*t*-butoxycarbonyl-[3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl]carbamate as a solid (0.62 g, 86%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.84 (s, 2H), 7.04 (m, 1H), 6.66 (m, 1H), 6.51 (m, 1H), 5.18 (s, 2H), 3.41 (s, 3H), 3.15 (m, 1H), 1.22 (s, 18H), 1.13 (d, J = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.68.

Step f:

[1073] To a stirred solution of *t*-butyl *N*-*t*-butoxycarbonyl-[3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl]carbamate (0.62 g, 0.96 mmol) in methanol (20.0 mL) was added 2 M NaOH (2.88 mL, 5.77 mmol). The reaction mixture was stirred at rt for 4.5 h and the solvent was evaporated under reduced pressure. The reaction mixture was treated with saturated aqueous ammonium chloride, diluted with ethyl acetate and H₂O, partitioned, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over MgSO₄, and concentrated to afford *t*-butyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl]carbamate as an oil (0.62 g, 86%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.79 (s, 1H), 7.87 (s, 2H), 6.97 (m, 1H), 6.77 (m, 1H), 6.39 (m, 1H), 5.17 (s, 2H), 3.41 (s, 3H), 3.14 (m, 1H), 1.50 (s, 9H), 1.17 (d, *J* = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:5); R_f = 0.68.

Step g:

[1074] To a stirring mixture of *t*-butyl [3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl]carbamate (0.11 g, 0.20 mmol) and acetonitrile (3.0 mL) was added Cs₂CO₃ (0.859 g, 2.64 mmol) followed by ethyl [(4-methylphenyl)sulfonyloxymethyl]methylphosphinate (compound 74, 0.059 g, 0.20 mmol). The reaction mixture was stirred at reflux for 16 h then partitioned with ethyl acetate and H₂O. The organic layer was concentrated and the crude product was purified by preparatory thin-layer chromatography on silica gel, eluting with ethyl acetate-hexanes (4:1) to afford ethyl *N*-*t*-butoxycarbonyl-[[(3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenyl)amino)methyl]methylphosphinate as an oil (0.053 g, 39%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.88 (s, 2H), 6.99 (m, 1H), 6.72 (m, 1H), 6.47 (m, 1H), 5.18 (s, 2H), 4.13 (m, 2H), 3.93 (m, 1H), 3.75 (m, 1H), 3.41 (s, 3H), 3.14 (m, 1H), 1.43 (s, 9H), 1.12 (d, *J* = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (4:1); R_f = 0.17.

Step h:

[1075] To a mixture of ethyl *N*-*t*-butoxycarbonyl-[*(3,5-dibromo-4-(3'-isopropyl-4'-methoxymethoxyphenoxy)phenylamino)methyl*]methylphosphinate (0.27 g, 0.41 mmol) in methanol (6.0 mL) was added 3 N HCl (0.68 mL, 2.03 mmol). The reaction mixture was heated with microwave radiation at 100 °C in a sealed vial for 5 minutes. The solvent was removed and the residue was partitioned with ethyl acetate and brine, partitioned, and the aqueous solution was extracted with ethyl acetate. The combined organic layers were coevaporated with methanol and concentrated under reduced pressure. The crude residue was purified by preparatory thin-layer chromatography on silica gel, eluting with methanol-ethyl acetate (5:95) to afford ethyl [*(3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)phenylamino)methyl*]methylphosphinate (0.16 g, 77%) as an oil: ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.97 (s, 1H), 7.11 (s, 2H), 6.65 (m, 2H), 6.26 (m, 2H), 4.06 (m, 2H), 3.55 (m, 2H), 3.14 (m, 1H), 1.48 (d, J = 6.0 Hz, 6H), 1.22 (m, 3H), 1.12 (d, J = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methanol-ethyl acetate (5:95); R_f = 0.35.


Step i:

[1076] To a solution of ethyl [*(3,5-dibromo-4-(4'-hydroxy-3'-isopropylphenoxy)phenylamino)methyl*]methylphosphinate (0.08 g, 0.16 mmol) in CH₂Cl₂ (2.0 mL) at -30 °C was added bromotrimethylsilane (0.21 mL, 1.55 mmol). The reaction mixture was stirred at -30 °C for 4 h, then rt for 12 h and the solvent was removed under reduced pressure. The residue was treated with acetonitrile- H₂O (4:1, 5.0 mL) and stirred at 38 °C for 30 min. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with H₂O. The organic solution was filtered and concentrated under reduced pressure to afford the title compound as an off-white powder (0.076 g, 100%); ¹H NMR (300 MHz, CD₃OD): δ 6.92 (s, 2H), 6.51 (m, 2H), 6.20 (m, 1H), 3.38 (m, 2H), 3.12 (m, 1H), 1.43 (d, J = 15.0 Hz, 3H), 1.05 (d, J = 6.0 Hz, 6H); LC-MS m/z = 494 [C₁₇H₂₀Br₂NO₄P - H]⁺; HPLC conditions: Column = Shimadzu LC-A8, SPD-10A; YMC Pack RP-18 filter, 150×4.6; Mobile phase = Solvent A Acetonitrile/0.05% TFA; Solvent B = H₂O/0.05% TFA. Flow rate = 2.0 mL/min; UV@ 254 nm. rt = 14.52 min

- 526 -

Example 85


Compound 85: 2-[3,5-Dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)-phenyl]ethylphosphonic acid



[1077] The title compound was prepared from dimethyl 2-[3,5-Dimethyl-4-(3'-(4-fluorobenzyl)-4'-hydroxybenzyl)phenyl]ethylphosphonate (compound 78, step k) according to the procedure described for the synthesis of compound 7, step b (40 mg, 100%): ^1H NMR (200 MHz, DMSO- d_6): δ 9.17 (s, 1 H), 7.11 (m, 4 H), 6.85 (s, 2 H), 6.53 – 6.73 (m, 3 H), 3.76 (s, 4 H), 2.64 (m, 2 H), 2.12 (s, 6 H), 1.78 (m, 2 H); LC-MS m/z = 429 [$\text{C}_{24}\text{H}_{26}\text{FO}_4\text{P} + \text{H}]^+$; Anal Calcd for ($\text{C}_{24}\text{H}_{26}\text{FO}_4\text{P} + 2.3\text{H}_2\text{O}$): C, 61.35; H, 6.56. Found: C, 61.04; H, 6.36.

Example 86

Compound 86: dimethyl [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-2-oxo-ethyl]phosphonic acid




[1078] The title compound was prepared from (60 mg, 94%) from dimethyl [2-(3,5-dimethyl-4-(3'-(4-fluorobenzyl)-4'-methoxymethoxybenzyl)phenyl)-

- 527 -

2-oxo-ethyl]phosphonate (compound 78, step h) according to the procedure described for the synthesis of compound 7, step b (60 mg, 94%): ^1H NMR (300 MHz, DMSO- d_6): δ 9.23 (s, 1 H), 7.66 (s, 2 H), 7.15 (m, 2 H), 7.07 (m, 2 H), 6.76 (d, J = 2.1 Hz, 1 H), 6.66 (d, J = 8.1 Hz, 1 H), 6.55 (dd, J = 2.1, 8.1 Hz, 1 H), 3.90 (s, 2 H), 3.77 (s, 2 H), 3.47 (d, J = 22.5 Hz, 2 H), 2.23 (s, 6 H); LC-MS m/z = 443 [C₂₄H₂₄FO₅P + H]⁺; Anal Calcd for (C₂₄H₂₄FO₅P + 0.1HBr + 0.2EtOAc + 0.8H₂O): C, 61.73; H, 5.70; Br, 1.66. Found: C, 61.59; H, 5.64; Br, 1.84.

Example 87


Compound 87: [4-(4'-Hydroxy-3'-methanesulfonylbenzyl)-3,5-dimethyl-phenoxy(methyl]-phosphonic acid



[1079] The title compound was prepared from (compound 76, step a) according to the procedure described for the synthesis of compound 7, step b: ^1H NMR (200 MHz, DMSO- d_6): δ 10.82 (s, 1 H), 7.33 (d, J = 2.0 Hz, 1 H), 7.11 (dd, J = 2.0, 8.4 Hz, 1 H), 6.95 (d, J = 8.4 Hz, 1 H), 6.72 (s, 2 H,), 4.03 (d, J = 10.2 Hz, 2 H), 3.88 (s, 2 H), 3.20 (s, 3 H), 2.15 (s, 6 H); LC-MS m/z = 401 [C₁₇H₂₁O₇PS + H]⁺; Anal Calcd for (C₁₇H₂₁O₇PS + 0.8H₂O): C, 49.23; H, 5.49. Found: C, 49.11; H, 5.61.

Example 88

Compound 88: [(3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)-phenoxy)methyl]methylphosphinic acid



Step a:

[1080] To a stirring mixture of DMF (20.0 mL) and NaH (0.074 g, 1.86 mmol) at 0 °C was added 3,5-dibromo-4-(3-isopropyl-4-hydroxyphenoxy)phenol (Intermediate for the synthesis of compound 8-1, 0.75 g, 1.86 mmol) dissolved in DMF (2.0 mL). The reaction mixture was allowed to stir at rt 1 hr and cooled to 0 °C. To the stirred mixture was ethyl [(4-methylphenyl)sulfonyloxy)methyl]methylphosphinate (compound 74, 0.52 g, 1.77 mmol) and the reaction was stirred at rt for 16 h. The reaction was quenched with ice/H₂O and the solvent was evaporated. The pH was adjusted to 1 with 2 M HCl and the mixture was partitioned with ethyl acetate and H₂O. The aqueous solution was extracted with ethyl acetate and the combined organic layers were concentrated under reduced pressure was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (9:1) to afford crude product mixture (555 mg) and recovered starting material (270 mg). The crude product residue was treated with acetone to afford ethyl [(3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy)methyl]methylphosphinate as a white solid (0.23 g, 24%): ¹H NMR (200 MHz, DMSO-d₆): δ 9.03 (s, 1 H), 7.50 (s, 2 H), 6.67 (m, 2 H), 6.27 (m, 1 H), 4.49 (m, 2 H), 4.02 (m, 2 H), 3.14 (m, 1 H), 1.58 (d, J = 16.0 Hz, 3 H); 1.23 (m, 3 H), 1.12 (d, J = 6.0 Hz, 6 H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.26


Step b:

[1081] To a stirring suspension of ethyl [(3,5-dibromo-4-(4'-hydroxy-3'-*iso*-propylphenoxy)phenoxy)methyl]methylphosphinate (0.24, 0.45 mmol) in CH₂Cl₂ (6.0 mL) at - 30 °C was added bromotrimethylsilane (0.59 mL, 4.50 mmol). The reaction mixture was stirred at rt for 16 h and the solvent was removed under reduced pressure. The residue was treated with

acetonitrile- H₂O (5:1, 5.0 mL) and stirred at 38 °C for 20 min. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with H₂O. The organic solution was concentrated, coevaporated with MeOH, and filtered to afford the title compound as a white powder (0.215 g, 97%); ¹H NMR (200 MHz, DMSO-d₆): δ 9.02 (s, 1 H), 7.47 (s, 2 H), 6.63 (m, 2 H), 6.26 (m, 1 H), 4.26 (d, J = 12.0 Hz, 2 H), 3.14 (m, 1 H), 1.45 (d, J = 14.0 Hz, 3 H), 1.12 (d, J = 6.0 Hz, 6 H); LC-MS m/z = 495 [C₁₇H₂₀Br₂O₃P - H]⁺; Anal. Calcd for (C₁₇H₂₀Br₂O₃P + 0.2 H₂O + 0.1 CH₃COCH₃): C, 41.27; H, 4.00 Found: C, 41.22; H, 4.06 HPLC conditions: Column = Shimadzu LC-A8, SPD-10A; YMC Pack RP-18 filter, 150×4.6; Mobile phase = Solvent A Acetonitrile/0.05% TFA; Solvent B = H₂O/0.05% TFA. Flow rate = 2.0 mL/min; UV@ 254 nm. Retention time. (rt = 8.93 min).

Example 89

Compound 89: [4-(5'-bromo-6'-hydroxynaphthyl)-3,5-dimethylphenoxy]-methylphosphonic acid



Step a:

[1082] To a stirred solution of 6-methoxy-1-naphthol (Kasturi, T.R. Arunachalam, *T. Can. Journal. Chem.* 3625 (1968), 3.0 g, 17.2 mmol) in anhydrous CH₂Cl₂ (50 mL) at -40 °C was added Et₃N (4.66 mL, 34.4 mmol) and the reaction mixture was stirred at -40 °C for 15 min. The trifluoromethanesulfonyl anhydride (5.8 g, 20.6 mmol) CH₂Cl₂ in (5 mL) was added and the reaction mixture was stirred for 2 h at -10 °C and for 30 min at room temperature. The reaction mixture was quenched with saturated

- 530 -

NaHCO₃ (50 mL) and extracted with CH₂Cl₂ (2x100 mL). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 6-methoxy-1-naphthyl trifluoromethanesulfonate as a colorless oil (5.10 g, 92%): ¹H NMR (300 MHz, CDCl₃): δ 8.0 (d, *J*= 9.0 Hz, 1H), 7.77 (d, *J*= 8.4 Hz, 1H), 7.44 (t, *J*= 8.1 Hz, 1H), 7.35 -7.32 (m, 2H), 7.22 (s, 1H), 3.98 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.6.

Step b:

[1083] A mixture of 6-methoxy-1-naphthyl trifluoromethanesulfonate (0.85 g, 2.6 mmol), bis-picolinato-diborane (1.07 g, 3.95 mmol) and anhydrous potassium acetate (0.77 g, 7.8 mmol) in DMSO (30 mL) was degassed by nitrogen sparge for 30 min and PdCl₂dppf.dichloromethane (0.43 g, 0.52 mmol) was added. The reaction mixture was heated to 85 °C for 4 h. The reaction mixture was filtered through a Celite plug and washed with ethyl acetate (2x50 mL) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:4) to afford 1,1,2,2-tetramethyl-6-methoxynaphthyl-1-boronate as a pale yellow solid (0.64 g, 86%): ¹H NMR (300 MHz, CDCl₃): δ 8.69 (d, *J*= 9.3 Hz, 1H), 7.98 (d, *J*= 7.8 Hz, 1H), 7.85 (d, *J*= 7.8 Hz, 1H), 7.46 (dd, *J*= 1.5, 6.6 Hz, 1H), 7.22 (dd, *J*= 2.4, 9.0 Hz, 1H), 7.16 (d, *J*= 2.4 Hz 1H), 3.96 (s, 3H), 1.45 (s, 12H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.65.

Step c:

[1084] To a stirred suspension of NaH (0.5 g, 22.0 mmol) in anhydrous DMF (20 mL) at 0 °C was added 3,5-dimethyl-4-bromophenol (2.2 g, 11.0 mmol) in DMF (5 mL) followed by diethyl tosyloxymethylphosphonate (3.9 g, 24.2 mmol) in DMF (5.0 mL) 30 min later. The reaction mixture was stirred for 14 h at room temperature and poured into water (30 mL). The aqueous solution was extracted with ethyl acetate (2x100 mL) and the combined organic layers

were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:3) to afford diethyl (3,5-dimethyl-4-bromophenoxy)methylphosphonate as a syrup. (1.85 g, 48%): ^1H NMR (300 MHz, CDCl_3): δ 6.88 (s, 2H), 4.15-4.25 (m, 6H), 2.41 (s, 2H), 1.40 (t, J = 6.0 Hz, 6H); LC-MS m/z = 351 [$\text{C}_{13}\text{H}_{20}\text{BrO}_4\text{P}+\text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.3.

Step d:

[1085] To a stirred solution of 1,1,2,2-tetramethyl-6-methoxynaphthal-1-boronate (0.5 g, 1.76 mmol) and diethyl (3,5-dimethyl-4-bromophenoxy)methylphosphonate (0.675 g, 1.93 mmol) in anhydrous DME (40 mL) degassed by nitrogen for 10 min. Palladium tetrakis(triphenylphosphine) (0.4 g, 0.35 mmol) and an aqueous solution of sodium carbonate (0.55 g, 5.28 mmol) in water (10 mL) were added. The reaction mixture was heated 85 °C for 24 h. and the reaction mixture was poured into water (30 mL). The aqueous solution was extracted with ethyl acetate (2x100 mL) and the combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:2) to afford diethyl [3,5-dimethyl-4-(6'-methoxynaphthyl)phenoxy]methylphosphonate as a syrup. (0.45 g, 45%): ^1H NMR (300 MHz, CDCl_3): δ 7.77 (d, J = 8.1 Hz, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.27 (d, J = 6.0 Hz, 1H), 7.24-7.23 (m, 2H), 7.13 (d, J = 1.5 Hz, 1H), 7.05 (dd, J = 2.7, 9.0 Hz, 1H), 6.81 (s, 2H), 4.34-4.27 (m, 6H), 3.96 (s, 3H), 1.91 (s, 6H), 1.42 (t, J = 5.1 Hz, 6H); LC-MS m/z = 429 [$\text{C}_{24}\text{H}_{29}\text{O}_5\text{P}+\text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.3.

Step e:

[1086] To a stirred solution of diethyl [3,5-dimethyl-4-(6'-methoxynaphthyl)phenoxy]methylphosphonate (130 mg, 0.30 mmol) in

anhydrous CH₂Cl₂ (10 mL) was added bromine (50 mg, 0.32 mmol), the solution was stirred for 30 min. and the reaction mixture was washed with aqueous sodium bisulfite. The resulting solution was extracted with CH₂Cl₂ (2x50 mL) and the combined organic layers were washed with saturated NaHCO₃ (25 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:3) to afford diethyl [4-(5'-bromo-6'-methoxynaphthyl)-3,5-dimethylphenoxy]methylphosphonate as a brownish solid (140 mg, 93%): ¹H NMR (300 MHz, CDCl₃): δ 8.30 (d, *J* = 8.0 Hz, 1H), 7.65 (t, *J* = 7.2 Hz, 1H), 7.34-7.32 (m, 2H), 7.20-7.15 (m, 2H), 6.82 (s, 2H), 4.39-4.29 (m, 6H), 4.04 (s, 3H), 1.90 (s, 6H), 1.44 (t, *J* = 6.9 Hz, 6H); LC-MS *m/z* = 507 [C₂₄H₂₈BrO₅P]⁺; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.28.

Step f:

[1087] To a stirred solution of diethyl [4-(5'-bromo-6'-methoxynaphthyl)-3,5-dimethylphenoxy]methylphosphonate (130 mg, 0.25 mmol) in CH₂Cl₂ (5 mL) at 0 °C was added TMSBr (0.38 g, 0.35 mL, 2.5 mmol). The reaction mixture was stirred at 0 °C for 30 min, allowed to warm to room temperature and stirred for 16 h. The solvent was removed under reduced pressure, the residue was dissolved in CH₃OH (3 mL) and the solvent was removed under reduced pressure. The residue was triturated with acetonitrile and dried under reduced pressure to afford [4-(5'-bromo-6'-methoxynaphthyl)-3,5-dimethylphenoxy] methylphosphonic acid as a white solid (0.12 g 100%, crude): ¹H NMR (300 MHz, CD₃OD): δ 8.12 (d, *J* = 8.8 Hz, 1H), 7.55 (t, *J* = 7.0 Hz, 1H), 7.13-6.92 (m, 3H), 6.80 (s, 2H), 4.20 (d, *J* = 10.4 Hz, 2H), 3.96 (s, 3H), 1.91 (s, 6H); LC-MS *m/z* = 451 [C₂₀H₂₀BrO₅P]⁺;


Step g:

[1088] To a stirred solution of [4-(5'-bromo-6'-methoxynaphthyl)-3,5-dimethylphenoxy]methylphosphonic acid (0.12 g, 0.26 mmol) in CH₂Cl₂ (5 mL) at -78 °C was added BB₃ (0.1 g, 0.39 mmol) in CH₂Cl₂ (5 mL). The reaction mixture was stirred at rt for 3 h and poured into ice water (25 mL) and

stirred for 1 h. The reaction mixture was extracted with ethyl acetate (2x50 mL). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was recrystallized from CH₂Cl₂, filtered and dried under reduced pressure to afford the title compound as a yellow solid (70 mg, 92%, 94% pure): ¹H NMR (200 MHz, CD₃OD): δ 8.14 (d, *J* = 8.8 Hz, 1H), 7.39 (t, *J* = 7.0 Hz, 1H), 7.15-6.99 (m, 3H), 6.81 (s, 2H), 4.19 (d, *J* = 10.4 Hz, 2H), 1.81 (s, 6H); LC-MS *m/z* = 437 [C₁₉H₁₈BrO₅P+H]⁺; HPLC conditions: YMC pack ODS-AQ12S051546W column; mobile phase = TFA/ACN (0.05%) and TFA/H₂O (0.05%) flow rate = 1.0 mL/min; detection = UV@254 nm retention time in min: 7.14; Anal Calcd: (MF:C₁₉H₁₈BrO₅P+0.8 CH₂Cl₂) Calcd: C:47.36, H:3.92, Found: C: 47.12, H:3.58.

Example 90

Compound 90: [3,5-dichloro-4-(4'-*O*-hydroxynaphthoxy)phenylamino]-methylphosphonic acid



Step a:

[1089] To a stirred solution of 4-methoxy-1-naphthol (0.5 g, 2.86 mmol) and 3,5-dichloro-4-iodonitrobenzene (1.0 g, 3.16 mmol) in DMSO (30 mL) at room temperature was added K₂CO₃ (0.6 g, 4.30 mmol). The reaction mixture was heated at 125 °C for 18 h, cooled to room temperature and poured into water. The aqueous layer was extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with brine and water, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product

was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1: 9) to afford 3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)-nitrobenzene as a yellow solid (0.8 g, 78%): ¹H NMR (300 MHz, CDCl₃): δ 8.15 (s, 2H), 8.0-8.16 (m, 1H), 7.40-7.50 (m, 3H), 6.34 (d, *J* = 8.4 Hz, 1H), 6.06 (d, *J* = 8.4 Hz, 1H), 3.76 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:4); R_f = 0.7.

Step b:

[1090] A suspension of 3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)-nitrobenzene (0.47 g, 2.6 mmol) in acetic acid (20 mL) and water (2 mL) was heated at 50 °C until all material was dissolved then cooled to rt. Iron powder (108 mg, 1.94 mmol) was added at room temperature and the reaction mixture was stirred overnight, filtered through a Celite plug and washed with EtOAc (100 mL). The filtrate was extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)aminobenzene as a brownish solid (0.32 g, 75%): ¹H NMR (200 MHz, CD₃OD): δ 8.15 (dd, *J* = 2.2, 5.8 Hz, 1H), 8.0 (dd, *J* = 2.2, 5.8 Hz, 1H), 7.37-7.31 (m, 2H), 6.58 (s, 2H), 6.45 (d, *J* = 8.4 Hz, 1H), 6.07 (d, *J* = 8.4 Hz, 1H), 3.73 (s, 3H); TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (2:3); R_f = 0.3.

Step c:

[1091] To a stirred solution of 3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)aminobenzene (**14**, 0.3 g, 0.90 mmol) in CH₂Cl₂ (10 mL) at 0 °C were added Et₃N (0.27 g, 2.25 mmol), (Boc)₂O (0.21 g, 1.0 mmol) and a catalytic amount of DMAP (25 mg). The reaction mixture was stirred at rt for 4 h and quenched with water (15 mL). The reaction mixture was extracted with CH₂Cl₂ (2x50 mL). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (2:8) to afford *t*-butyl *N*-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)benzene]carbamate as a yellow solid (0.22 g,

58%): ^1H NMR (300 MHz, CDCl_3): δ 8.21 (dd, $J = 2.2, 6.0$ Hz, 1H), 8.04 (d, $J = 2.2, 6.0$ Hz, 1H) 7.43-7.36 (m, 2H), 7.07 (s, 2H), 6.33 (d, $J = 8.4$ Hz, 1H), 6.07 (d, $J = 8.4$ Hz, 1H), 3.74 (s, 3H), 1.32 (s, 9H).

Step d:

[1092] To a stirred solution of *t*-butyl *N*-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)benzene]carbamate (0.22 g, 0.5 mmol) in anhydrous acetonitrile (15 mL) at room temperature were added Cs_2CO_3 (0.33 g, 1.0 mmol) and diethyl tosyloxymethylphosphonate (0.16 g, 0.5 mmol). The reaction mixture was heated at 80 °C for 8 h and cool to room temperature, then poured into water (20 mL). The aqueous solution was extracted with ethyl acetate (2x50 mL) and the combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:1) to afford diethyl *N*-*t*-butoxycarbonyl-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino]methylphosphonate as a viscous. (145 mg, 50%): ^1H NMR (200 MHz, CDCl_3): δ 8.21 (dd, $J = 1.8, 7.4$ Hz, 1H), 8.04 (dd, $J = 2.0, 6.2$ Hz, 1H), 7.43-7.36 (m, 2H), 7.24 (s, 2H), 6.33 (d, $J = 8.4$ Hz, 1H), 6.07 (d, $J = 8.4$ Hz, 1H), 4.0-3.86 (m, 6H), 3.75 (s, 3H), 1.29 (s, 12H), 1.11 (t, $J = 6.9$ Hz, 6H); LC-MS $m/z = 584$ [$\text{C}_{28}\text{H}_{34}\text{Cl}_2\text{NO}_5\text{P}+2\text{H}]^+$; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.3$.

Step e:


[1093] [3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino]methyl-phosphonic acid was prepared from diethyl *N*-*t*-butoxycarbonyl-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino]methylphosphonate according to the procedure described for the synthesis of compound 89, step f; brownish solid (92 mg, 100%): ^1H NMR (200 MHz, CD_3OD): δ 8.13 (dd, $J = 2.2, 6.6$ Hz, 1H), 7.99 (dd, $J = 2.6, 6.0$ Hz, 1H), 7.40-7.31 (m, 2H), 6.67 (s, 2H), 6.44 (d, $J = 8.4$ Hz, 1H), 6.07 (d, $J = 8.4$ Hz, 1H), 3.74 (s, 3H), 3.27 (d, $J = 12.0$ Hz, 2H); LC-MS $m/z = 427$ [$\text{C}_{18}\text{H}_{16}\text{Cl}_2\text{NO}_5\text{P}+\text{H}]^+$;

Step f:

[1094] The title compound was prepared from [3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino]methylphosphonic acid according to the procedure described for the synthesis of compound 89, step g; brown solid (38 mg, 40%): ^1H NMR (200 MHz, CD_3OD): δ 8.09 (dd, $J = 2.2, 6.6$ Hz, 1H), 7.95 (dd, $J = 2.6, 6.0$ Hz, 1H), 7.33-7.28 (m, 2H), 6.64 (s, 2H), 6.35 (d, $J = 8.4$ Hz, 1H), 5.97 (d, $J = 8.4$ Hz, 1H), 3.21 (d, $J = 12.0$ Hz, 2H); LC-MS $m/z = 414$ [$\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{NO}_5\text{P}+\text{H}]^+$; HPLC conditions: YMC pack ODS-AQ12S051546W column; mobile phase = TFA/ACN (0.05%) and TFA/ H_2O (0.05%) flow rate = 1.0 mL/min; detection = UV@254 nm retention time in min: 9.58; Anal Calcd: ($\text{MF:C}_{17}\text{H}_{14}\text{Cl}_2\text{NO}_5\text{P}+1.0 \text{ H}_2\text{O}$) Calcd: C:47.24, H:3.73, N:3.24 Found: C: 47.35, H:3.51, N:3.00.

Example 91:

Compound 91: [(3,5-dichloro-4-(4'-*O*-hydroxynaphthoxy)phenylamino)-methyl]methylphosphinic acid



Step a:

[1095] Ethyl *N*-t-butoxycarbonyl-[(3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino)methyl]methylphosphinate was prepared from *t*-butyl *N*-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)benzene]carbamate (compound 90, step c) and ethyl [(4-methylphenyl)sulfonyloxymethyl]methylphosphinate (compound 74) according to the procedure described for the synthesis of compound 90, step d; syrup (80 mg, 29%): ^1H NMR (200 MHz, CDCl_3): δ 8.21 (dd, $J = 1.8, 7.4$ Hz, 1H), 8.04 (dd, $J = 2.0, 6.2$ Hz, 1H), 7.45-7.36 (m, 2H), 7.26 (s, 2H), 6.33 (d, $J = 8.4$ Hz, 1H), 6.06 (d, $J = 8.4$ Hz, 1H), 4.0-3.86 (m, 4H), 3.75 (s, 3H), 1.35 (d, $J = 13.8$ Hz, 3H), 1.29 (s, 12H), 1.07 (t, $J = 6.9$

- 537 -

Hz, 3H); LC-MS *m/z* = 555 [C₂₆H₃₂Cl₂NO₅P+H]⁺; TLC conditions: Uniplate silica gel, 250 microns; mobile phase = ethyl acetate-hexanes (1:1); R_f = 0.3.

Step b:


[1096] [(3,5-dichloro-4-(4'-*O*-methoxynaphthyloxy)phenylamino)methyl]-methylphosphinic acid was prepared from ethyl [(3,5-dichloro-4-(4'-*O*-methoxynaphthyloxy)phenylamino)methyl]methylphosphinate according to the procedure described for the synthesis of compound 89, step f; brown solid (50 mg, 88%): ¹H NMR (200 MHz, CD₃OD): δ 8.12 (dd, *J* = 2.2, 6.6 Hz, 1H), 7.98 (dd, *J* = 2.6, 6.0 Hz, 1H), 7.41-7.31 (m, 2H), 6.69 (s, 2H), 6.45 (d, *J* = 8.4 Hz, 1H), 6.07 (d, *J* = 8.4 Hz, 1H), 3.74 (s, 3H), 3.29 (d, *J* = 12.0 Hz, 2H), 1.38 (d, *J* = 14.0 Hz, 3H); LC-MS *m/z* = 427 [C₁₈H₁₆Cl₂NO₃P+H]⁺

Step c:

[1097] The title compound was prepared from [(3,5-dichloro-4-(4'-*O*-methoxynaphthyloxy)phenylamino)methyl]methylphosphinic acid according to the procedure described for the synthesis of compound 89, step g; brownish solid (24 mg, 50%): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.58 (s, 1H), 8.01 (d, *J* = 7.8 Hz, 1H), 7.89 (d, *J* = 7.8 Hz, 1H), 7.48-7.34 (m, 2H), 6.73 (s, 2H), 6.43 (d, *J* = 8.0 Hz, 1H), 5.99 (d, *J* = 8.0 Hz, 1H), 3.13 (d, *J* = 10.4 Hz, 2H), 1.14 (d, *J* = 13.8 Hz, 3H); LC-MS *m/z* = 412 [C₁₈H₁₆Cl₂NO₃P+H]⁺.

Example 92

Compound 92: [(3,5-Dibromo-4-(3'-(4-fluorobenzyl)-4'-hydroxyphenoxy)-methyl)methylphosphinic acid



Step a

[1098] Ethyl [(3,5-Dibromo-4-(4'-hydroxy-3'-(4-fluorobenzyl)phenoxy)-methyl)methyl phosphinate was prepared from 3,5-dibromo-4-[3'-(4-


fluorobenzyl)-4'-hydroxyphenoxy] phenol (compound 82, step g) and ethyl [(4-methylphenyl)sulfonyloxyethyl]methylphosphinate (compound 74) according to the procedure described for the synthesis of compound 77, step a; (0.014.8 gm, 14%); ^1H NMR (200 MHz, CD₃OD): δ 7.18 (s, 2H), 6.944 (m, 2H), 6.74 (t, J = 8.6 Hz, 2H), 6.48 (d, J = 8.8 Hz, 1H), 6.70 (m, 2H), 4.23 (dd, J = 5, 8.6 Hz, 2H), 3.96 (m, 2H), 3.65 (s, 2H), 1.46 (d, 3 H, J = 14.6 Hz), 1.16 (t, J = 7 Hz, 3H); TLC conditions: Uniplate silica gel, 250 microns; ethyl acetate; R_f = 0.18; LC-MS m/z 589 [C₂₃H₂₂Br₂FO₅P + H]⁺.

Step b:

[1099] The title compound was prepared according to the procedure described for the synthesis of compound 7, step b; (0.010 gm, 81%); ^1H NMR (200 MHz, CD₃OD): δ 7.36 (s, 2H), 7.14 (m, 2H), 6.94 (t, J = 8.8 Hz, 2H), 6.65 (d, J = 8.4 Hz, 1H), 6.70 (m, 2H), 4.28 (d, J = 8.6 Hz, 2H), 3.96 (m, 2H), 3.85 (s, 2H), 1.65 (d, 3 H, J = 15.2 Hz); TLC conditions: Uniplate silica gel, 250 microns; IPA/AcOH/H₂O [7:2:1]; R_f = 0.73; LC-MS m/z 559 [C₂₁H₁₈Br₂FO₅P - H]⁺.

Example 93

Compound 93: [3,5-Dimethyl-4-(3'-Isopropyl-1'H-indol-5'-ylmethyl)-phenoxy]methylphosphonic acid



Step a:

[1100] To the suspension of 4-bromophenylhydrazine hydrochloride (6.0 g mg, 26.85 mmol) in water was added 3.5 M NaOH (11.5 ml, 40.82 mmol), followed by isovaleraldehyde (2.77g, 32.21 mmol). The reaction was stirred for 10 min, then the reaction was acidified with AcOH (25 ml). The reaction was stirred further for 30 min, and toluene was then added to extract the

product twice. The combined toluene layer was washed with Sat. NaHCO₃, dried over MgSO₄, filtrated and concentrated to afford *N*-(4-bromo-phenyl)-*N'*-(3-methyl-butyl)-hydrazide (7.6 g, 100%): ¹H NMR (200 MHz, CDCl₃): δ 9.63 (s, 1H), 7.07 (d, *J* = 8.6 Hz, 1H), 6.97 (m, 1H), 6.62 (d, *J* = 8.6 Hz, 2H), 1.88 (m, 2H), 1.60 (m, 1H), 0.71 (d, *J* = 6.6 Hz, 6H).

Step b:

[1101] To the solution of *N*-(4-bromo-phenyl)-*N'*-(3-methyl-butyl)-hydrazide (7.6 g, 31.54 mmol) in xylene (150 ml) was added ZnCl₂ (5.16 g, 37.84 mmol). Let the reaction was refluxed for 1.5 hrs, then concentrated, and the residue was partitioned between toluene and sat. NaHCO₃. The organic layer was collected and the water layer was further extracted with toluene once. The combined organic layers was dried over MgSO₄, filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford 5-bromo-3-isopropyl-1H-indole (4.55 g, 60.9%): ¹H NMR (300 MHz, CDCl₃): δ 8.72 (s, 1H), 8.57 (s, 1H), 8.05 (m, 2H), 7.77 (s, 1H), 3.95 (m, 1H), 2.15 (d, *J* = 6.6 Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:9); R_f = 0.51.

Step c:

[1102] To a suspension of NaH (509 mg, 20.16 mmol) in THF (50 ml) was added 5-bromo-3-isopropyl-1H-indole (4.55 g, 19.20 mmol). The reaction mixture was stirred at r.t. for 30 min, and TIPSCI was then added at r.t. The reaction was stirred further for 1 hr, diluted with EtOAc, and water was added to quench the reaction. The organic layer was collected and the water layer was further extracted with EtOAc once. The combined organic layer was dried over MgSO₄, filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with hexane to afford 5-bromo-3-isopropyl-1-triisopropylsilyl-1H-indole (5.1 g, 67.6%): ¹H NMR (200 MHz, CDCl₃): δ 7.53 (d, *J* = 1.8 Hz, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 6.99 (m, 1H), 6.76 (s, 1H), 2.92 (m, 1H), 1.44 (m, 3H), 1.14 (d, *J* = 6.6 Hz, 6H), 0.93 (d, *J* =

7.4 Hz, 18H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = Hexane (1:9); R_f = 0.65.

Step d:

[1103] (2,6-Dimethyl-4-triisopropylsilyloxyphenyl)-(3-isopropyl-1-triisopropylsilyl-1H-indol-5-yl)-methanol was prepared from 5-bromo-3-isopropyl-1-triisopropylsilyl-1H-indole and 2,6-Dimethyl-4-triisopropylsilyloxybenzaldehyde according to the procedure described for the synthesis of compound 27, step c; brown oil (2.44g, 77.2%): ^1H NMR (200 MHz, CDCl_3): δ 7.47 (s, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.93 (s, 1H), 6.58 (s, 2H), 6.40 (d, J = 3.6 Hz, 1H), 3.10 (m, 1H), 2.24 (s, 6H), 1.69 (m, 6H), 1.28 (d, J = 6.6 Hz, 6H), 1.12 (d, J = 6.2 Hz, 36H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:19); R_f = 0.62.

Step e:

[1104] To a solution of (2,6-dimethyl-4-triisopropylsilyloxyphenyl)-(3-isopropyl-1-triisopropylsilyl-1H-indol-5-yl)-methanol (1.86 g, 3.0 mmol) in CH_2Cl_2 (20 ml) was added tiethylsilane (1.74 g, 15.0 mmol), followed by AcOH (1.11 ml), then TFA (1.11 ml, 15.0 mmol). The reaction was stirred at r.t. for 1 hr, the reaction mixture was diluted with EtOAc and water and the layers were separated. The EtOAc layer was collected and the water layer was further extracted with EtOAc once. The combined organic layers was washed with Sat. NaHCO_3 , water and brine, dried over MgSO_4 , filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:49) to afford 5-(2,6-dimethyl-4-triisopropylsilyloxybenzyl)-3-isopropyl-1H-indole (1.0 g, 74.6%): ^1H NMR (200 MHz, CDCl_3): δ 7.59 (s, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.97 (s, 1H), 6.70 (s, 1H), 6.63 (d, J = 8.2 Hz, 1H), 3.89 (s, 2H), 2.88 (m, 1H), 2.01 (s, 6H), 1.2 (m, 3H), 1.05 (d, J = 6.6 Hz, 6H), 0.99 (d, J = 6.2 Hz, 18H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:49); R_f = 0.70.

Step f:

- 541 -

[1105] 3,5-Dimethyl-4-(3-isopropyl-1H-indol-5-ylmethyl)phenol was prepared according to the procedure described for the synthesis of compound 35, step e; yellow oil (420mg, 64%): ^1H NMR (200 MHz, CDCl_3): δ 7.61 (s, 1H), 7.06 (s, 1H), 7.02 (d, $J = 8.0$ Hz, 1H), 6.72 (s, 1H), 6.63 (d, $J = 8.2$ Hz, 2H), 6.38 (s, 2H), 3.89 (s, 2H), 2.93 (s, 1H), 2.04 (s, 6H), 1.05 (d, $J = 7.2$ Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:3); $R_f = 0.65$.

Step g:


[1106] Diethyl [3,5-dimethyl-4-(3'-isopropyl-1'H-indol-5'-ylmethyl)-phenoxy]methylphosphonate was prepared by the procedure used for the synthesis of compound 35, step f as a colorless oil (130 mg, 43%): ^1H NMR (200 MHz, CDCl_3): δ 7.82 (s, 1H), 7.23 (s, 1H), 7.20 (d, $J = 8.8$ Hz, 1H), 6.90 (s, 1H), 6.79 (d, $J = 8.8$ Hz, 1H), 6.68 (s, 2H), 4.11 (m, 6H), 4.09 (s, 2H), 3.07 (m, 1H), 2.24 (s, 6H), 1.28 (m, 12H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:1); $R_f = 0.65$.

Step h:

[1107] The title compound was prepared according to the procedure described for the synthesis of compound 35, step h; yellow foam (50 mg, 63.6%): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): δ 10.60 (s, 1H), 7.18 (D, $J = 8.0$ Hz, 1H), 7.13 (s, 1H), 6.98 (s, 1H), 6.71 (s, 2H), 6.63 (d, $J = 8.0$ Hz, 1H), 4.02 (m, 4H), 3.02 (m, 1H), 2.20 (s, 6H), 1.22 (d, $J = 7.0$ Hz, 6H). LC-MS $m/z = 388$ [$\text{C}_{21}\text{H}_{26}\text{NO}_4\text{P} + \text{H}]^+$; Anal. Calcd for ($\text{C}_{21}\text{H}_{26}\text{NO}_4\text{P} + 0.5 \text{ HBr}$): C, 58.95; H, 6.24; N, 3.27. Found: C, 58.99; H, 6.42; N, 3.20.

Example 94:

Compound 94: Methylphosphonic acid mono-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzyl] ester



Step a:

[1108] To a solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenol (example 38, step c, 1.11 g, 3.52 mmol) and DMAP (1.72 g, 14.1 mmol) in CH₂Cl₂ (27 mL) at 0 °C was slowly added trifluoromethanesulfonyl anhydride (0.89 mL, 5.27 mmol). The reaction mixture was stirred at 0 °C for 2 h and quenched by water (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)-phenyl trifluoromethanesulfonate as an oil (1.39 g, 89%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.14 – 7.28 (m, 7H), 6.94 (d, *J* = 8.4 Hz, 1H), 6.85 (d, *J* = 2.4 Hz, 1H), 6.70 (m, 1H), 5.15 (s, 2H), 3.94 (s, 2H), 3.88 (s, 2H), 3.27 (s, 3H), 2.24 (s, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:85); R_f = 0.55.

Step b:

[1109] To a solution of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)phenyl trifluoromethanesulfonate (1.36 g, 3.05 mmol) in DMF (15.3 mL) in a bomb apparatus was added MeOH (2.5 mL, 61.6 mmol), Pd(OAc)₂ (68 mg, 0.3 mmol), bis-(diphenylphosphino)propane (138 mg, 0.3 mmol) and Et₃N (0.85 mL, 6.1 mmol). 60 psi of CO was then infused and the reaction mixture was stirred at 90 °C for 16 h. The cooled bomb was vented and the reaction mixture was poured into cold 1N HCl, extracted with EtOAc twice, the combined EtOAc were washed with brine, dried over Na₂SO₄, filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate-hexanes (1:9) to afford methyl 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)benzoate as a yellow oil (1.00 g, 92.3%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.66 (s, 2H), 7.16 (m, 5H), 6.90 (m, 2H), 6.71 (m, 1H), 5.15 (s, 2H), 3.98 (s, 2H), 3.87 (s, 2H), 3.85 (s, 3H), 3.26 (s, 3H), 2.25 (s, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:85); R_f = 0.50.

Step c:

[1110] To a mixture of methyl 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl)benzoate (1.00 g, 2.81 mmol) in THF (11.3 mL) at 0

°C was added a solution of DIBAL-H (8.44 mL, 8.44 mmol, 1.0 M solution in hexanes). The reaction mixture was stirred at room temperature for 16 h, quenched with cold 1 N HCl and diluted with ethyl acetate. The organic layer was washed with 1 N HCl and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxy-benzyl)benzyl alcohol as an off-white solid (0.75 g, 81.3%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.54 (s, 2H), 6.81 (m, 2H), 6.40 (m, 1H), 5.51 (m, 1H), 4.54 (d, *J* = 6.0 Hz, 2H), 3.75 (s, 3H), 3.21 (m, 1H), 1.13 (d, *J* = 6.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (15:85); R_f = 0.27.


Step d:

[1111] To a mixture of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxy-benzyl)benzyl alcohol (0.26 g, 0.79 mmol) in dichloromethane (1.5 mL) was added TEA (0.11 mL, 0.79 mmol) and a solution of methylphosphonic dichloride (0.11 g, 0.79 mmol) in dichloromethane (0.5 mL). The reaction mixture was stirred at room temperature for 2.75 h, filtered to remove salts, and the filtrate was then concentrated to remove dichloromethane. The reaction mixture was taken up in ethyl acetate, and extracted into 1N NaOH (2 x 10 mL). The basic layer was then acidified to pH = 2 with 1N HCl and extracted into ethyl acetate (2 x 10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was then purified by preparative TLC 500 μm silica gel plate eluted with methanol / ethyl acetate [3 : 7] to give methylphosphonic acid mono-[3,5-dimethyl-4-(3'-*isopropyl-4'-methoxymethoxy-benzyl)benzyl] ester (55 mg, 17.1%): ¹H NMR (300 MHz, CDCl₃): δ 7.07 (s, 2H), 6.94 (s, 1H), 6.88 (d, *J* = 8.4 Hz, 1H), 6.62 (d, *J* = 6.0 Hz, 1H), 5.14 (s, 2H), 5.00 (d, *J* = 7.5 Hz, 2H), 3.96 (s, 2H), 3.46 (s, 3H), 3.30-3.26 (m, *J* = 13.8 Hz, 1H), 2.24 (s, 6H), 1.56 (d, *J* = 18.3 Hz, 3H), 1.19 (d, *J* = 7.2 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.05.*

Step e:

[1112] To a mixture of methylphosphonic acid mono-[3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxy-benzyl)benzyl] ester (40 mg, 0.10 mmol) in methanol (0.98 mL) was added 1N HCl (0.49 mL, 0.49 mmol). The reaction mixture was stirred at room temperature for 7 days and concentrated to remove methanol. The reaction mixture was taken up in ethyl acetate (5 mL) and 1N HCl (5 mL). The organic layer was rinsed with H₂O, brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was then purified by preparative TLC 250 μm silica gel plate eluted with methanol-ethyl acetate [5 : 95] to give the title compound (7.0 mg, 19.6 %): ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.02 (s, 1H), 7.04 (s, 2H), 6.85 (s, 1H), 6.63 (d, *J* = 8.2 Hz, 1H), 6.46 (d, *J* = 7.0 Hz, 1H), 4.85 (d, *J* = 7.8 Hz, 2H), 3.87 (s, 2H), 3.16 (m, *J* = 14.4 Hz, 1H), 2.20 (s, 6H), 1.38 (d, *J* = 17.2 Hz, 3H), 1.11 (d, *J* = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methanol-ethyl acetate [3 : 7]; R_f = 0.70.

Compound 94-1: Phosphoric acid [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl) benzyl] ester methyl ester



Step a:

[1113] To a mixture of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-methoxymethoxybenzyl) benzyl alcohol (0.10 g, 0.30 mmol) in methanol (1.5 mL) was added 1N HCl (1.5 mL, 1.5 mmol). The reaction mixture was stirred at 45°C for 16 h, then cooled to room temperature and concentrated to remove methanol. The reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted twice with ethyl acetate. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. 3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)benzyl alcohol (73 mg, 84.5%) was used without further purification: ¹H NMR (300 MHz,

- 545 -

CDCl_3): δ 7.06 (s, 2H), 6.95 (s, 1H), 6.57 (m, J = 5.1 Hz, 2H), 4.64 (s, 2H), 3.96 (s, 2H), 3.17 (m, J = 14.1 Hz, 1H), 2.25 (s, 6H), 1.22 (d, J = 2.7 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes [1 : 1]; R_f = 0.54.

Step b:

[1114] To a mixture of 3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)-benzyl alcohol (73 mg, 0.26 mmol) in tetrahydrofuran (2.0 mL) was added *t*-BuMgCl (0.26 mL, 1.0 M in THF, 0.26 mmol) and dimethyl chlorophosphate (0.03 mL, 0.26 mmol). The reaction mixture was stirred at 45°C for 16 h, then cooled to room temperature and concentrated to remove dichloromethane. The reaction mixture was taken up in ethyl acetate, and extracted into 1N NaOH (2 x 10 mL). The basic layer was then acidified to pH = 2 with 1N HCl and extracted into ethyl acetate (2 x 10 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was then purified by preparative TLC 500 μm silica gel plate eluted with ethyl acetate-hexanes [7 : 3] to give phosphoric acid [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)benzyl] ester dimethyl ester (31 mg, 30.7%): ^1H NMR (300 MHz, CDCl_3): δ 7.11 (d, J = 9.3 Hz, 2H), 7.05 (s, 2H), 7.00 (s, 1H), 6.67 (d, J = 10.5 Hz, 1H), 4.62 (s, 2H), 3.98 (s, 2H), 3.85 (s, 3H), 3.82 (s, 3H), 3.30 (m, J = 13.8 Hz, 1H), 2.22 (s, 6H), 1.20 (d, J = 6.9 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes [1 : 1]; R_f = 0.24.


Step c:

[1115] To a solution of phosphoric acid [3,5-dimethyl-4-(3'-*iso*-propyl-4'-hydroxybenzyl)benzyl] ester dimethyl ester (31 mg, 0.08 mmol) in THF (0.4 mL) was added 1N NaOH (0.4 mL, 0.40 mmol). The reaction mixture was stirred at 60°C for 16 h, then cooled to room temperature and concentrated to remove solvent. The reaction mixture was taken up in ethyl acetate and extracted into 1N NaOH (2 x 10 mL). The basic layer was then acidified to pH = 2 with 1N HCl and extracted into ethyl acetate (2 x 10 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure

to give the title compound (3.1 mg, 10.4%): ^1H NMR (300 MHz, CDCl_3): δ 7.07 (m, 3H), 6.99 (s, 1H), 6.64 (d, $J = 8.4$ Hz, 2H), 4.63 (s, 2H), 3.99 (s, 2H), 3.79 (d, $J = 11.4$ Hz, 3H), 3.29 (m, 1H), 2.22 (s, 6H), 1.17 (d, $J = 6.6$ Hz, 6H); LC-MS $m/z = 377.4$ [$\text{C}_{20}\text{H}_{27}\text{O}_5\text{P-H}$]; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = methanol-ethyl acetate [3 : 7]; $R_f = 0.45$.

Example 95:

Compound 95: [4-(4-Hydroxy-3-isopropylbenzyl)-3,5-dimethyl-phenoxy]methylphosphamic acid



Step a:

[1116] To a solution of [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-phenoxy]methylphosphonic acid (compound 7, 0.49 g, 1.36 mmol) in acetonitrile (13.6 mL), was added diisopropylethylamine (0.90 mL, 5.43 mmol) and benzyl bromide (0.65 mL, 5.43 mmol). The reaction mixture was stirred at 80°C for 16 h, then cooled to room temperature and concentrated to remove dichloromethane. The reaction mixture was taken up in ethyl acetate, rinsed with water, a saturated solution of sodium bicarbonate, and brine. The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was then purified by column chromatography on silica gel, eluted with ethyl acetate-hexanes [1 : 9] to give dibenzyl [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonate (0.50 g, 0.92 mmol): ^1H NMR (200 MHz, $\text{DMSO}-d_6$): δ 9.00 (s, 1H), 7.37 (m, $J = 6.6$ Hz, 5H), 6.83 (s, 1H), 6.70 (s, 2H), 6.61 (d, $J = 8.6$ Hz, 2H), 6.44 (d, $J = 8.2$ Hz, 1H), 5.14 (d, $J = 8.2$ Hz, 2H), 4.50 (d, $J = 9.8$ Hz, 2H), 3.79 (s, 2H), 3.14 (m, $J = 13.2$ Hz, 1H), 2.15 (s, 6H), 1.10 (d, $J = 7.0$ Hz, 6H); ; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes [1 : 1]; $R_f = 0.77$.

Step b:

[1117] To a solution of dibenzyl [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonate (0.50 g, 0.92 mmol) in tetrahydrofuran (4.6 mL), was added 1N NaOH (4.6 mL, 4.6 mmol). The reaction mixture was allowed to stir at room temperature for 16 h. The reaction mixture was diluted in ethyl acetate and 1N NaOH. The organic layer was extracted with water, and then the pH was adjusted to pH = 12 with 1N NaOH. The aqueous layer was then extracted with ethyl acetate. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonic acid monobenzyl ester (0.45 g, 100%) as a yellow foam: ¹H NMR (200 MHz, DMSO-*d*₆): δ 9.12 (s, 1H), 7.35 (m, *J* = 31.4 Hz, 5H), 6.84 (s, 1H), 6.64 (d, *J* = 10.2 Hz, 1H), 6.59 (s, 2H), 6.44 (d, *J* = 8.0 Hz, 1H), 4.83 (d, *J* = 7.0 Hz, 2H), 3.77 (m, *J* = 9.2 Hz, 4H), 3.15 (m, *J* = 14.0 Hz, 1H), 2.13 (s, 6H), 1.11 (d, *J* = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes [1 : 1]; R_f = 0.04.

Step c :

[1118] To a mixture of [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonic acid monobenzyl ester (108 mg, 0.238 mmol) and DMF (0.1 mL, 1.29 mmol) in dichloromethane (1.0 mL) at 0°C, was added oxalyl chloride (0.04 mL, 0.476 mmol). After 3 h, the reaction mixture was concentrated under reduced pressure, redissolved in dichloromethane (1.5 mL), and cooled to -78°C. To the reaction mixture triethylamine (0.07 mL, 0.476 mmol) was added, followed by liquid ammonia at -78°C (0.25 mL). The reaction mixture was stirred in a sealed vial warming to room temperature over 16 h. The vial was cooled to 0°C, vented and concentrated under reduced pressure. The reaction mixture was taken up in ethyl acetate and 1N NaOH. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was then purified by preparative TLC 1000 μm silica gel plate eluted with ethyl acetate to give [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]-methylphosphamic benzyl ester (18 mg, 16.7%):

¹H NMR (300 MHz, CDCl₃): δ 7.40 (m, 5H), 6.93 (s, 1H), 6.65 (d, *J* = 8.1 Hz, 1H), 6.61 (s, 2H), 6.51 (d, *J* = 8.4 Hz, 1H), 5.17 (d, *J* = 8.1 Hz, 2H), 4.28 (dd, *J* = 10.5, 5.4 Hz, 2H), 3.89 (s, 2H), 3.22 (m, 1H), 2.19 (s, 6H), 1.22 (d, *J* = 6.6 Hz, 6H); LC-MS *m/z* = 454.4 [C₂₆H₃₂NO₄P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.56.

Step d:

[1119] The title compound is obtained from [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphamic benzyl ester according to the procedure described by Valentijn *et al.*, *SYNLETT*, 9:663 (1991).

Compound 95-2: N-methyl-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphamic benzyl ester


[1120] To a mixture of [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonic acid monobenzyl ester (108 mg, 0.238 mmol) and DMF (0.1 mL, 1.29 mmol) in dichloromethane (1.0 mL) at 0°C, was added oxalyl chloride (0.04 mL, 0.476 mmol). After 3 h, the reaction mixture was concentrated under reduced pressure, redissolved in dichloromethane (1.5 mL), and cooled to -78°C. To the reaction mixture triethylamine (0.07 mL, 0.476 mmol) was added, followed by methylamine (0.24 mL, 2.0 M solution in THF, 0.476 mmol) at -78°C (0.25 mL). The reaction mixture was stirred, warming to room temperature over 16 h, then concentrated under reduced pressure. The reaction mixture was taken up in ethyl acetate and 1N NaOH. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was then purified by preparative TLC 1000 μm silica gel plate eluted with ethyl acetate to give N-methyl-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphamic benzyl ester (23 mg, 20.7%): ¹H NMR (300 MHz, CDCl₃): δ 7.39 (m, 5H), 6.92 (s, 1H), 6.63 (s, 2H), 6.62 (d, *J* = 8.1 Hz, 1H), 6.51 (d, *J* = 2.1 Hz, 1H), 5.14 (m, 2H), 5.05 (s, 1H), 4.30 (dd, *J* = 10.2, 3.6 Hz, 2H), 3.89 (s, 3H), 3.19 (m, 1H), 2.71 (d, *J* = 10.8 Hz, 3H), 2.19 (s, 6H), 1.22 (d, *J* = 6.9 Hz, 6H); LC-MS *m/z* = 468.4 [C₂₇H₃₄NO₄P + H]⁺; TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.44.

Step b:

[1121] The title compound is obtained from *N*-methyl [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphamic benzyl ester according to the procedure described by Valentijn *et al.*, *SYNLETT*, 9:663 (1991).

Example 96

Compound 96: [(3,5-Dimethyl-4-(3'-Isopropyl-1'H-indol-5'-ylmethyl)-phenoxy)methyl]methylphosphinic acid

**Step a:**

[1122] To the solution of 3,5-dimethyl-4-(3-isopropyl-1H-indol-5-ylmethyl)phenol (compound 93, step f, 200 mg, 0.683mmol) in acetonitrile (10 ml) was added Cs₂CO₃ (450 mg, 1.365 mmol), followed by ethyl [(4-methylphenyl)sulfonyloxymethyl]methylphosphinate (compound 74, 200 mg, 0.683 mmol) at r.t, the reaction mixture was then heated to reflux overnight. The second day, concentrated down, the residue was partitioned between EtOAc and water, collected the org. layer, water layer was further extracted with EtOAc once, the combined org. layer was dried over MgSO₄, filtrated and concentrated. The residue was purified by column chromatography on silica gel, eluting with ethyl MeOH- EtOAc (1:49) to afford ethyl [(3,5-dimethyl-4-(3'-Isopropyl-1'H-indol-5'-ylmethyl)phenoxy)methyl]-methylphosphinate (131 mg, 46.4%): ¹H NMR (300 MHz, CDCl₃): δ 7.85 (s, 1H), 7.26 (s, 1H), 7.24 (d, *J* = 8.4 Hz, 1H), 6.95 (s, 1H), 6.84 (d, *J* = 8.4 Hz, 1H), 6.72 (s, 2H), 4.20 (m, 4H), 4.14 (s, 2H), 3.15 (m, 1H), 2.30 (s, 1H), 1.67 (d, *J* = 14.7 Hz, 3H), 1.40 (m, 3H), 1.34 (d, *J* = 6.6 Hz, 6H). TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate; R_f = 0.33.


- 550 -

Step b:

[1123] The title compound was prepared from ethyl [(3,5-dimethyl-4-(3'-isopropyl-1'H-indol-5'-ylmethyl)phenoxy)methyl]methylphosphinate according to the procedure described for the synthesis of compound 93, step h; (100 mg, 81.3%): ^1H NMR (300 MHz, DMSO- d_6): δ 10.58 (s, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.13 (s, 1H), 6.98 (d, J = 1.8 Hz, 1H), 6.72 (s, 2H), 6.67 (dd, J = 8.4, 1.8 Hz, 1H), 4.08 (d, J = 8.4 Hz, 2H), 3.99 (s, 2H), 2.98 (m, 1H), 2.19 (s, 6H), 1.40 (d, J = 14.4 Hz, 3H), 1.22 (d, J = 6.9 Hz, 6H). LC-MS m/z = 386 [C₂₂H₂₈NO₃P + H]⁺; Anal. Calcd for (C₂₁H₂₆NO₄P + 0.2 HBr): C, 65.79; H, 7.08; N, 3.49. Found: C, 65.97; H, 7.28; N, 3.30.

Example 105

Compound 105-1: Methylphosphonic acid 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzyl ester



Step a


[1124] A mixture of methyl-3,5-dimethyl-4-(3'-isopropyl-4'-methoxymethoxybenzyl)benzoate (Example 24-1, 1.52 g, 4.26 mmol) in methanol (8.0 mL) and 4 N HCl-dioxane (3.2 mL, 12.8 mmol) was heated at 100 °C for 5 min in a microwave oven. The solvent was removed under reduced pressure and the residue was dissolved in THF (25.0 mL). The solution was cooled to 0 °C and to it was slowly added DIBAL (14.7 mL, 14.7 mmol). The reaction mixture was stirred at 0 °C for 2 h, quenched with saturated sodium potassium tartrate and diluted with hexanes (20 mL). The reaction mixture was stirred at room temperature for 2 h and the organic layer was separated. The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(4'-hydroxy 3'-

isopropyl-benzyl)benzyl alcohol (1.01 g, 83%) as white solid: ^1H NMR (300 MHz, CD₃OD): δ 7.05 (s, 2H), 6.84 (d, J = 2.1 Hz, 1H), 6.58 (m, 2H), 4.55 (s, 2H), 3.96 (s, 2H), 3.22 (m, 1H), 2.25 (s, 6H), 1.14 (d, J = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = ethyl acetate-hexanes (1:3); R_f = 0.4.

Step b

[1125] To a solution of 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)benzyl alcohol (0.13 g, 0.46 mmol), methylphosphonic acid (0.04 g, 0.38 mmol) and pyridine (0.11 mL) in DMF (3.5 mL) at room temperature was slowly added EDCI (0.18 g, 0.91 mmol). The reaction mixture was stirred at 70 °C for 24 h and allowed to cool to room temperature. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with 20% methanol in dichloromethane to afford the title compound (0.04 g, 24%) as a white solid: MP: 125-127 °C; ^1H NMR (300 MHz, CD₃OD): δ 7.09 (s, 2H), 6.83 (d, J = 2.1 Hz, 1H), 6.56 (m, 2H), 4.87 (d, J = 6.9 Hz, 1H), 3.96 (s, 2H), 3.21 (m, 1H), 2.24 (s, 6H), 1.30 (d, J = 17.7 Hz, 3H), 1.15 (d, J = 7.0 Hz, 6H); LC-MS m/z = 361 [C₂₀H₂₇O₄P-H]⁺.

Compound 105-2: Methylphosphonic acid 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenyl ester



Step a

[1126] To a solution of 3,5-dimethyl-4-(3-isopropyl-4-methoxymethoxybenzyl)phenol (Chiellini *et al.*, *Bioorg. Med. Chem. Lett.* 10:2607 (2000), 0.30 g, 0.95 mmol) in methanol (6.0 mL) was added 2 N HCl (1.4 mL, 2.8 mmol). The reaction mixture was stirred at room temperature for 72 h, diluted with water (15 mL) and extracted with ethyl acetate (10 mL).


The organic solution was dried over MgSO₄, filtered and concentrated under reduced pressure to afford 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenol (0.23 g, 89%) as colorless oil: ¹H NMR (300 MHz, CD₃OD): δ 6.84 (d, *J* = 2.1 Hz, 1H), 6.58 (m, 2H), 6.53 (s, 2H), 3.87 (s, 2H), 3.23 (m, 1H), 2.17 (s, 6H), 1.15 (d, *J* = 7.0 Hz, 6H); TLC conditions: Uniplate silica gel, 250 microns; Mobile phase = acetone-hexanes (1:3); R_f = 0.5.

Step b

[1127] The title compound was prepared from 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenol according to the procedure described for the synthesis of compound 105-1. MP: 53-56 °C; ¹H NMR (300 MHz, CD₃OD): δ 6.91 (s, 2H), 6.84 (d, *J* = 2.1 Hz, 1H), 6.54 (m, 2H), 3.96 (s, 2H), 3.21 (m, 1H), 2.24 (s, 6H), 1.59 (d, *J* = 17.7 Hz, 3H), 1.14 (d, *J* = 7.0 Hz, 6H); LC-MS *m/z* = 349 [C₁₉H₂₅O₄P + H]⁺; Anal. Calcd for (C₁₉H₂₅O₄P): C, 65.51; H, 7.23. Found: C, 65.23; H, 7.47.

Example 113

Compound 113: 3,5-Dichloro-4-(4'-hydroxynaphthoxy)phenylaminomethyl-phosphonic acid monomethyl ester



[1128] To a stirred solution of dimethyl-*N*-*t*-butoxycarbonyl-[3,5-dichloro-4-(4'-*O*-methoxynaphthoxy)phenylamino]methylphosphonate, prepared according to the procedure described for the synthesis of compound 90, step d, (220 mg, 0.48 mmol) in CH₂Cl₂ (10 mL) at -78 °C was added BBr₃ (0.3 g, 1.4 mmol). The reaction mixture was allowed to warm to rt and stirred for 14 h and poured into ice water (100 mL) and stirred for 1 h. The reaction mixture was extracted with ethyl acetate (2x50 mL). The combined organic layers were washed with water and brine, dried over MgSO₄, filtered and

concentrated under reduced pressure. Crude dimethyl 3,5-dichloro-4-(4'-hydroxynaphthoxy)phenylaminomethyl phosphonate (140 mg, 0.3 mmol) was dissolved in *tert*-butylamine (11.4 mL, 11.4 mmol) and the reaction mixture was heated at 70 °C for 12 h. The solvent was removed under reduced pressure and the crude residue was purified by preparative HPLC to afford the title compound (20 mg, 34%, MP: 85-87 °C). ¹H NMR (300 MHz, CD₃OD): δ 8.33 (dd, *J* = 0.9, 7.5 Hz, 1H), 8.22 (dd, *J* = 0.9, 7.5 Hz, 1H), 7.56-7.51 (m, 2H), 6.86 (s, 2H), 6.59 (d, *J* = 7.8 Hz, 1H), 6.21 (d, *J* = 8.1 Hz, 1H), 3.72 (d, *J* = 10.5 Hz, 3H), 3.44 (d, *J* = 12.3 Hz, 2H); LC-MS *m/z* = 428 [C₁₈H₁₆Cl₂NO₃P+H]⁺; HPLC conditions: Agilent Zorbax SB-Aq-3.0 x150 mm column; mobile phase = CH₃OH:TFA (7:3) flow rate = 1.0 mL/min; detection = UV 220, 254, 280 nm retention time in min: 9.01; Anal. Calcd: (MF: C₁₈H₁₆Cl₂NO₃P + 0.35 t-BuNH₂+0.64 TFA) Calcd: C:47.15, H:3.92, N:3.59 Found: C: 46.86, H:4.23, N:4.04.

[1129] For all chemical structures pictured herein, when an oxygen is depicted with only a single bond to another atom, the presence of a hydrogen bonded to the oxygen is to be assumed. When a nitrogen is depicted with only two bonds to one or more other atoms, the presence of a hydrogen bonded to the nitrogen is to be assumed.

CH₂Cl₂: dichloromethane

DMF: dimethylformamide

TEA: triethylamine

THF: tetrahydrofuran

TFA: trifluoroacetic acid

MgSO₄: magnesium sulfate

TBSCl: *t*-butyldimethylsilyl chloride

H₂O: water

DMSO: dimethyl sulfoxide

CH₃CN: acetonitrile

[1130] Examples of use of the method of the invention includes the following.

It will be understood that these examples are exemplary and that the method of the invention is not limited solely to these examples.

[1131] For the purposes of clarity and brevity, chemical compounds are referred to by their synthetic example numbers in the biological examples below.

Example A: Receptor Binding

[1132] The purpose of these studies was to determine the affinity of T3 and various thyromimetics for human thyroid hormone receptors TR α 1 and TR β 1.

[1133] *Methods:* Baculoviruses expressing TR α 1, TR β 1 and RXR α were generated using cDNA and other reagents from Invitrogen (Carlsbad, CA). To produce TR/RXR heterodimer proteins, the sf9 insect cells were first grown to a density of 1-5x10⁵ cells/ mL. TR α 1 or TR β 1 and RXR α baculovirus stocks were added to the cell culture with a ratio of 1 to 1 (multiplicity of infection =10). The cells were harvested three days after the infection. The cells were lysed in assay buffer (50 mM NaCl, 10% Glycerol, 20 mM Tris, pH 7.6 2 mM EDTA, 5 mM β -mercaptoethanol and 1.25% CHAPS) and the lysates were assayed for T3 binding as follows: ¹²⁵I-T3 was incubated with the lysates of TR and RXR recombinant baculoviruses coinfecting cells (50 μ l) in assay buffer for one h and then the ¹²⁵I-T3-TR/RXR complex was separated from free ¹²⁵I-T3 by a mini-gel-filtration (Sephadex G50) column. The bound ¹²⁵I-T3 was counted with a scintillation counter.

[1134] Binding of compounds to either the TR α 1 or TR β 1 were also performed by means of scintillation proximity assays (SPA). The SPA assay, a common method used for the quantitation of receptor-ligand equilibria, makes use of special beads coated with a scintillant and a capture molecule, copper, which binds to the histidine-tagged α or β receptor. When labeled T3 is mixed with receptor and the SPA beads, radioactive counts are observed only when the complex of protein and radiolabeled ligand is captured on the

surface of the bead. Displacement curves were also generated with labeled T3 and increasing concentrations of unlabeled thyromimetics of interest.

[1135] *Results:* Examples of representative T3 binding results using the gel filtration method are shown in Figure 1(a). SPA assay results for T3 are shown in Figures 1(b) and 1(c). Table 3 below shows the SPA data generated with various thyromimetics of interest. Binding results for T3 demonstrated a $K_d=0.29\text{nM}$ for TR α and a $K_d=0.67\text{nM}$ for TR β .

TABLE 3

Compound	$K_i\text{ TR}\alpha\text{ (nM)}$	$K_i\text{ TR}\beta\text{ (nM)}$
17	1.21	0.29
1	285	36.1
12-1	1666	662
3	46	5.42
6	16	26
9	350	204
11	121	30.3
13-1- <i>cis</i>	2583	1979
13-1- <i>trans</i>	1744	1322
13-6- <i>cis</i>	4710	3589
13-2- <i>cis</i>	488	419
13-2- <i>trans</i>	1354	469
13-3- <i>cis</i>	2837	3431
13-3- <i>trans</i>	2006	2456
13-6- <i>trans</i>	1526	1574
13-5- <i>trans</i>	354	281
13-5- <i>cis</i>	4432	1008
13-7- <i>trans</i>	1554	3798
13-4- <i>trans</i>	2129	1815
13-4- <i>cis</i>	5531	1521
13-7- <i>cis</i>	49632	45135
7	58	3.3
2	1416	271
4	14.1	0.99
5	1.84	0.84
8	3.74	0.97
10	>2000	>2000
8-1	18.6	2.51
15-3	>2000	>2000
19	304	52
8-2	114	20
24-1	378	31
7-5	67	9.5
25	>2000	363
22	186	31

Compound	Ki TR α (nM)	Ki TR β (nM)
21	>1400	>180
7-6	98	7.6
24-2	>2000	24
26	594	87
19-2	343	20
7-4	>2000	>2000
30	>2000	>2000
23	>2000	>2000
19-3	1760	128
28	375	14.0
20	>2000	>2000
7-3	31	6.6
7-2	>2000	146
29	661	47
7-1	1166	106
32	284	96
24	>2000	>2000
27	>2000	>2000
31	540	73
24-3	113	2.87
33	267	16.7
34	118	6.5
41-2	>2000	>2000
38	254	5.4
42-2	>2000	>2000
39	>2000	58
7-7	898	90
41-3	>2000	280
24-4	>2000	92
7-8	62	9.7
42	794	16.2
40	30	1.1
7-14	429	52
7-9	110	5.4
35	>2000	>2000
37	294	23
36	>2000	106
7-12	>2000	61
12-3	738	156
41	>2000	181
7-10	112	48
47	24.3	2.5
48	128.6	9
45	216	14
46	20	2
52	>2000	48
44	832	44
54	143	42

Compound	Ki TR α (nM)	Ki TR β (nM)
43	363	108
71	4	0.4
69-2	2.8	0.8
61	42.7	1.4
69	13.5	3
22-1	10.3	1.5
70	183	5.4
67	37	1.8
66	863.2	121

[1136] Conclusion: The parent thyromimetics tested had good to excellent affinity for the TR α 1 and/or TR β 1 receptors. The prodrugs had poor affinity for the receptors and are therefore unlikely to exert a thyromimetic effect until activated in the liver.

Example B: Subacute Studies in Normal Mice/Rats Demonstrating Liver versus Heart Selectivity of Phosphonic Acid and Carboxylic Acid T3 Mimetics.

[1137] The purpose of these studies was to compare the difference in efficacy, cardiac effects and endocrine effects between T3 and T3 mimetics that are carboxylic acids and T3 mimetics that are phosphonic acids. In one example, T3 and Compounds 7 and 17, which differ only in that for Compound 7 X is -P(O)OH₂ and for Compound 17 X is -C(O)OH, were compared. Efficacy endpoints include serum cholesterol, liver mitochondrial glycerol phosphate dehydrogenase (mGPDH) activity and the expression of relevant liver genes (e.g., the LDL-receptor, apoB, cpt-1, spot14 and apoAI). Safety parameters include heart weight, heart rate, heart mGPDH activity, the expression and key genes involved in cardiac structure and function (e.g., Serca2, HCN2, Kv1.5, MHC α , MHC β , Alpha1c), and standard plasma chemistry analysis (liver enzymes, electrolytes, creatinine). Endocrine effects are monitored by analysis of serum thyroid stimulating hormone (TSH). [Taylor *et al.*, *Mol Pharmacol* 52(3): 542-7 (1997); Weitzel *et al.*, *Eur J Biochem* 268(14):4095-4103 (2001)]

[1138] *Methods:* mGPDH activity was analyzed in isolated mitochondria using 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium chloride as the terminal electron acceptor (Gardner RS, Analytical Biochemistry 59:272 (1974)). Commercially available GPDH was used in each assay as a standard (Sigma, St. Louis, MO). Changes in levels of mRNA for liver and heart genes are analyzed using reverse transcriptase followed by real-time PCR analysis. The analysis is performed using an iCycler instrument (Biorad) and appropriate primers by means of standard methodology [*e.g.*, Schwab DA *et al.* (2000) *Life Sciences* 66: 1683-94]. The amounts of mRNA are normalized to an internal control, typically, cyclophilin. Serum TSH is measured using an enzyme immunoassay (EIA) kit designed for rat TSH (Amersham Pharmacia Biotech, Arlington Heights, IL). Serum cholesterol is analyzed using a commercially available enzymatic kit (Sigma Diagnostics, St. Louis, MO).

[1139] Normal rats (Sprague-Dawley) were maintained on a standard diet. Compounds 7 and 17, or T3 were administered by continuous infusion using an osmotic pump (Alzet; subcutaneous implant) at a dose of 1 mg/kg/day. The compounds were dissolved in 0.1N NaOH solution and the pH adjusted to 7.4-8.0. The compounds were brought up to an appropriate volume using PBS and BSA to maintain solubility within the pump. The compounds were chemically stable in the excipient at 37 °C for 7 days.

[1140] *Results:* Compound 7, a phosphonic acid T3 mimetic, produced a significant thyromimetic effect in the liver equivalent to that of T3 or Compound 17, a carboxylic acid T3 mimetic, without producing any significant effect in the heart. Compound 17 produced a significant thyromimetic effect comparable to that of T3 in both organs. Values are expressed as percent of control. (Table 4)

TABLE 4

	Liver GPDH	Heart GPDH	Heart Weight
control	100	100	100
T3	406	284	146
Compound 17	426	277	134
Compound 7	399	112	108

[1141] *Conclusion:* Based on mGPDH enzyme activity, Compound 7 had significant thyromimetic activity in the liver and none in the heart. In addition, Compound 7 did not cause cardiac hypertrophy. T3 and Compound 17, in contrast, did not show liver-selective thyromimetic effects. Thus, the results demonstrate that phosphonic acid T3 mimetics have a greater selectivity for the heart in terms of drug activity and distribution than carboxylic acid T3 mimetics.

Example C: Subacute Studies in ZDF Rats Demonstrating
Improved Therapeutic Index for Phosphonic Acid Containing T3
Mimetics

[1142] ZDF rats were treated with either Compound 18 (a carboxylic acid T3 mimetic) or Compound *cis*-13-1 (a HepDirect prodrug of a phosphonic acid T3 mimetic) for 28 days dosed orally once a day. Compound 18 was administered at doses up to 5 mg/kg/d. Compound *cis*-13-1 was administered at doses up to 50 mg/kg/d. We reasoned that the ZDF rat, as a metabolically challenged animal model, would be more sensitive to the potential adverse cardiac effects of thyromimetics than a normal, cholesterol-fed rat. At sacrifice, heart rate, and the first derivative of left ventricular pressure (LV dP/dt) were measured with a Millar catheter inserted into the left ventricle. The therapeutic index (TI) for Compound 18 in the cholesterol-fed rat was 40 with respect to heart rate increases (Grover *et al.* PNAS 2003). The measurement of TI was a dose that ED15 for heart rate, *i.e.*, a dose that increased heart rate greater than or equal to 15% compared to the ED50 for cholesterol lowering. The therapeutic index for Compound 18 in the ZDF rats with respect to heart rate was 0.4, indicating that the model is much more sensitive to cardiac effects than a non-metabolically challenged animal. Additionally, the TI for LV dP/dt was 0.15. An increase in LV dP/dt of 25% was the value used in the TI calculation. The most sensitive measure of cardiac effects in this animal was LV dP/dt. ZDF rats treated with Compound *cis*-13-1 showed no changes in any of the parameters measured. Since we only dosed up to 50 mg/kg/d, we do not know the exact therapeutic index for

some of these parameters. However, the TI improvement over Compound 18 is listed in the table below:

Parameter	TI Improvement
ED15 HR	>39
ED25 LV dP/dt	>102

[1143] The reason that the TI is listed as greater than, *i.e.*, “>” is that the doses of Compound *cis*-13-1 were not high enough to reach the 15% or 25% threshold even at 50 mg/kg/d. By extrapolation with the cholesterol-fed rat for the Compound 18 data, the ZDF rats were 100-times more sensitive to the cardiac effects of the compound (a TI of ED15 HR/ED50 cholesterol from 40 in the normal rat to 0.4 in the ZDF rat). Therefore we calculate that the TI in a non-metabolically challenged animal would be >3900 with respect to heart rate and >10,000 with respect to LV dP/dt. We chose not to dose at such high levels at this time since the results from the ZDF animals demonstrated a significantly improved safety window. Thus the compounds of the present invention demonstrate a TI that is unexpected and vastly superior than carboxylic acid T3 mimetics.

Example D: Subacute Studies in Cholesterol-fed Rats

[1144] The cholesterol-fed rat is an animal model of hypercholesterolemia generated by feeding the animals a diet with high cholesterol content. The purpose of these studies was to evaluate the effects of Compounds 7 and 17 on serum cholesterol (an efficacy parameter) and on heart weight and heart mGPDH activity (potential toxicity parameters).

[1145] *Methods:* Rats were maintained on a diet containing 1.5% cholesterol and 0.5% cholic acid for 2 weeks prior to initiation of treatment. Serum cholesterol values were assessed and the animals randomized into groups for treatment. Serum cholesterol was analyzed using a commercially available enzymatic kit (Sigma Diagnostics, St. Louis, MO). Compound 17 and

Compound 7 at various concentrations were administered IP once-a-day for seven days.

[1146] *Results:* Doses of 0.1-1 mg/kg/day Compound 17 significantly decreased serum cholesterol. Doses of Compound 7 from 1-100 mg/kg/day significantly decreased serum cholesterol. The decreases of serum cholesterol at 1 mg/kg/day were identical for Compound 17 and Compound 7 (*see Fig. 2*). Undesirable cardiac hypertrophy was observed with Compound 17 at all doses which significantly decreased serum cholesterol, 0.1-1 mg/kg/day. No cardiac hypertrophy was observed with Compound 7 (*see Fig. 3*). Cardiac GPDH activity was also increased by Compound 17 at 1 mg/kg/day whereas a trend towards increased heart GPDH activity was observed with compound 7 only at 100 mg/kg (*see Fig. 4*). No adverse cardiac effects were observed with Compound 7 at any dose. These studies also indicate that cardiac weight is more sensitive to thyromimetic effects than GPDH activity.

[1147] *Conclusion:* There is no separation between efficacy (cholesterol lowering) and toxicity (cardiac hypertrophy, induction of heart GPDH) for compound 17. Compound 7, in contrast, showed a therapeutic window of 10- to 100-fold. Thus, the results demonstrate that phosphonic acid T3 mimetics have a greater therapeutic window than carboxylic acid T3 mimetics.

Example E: Microsome/Primary Hepatocyte Stability Studies

i. Prodrug activation in Rat Liver Microsomes

[1148] The purpose of these studies was to determine the kinetics of activation of prodrugs of thyromimetics in microsomal preparations. Microsomes contain the P450 enzyme that is required for the activation of many of the prodrugs prepared. The Km, Vmax, and intrinsic clearance values determined are measures of prodrug affinity for the microsomal enzymes, the rate at which the prodrug is activated, and the catalytic efficiency with which the prodrug is activated, respectively.

[1149] *Methods:* Activation of prodrugs by dexamethasone treated rat hepatocyte microsomes. Microsomes were isolated by standard differential

centrifugation methods from dexamethasone-treated rats. The treatment is to increase cytochrome P450-3A (CYP3A4) activity. Induction of CYP3A4 was confirmed by an increase in testosterone hydroxylation.

[1150] Various concentrations of HepDirect™ Compound 7 were incubated with rat hepatocytes microsomes. Compound 7 formation was analyzed by HPLC using UV-Vis detection. Kinetic parameters (V_{max} and K_m) were calculated from the transformed data and the intrinsic clearance calculated from the kinetic parameters.

[1151] *Results and conclusion:* Table 5 shows that prodrugs of Compound 7 are well activated in rat liver microsomes and have good affinity for the microsomal enzyme(s) catalyzing their activation:

TABLE 5

Compound	V_{max} (pmol/min/mg)	K_m (μ M)	CLint (μ L/min/mg)
13-1-cis	1746	31	56
13-6-cis	598	10	62
13-2-cis	694	8	86
13-3-cis	2118	46	46
13-5-cis	3266	113	29
Compound 12-3	775	14	54
13-4-cis	2983	100	30

ii. Activation of Prodrug by Human Liver S9

[1152] Prodrugs are tested for conversion to their respective parent compounds by human liver S9. The S9 fraction is a fraction that contains both cytosolic and microsomal protein.

[1153] *Method:* Reaction mixtures (0.5 mL at 37 °C) consist of 0.2 M potassium phosphate pH 7.4, 13 mM glucose-6-phosphate, 2.2 mM NADP⁺, 1 unit of glucose-6-phosphate dehydrogenase, 0-2.5 mg/mL human liver S9 fraction (In Vitro Technologies, Inc.), and up to 250 μ M of prodrug. The activation of the prodrugs to the respective parent compounds is monitored by reverse phase HPLC or LC-MS/MS (Example F).

[1154] *Results:* The rate of formation of the parent compound is measured.

The enzyme kinetic parameters of V_{max} , K_m , and intrinsic clearance CL_{int} are calculated.

[1155] *Conclusion:* Prodrugs of T3 mimetics are readily activated to their respective parent compound by human liver S9.

iii. Activation of Prodrug in Isolated Rat Hepatocytes

[1156] The purpose of these studies was to monitor the uptake and activation of the prodrugs of T3 mimetics to their respective active species in fresh, isolated rat hepatocytes.

[1157] *Method:* Hepatocytes are prepared from fed Sprague-Dawley rats (250-300 g) according to the procedure of Berry and Friend (Berry, M. N., Friend, D. S. *J. Cell Biol.* 43, 506-520 (1969)) as modified by Groen (Groen, A. K. *et al.*, *Eur J. Biochem* 122, 87-93 (1982)). Hepatocytes (60 mg wet weight/ mL) are incubated in 1 mL Krebs-bicarbonate buffer containing 10 mM glucose, and 1 mg/ mL BSA. Incubations are carried out in a 95% oxygen, 5% carbon dioxide atmosphere in closed, 50-mL Falcon tubes submerged in a rapidly shaking water bath (37 °C). Prodrugs are dissolved in DMSO to yield 10 mM stock solutions, and then diluted into the cell suspension to yield a final concentration of 100 µM. At appropriate time points over the course of 1 h, aliquots of the cell suspension are removed and spun through a silicon/mineral oil layer into 10% perchloric acid. The cell extracts in the acid layers are neutralized, and the intracellular prodrug metabolite content analyzed by reverse phase HPLC or LC-MS/MS (Example F). The AUC of the active species in the hepatocytes is calculated from the concentration-time profile of parent compound.

[1158] *Results:* Results are shown in Table 6 below:

TABLE 6

Compound	AUC (0-2h) (nmole*h/g)
Compound 13-1- <i>cis</i>	967
Compound 13-6- <i>cis</i>	433
Compound 13-2- <i>cis</i>	533
Compound 3-3- <i>cis</i>	459
Compound 13-5- <i>cis</i>	1988
Compound-13-7- <i>cis</i>	806
Compound 13-4- <i>cis</i>	784

[1159] *Conclusion:* Prodrugs of T3 mimetics are readily taken up and activated to their active species in fresh rat hepatocytes.

Example F: Oral Bioavailability/Efficacy Studies in Normal Rats

i. Oral Bioavailability

[1160] The oral bioavailability (OBAV) of Compound 12-1, a bisPOM prodrug of Compound 7, was estimated by comparison of the dose-normalized area under the curve (AUC) of the plasma concentration-time profile of Compound 7 following IV and PO administration of Compound 7 and Compound 12-1, respectively, to normal rats.

[1161] *Method:* Groups of non-fasted male SD rats were administered either 5 mg/kg of Compound 7 by IV bolus or 20 mg/kg of Compound 12-1 by oral gavage. Prior to drug administration, the rats were catheterized at the tail artery to facilitate blood collection. Plasma samples were obtained at pre-specified time points following dosing, extracted with 1.5 volumes of methanol, and then assayed by an LC-UV method using a C18 column eluted with a gradient of 20% to 45% v/v acetonitrile in a potassium phosphate buffer pH 6.2 over 15 min with UV absorbance monitoring at 280 nm. The AUC values were determined noncompartmentally from the plasma concentration-time plots by trapezoidal summation to the last measurable time point.

[1162] In another experiment the OBAV of Compound 19-2, a phosphonic acid T3 mimetic, was assessed using catheterized rats. Plasma levels of

compound were analyzed by HPLC and the AUCs for the i.v. dose of 5 mg/kg and the p.o. dose of 20 mg/kg were compared. The maximum OBAV for Compound 19-2 was 0.003%. Typically, compounds that are taken forward as an oral drug candidate have OBAV values of at least 15-20%, when tested in an animal model. This minimal requirement for OBAV in a genetically homogenous model system insures that exposure can be accurately monitored when humans are treated with the compound. Furthermore, in a genetically variable background such as humans, the variability for a compound with low OBAV in genetically homogenous model systems, can be widely variable, leading some subjects to have much higher than anticipated exposure, while other subjects have no exposure. OBAV of Compound *cis*-13-1 is calculated to be 25% when AUC's of Compound *cis*-13-1 are used and to be 40-50% when comparing the AUC's of Compound 7 using serial plasma samples of a i.v. administered compound versus a p.o. administered compound. The liver levels at 1.5h post-dosing of Compound 7 and prodrugs thereof are listed in Table 7, example F (ii).

[1163] *Results:* Compound 12-1 was adequately absorbed in the rat with an estimated OBAV of 25%. Following oral administration of the prodrug, the plasma concentrations of the generated Compound 7 ($C_{max} = 1.2 \pm 0.2 \mu\text{g/mL}$ at a $T_{max} = 3 \pm 1 \text{ hr}$) were sustained over an 8 h period ($t_{1/2} = 6 \pm 6 \text{ hr}$). Compound 19-2 was not adequately absorbed.

[1164] *Conclusion:* Adequate systemic exposure of Compound 7 was maintained over 8 h after an oral administration of Compound 12-1 to rats.

ii. Liver Distribution Following Oral Administration

[1165] Liver levels of Compound 7 were assessed in normal rats following oral administration of the HepDirect™ or other prodrugs. The levels were used to estimate potential efficacy. Liver levels were assessed by LC-MS using the 363.3/63.0 peak area to estimate levels of Compound 7 generated by orally administered prodrugs.

[1166] *Results:* Results are shown in Table 7.

TABLE 7

Compound	Liver Levels (ug/g)
	(10 mg/kg@1.5h)
Compound 7	Not Detected
Compound 12-1	1.39
Compound 13-1- <i>cis</i>	0.98
Compound 13-6- <i>cis</i>	0.39
Compound 13-2- <i>cis</i>	0.25
Compound 13-3- <i>cis</i>	0.77
Compound 12-2	0.67
Compound 13-5- <i>cis</i>	0.56
Compound 13-7- <i>cis</i>	0.23
Compound 13-4- <i>cis</i>	0.32

[1167] *Conclusion:* All compounds tested produced adequate liver levels of compound 7. All are predicted to induce thyromimetic effects *in vivo* following oral administration.

Example G: Oxygen Consumption Study

[1168] Thermogenesis is a measurement of energy consumption. Compounds that increase thermogenesis are likely to increase caloric expenditure and thereby cause body weight loss and its associated benefits to metabolic status (e.g., insulin sensitivity). Thermogenesis is assessed in subcellular fractions of various tissues, isolated cells, whole tissues, or in whole animals using changes in oxygen consumption as the endpoint. Oxygen is used up when calories are burned by various metabolic processes.

[1169] *Methods:* Animals are dosed once or several times a day via a parenteral or oral route for a treatment period ranging from 1 day to several weeks. Oxygen consumption is measured following a single or multiple days of treatment.

[1170] Mitochondrial thermogenesis is measured polargraphically with a Clark-type oxygen electrode using mitochondria isolated from various tissues, including liver. Mitochondria are isolated by differential centrifugation. As those skilled in the art are familiar, state 3 respiration or cytochrome c oxidase activity are measured in isolated mitochondria. The mitochondria are incubated at 30 °C in a buffered medium containing 80 mM KCl, 50 mM HEPES, 5 mM KH₂PO₄, 1 mM EGTA, 0.1% (w/v) fatty acid-free bovine serum albumin (BSA), pH 7.0 in the presence of 10 mM succinate, 3/75 µM rotenone and 0.3 mM ADP (Iossa, S, *FEBS Letters*, 544: 133-7 (2003)).

[1171] Oxygen consumption rates are measured in isolated hepatocytes using a portable Clark-type oxygen electrode placed in the hepatocyte medium. Hepatocytes are isolated from liver using a two-step collagenase perfusion (Berry, M. N., Friend, D. S. *J. Cell Biol.* 43: 506-520 (1969)) as modified by Groen (Groen, A. K. et al., *Eur J. Biochem* 122: 87-93 (1982)). Non-parenchymal cells are removed using a Percoll gradient and the cells are resuspended in tissue culture medium in a spinner flask. The oxygen consumption of the cells is measured over time once the system is sealed.

[1172] Oxygen consumption is measured in isolated perfused liver (Fernandez, V., *Toxicol Lett.* 69:205-10(1993)). Liver is perfused *in situ* and oxygen consumption is calculated by measuring the difference between the oxygen saturation of the inflow buffer and the outflow buffer maintained at a constant flow.

[1173] In one assay, whole animal oxygen consumption is measured using an indirect calorimeter (Oxymax, Columbus Instruments, Columbus, OH). Animals are removed from their cages and placed in the chambers. The resting oxygen consumption is measured in animals during periods of inactivity as measured by activity monitors. The oxygen consumption is calculated based on the flow through the chamber and the difference in oxygen partial pressures at the inflow and outlet ports. Carbon dioxide (CO₂) efflux is also measured in parallel using a CO₂ electrode.

[1174] Male Sprague Dawley rats were treated with 3, 10, or 30 mg/kg/d of Compound cis-1-1 orally for 14 days. Rats were placed in the FoxBox

apparatus (Sable Systems, Las Vegas, NV), allowed to acclimate and the resting oxygen consumption was measured. The oxygen consumption rates were compared to pre-dose measurements taken on each individual animal. Oxygen consumption following treatment was 116, 125, 132% of the pre-dose rate, for 3, 10, and 30, respectively. Thus, the compounds of the present invention are useful in increasing oxygen consumption.

Example H: Tissue Distribution Studies

[1175] The tissue distribution and the pharmacokinetics of Compound 7 and the Compound 17 were assessed following IP administration to normal rats.

[1176] *Method:* In separate studies, the T3 mimetic phosphonate Compound 7 and its carboxylate analog Compound 17 were administered at 10 mg/kg to groups of male SD rats via the peritoneal cavity. At pre-selected time points following dosing, the rats were anesthetized using isofluorane and the peritoneal cavity was then opened and a blood sample was obtained from the abdominal vena cava. In addition, liver, kidney, and heart were excised and immersed in 3 volumes of cold 60% acetonitrile. The blood samples were briefly centrifuged and the plasma fraction was then extracted with 1.5 volumes of methanol, processed, and analyzed by LC-UV as described in Example G. The frozen liver, kidney, and heart tissue were homogenized in 60% v/v acetonitrile, centrifuged, and then analyzed by LC-UV. Pharmacokinetic parameters and AUC of the plasma and tissue concentration-time profiles were determined noncompartmentally by WinNonLin.

[1177] *Results:* The following plasma pharmacokinetics were calculated for Compound 17 and Compound 7 and shown in Table 8.

TABLE 8

PARAMETER	UNIT	Compound 17	Compound 7
Dosing time	hr	0	0
Rsq		0.9966	0.9893
Tmax	hr	0.3333	0.3333
Cmax	µg/mL	3.49	25.97

Tlast	hr	2	4
Vz(observed)/F	L/kg	2.2049	0.4008
Cl(observed)/F	L/hr/kg	3.3628	0.3006
AUMClast	µg·hr ² /mL	1.7683	33.7098

[1178] The AUC values of the plasma and tissue concentration-time profiles were calculated for Compound 17 and Compound 7 and shown in Table 9.

TABLE 9

T3 Mimetic	Plasma AUC	Liver AUC	Heart AUC	Kidney AUC
Compound 17	2.8 µg·hr/mL	48.5 nmol·hr/g	27.6 nmol·hr/g	1.1 nmol·hr/g
Compound 7	31.6 µg·hr/mL	301.7 nmol·hr/g	32.8 nmol·hr/g	5.0 nmol·hr/g

[1179] *Conclusion:* Compared to the phosphonic acid T3 mimetic (Compound 7), the carboxylic acid T3 mimetic (Compound 17) had significantly higher plasma clearance and volume of distribution in the rat. Substantially higher levels of Compound 7 measured in the liver indicated good penetration of the T3 mimetic phosphonate into the target organ. Compound 7 showed higher liver exposure relative to Compound 17. Thus, phosphonic acid T3 mimetics have greater liver specificity, as compared to heart tissue, than do carboxylic acid T3 mimetics.

Example I: Subacute Studies in Cholesterol fed Rats Cholesterol Reduction

[1180] The purpose of these studies was to evaluate the effects of a carboxylic acid T3 mimetic (Compound 18) a phosphonic acid T3 mimetic prodrug (Compound 13-1-cis) on serum cholesterol and TSH levels, hepatic and cardiac gene expression and enzyme activities, heart weight, and clinical chemistry parameters.

[1181] *Methods:* Rats were maintained on a diet containing 1.5% cholesterol and 0.5% cholic acid for 2 weeks prior to initiation of treatment. Serum cholesterol values were assessed and the animals randomized into groups for

treatment. Serum cholesterol was analyzed using a commercially available enzymatic kit (Sigma Diagnostics, St. Louis, MO). Compound 13-1-*cis* and Compound 18 were administered PO once a day for seven days. Serum TSH is measured using an enzyme immunoassay (EIA) kit designed for rat TSH (Amersham Pharmacia Biotech, Arlington Heights, IL). Expression levels of liver genes (*e.g.*, the LDL-receptor, apoB, cpt-1, spot14 and apoAI) and heart genes (*e.g.*, Serca2, HCN2,Kv1.5, MHC α , MHC β , Alpha1c) are quantified by Northern blot analysis or by RT-PCR. For Northern analyses, RNA is isolated from liver tissue by a guanidinium thiocyanate method, and total RNA is obtained using an RNeasy column (Qiagen). mRNA is separated on a 1% agarose gel and transferred to a nylon membrane. Oligonucleotides specific for the complementary gene sequences are used to make 32 P-labeled probes (Multiprime DNA labeling systems, Amersham Pharmacia Biotech). Following hybridization of the probes to the nylon membranes, radioactivity is assessed on a blue film (Eastman Kodak Co.), and the resulting image quantified using the appropriate software. RT-PCR is performed using an iCycler instrument (Biorad) using appropriate primers by means of standard methodology [*e.g.*, Schwab DA *et al.* (2000) *Life Sciences* 66: 1683-94]. GPDH activity in liver and heart are measured as described in Example B. The activities of PEPCK and glucose 6-phosphatase in liver are measured by means of direct enzymatic assays of homogenized liver tissue as described by Andrikopoulos S *et al.* (1993) *Diabetes* 42: 1731-1736. Alternatively, expression levels of the corresponding genes are determined by Northern blot analysis or RT-PCR as described above.

[1182] *Results:* Doses of 0.6-50 mg/kg/day of Compound 13-1-*cis* significantly decreased serum cholesterol (*see* Figure 5). Compound 18 at 1 mg/kg/day significantly decreased serum cholesterol. No significant undesirable cardiac hypertrophy was observed with Compound 13-1-*cis* at any dose tested.

[1183] *Conclusion:* Compound 13-1 showed significant cholesterol lowering even at the lowest dose evaluated (0.6 mg/kg). Furthermore, no evidence of

undesirable effects on heart weight was observed across the entire dose range tested (up to 50 mg/kg).

Example J: Decreases In Hepatic Fat Content Following Treatment With A Phosphonic Acid Thyromimetic:

[1184] Normal rats were chronically infused with Compound 7 for 7 days. Liver triglycerides were analyzed following lipid extraction by the Bligh Dyer method (Bligh EG and Dyer WJ, A rapid method of total lipid extraction and purification. Can J Med Sci. 1959 (August); 37(8):911-7, incorporated herein by reference). Total triglycerides were analyzed in the liver extracts by an enzymatic assay (Thermo Electron Corporation). Total lipid was normalized to initial liver weight and triglyceride content was normalized to liver weight. T3 administration would not be expected to decrease liver triglyceride content. Analysis of hepatic triglyceride content in the T3 infused rats showed no significant decrease in triglyceride content. There was a 4% reduction in liver triglycerides for this group and the results were not statistically significant. The Compound 7 infused animals demonstrated a decrease in hepatic triglyceride content of 64%, an unexpected and significantly different result.

[1185] In other experiments, Compound 7 was orally administered to ZDF rats for 28 days. Liver triglycerides were analyzed as described above. Total liver triglycerides were reduced in the treated animals 42% in the 2.5 mg/kg/d group. Histologic analysis of liver sections following H&E staining demonstrated a pronounced and diffuse microvesicular steatosis throughout the hepatic lobule in the vehicle treated group. The hepatic steatosis is a well known and described phenomenon for the ZDF rat, and therefore not attributable to vehicle treatment. There was a dose dependent reduction in the microvesicular steatosis and a noticeable appearance of intact cytoplasm within the hepatocytes consistent with a non-steatotic liver.

Example K: Effects of Phosphonic Acid T3 Mimetic Prodrugs *In Vivo* on Cholesterol

[1186] Another experimental assay was to evaluate the effects of prodrugs of phosphonic acid T3 mimetics of the present invention on serum cholesterol. Rats were made hypercholesterolemic by maintenance on a diet containing 1.5% cholesterol and 0.5% cholic acid for at least 2 weeks prior to initiation of treatment. Plasma cholesterol values were assessed prior to and following treatment and the effects of compound were expressed as a percentage change from the pre-dose cholesterol levels. Total cholesterol was analyzed using a commercially available enzymatic kit (Sigma Diagnostics, St. Louis, MO). Compounds were routinely tested for oral efficacy at a dose of 0.5 mg/kg/d. Hypercholesterolemic rats were treated with vehicle, Compound 13-1-cis (a HepDirect version of Compound 7), Compound 19-1 (a diethyl ester of Compound 19-2), Compound 13-9 (a HepDirect version of Compound 19-2), Compound 12-5 (a bisPom version of compound 19-2), or Compound 15-5 (a bisamide version of Compound 19-2) at 0.5 mg/kg/d orally. Compound 13-1-cis has been extensively characterized and was used as the positive control for the assay. Vehicle, Compound 13-9 and Compound 19-1 failed to demonstrate cholesterol lowering in this assay while Compound 13-1-cis, Compound 12-5 and Compound 15-5 demonstrated a significant lowering of cholesterol. HepDirect versions of the phosphonic acid T3 mimetics normally show good results, however, diethyl ester versions of the phosphonic acid T3 mimetics of the present invention were found not to be suitable as prodrugs.

[1187] In another experiment, the efficacy of Compound 7 was compared to Compounds 12-9, *cis*-13-2 and 15-6, which are prodrugs of a compound that binds poorly to both TR α and TR β (Ki of about 300nM). Compound 7 was efficacious whereas Compounds 12-9, *cis*-13-2 and 15-6 were not efficacious in lowering cholesterol.

[1188] Table 10 (below) shows the results for additional compounds of the present invention assayed in the present method.

TABLE 10

<u>Compound delivered i.p.</u> <u>(0.2 mg/kg/d)</u>	<u>% Cholesterol</u> <u>Lowering</u>
Untreated	-3.6
Vehicle	-5.3
40	-64.2
7-5	-63.3
7-9	-63.2
24-3	-48.6
8-2	-48.0
45	-46.3
7-3	-45.4
22	-44.0
66	-42.9
7	-41.5
11	-36.4
24-1	-35.4
7-14	-32.9
33	-32.5
46	-29.6
47	-29.3
42	-28.8
7-8	-28.6
7-10	-25.8
8	-24.3
48	-23.4
29	-21.9
38	-21.7
31	-21.1
27	-20.8
24-2	-20.5

- 574 -

28	-20.5
6	-20.5
19	-19
52	-18.8
7-6	-13.5
37	-0.4

<u>Compound delivered p.o.</u> <u>(0.5 mg/kg/d)</u>	<u>% Cholesterol Lowering</u>
Untreated	-4.0
Vehicle	-5.1
15-4	-39.6
12-8	-33.7
12-5	-32.5
<i>cis</i> -13-1	-31.8
12-4	-30.5
15-5	-29.9
15-7	-29.1
13-8	-26.5
13-11	-24.8
13-9	-10.9
19-1	-6.6
12-7	-39.1
13-10	-25.8
15-8	-31.1

<u>Compound delivered p.o.</u> <u>(0.2 mg/kg/d)</u>	<u>% Cholesterol Lowering</u>
Vehicle	-5.1
71	-54.4
69-2	-49.9
69	-41.9

45	-40.4
7-9	-38.4
7-5	-38.0
7-3	-36.5
61	-33.7
70	-32.8
8-1	-32.2
40	-27.3
46	-23.8
8	-20.6
22-1	-19.9
67	-17.0
22	-16.5
66	-12.5
7-1	-12.2
11	-5.1

Example L: Effects of Phosphonic Acid T3 Mimetic Prodrugs *In Vivo* on Circulating TSH

[1189] Another concern with synthetic thyromimetics is the suppression of the endogenous thyroid axis. Thyroid homeostasis is maintained by the action of thyroid releasing hormone (TRH) and thyroid stimulating hormone (TSH). TRH is produced in the paraventricular region of the hypothalamus (Dupre, SM et al, Endocrinology 145:2337-2345 (2004)). TRH acts on the pituitary releasing TSH which then acts on the thyroid organ itself. The levels of TRH and TSH are controlled by a feed-back sensing mechanism so that low levels of thyroid hormone (TH) (T3 or T4) will cause an increase in TRH and TSH and elevated levels of TH will cause a suppression of TRH and TSH. Because TSH can be measured more readily than TRH, levels of TSH are tested as a measure of systemic effects of TH or synthetic thyromimetics. Decreased TSH levels are a concern because suppression of the thyroid axis could lead to

systemic hypothyroidism. Although this particular side effect has been noted, it has typically been treated with less concern than the cardiac safety issues. However, new evidence indicates that, in addition to possible systemic hypothyroidism, which is a concern for any potential long-term therapy, TSH suppression will enhance osteoclast function leading to a decrease in bone mass and loss of bone structural integrity (Abe, E et al, Cell 115:151-62 (2003)). Therefore previous investigators have measured TSH levels when testing synthetic thyromimetics and have used a 30% decrease of TSH as the denominator in their therapeutic index calculations. The therapeutic index of TSH levels in cholesterol-fed rats, treated with either Compound 17 or Compound 18 (both carboxylic acid T3 mimetics) for 7 days, are 0.8 and 0.4, respectively. Therefore, both compounds suppress TSH as doses lower than that required to decrease circulating cholesterol. In ZDF rats treated with 50 mg/kg/d Compound 7 for 28 days, no statistically significant difference from vehicle was measured for TSH. However, 0.2 mg/kg/d of Compound 18 in 28 day treated ZDF rats, decreased TSH levels greater than 90%. In mice treated with 10 mg/kg/d Compound 7 for 77 days, no decrease in TSH was observed, indicating that Compound 7 can significantly decrease cholesterol levels without producing an adverse effect on the endogenous thyroid axis.

Example M: Effects of Phosphonic Acid T3 Mimetic Prodrugs In Vivo on Glucose

[1190] Plasma glucose in Compound 7 treated ZDF rats at sacrifice decreased from 618 mg/dL to 437 mg/dL following 4 weeks of treatment with Compound *cis*-13-1. The decrease was dose dependent. Blood glucose levels at those doses corresponded to 442 mg/dL and 243 mg/dL, respectively. Similar changes were also evident at two weeks, post-treatment. There was a dose-dependent decrease in the water consumption of the treated animals, which is consistent with an improvement in glycemic control.

Example N: T3 and T3 mimetic mediated myosin heavy chain gene transcription in the heart

[1191] An RT-PCR assay as disclosed in: Sara Danzi, Kaie Ojamaa, and Irwin Klein *Am J Physiol Heart Circ Physiol* 284: H2255-H2262, 2003 (incorporated herein by reference) is used to study both the time course and the mechanism for the triiodothyronine (T3)-induced transcription of the α - and β -myosin heavy chain (MHC) genes in vivo on the basis of the quantity of specific heterogeneous nuclear RNA (hnRNA). The temporal relationship of changes in transcriptional activity to the amount of α -MHC mRNA and the coordinated regulation of transcription of more than one gene in response to T3 and T3 mimetics are demonstrated. Analysis of a time course of T3 and T3 mimetics that are not liver specific show mediated induction of α -MHC hnRNA and repression of β -MHC hnRNA, whereas no significant affect is observed with compounds of the present invention at doses that are therapeutically useful.

Example O: Cardiovascular activity of T3 Mimetics in the Rat

[1192] The objective of these experiments was to evaluate the effect of phosphonic acid containing T3 mimetics versus carboxylic acid containing T3 mimetics, on cardiovascular function (heart rate, inotropic state, and aortic pressure) in the Sprague Dawley (SD) rat model.

[1193] *Method:* Compound *cis*-13-1 (a HepDirect prodrug of Compound 7) was dissolved in PEG400 and administered daily to SD male rats (n=6/group) by oral gavage (1, 5, 10, 30, 50 mg/kg/day) at 1 ml/kg body weight. The control group (n=6) was given vehicle only. Compound 18 (a carboxylic acid T3 mimetic) was administered at 1 mg/kg p.o. as a positive control (n=6). On the 7th day after the start of dosing, animals were anesthetized with Isoflurane and the left ventricle cannulated with a high fidelity catheter tip transducer via the right carotid artery. Left ventricular pressure, its first derivative (LVdP/dt), lead I ECG, and heart rate (HR) triggered off the ECG waveform, were digitally recorded. LV dP/dt is a well accepted measure of

ionotropic state. Systolic and diastolic aortic pressures were measured by retracting the catheter into the proximal aorta.

[1194] *Results:* Compared to vehicle treated animals, Compound 18 administration resulted in marked and statistically significant increases in HR, LV dP/dt, and systolic aortic pressure after 7 days of treatment. In contrast, HR, LV dP/dt, systolic and diastolic aortic pressures in all groups treated with Compound *cis*-13-1 were not significantly different compared to vehicle treated animals. Heart weight and heart weight normalized to body weight in Compound 18 treated animals were significantly increased compared to control animals. There were no significant changes in heart weight or heart weight/body weight ratios in Compound *cis*-13-1 treated groups.

[1195] *Conclusions:* It is concluded that Compound *cis*-13-1 when administered at doses up to 50 mg/kg/day for 7 days is devoid of significant chronotropic and inotropic effects in the normal SD rat. This stands in contrast to Compound 18 which is associated with marked effects when given at 1 mg/kg/day.

Example P: Continuous Infusion Study

[1196] Screening for thyromimetic activity was performed in normal rats maintained on a cholesterol-containing diet. Compounds were administered by continuous infusion using an osmotic pump at 1 mg/kg/day. The compounds were dissolved in 0.1N NaOH solution and the pH adjusted to 7.4-8.0. The compounds were chemically stable as an aqueous solution at 37°C for 14 days.

[1197] Compounds 7, 69, 70, and 69-1 were compared to 17 and vehicle testing changes in heart rate, LV dP/dt, systolic and diastolic blood pressure, and reductions in total cholesterol. Compound 17 increased heart rate by 40% when analyzed at day 7 and the elevation was through d14. At the end-of-life it was demonstrated that Compound 17 also increased LV dP/dt by 71% and left ventricular weight. Systolic and diastolic blood pressure was also increased by 30%. Compound 17 produced a significant decrease in


cholesterol when measured at day 7, but no significant decrease in cholesterol was observed at day 14. For some reason, Compound 17 ceased to produce a cholesterol-lowering effect at the longer time, while still maintaining adverse cardiovascular effects.

[1198] Compounds 7, 69, 70, and 69-1 demonstrated no changes in any of the cardiovascular parameters at either day 7 or day 14. Compounds 7, 69, 70, and 69-1 demonstrated cholesterol lowering effects at day 7 and at day 14. Reductions in cholesterol at day 7 were equivalent for all the compounds tested.

[1199] Having now fully described the invention, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

What is Claimed Is:

1. A compound of Formula VIII:



wherein:

G is selected from the group consisting of -Se- and CH_2 linked to any of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵²)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a₂)_k, -CR^b=CR^b-(CR^a₂)_n, -(CR^a₂)_mCR^b=CR^b-, -(CR^a₂)-CR^b=CR^b-(CR^a₂)_n, -O(CR^b)(CR^a₂)_n-, -S(CR^b)(CR^a₂)_m-, -N(R^c)(CR^b)(CR^a₂)_n-, -N(R^b)C(O)(CR^a₂)_n-, -(CR^a₂)_mC(R^b)(NR^bR^c)-, -C(O)(CR^a₂)_m-, -(CR^a₂)_mC(O)-, -(CR^b₂)-O-(CR^b₂)-(CR^a₂)_p-, -(CR^b₂)-S-(CR^b₂)-(CR^a₂)_p-, -(CR^b₂)-N(R^c)-(CR^b₂)-(CR^a₂)_p-,

$-(CR^a_2)_p-(CR^b_2)-O-(CR^b_2)-$,
 $-(CR^a_2)_p-(CR^b_2)-N(R^c)-(CR^b_2)$ - and $-(CH_2)_pC(O)N(R^b)C(R^a_2)-$;

$-(CR^a_2)_p-(CR^b_2)-S-(CR^b_2)-$,

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_4$ alkyl, halogen, $-OH$, optionally substituted $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-S-C_1-C_4$ alkyl, $-NR^bR^c$, optionally substituted $-C_2-C_4$ alkenyl, and optionally substituted $-C_2-C_4$ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted $-C_1-C_4$ alkyl;

Each R^c is independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-C(O)-C_1-C_4$ alkyl, and $-C(O)H$;

R^1 , R^2 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, and cyano; with the proviso that at least one of R^1 and R^2 is not hydrogen;

R^8 and R^9 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, hydroxy, $-(CR^a_2)aryl$, $-(CR^a_2)cycloalkyl$, $-(CR^a_2)heterocycloalkyl$, $-C(O)aryl$, $-C(O)cycloalkyl$, $-C(O)heterocycloalkyl$, $-C(O)alkyl$ and cyano;

or R⁶ and T are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached, including 0 to 2 heteroatoms independently selected from -NRⁱ-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; and X is attached to this ring by a direct bond to a ring carbon, or by -(CR^a₂)- or -C(O)- bonded to a ring carbon or a ring nitrogen;

R¹ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, -C₁-C₄ alkyl, and -C₁-C₄-aryl; or

R¹ and R⁷ are taken together along with the carbons to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R¹ and R⁷ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a₂)_maryl, optionally substituted -(CR^a₂)_mcycloalkyl, optionally substituted -(CR^a₂)_nheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a₂)_n(CR^b₂)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)₂NR^fR^g, -C(O)NR^fR^g, -C(O)OR^b, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b₂)_naryl, optionally

substituted $-(CR_2^b)_n$ cycloalkyl, optionally substituted
 $-(CR_2^b)_n$ heterocycloalkyl, and $-C(O)NR^fR^g$;

Each R^e is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR_2^a)_n$ aryl, optionally substituted $-(CR_2^a)_n$ cycloalkyl, and optionally substituted $-(CR_2^a)_n$ heterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR_2^b)_n$ aryl, optionally substituted $-(CR_2^b)_n$ cycloalkyl, and optionally substituted $-(CR_2^b)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, said heterocyclic ring may contain a second heterogroup within the ring selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^b$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR_2^b)_n$ aryl, optionally substituted $-(CR_2^b)_n$ cycloalkyl, and optionally substituted $-(CR_2^b)_n$ heterocycloalkyl; or

R^3 and R^8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^8 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^6$, $-OC(O)OR^h$, $-NHC(O)OR^h$, $-OC(O)NH(R^h)$, $-F$, $-NHC(O)R^6$, $-NHS(=O)R^6$, $-NHS(=O)R^e$, $-NHC(=S)NH(R^h)$, and $-NHC(O)NH(R^h)$;

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h-$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)(YR^{11})(Y'R^{11})$;

Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^V-$;


when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z$, $-NR^z-C(O)-R^y$, $-C(R^z)_2OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhyd$ roxy, and $-alkyl-S-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^V-$, then R^{11} attached to $-NR^V-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-C(O)OR^y$, $-C(R^x)_2C(O)OR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-C(O)OR^y$;

when Y is $-O-$ and Y' is NR^y , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -

heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^y- is independently selected from the group consisting of -H, -[C(R^z)₂]_qC(O)OR^y, -C(R^z)₂C(O)OR^y, -[C(R^z)₂]_qC(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^y-, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an

aryl group at the beta and gamma position to the Y attached to the phosphorus;
or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C=CR^z)OH, -R^z, -NR^z, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

with the provisos that:

- a) when G is -CH₂-O-, wherein the oxygen atom is attached to the ring bearing the T group, T is -(CH₂)₁₋₂CH(R^{cc}), R^{cc} is -OH, -SH, -NH₂,


or -NH(C₁₋₄), R¹ and R² are each independently selected from chlorine, bromine, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, then X is not phosphonic acid or phosphamic acid or a lower alkyl ester thereof;

b) V, Z, W, W' are not all -H; and

c) when Z is -R², then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

2. A compound of Formula VIII:



wherein:

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C_{1-C4} alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein:

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵³)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C_{1-C4} alkyl, C_{2-C4} alkenyl, C_{2-C4} alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C_{1-C4} alkyl, C_{2-C4} alkenyl, C_{2-C4} alkynyl, C_{1-C4} alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R^{52} is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a)₁₋₂-O-(CR^a)₁₋₂- and -(CH₂)_pC(O)N(R^b)C(R^a)₂-,

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R¹, R², R⁶, and R⁷ are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted-O-C₁-C₃ alkyl, and cyano; with the proviso that at least one of R¹ and R² is not hydrogen;

R⁸ and R⁹ are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F,

optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)₂aryl, -(CR^a)₂cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

or R⁶ and T are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached, including 0 to 2 heteroatoms independently selected from -NRⁱ-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; and X is attached to this ring by a direct bond to a ring carbon, or by -(CR^a)₂- or -C(O)- bonded to a ring carbon or a ring nitrogen;

R¹ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, -C₁-C₄ alkyl, and -C₁-C₄-aryl; or

R¹ and R⁷ are taken together along with the carbons to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R¹ and R⁷ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_nheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)₂NR^fR^g, -C(O)NR^fR^g, -C(O)OR^b, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g;

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, said heterocyclic ring may contain a second heterogroup within the ring selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C₁-C₄ alkyl, -OR^b, oxo, cyano, -CF₃, -CHF₂, -CH₂F, optionally substituted phenyl, and -C(O)OR^h;

Each R^h is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl; or

R³ and R⁸ are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁸ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring

and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R^3 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^6$, $-OC(O)OR^h$, $-NHC(O)OR^h$, $-OC(O)NH(R^h)$, $-F$, $-NHC(O)R^6$, $-NHS(=O)R^6$, $-NHS(=O)_2R^6$, $-NHC(S)NH(R^h)$, and $-NHC(O)NH(R^h)$; or

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)(YR^{11})(Y'R^{11})$;


Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^V-$;

when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^2)_2OC(O)NR^2_2$, $-NR^2-C(O)-R^Y$, $-C(R^2)_2-OC(O)R^Y$, $-C(R^2)_2-O-C(O)OR^Y$, $-C(R^2)_2OC(O)SR^Y$, $-alkyl-S-C(O)R^Y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^V-$, then R^{11} attached to $-NR^V-$ is independently selected from the group consisting of $-H$, $-[C(R^2)_2]_q-C(O)OR^Y$, $-C(R^X)_2C(O)OR^Y$, $-[C(R^2)_2]_q-C(O)SR^Y$, and $-cycloalkylene-C(O)OR^Y$;

when Y is -O- and Y' is NR^y, then R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^x)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^x)₂-OC(O)R^y, -C(R^x)₂O-C(O)OR^y, -C(R^x)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^y- is independently selected from the group consisting of -H, -[C(R^x)₂]q-C(O)OR^y, -C(R^x)₂C(O)OR^y, -[C(R^x)₂]q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^y-, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C≡CR^z)OH, -R^z, -NR^z, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;


Each R^y is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;

with the provisos that:

- a) V, Z, W, W' are not all -H; and
- b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

3. A compound of Formula VIII:



wherein:

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂, -CH₂, -CF₂, -CHF₂, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)≡C(R⁵³)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl,

fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of $-(CR^a_2)_k-$, $-CR^b=CR^b-$, $(CR^a_2)_n-$, $-(CR^a_2)_n-CR^b=CR^b-$, $-(CR^a_2)-CR^b=CR^b-(CR^a_2)-$, $-O(CR^b_2)(CR^a_2)_n-$, $-S(CR^b_2)(CR^a_2)_n-$, $-N(R^c)(CR^b_2)(CR^a_2)_n-$, $-N(R^b)C(O)(CR^a_2)_n-$, $-(CR^a_2)_mC(R^b)-$, $-C(O)(CR^a_2)_m-$, $-(CR^a_2)_mC(O)-$, $-(CR^b_2)-O-(CR^b_2)-(CR^a_2)_p-$, $-(CR^b_2)-S-(CR^b_2)-(CR^a_2)_p-$, $-(CR^b_2)_p-(CR^b_2)-(CR^a_2)_p-$, $-(CR^b_2)_p-(CR^b_2)-O-(CR^b_2)-$, $-(CR^a_2)_p-(CR^b_2)-S-(CR^b_2)-$, $-(CR^a_2)_p-C(O)N(R^b)C(R^a_2)-$; and $-(CH_2)_pC(O)N(R^b)C(R^a_2)-$;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_4$ alkyl, halogen, $-OH$, optionally substituted $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-S-C_1-C_4$ alkyl, $-NR^bR^c$, optionally substituted $-C_2-C_4$ alkenyl, and optionally substituted $-C_2-C_4$ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted $-C_1-C_4$ alkyl;

Each R^c is independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-C(O)-C_1-C_4$ alkyl, and $-C(O)H$;

R^1 , R^2 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, and cyano; with the proviso that at least one of R^1 and R^2 is not hydrogen;

R^8 and R^9 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, hydroxy, $-(CR^2)_n$ aryl, $-(CR^2)_n$ cycloalkyl, $-(CR^2)_n$ heterocycloalkyl, $-C(O)aryl$, $-C(O)cycloalkyl$, $-C(O)heterocycloalkyl$, $-C(O)alkyl$ and cyano;

or R^6 and T are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^i$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; and X is attached to this ring by a direct bond to a ring carbon, or by $-(CR^2)_n$ - or $-C(O)-$ bonded to a ring carbon or a ring nitrogen;

R^i is selected from the group consisting of hydrogen, $-C(O)C_1-C_4$ alkyl, $-C_1-C_4$ alkyl, and $-C_1-C_4$ aryl; or

R^1 and R^7 are taken together along with the carbons to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^1 and R^7 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^4 is selected from the group consisting of hydrogen, halogen, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, cyano, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^2)_n$ aryl, optionally substituted $-(CR^2)_n$ cycloalkyl, optionally substituted $-(CR^2)_n$ heterocycloalkyl, $-C(R^b)=C(R^b)$ aryl, $-C(R^b)=C(R^b)$ cycloalkyl, $-C(R^b)=C(R^b)$ heterocycloalkyl, $-C\equiv C(aryl)$, $-C\equiv C(cycloalkyl)$,

-C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^c, -S(=O)₂R^c, -S(=O)NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)R^e, -N(R^b)C(O)R^c, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^c, -N(R^b)S(=O)NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g,

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, said heterocyclic ring may contain a second heterogroup within the ring selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C₁-C₄ alkyl, -OR^h, oxo, cyano, -CF₃, -CHF₂, -CH₂F, optionally substituted phenyl, and -C(O)OR^h;

Each R^h is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)(YR^{11})(Y'R^{11})$;

Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^v-$;


when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^v-$, then R^{11} attached to $-NR^v-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-C(O)OR^y$, $-C(R^x)_2C(O)OR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-C(O)OR^y$;

when Y is $-O-$ and Y' is NR^v , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)R^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-S-alkylhydroxy$;

and R¹¹ attached to -NR^v- is independently selected from the group consisting of -H, -[C(R^z)₂]_q-C(O)OR^y, -C(R^x)₂C(O)OR^y, -[C(R^z)₂]_q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^v-, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected

from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)₂OH, -CH(C≡CR^z)OH, -R^z, -NR^z, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

with the provisos that:

- a) when G is O, T is -(CH₂)₁₋₃₋ or -(CH₂)₁₋₂CH(R^{aa}), R^{aa} is -OH, -NH₂, -NH(C₁₋₄alkyl), -NH(C₂₋₄alkenyl), or -NH(C₂₋₄alkynyl), R⁴ is hydrogen, R¹ and R² are independently selected from halogen, C₁ alkyl substituted with 1, 2, or 3 hydrogen, fluorine, or a bioisosteric equivalent, C₁₋₄ alkyl and CF₃, and R³ and R⁵ are taken together along with the carbon atoms to which they are attached to form a five member heterocyclic ring of formula -A-C(R^{bb})=B- wherein A, attached where the R⁵ group is attached, is selected

from $-O-$, $-S-$, and $-NR^h$, B is selected from $-CH-$, and $-N-$, R^{bb} is selected from C_{6-10} aryl, C_5 heteroaryl, or C_{1-4} alkyl, then X is not phosphonic acid, phosphamic acid, or a lower alkyl ester or acyloxyalkyl ester thereof;


b) when G is $-CH_2-O-$, wherein the oxygen atom is attached to the ring bearing the T group, T is $-(CH_2)_{1-2}CH(R^{gg})$, R^{gg} is $-OH$, $-SH$, $-NH_2$, or $-NH(C_{1-4})$, R^1 and R^2 are each independently selected from chlorine, bromine, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl, then X is not phosphonic acid or phosphamic acid or a lower alkyl ester thereof;

c) V, Z, W, W' are not all $-H$; and

d) when Z is $-R^z$, then at least one of V, W, and W' is not $-H$, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

4. A compound of Formula VIII:



wherein:

G is selected from the group consisting of $-O-$, $-S-$, $-Se-$, $-S(=O)-$, $-S(=O)_2$, $-Se-$, $-CH_2-$, $-CF_2-$, $-CHF-$, $-C(O)-$, $-CH(OH)-$, $-CH(C_{1-4}$ alkyl $)-$, $-CH(C_{1-4}$ alkoxy $)-$, $-C(=CH_2)-$, $-NH-$, and $-N(C_{1-4}$ alkyl $)-$, or CH_2 linked to any of the preceding groups;

or G is $R^{50}-R^{51}$ wherein;

$R^{50}-R^{51}$ together are $-C(R^{52})=C(R^{52})-$ or alternatively R^{50} and R^{51} are independently selected from O, S and $-CH(R^{53})-$, with the provisos that at least one R^{50} and R^{51} is $-CH(R^{53})-$, and when one of R^{50} and R^{51} is O or S, then R^{53} is R^{54} ;

R^{54} is hydrogen, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R^{53} is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R^{52} is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a)_k-, -CR^b=CR^b-(CR^a)_n-, -(CR^a)_n-CR^b=CR^b-, -(CR^a)₂-CR^b=CR^b-(CR^a)_n-, -O(CR^b)₂(CR^a)_n-, -S(CR^b)₂(CR^a)_n-, -N(R^c)(CR^b)₂(CR^a)_n-, -N(R^b)C(O)(CR^a)_n-, -(CR^a)_mC(R^b)(NR^bR^c)-, -C(O)(CR^a)_m-, -(CR^a)_mC(O)-, -(CR^b)₂-O-(CR^b)_p-, -(CR^a)₂-S-(CR^b)_p-, -(CR^b)₂-N(R^c)-(CR^b)_p-, -(CR^a)_p-(CR^b)₂-S-(CR^b)_p-, and -(CH₂)_pC(O)N(R^b)C(R^a)₂;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R² and R⁶ are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano; with the proviso that at least one of R¹ and R² is not hydrogen;

R⁸ and R⁹ are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)₂aryl, -(CR^a)₂cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano; or

R⁶ and T are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations including 0 to 2 heteroatoms independently selected from -NR^l-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; and X is attached to this ring by a direct bond to a ring carbon, or by -(CR^a)₂- or -C(O)- bonded to a ring carbon or a ring nitrogen;

Rⁱ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, and -C₁-C₄ alkyl;

R¹ and R⁷ are taken together along with the carbons to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R¹ and R⁷ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring

and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^3 and R^4 are each independently selected from the group consisting of hydrogen, halogen, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, cyano, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a_2)_n$ aryl, optionally substituted $-(CR^a_2)_n$ cycloalkyl, optionally substituted $-(CR^a_2)_n$ heterocycloalkyl, $-C(R^b)=C(R^b)$ -aryl, $-C(R^b)=C(R^b)$ -cycloalkyl, $-C(R^b)=C(R^b)$ -heterocycloalkyl, $-C\equiv C(aryl)$, $-C\equiv C(cycloalkyl)$, $-C\equiv C(heterocycloalkyl)$, $-(CR^a_2)_n(CR^b_2)NR^fR^g$, $-OR^d$, $-SR^d$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)_2NR^fR^g$, $-C(O)NR^fR^g$, $-C(O)OR^h$, $-C(O)R^e$, $-N(R^b)C(O)R^e$, $-N(R^b)C(O)NR^fR^g$, $-N(R^b)S(O)_2R^e$, $-N(R^b)S(O)_2NR^fR^g$, and $-NR^fR^g$,

Each R^d is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, and $-C(O)NR^fR^g$;

Each R^e is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a_2)_n$ aryl, optionally substituted $-(CR^a_2)_n$ cycloalkyl, and optionally substituted $-(CR^a_2)_n$ heterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, said heterocyclic ring may contain a second heterogroup within the ring selected from the group consisting of O, NR^e , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4

substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^h$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b)_n$ aryl, optionally substituted $-(CR^b)_n$ cycloalkyl, and optionally substituted $-(CR^b)_n$ heterocycloalkyl; or

R^3 and R^8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^8 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h-$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^e$, $-OC(O)OR^h$, $-NHC(O)OR^h$, $-OC(O)NH(R^h)$, $-F$, $-NHC(O)R^e$, $-NHS(=O)R^e$, $-NHS(=O)_2R^e$, $-NHC(=S)NH(R^h)$, and $-NHC(O)NH(R^h)$; or

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h-$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)YR^{11}Y'R^{11}$;


Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^v-$;

when Y and Y' are both -O-, R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R²)₂OC(O)NR², -NR²-C(O)-R^y, -C(R²)₂-OC(O)R^y, -C(R²)₂-O-C(O)OR^y, -C(R²)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-S-alkylhydroxy;

when Y and Y' are both -NR^y, then R¹¹ attached to -NR^y is independently selected from the group consisting of -H, -[C(R²)₂]q-C(O)OR^y, -C(R²)₂C(O)OR^y, -[C(R²)₂]q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

when Y is -O- and Y' is NR^y, then R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R²)₂OC(O)NR², -NR²-C(O)-R^y, -C(R²)₂-OC(O)R^y, -C(R²)₂-O-C(O)OR^y, -C(R²)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-S-alkylhydroxy; and R¹¹ attached to -NR^y is independently selected from the group consisting of -H, -[C(R²)₂]q-COOR^y, -C(R²)₂COOR^y, -[C(R²)₂]q-C(O)SR^y, and -cycloalkylene-COOR^y;

or when Y and Y' are independently selected from -O- and -NR^y, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOC(O)CO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)₂OH,

-CH(C≡CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

5. A compound of Formula II:



wherein:

A is selected from the group consisting of -NRⁱ-, -O-, and -S-;

B is selected from the group consisting of -CR^b-, and -N-;

Rⁱ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, and -C₁-C₄ alkyl;

R^b is selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

G is selected from the group consisting of -Se- and CH₂ linked to any of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵²)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

D is selected from the group consisting of a bond, -(CR^a)₂-, and -C(O)-;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄

alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R⁸ is selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)aryl, -(CR^a)cycloalkyl, -(CR^a)heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_ncycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C=C(aryl), -C=C(cycloalkyl), -C=C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^b)_ncycloalkyl, optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g;

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂

alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^e, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, -OR^b, oxo, cyano, -CF₃, -CHF₂, -CH₂F, optionally substituted phenyl, and -C(O)OR^h;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl; or

R³ and R⁸ are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁸ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom ; or

R⁸ and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising -CH=CH-CH=, -N=CH-CH=, -CH=N-CH= or -CH=CH-N=;

R⁵ is selected from the group consisting of -OH, optionally substituted $-OC_1-C_6$ alkyl, -OC(O)R^e, -OC(O)OR^h, -NHC(O)OR^h, -OC(O)NH(R^h), -F, -NHC(O)R^e, -NHS(-O)R^e, -NHS(=O)₂R^e, -NHC(=S)NH(R^h), and -NHC(O)NH(R^h); or

R³ and R⁵ are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached, including 0 to 2 heteroatoms independently selected from -NR^h-, -O-, and -S-,

with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)YR^{11}Y'R^{11}$;


Y and Y' are each independently selected from the group consisting of -O-, and -NR^y-;

when Y and Y' are both -O-, R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)OR^y, -C(R^z)₂-O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy;

when Y and Y' are both -NR^y, then R¹¹ attached to -NR^y is independently selected from the group consisting of -H, -[C(R^z)₂]_q-C(O)OR^y, -C(R^z)₂C(O)OR^y, -[C(R^z)₂]_q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

when Y is -O- and Y' is NR^y, then R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂-O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^y is independently selected from the group consisting of -H, -[C(R^z)₂]_q-C(O)OR^y, -C(R^z)₂C(O)OR^y, -[C(R^z)₂]_q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^y, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl- to form a cyclic group, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOC(=O)CO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C=CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^x is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

6. A compound of Formula II:



wherein:

A is selected from the group consisting of -NRⁱ-, -O-, and -S-;

B is selected from the group consisting of -CR^b-, and -N-;

Rⁱ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, and -C₁-C₄ alkyl;

R^b is selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵³)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

D is selected from the group consisting of a bond, -(CR^a)₂-, and -C(O)-;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and

optionally substituted $-C_2-C_4$ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

R^1 and R^2 are each independently selected from the group consisting of halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, and cyano;

R^8 is selected from the group consisting of halogen, optionally substituted $-C_1-C_4$ alkyl, optionally substituted $-S-C_1-C_3$ alkyl, optionally substituted $-C_2-C_4$ alkenyl, optionally substituted $-C_2-C_4$ alkynyl, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, optionally substituted $-O-C_1-C_3$ alkyl, hydroxy, $-(CR^a)_2$ aryl, $-(CR^a)_2$ cycloalkyl, $-(CR^a)_2$ heterocycloalkyl, $-C(O)aryl$, $-C(O)cycloalkyl$, $-C(O)heterocycloalkyl$, $-C(O)alkyl$ and cyano;

R^3 and R^4 are each independently selected from the group consisting of hydrogen, halogen, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, cyano, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a)_2$ aryl, optionally substituted $-(CR^a)_2$ cycloalkyl, optionally substituted $-(CR^a)_2$ heterocycloalkyl, $-C(R^b)=C(R^b)$ aryl, $-C(R^b)=C(R^b)$ cycloalkyl, $-C(R^b)=C(R^b)$ heterocycloalkyl, $-C\equiv C(aryl)$, $-C\equiv C(cycloalkyl)$, $-C\equiv C(heterocycloalkyl)$, $-(CR^a)_2(CR^b)_2NR^fR^g$, $-OR^d$, $-SR^d$, $-S(=O)R^e$, $-S(=O)_2R^e$, $-S(=O)_2NR^fR^g$, $-C(O)NR^fR^g$, $-C(O)OR^h$, $-C(O)R^e$, $-N(R^b)C(O)R^e$, $-N(R^b)C(O)NR^fR^g$, $-N(R^b)S(=O)_2R^e$, $-N(R^b)S(=O)_2NR^fR^g$, and $-NR^fR^g$;

Each R^4 is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b)_2$ aryl, optionally substituted $-(CR^b)_2$ cycloalkyl, optionally substituted $-(CR^b)_2$ heterocycloalkyl, and $-C(O)NR^fR^g$;

Each R^e is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally

substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a)_n$ aryl, optionally substituted $-(CR^a)_n$ cycloalkyl, and optionally substituted $-(CR^a)_n$ heterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b)_n$ aryl, optionally substituted $-(CR^b)_n$ cycloalkyl, and optionally substituted $-(CR^b)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^b$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b)_n$ aryl, optionally substituted $-(CR^b)_n$ cycloalkyl, and optionally substituted $-(CR^b)_n$ heterocycloalkyl; or

R^3 and R^8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^8 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom ; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^e$, $-OC(O)OR^b$, $-NHC(O)OR^b$,

-OC(O)NH(R^b), -F, -NHC(O)R^c, -NHS(=O)R^c, -NHS(=O)₂R^c, -NHC(=S)NH(R^b), and -NHC(O)NH(R^b); or

R³ and R⁵ are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached, including 0 to 2 heteroatoms independently selected from -NR^b-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is P(O)YR¹¹Y'R¹¹;

Y and Y' are each independently selected from the group consisting of -O-, and -NR^v-;


when Y and Y' are both -O-, R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂-O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy;

when Y and Y' are both -NR^v, then R¹¹ attached to -NR^v- is independently selected from the group consisting of -H, -[C(R^z)₂]q-C(O)OR^y, -C(R^z)₂C(O)OR^y, -[C(R^z)₂]q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

when Y is -O- and Y' is NR^v, then R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂-O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^v- is independently selected from the group consisting

of -H, -[C(R^z)_q-C(O)OR^y, -C(R^x)₂C(O)OR^y, -[C(R^z)_q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^y-, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl- to form a cyclic group, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy,

alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C=CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

7. A compound of Formula II:



wherein:

A is selected from the group consisting of -NRⁱ-, -O-, and -S-;

B is selected from the group consisting of -CR^b-, and -N-;

Rⁱ is selected from the group consisting of hydrogen, -C(O)C₁-C₄ alkyl, and -C₁-C₄ alkyl;

R^b is selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵³)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³), with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

D is selected from the group consisting of a bond, -(CR^a)₂-, and -C(O)-;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R³ is selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)aryl, -(CR^a)cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R⁴ is selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)₂NR^fR^g, -C(O)NR^fR^g, -C(O)OR^b, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g;

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C₁-C₄ alkyl, -OR^b, oxo, cyano, -CF₃, -CHF₂, -CH₂F, optionally substituted phenyl, and -C(O)OR^b;

Each R^h is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl; or

R⁸ and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising -CH=CH-CH=, -N=CH-CH=, -CH=N-CH= or -CH=CH-N=;

R³ and R⁵ are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached,

including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

X is $P(O)YR^{11}Y'R^{11}$;


Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^v-$;

when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^v-$, then R^{11} attached to $-NR^v-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-C(O)OR^y$, $-C(R^z)_2C(O)OR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-C(O)OR^y$;

when Y is $-O-$ and Y' is NR^v , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-alkylhydroxy$; and R^{11} attached to $-NR^v-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-C(O)OR^y$, $-C(R^z)_2C(O)OR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-C(O)OR^y$;

or when Y and Y' are independently selected from $-O-$ and $-NR^v-$, then R^{11} and R^{11} together form a cyclic group comprising $-alkyl-S-S-alkyl-$ to form a cyclic group, or together R^{11} and R^{11} are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C≡CR^z)OH, -R^z, -NR^z, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;


and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

8. The compound of any one of claims 5-7 wherein D is selected from the group consisting of a bond and -CH₂-.

9. The compound of any one of claims 5-7 wherein A is selected from the group consisting of -NH-, -NMe-, -O-, and -S-.

10. The compound of any one of claims 5-7 wherein B is selected from the group consisting of -CH-, -CMe-, and -N-.

11. A compound of Formula III:



wherein:

G is selected from the group consisting of -Se and CH₂ linked to any of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵²)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of $-(CR^a_2)_k-$, $-CR^b=CR^b-(CR^a_2)_n-$, $-(CR^a_2)_n-CR^b=CR^b-$, $-(CR^a_2)-CR^b=CR^b-(CR^a_2)-$, $-O(CR^b_2)(CR^a_2)_n-$, $-S(CR^b_2)(CR^a_2)_n-$, $-N(R^c)(CR^b_2)(CR^a_2)_n-$, $-N(R^b)C(O)(CR^a_2)_n-$, $-(CR^a_2)_mC(R^b)(NR^bR^c)-$, $-C(O)(CR^a_2)_m-$, $-(CR^a_2)_mC(O)-$, $-(CR^b_2)-O-(CR^b_2)-(CR^a_2)_p-$, $-(CR^b_2)-N(R^c)-(CR^b_2)-(CR^a_2)_p-$, $-(CR^a_2)_p-(CR^b_2)-S-(CR^b_2)-$, and $-(CH_2)_pC(O)N(R^b)C(R^a_2)-$;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R⁸ is selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄

alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)₂aryl, -(CR^a)₂cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C=C(aryl), -C=C(cycloalkyl), -C=C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)₂NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)OR^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g,

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g,

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the

group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C₁-C₄ alkyl, -OR^b, oxo, cyano, -CF₃, -CHF₂, -CH₂F, optionally substituted phenyl, and -C(O)OR^b;

Each R^b is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl; or

R³ and R⁸ are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁸ are attached, including 0 to 2 heteroatoms independently selected from -NR^b-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R⁸ and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising -CH=CH-CH=, -N=CH-CH=, -CH=N-CH= or -CH=CH-N=;

R⁵ is selected from the group consisting of -OH, optionally substituted -OC₁-C₆ alkyl, -OC(O)R^c, -OC(O)OR^b, -NHC(O)OR^b, -OC(O)NH(R^b), -F, -NHC(O)R^c, -NHS(=O)R^c, -NHS(=O)₂R^c, -NHC(=S)NH(R^b), and -NHC(O)NH(R^b); or

R³ and R⁵ are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R³ and R⁵ are attached, including 0 to 2 heteroatoms independently selected from -NR^b-, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^7 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, $-CF_3$, $-CHF_2$, $-CH_2F$, cyano, $-SH$ and $-S-C_1-C_4$ alkyl;

X is $P(O)YR^{11}Y'R^{11}$;


Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^y-$;

when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^y-$, then R^{11} attached to $-NR^y-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-COOR^y$, $-C(R^x)_2COOR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-COOR^y$;

when Y is $-O-$ and Y' is NR^y , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-alkylhydroxy$; and R^{11} attached to $-NR^y-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-C(O)OR^y$, $-C(R^x)_2C(O)OR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-C(O)OR^y$;

when Y and Y' are independently selected from $-O-$ and $-NR^y-$, then R^{11} and R^{11} together form a cyclic group comprising $-alkyl-S-S-alkyl-$, or together R^{11} and R^{11} are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C≡CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^y is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

12. A compound of Formula III:



wherein:

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵²)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a₂)₁₋₂-O-(CR^a₂)₁₋₂- and -(CH₂)_pC(O)N(R^b)C(R^a₂)-;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R⁸ is selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)aryl, -(CR^a)cycloalkyl, -(CR^a)heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -(CR^b)=C(R^b)-aryl, -(CR^b)=C(R^b)-cycloalkyl, -(CR^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)₂NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally

substituted $-(CR^b_2)_n$ cycloalkyl, optionally substituted
 $-(CR^b_2)_n$ heterocycloalkyl, and $-C(O)NR^fR^g$;

Each R^e is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a_2)_n$ aryl, optionally substituted $-(CR^a_2)_n$ cycloalkyl, and optionally substituted $-(CR^a_2)_n$ heterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^e, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^h$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl; or

R^3 and R^8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^8 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$ -, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^6$, $-OC(O)OR^h$, $-NHC(O)OR^h$, $-OC(O)NH(R^h)$, $-F$, $-NHC(O)R^6$, $-NHS(=O)R^6$, $-NHS(=O)_2R^6$, $-NHC(=S)NH(R^h)$, and $-NHC(O)NH(R^h)$; or

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^7 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, $-CF_3$, $-CHF_2$, $-CH_2F$, cyano, $-SH$ and $-S-C_1-C_4$ alkyl;

X is $P(O)YR^{11}Y'R^{11}$;

Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^v-$;


when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted $-alkylaryl$, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, $-alkyl-S-C(O)R^y$, $-alkyl-S-S-alkylhydroxy$, and $-alkyl-S-S-alkylhydroxy$;

when Y and Y' are both $-NR^v-$, then R^{11} attached to $-NR^v-$ is independently selected from the group consisting of $-H$, $-[C(R^z)_2]_q-COOR^y$, $-C(R^z)_2COOR^y$, $-[C(R^z)_2]_q-C(O)SR^y$, and $-cycloalkylene-COOR^y$;

when Y is $-O-$ and Y' is NR^v , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl,

optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, $-\text{C}(\text{R}^z)_2\text{OC(O)NR}^z_2$, $-\text{NR}^z\text{-C(O)-R}^y$, $-\text{C}(\text{R}^z)_2\text{-OC(O)R}^y$, $-\text{C}(\text{R}^z)_2\text{-O-C(O)OR}^y$, $-\text{C}(\text{R}^z)_2\text{-OC(O)SR}^y$, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^y- is independently selected from the group consisting of -H, $-\text{[C}(\text{R}^z)_2\text{]-C(O)OR}^y$, $-\text{C}(\text{R}^x)_2\text{C(O)OR}^y$, $-\text{[C}(\text{R}^z)_2\text{]-C(O)SR}^y$, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^y-, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 – 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0–1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an

aryl group at the beta and gamma position to the Y attached to the phosphorus;
or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C≡CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^y is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

13. A compound of Formula III:



wherein:

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵²)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a)_n-, -CR^b=CR^b-(CR^a)_n-, -(CR^a)_n-CR^b=CR^b-, -(CR^a)_n-CR^b=CR^b-(CR^a)_n-, -O(CR^b)_n(CR^a)_n-, -S(CR^b)_n(CR^a)_n-, -N(R^c)(CR^b)_n(CR^a)_n-, -N(R^b)C(O)(CR^a)_n-, -(CR^a)_nC(R^b)(NR^bR^c)-, -C(O)(CR^a)_m-, -(CR^a)_mC(O)-, -(CR^b)_nO-(CR^b)-(CR^a)_n-, -(CR^b)_nN(R^c)-(CR^b)-(CR^a)_n-, -(CR^a)_p-(CR^b)-S-(CR^b)-, and -(CH₂)_pC(O)N(R^b)C(R^a)_n;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted -C₂-C₄ alkenyl, and optionally substituted -C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R⁸ is selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂,

-CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)₂aryl, -(CR^a)₂cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)R^e, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, optionally substituted -(CR^b)_nheterocycloalkyl, and -C(O)NR^fR^g;

Each R^e is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally substituted -(CR^a)_ncycloalkyl, and optionally substituted -(CR^a)_nheterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^b)_naryl, optionally substituted -(CR^b)_ncycloalkyl, and optionally substituted -(CR^b)_nheterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^c, and S, wherein said optionally substituted

heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^b$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl; or

R^3 and R^8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^8 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$ -, $-O$ -, and $-S$ -, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$; or

R^5 is selected from the group consisting of $-OH$, optionally substituted $-OC_1-C_6$ alkyl, $-OC(O)R^e$, $-OC(O)OR^h$, $-NHC(O)OR^h$, $-OC(O)NH(R^h)$, $-F$, $-NHC(O)R^e$, $-NHS(=O)R^e$, $-NHS(=O)_2R^e$, $-NHC(=S)NH(R^h)$, and $-NHC(O)NH(R^h)$; or

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$ -, $-O$ -, and $-S$ -, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^7 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, $-CF_3$, $-CHF_2$, $-CH_2F$, cyano, $-SH$ and $-S-C_1-C_4$ alkyl;

X is P(O)YR¹¹Y'R¹¹;


Y and Y' are each independently selected from the group consisting of -O-, and -NR^v-;

when Y and Y' are both -O-, R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy;

when Y and Y' are both -NR^v, then R¹¹ attached to -NR^v- is independently selected from the group consisting of -H, -[C(R^z)₂]_q-COOR^y, -C(R^z)₂COOR^y, -[C(R^z)₂]_q-C(O)SR^y, and -cycloalkylene-COOR^y;

when Y is -O- and Y' is NR^v, then R¹¹ attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH₂-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R^z)₂OC(O)NR^z, -NR^z-C(O)-R^y, -C(R^z)₂-OC(O)R^y, -C(R^z)₂O-C(O)OR^y, -C(R^z)₂OC(O)SR^y, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R¹¹ attached to -NR^v- is independently selected from the group consisting of -H, -[C(R^z)₂]_q-C(O)OR^y, -C(R^z)₂C(O)OR^y, -[C(R^z)₂]_q-C(O)SR^y, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from -O- and -NR^v, then R¹¹ and R¹¹ together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R¹¹ and R¹¹ are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z,

-SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)OH, -CH(C≡CR^z)OH, -R^z, -NR^z₂, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCOR^z, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z,

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;


with the provisos that:

a) V, Z, W, W' are not all -H; and

b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

14. A compound of Formula III:



wherein:

G is selected from the group consisting of -O-, -S-, -Se-, -S(=O)-, -S(=O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-, or CH₂ linked to any of the preceding groups;

or G is R⁵⁰-R⁵¹ wherein;

R⁵⁰-R⁵¹ together are -C(R⁵²)=C(R⁵³)- or alternatively R⁵⁰ and R⁵¹ are independently selected from O, S and -CH(R⁵³)-, with the provisos that at

least one R⁵⁰ and R⁵¹ is -CH(R⁵³)-, and when one of R⁵⁰ and R⁵¹ is O or S, then R⁵³ is R⁵⁴;

R⁵⁴ is hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R⁵³ is selected from hydrogen, halogen, hydroxyl, mercapto, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

R⁵² is selected from hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;

T is selected from the group consisting of -(CR^a)_k-, -CR^b=CR^b-(CR^a)_n-, -(CR^a)_n-CR^b=CR^b-, -(CR^a)₂-CR^b=CR^b-(CR^a)₂-, -O(CR^b)(CR^a)_n-, -S(CR^b)(CR^a)_n-, -N(R^c)(CR^b)(CR^a)_n-, -N(R^b)C(O)(CR^a)_n-, -(CR^a)_mC(R^b)(NR^bR^c)-, -C(O)(CR^a)_m-, -(CR^a)_mC(O)-, -(CR^b)₂-O-(CR^b)-(CR^a)_p-, -(CR^b)₂-S-(CR^a)_p-, -(CR^b)₂-N(R^c)-(CR^b)-(CR^a)_p-, -(CR^a)_p-(CR^b)-S-(CR^b)₂-, -(CR^a)_p-(CR^b)-N(R^c)-(CR^b)₂-; and -(CH₂)_pC(O)N(R^b)C(R^a)₂;

k is an integer from 0-4;

m is an integer from 0-3;

n is an integer from 0-2;

p is an integer from 0-1;

Each R^a is independently selected from the group consisting of hydrogen, optionally substituted C₁-C₄ alkyl, halogen, -OH, optionally substituted -O-C₁-C₄ alkyl, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -S-C₁-C₄ alkyl, -NR^bR^c, optionally substituted C₂-C₄ alkenyl, and optionally substituted C₂-C₄ alkynyl; with the proviso that when one R^a is attached to C through an O, S, or N atom, then the other R^a attached to the same C is a hydrogen, or attached via a carbon atom;

Each R^b is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl;

Each R^c is independently selected from the group consisting of hydrogen and optionally substituted -C₁-C₄ alkyl, optionally substituted -C(O)-C₁-C₄ alkyl, and -C(O)H;

R¹ and R² are each independently selected from the group consisting of halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, and cyano;

R³ is selected from the group consisting of hydrogen, halogen, optionally substituted -C₁-C₄ alkyl, optionally substituted -S-C₁-C₃ alkyl, optionally substituted -C₂-C₄ alkenyl, optionally substituted -C₂-C₄ alkynyl, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, optionally substituted -O-C₁-C₃ alkyl, hydroxy, -(CR^a)aryl, -(CR^a)cycloalkyl, -(CR^a)₂heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;

R⁴ is selected from the group consisting of hydrogen, halogen, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, cyano, optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_maryl, optionally substituted -(CR^a)_mcycloalkyl, optionally substituted -(CR^a)_mheterocycloalkyl, -C(R^b)=C(R^b)-aryl, -C(R^b)=C(R^b)-cycloalkyl, -C(R^b)=C(R^b)-heterocycloalkyl, -C≡C(aryl), -C≡C(cycloalkyl), -C≡C(heterocycloalkyl), -(CR^a)_n(CR^b)NR^fR^g, -OR^d, -SR^d, -S(=O)R^e, -S(=O)₂R^e, -S(=O)NR^fR^g, -C(O)NR^fR^g, -C(O)OR^h, -C(O)O^c, -N(R^b)C(O)R^e, -N(R^b)C(O)NR^fR^g, -N(R^b)S(=O)₂R^e, -N(R^b)S(=O)₂NR^fR^g, and -NR^fR^g;

Each R^d is selected from the group consisting of optionally substituted -C₁-C₁₂ alkyl, optionally substituted -C₂-C₁₂ alkenyl, optionally substituted -C₂-C₁₂ alkynyl, optionally substituted -(CR^a)_naryl, optionally

substituted $-(CR^b_2)_n$ cycloalkyl, optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, and $-C(O)NR^fR^g$;

Each R^e is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^a_2)_n$ aryl, optionally substituted $-(CR^a_2)_n$ cycloalkyl, and optionally substituted $-(CR^a_2)_n$ heterocycloalkyl;

R^f and R^g are each independently selected from the group consisting of hydrogen, optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl, or R^f and R^g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR^c, and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted $-C_1-C_4$ alkyl, $-OR^b$, oxo, cyano, $-CF_3$, $-CHF_2$, $-CH_2F$, optionally substituted phenyl, and $-C(O)OR^h$;

Each R^h is selected from the group consisting of optionally substituted $-C_1-C_{12}$ alkyl, optionally substituted $-C_2-C_{12}$ alkenyl, optionally substituted $-C_2-C_{12}$ alkynyl, optionally substituted $-(CR^b_2)_n$ aryl, optionally substituted $-(CR^b_2)_n$ cycloalkyl, and optionally substituted $-(CR^b_2)_n$ heterocycloalkyl; or

R^8 and G are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring comprising $-CH=CH-CH=$, $-N=CH-CH=$, $-CH=N-CH=$ or $-CH=CH-N=$;

R^3 and R^5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R^3 and R^5 are attached, including 0 to 2 heteroatoms independently selected from $-NR^h$, $-O-$, and $-S-$, with the proviso that when there are 2 heteroatoms in the ring and both

heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;

R^7 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, $-O-C_1-C_4$ alkyl, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, $-CF_3$, $-CHF_2$, $-CH_2F$, cyano, $-SH$ and $-S-C_1-C_4$ alkyl;

X is $P(O)YR^{11}Y'R^{11}$;


Y and Y' are each independently selected from the group consisting of $-O-$, and $-NR^Y-$;

when Y and Y' are both $-O-$, R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy;

when Y and Y' are both $-NR^Y-$, then R^{11} attached to $-NR^Y-$ is independently selected from the group consisting of $-H$, $-(C(R^z)_2)_qCOOR^y$, $-C(R^x)_2COOR^y$, $-(C(R^z)_2)_q-C(O)SR^y$, and -cycloalkylene-COOR^y;

when Y is $-O-$ and Y' is NR^y , then R^{11} attached to $-O-$ is independently selected from the group consisting of $-H$, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH_2 -heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, $-C(R^z)_2OC(O)NR^z_2$, $-NR^z-C(O)-R^y$, $-C(R^z)_2-OC(O)R^y$, $-C(R^z)_2-O-C(O)OR^y$, $-C(R^z)_2OC(O)SR^y$, -alkyl-S-C(O)R^y, -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-alkylhydroxy; and R^{11} attached to $-NR^Y-$ is independently selected from the group consisting of $-H$, $-(C(R^z)_2)_q-C(O)OR^y$, $-C(R^x)_2C(O)OR^y$, $-(C(R^z)_2)_q-C(O)SR^y$, and -cycloalkylene-C(O)OR^y;

or when Y and Y' are independently selected from $-O-$ and $-NR^Y-$, then R^{11} and R^{11} together form a cyclic group comprising -alkyl-S-S-alkyl-, or together R^{11} and R^{11} are the group:



wherein:

V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and said cyclic group is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus; or

together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

Z is selected from the group consisting of -CHR^zOH, -CHR^zOC(O)R^y, -CHR^zOC(S)R^y, -CHR^zOC(S)OR^y, -CHR^zOC(O)SR^y, -CHR^zOCO₂R^y, -OR^z, -SR^z, -CHR^zN₃, -CH₂aryl, -CH(aryl)OH, -CH(CH=CR^z)₂OH, -CH(C≡CR^z)OH, -R^z, -NR^z, -OCOR^y, -OCO₂R^y, -SCOR^y, -SCO₂R^y, -NHCO₂R^y, -NHCO₂R^y, -CH₂NHaryl, -(CH₂)_q-OR^z, and -(CH₂)_q-SR^z;

q is an integer 2 or 3;

Each R^z is selected from the group consisting of R^y and -H;

Each R^y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

Each R^x is independently selected from the group consisting of -H, and alkyl, or together R^x and R^x form a cycloalkyl group;

Each R^v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxy carbonyloxyalkyl, and lower acyl;

with the provisos that:

- a) V, Z, W, W' are not all -H; and
- b) when Z is -R^z, then at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.

15. The compound of any one of claims 11-14 wherein R⁷ is selected from the group consisting of hydrogen, fluoro, chloro, amino, hydroxyl, and -O-CH₃.

16. The compound of any one of claims 1, 5, or 11 wherein G is R⁵⁰-R⁵¹.


17. The compound of any one of claims 2-4, 6, 7, or 12-14, wherein G is selected from the group consisting of -O-, -CH₂-, and R⁵⁰.R⁵¹.
18. The compound of any one of claims 1, 3, 4, 10, 11, 13, or 14 wherein T is selected from the group consisting of -(CR^a)_n-, -O(CR^b)₂(CR^a)_p-, -N(R^c)(CR^b)₂(CR^a)_p-, -S(CR^b)₂(CR^a)_p-, -N(R^b)C(O)-, and -CH₂C(R^b)(NR^cR^b)-.
19. The compound of claim 18 wherein T is -O(CR^b)₂(CR^a)_p- or -NH(CR^b)₂(CR^a)_p-.
20. The compound of any one of claims 1-7 or 11-14 wherein R¹ and R² are the same and are selected from the group consisting of halogen, -C₁-C₄ alkyl, -CF₃, and cyano.
21. The compound of claim 20 wherein R¹ and R² are both alkyl.
22. The compound of any one of claims 1-7 or 11-14 wherein R¹ and R² are different and are selected from the group consisting of halogen, -C₁-C₄ alkyl, -CF₃, and cyano.
23. The compound of claim 22 wherein R¹ and R² are not both halogen.

24. The compound of any one of claims 1-7 or 11-14 wherein R⁴ is selected from the group consisting of hydrogen, halogen, -C₁-C₄ alkyl, cyano and CF₃.
25. The compound of claim 24 wherein R⁴ is hydrogen.
26. The compound of any one of claims 1-3 wherein R⁶ and R⁷ are independently selected from the group consisting of hydrogen, halogen, -C₁-C₄ alkyl, cyano and CF₃.
27. The compound of claim 26 wherein R⁶ and R⁷ are independently hydrogen, halogen, or methyl.
28. The compound of any one of claims 1-4 wherein R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, -C₁-C₄ alkyl, -C₁-C₄ alkylaryl, C(O)aryl, cyano and CF₃.
29. The compound of claim 28 wherein R⁸ and R⁹ are independently hydrogen, halogen, methyl, benzyl, and benzoate.
30. The compound of any one of claims 1, 2, 4, 5, 6, or 11-13 wherein R⁵ is selected from the group consisting of -OH, -OC(O)R^c, -OC(O)OR^h, -F, and -NHC(O)R^e.

31. The compound of claim 30 wherein R⁵ is -OH.
32. The compound of any one of claims 1, 2, 4, 5, 6, or 11-13 wherein R³ is selected from the group consisting of halogen, optionally substituted -C₁-C₆ alkyl, -CF₃, cyano, -C(O)NR^fR^g, optionally substituted -(CR^h)₂haryl, -SO₂NR^fR^g, and -SO₂R^e.
33. The compound of claim 32 wherein R³ is isopropyl or 4-fluorobenzyl.
34. The compound of any one of claims 1-7 or 11-14 wherein X is selected from the group consisting of -PO₃H₂, -P(O)[-OCR^z₂OC(O)R^y]₂, -P(O)[-OCR^z₂OC(O)OR^y]₂, -P(O)[-N(H)CR^z₂C(O)OR^y]₂, -P(O)[-N(H)CR^z₂C(O)OR^y][-OR¹¹], -P(O)[-OCH(V)CH₂CH₂O-], -P(O)(OH)(OR⁵), -P(O)(OR^e)(OR^e), -P(O)[-OCR^z₂OC(O)R^y](OR⁵), -P(O)[-OCR^z₂OC(O)OR^y](OR⁵), -P(O)[-N(H)CR^z₂C(O)OR^y](OR⁶), and -P(O)(OH)(NH₂) wherein V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
35. The compound of claim 34, wherein X is selected from the group consisting of -PO₃H₂, -P(O)[-OCH₂OC(O)-*t*-butyl]₂, -P(O)[-OCH₂OC(O)-*i*-propyl]₂, -P(O)[-N(H)CH(CH₃)C(O)OCH₂CH₃]₂, -P(O)[-N(H)C(CH₃)₂C(O)OCH₂CH₃]₂, -P(O)[-N(H)CH(CH₃)₂C(O)OCH₂CH₃][3,4-methylenedioxypheyl], -P(O)[-N(H)C(CH₃)₂C(O)OCH₂CH₃][3,4-methylenedioxypheyl], -P(O)[-OCH(3-chlorophenyl)CH₂CH₂O-], -P(O)[-OCH(pyrid-4-yl)CH₂CH₂O-], -P(O)(OH)(OCH₃), -P(O)(OH)(OCH₂CH₃), -P(O)[-OCH₂OC(O)-

t-butyl](OCH₃), -P(O)[-OCH₂OC(O)O-*i*-propyl](OCH₃), -P(O)[-OCH(CH₃)OC(O)-*t*-butyl](OCH₃), -P(O)[-OCH(CH₃)C(O)OCH₂CH₃](OCH₃), -P(O)[-N(H)C(CH₃)₂C(O)OCH₂CH₃](OCH₃), -P(O)[-N(H)CH₂C(O)OCH₂CH₃](CH₃) and -P(O)(OH)(NH₂).

36. The compound of any one of claims 1-7 or 11-14 wherein Y and Y' are each independently selected from -O- and -NR^V-; together R¹¹ and R¹¹ are the group:



37. The compound of claim 36 wherein V is aryl.

38. The compound of claim 37 wherein Z is hydrogen, W is hydrogen, and W' is hydrogen.


39. The compound of claim 38 wherein V is selected from the group consisting of 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3-fluorophenyl, pyrid-4-yl, pyrid-3-yl and 3,5-dichlorophenyl.


40. The compound of claim 39 wherein the relative stereochemistry between the V-group substituent and T on the ring is *cis*.

41. The compound of claim 40 wherein said *cis* ring has *R* stereochemistry at the carbon where the V-group is attached.


42. The compound of claim 40 wherein said *cis* ring has *S* stereochemistry at the carbon where the V-group is attached.

43. A compound selected from the group consisting of:







- 659 -



- 660 -





and



and monomethyl esters thereof, and pharmaceutically acceptable salts and prodrugs of the compounds and monomethyl esters thereof.





44. A compound selected from the group consisting of:







and pharmaceutically acceptable salts thereof.


45. A compound selected from the group consisting of:





and monomethyl esters thereof, and pharmaceutically acceptable salts and prodrugs of the compounds and monomethyl esters thereof.

46. A compound selected from the group consisting of:













- 666 -









and pharmaceutically acceptable salts thereof.

47. A compound of any one of claims 1-7, 11-14, or 43-46 wherein said compound is in the form of a co-crystal.

48. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any one of claims 1-7, 11-14, or 43-46.

49. The pharmaceutical composition of claim 48 wherein said pharmaceutical composition in a form selected from the group consisting of a controlled release composition, transdermal patch, tablet, hard capsule, and soft capsule.

50. The pharmaceutical composition of claim 48 wherein said pharmaceutical composition comprises a crystalline form of said compound.
51. The pharmaceutical composition of claim 48 wherein said pharmaceutical composition comprises a salt form of said compound.
52. The pharmaceutical composition of claim 48 wherein said pharmaceutical composition is administered orally in a unit dose of about 0.375 µg/kg to 3.375 mg/kg.
53. The pharmaceutical composition of claim 48 wherein said pharmaceutical composition is administered orally in a total daily dose of about 0.375 µg/kg/day to about 3.75 mg/kg/day, equivalent of the free acid.
54. A method of preventing or treating a metabolic disease comprising administering to an animal a pharmaceutically effective amount of a phosphonic acid-containing compound of any one of claims 1-7, 11-14, or 43-46 or a pharmaceutically acceptable salt thereof, or prodrugs thereof or pharmaceutically acceptable salts of said prodrugs, wherein said phosphonic acid containing compound binds to a thyroid receptor.
55. The method of claim 54 wherein said phosphonic acid containing-compound binds to a thyroid receptor with a Ki of $\leq 1 \mu\text{M}$.

56. The method of claim 55 wherein said thyroid receptor is TR α 1.
57. The method of claim 55 wherein said thyroid receptor is TR β 1.
58. The method of claim 55 wherein said phosphonic acid-containing compound binds to a thyroid receptor with a Ki of \leq 100 nM.
59. The method of claim 58 wherein said thyroid receptor is TR α 1.
60. The method of claim 58 wherein said thyroid receptor is TR β 1.
61. The method of claim 54 wherein said metabolic disease is selected from the group consisting of obesity, hypercholesterolemia, hyperlipidemia, atherosclerosis, coronary heart disease, and hypertension.
62. The method of claim 61 wherein said metabolic disease is selected from the group consisting of obesity, hypercholesterolemia, and hyperlipidemia.
63. The method of claim 62 wherein said metabolic disease is hypercholesterolemia.

64. The method of claim 54 wherein said metabolic disease is fatty liver/steatosis, NAFLD, or NASH.
65. The method of claim 54 wherein said metabolic disease is selected from the group consisting of impaired glucose tolerance, diabetes, and metabolic syndrome X.
66. The method of claim 54, wherein said phosphonic acid-containing compound activates said thyroid receptor.
67. The method of claim 66 wherein said thyroid receptor is TR α 1.
68. The method of claim 66 wherein said thyroid receptor is TR β 1.
69. The method of claim 54 wherein said phosphonic acid containing-compound increases mRNA expression of a gene selected from the group consisting of LDL receptor, ACC, FAS, spot-14, CPT-1, CYP7A, apo AI, and mGPDH.
70. A method of activating a thyroid receptor in an animal by administering a phosphonic acid-containing-compound of any one of claims 1-7, 11-14, or 43-46, wherein said activation results in the 50% or greater increase in the mRNA expression of a gene selected

from the group consisting of LDL receptor, ACC, FAS, spot-14, CPT-1, CYP7A, apo AI, and mGPDH.

71. The method of claim 70 wherein said phosphonic acid-containing-compound binds to a thyroid receptor with a Ki of $\leq 1 \mu\text{M}$.
72. The method of claim 71 wherein said phosphonic acid-containing-compound binds to a thyroid receptor with a Ki of $\leq 100 \text{ nM}$.
73. A compound of Formula X:



wherein:

Ar^1 and Ar^2 are aryl groups;

G is an atom or group of atoms that links Ar^1 and Ar^2 through a single C, S, Se, O, or N atom, or through two atoms wherein one atom is C and the other atom is C, S, or O;







T is an atom or group of atoms linking Ar^2 to X through 1-4 contiguous atoms or is absent;

X is a phosphonic acid or phosphinic acid monoester or prodrug thereof;

wherein said compound has a Ki of $\leq 150 \text{ nM}$ relative to T3;

with the provisos that said compound is not:

- 674 -



74. A method of improving liver versus heart selectivity of a thyromimetic compound of Formula Y:



wherein:

Ar¹ and Ar² are aryl groups;

G is an atom or group of atoms that links Ar¹ and Ar² through a single C, S, Se, O, or N atom, or through two atoms wherein one atom is C and the other atom is C, S, or O;

T is an atom or group of atoms linking Ar² to E through 1-4 contiguous atoms or is absent;

E is selected from the group consisting of a functional group or moiety with a pKa ≤ 7.4, a carboxylic acid moiety or an atom or group of atoms containing an O or N that binds the thyroid hormone binding pocket of a TR α or TR β ,

comprising the step of replacing E with a phosphonic acid or phosphomeric acid monoester or prodrug thereof.

75. A method of increasing the therapeutic index of a thyromimetic compound of Formula Y:



wherein:

Ar¹ and Ar² are aryl groups;

G is an atom or group of atoms that links Ar¹ and Ar² through a single C, S, Se, O, or N atom, or through two atoms wherein one atom is C and the other atom is C, S, or O;

T is an atom or group of atoms linking Ar² to E through 1-4 atoms or is absent;

E is selected from the group consisting of a functional group or moiety with a pKa ≤ 7.4, a carboxylic acid moiety or an atom or group of atoms containing an O or N that binds the thyroid hormone binding pocket of a TRα or TRβ,

comprising the step of replacing E with a -P(O)(OH)₂ or prodrug thereof.

76. A method of designing a thyromimetic compound with improved liver versus heart selectivity comprising the steps of:

obtaining a molecular formula for a thyromimetic of Formula Y:



wherein:

Ar¹ and Ar² are aryl groups;

G is an atom or group of atoms that links Ar¹ and Ar² through a single C, S, Se, O, or N atom, or through two atoms wherein one atom is C and the other atom is C, S, or O;

T is an atom or group of atoms linking Ar² to E through 1-4 contiguous atoms or is absent;

E is selected from the group consisting of a functional group or moiety with a pKa ≤ 7.4, a carboxylic acid moiety, or an atom or group of atoms containing an O or N that binds the thyroid hormone binding pocket of a TRα or TRβ;

comprising the step of replacing E with a phosphonic acid or phosphonic acid monoester or prodrug thereof; and synthesizing a compound of Formula X wherein X is -P(O)(OH)₂ acid or prodrug thereof.

77. A method of designing a thyromimetic compound with an improved therapeutic index comprising the steps of:

obtaining a molecular formula for a thyromimetic of Formula Y;



wherein:

Ar¹ and Ar² are aryl groups;

G is an atom or group of atoms that links Ar¹ and Ar² through a single C, S, Se, O, or N atom, or through two atoms wherein one atom is C and the other atom is C, S, or O;


T is an atom or group of atoms linking Ar² to E through 1-4 atoms or is absent;

E is selected from the group consisting of a functional group or moiety with a pKa ≤ 7.4, a carboxylic acid moiety, or an atom or group of atoms containing an O or N that binds the thyroid hormone binding pocket of a TR α or TR β ;

comprising the step of replacing E with a phosphonic acid or phosphonic acid monoester or prodrug thereof; and synthesizing a compound of Formula X wherein X is -P(O)(OH)₂ acid or prodrug thereof.

1/12

HOMOLOGOUS DISPLACEMENT REACTIONS




T3 BINDING ASSAY RESULTS

FIG. 1(a)

2/12

HOMOLOGOUS DISPLACEMENT REACTIONS




T3 BINDING ASSAY RESULTS

FIG. 1(b)

3/12

HOMOLOGOUS DISPLACEMENT REACTIONS




COMPOUND 17 BINDING ASSAY RESULTS

FIG.1(c)

4/12


HOMOLOGOUS DISPLACEMENT REACTIONS



COMPOUND 17 BINDING ASSAY RESULTS

FIG.1(d)

HOMOLOGOUS DISPLACEMENT REACTIONS




COMPOUND 7 BINDING ASSAY RESULTS

FIG. 1(e)

6/12

HOMOLOGOUS DISPLACEMENT REACTIONS



COMPOUND 7 BINDING ASSAY RESULTS

FIG. 1(f)

7/12




FIG. 2(a)

8/12




FIG. 2(b)

9/12





FIG. 3(a)

10/12



11/12




FIG.4(a)

12/12




FIG. 5